

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/053075 A2

- (51) International Patent Classification⁷: C12N (74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrrel P.C., 66 E. Main Street, Marlton, NJ 08053 (US).
- (21) International Application Number: PCT/US2003/038739 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 5 December 2003 (05.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/431,097 5 December 2002 (05.12.2002) US
60/431,122 5 December 2002 (05.12.2002) US
- (71) Applicant (*for all designated States except US*): DI-ADEXUS, INC. [US/US]; 343 Oyster Point Boulevard, South San Francisco, CA 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): MACINA, Roberto, A. [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). TURNER, Leah, R. [US/US]; 939 Rosette Court, Sunnyvale, CA 94086 (US). SUN, Yongming [CN/US]; 551 Shoal Circle, Redwood City, CA 94065 (US).
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast, identifying breast tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered breast tissue for treatment and research.



WO 2004/053075 A2

**COMPOSITIONS, SPLICE VARIANTS AND METHODS
RELATING TO BREAST SPECIFIC GENES AND PROTEINS**

5

INTRODUCTION

This application claims the benefit of priority from U.S. Provisional Patent Application Serial No. 60/431,097 filed December 5, 2002 and 60/431,122 filed December 5, 2002 which are herein incorporated by reference in their entireties.

FIELD OF THE INVENTION

10

The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, post translational modifications (PTMs), variants, derivatives,

15

agonists and antagonists thereto and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast, identifying breast tissue and monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention.

20

The uses also include gene therapy, therapeutic molecules including but not limited to antibodies or antisense molecules, production of transgenic animals and cells, and production of engineered breast tissue for treatment and research.

BACKGROUND OF THE INVENTION

25

Breast cancer, also referred to as mammary tumor cancer, is the second most common cancer among women, accounting for a third of the cancers diagnosed in the United States. One in nine women will develop breast cancer in her lifetime and about 192,000 new cases of breast cancer are diagnosed annually with about 42,000 deaths.

30

Beyers, *Primary Prevention of Breast Cancer*, in Breast Cancer, 20-54 (Kelly K Hunt et al., ed., 2001); Kochanek et al., 49 *Nat'l. Vital Statistics Reports* 1, 14 (2001). Breast cancer is extremely rare in women younger than 20 and is very rare in women under 30. The incidence of breast cancer rises with age and becomes significant by age 50. White Non-Hispanic women have the highest incidence rate for breast cancer and Korean women have the lowest. Increased prevalence of the genetic mutations BRCA1 and BRCA2 that

promote breast and other cancers are found in Ashkenazi Jews. African American women have the highest mortality rate for breast cancer among these same groups (31 per 100,000), while Chinese women have the lowest at 11 per 100,000. Although men can get breast cancer, this is extremely rare. In the United States it is estimated there will be
5 212,600 new cases of breast cancer and 40,200 deaths due to breast cancer in 2003. (American Cancer Society Website: cancer.org at the world wide web). With the exception of those cases with associated genetic factors, precise causes of breast cancer are not known.

In the treatment of breast cancer, there is considerable emphasis on detection and
10 risk assessment because early and accurate staging of breast cancer has a significant impact on survival. For example, breast cancer detected at an early stage (stage T0, discussed below) has a five-year survival rate of 92%. Conversely, if the cancer is not detected until a late stage (i.e., stage T4 (IV)), the five-year survival rate is reduced to 13%. AJCC Cancer Staging Handbook pp. 164-65 (Irvin D. Fleming *et al.* eds., 5th ed.
15 1998). Some detection techniques, such as mammography and biopsy, involve increased discomfort, expense, and/or radiation, and are prescribed only to patients with an increased risk of breast cancer.

Current methods for predicting or detecting breast cancer risk are not optimal. One method for predicting the relative risk of breast cancer is by examining a patient's risk
20 factors and pursuing aggressive diagnostic and treatment regiments for high risk patients. A patient's risk of breast cancer has been positively associated with increasing age, nulliparity, family history of breast cancer, personal history of breast cancer, early menarche, late menopause, late age of first full term pregnancy, prior proliferative breast disease, irradiation of the breast at an early age and a personal history of malignancy.
25 Lifestyle factors such as fat consumption, alcohol consumption, education, and socioeconomic status have also been associated with an increased incidence of breast cancer although a direct cause and effect relationship has not been established. While these risk factors are statistically significant, their weak association with breast cancer limits their usefulness. Most women who develop breast cancer have none of the risk
30 factors listed above, other than the risk that comes with growing older. NIH Publication No. 00-1556 (2000).

Current screening methods for detecting cancer, such as breast self exam, ultrasound, and mammography have drawbacks that reduce their effectiveness or prevent

their widespread adoption. Breast self exams, while useful, are unreliable for the detection of breast cancer in the initial stages where the tumor is small and difficult to detect by palpation. Ultrasound measurements require skilled operators at an increased expense. Mammography, while sensitive, is subject to over diagnosis in the detection of lesions that have questionable malignant potential. There is also the fear of the radiation used in mammography because prior chest radiation is a factor associated with an increased incidence of breast cancer.

At this time, there are no adequate methods of breast cancer prevention. The current methods of breast cancer prevention involve prophylactic mastectomy (mastectomy performed before cancer diagnosis) and chemoprevention (chemotherapy before cancer diagnosis) which are drastic measures that limit their adoption even among women with increased risk of breast cancer. Bevers, *supra*.

A number of genetic markers have been associated with breast cancer. Examples of these markers include carcinoembryonic antigen (CEA) (Mughal *et al.*, *JAMA* 249:1881 (1983)), MUC-1 (Frische and Liu, *J. Clin. Ligand* 22:320 (2000)), HER-2/neu (Haris *et al.*, *Proc.Am.Soc.Clin.Oncology* 15:A96 (1996)), uPA, PAI-1, LPA, LPC, RAK and BRCA (Esteva and Fritsche, *Serum and Tissue Markers for Breast Cancer*, in Breast Cancer, 286-308 (2001)). These markers have problems with limited sensitivity, low correlation, and false negatives which limit their use for initial diagnosis. For example, while the BRCA1 gene mutation is useful as an indicator of an increased risk for breast cancer, it has limited use in cancer diagnosis because only 6.2 % of breast cancers are BRCA1 positive. Malone *et al.*, *JAMA* 279:922 (1998). See also, Mewman *et al.*, *JAMA* 279:915 (1998) (correlation of only 3.3%).

There are four primary classifications of breast cancer varying by the site of origin and the extent of disease development.

- I. Ductal carcinoma in situ (DCIS): Malignant transformation of ductal epithelial cells that remain in their normal position. DCIS is a purely localized disease, incapable of metastasis.
- II. Invasive ductal carcinoma (IDC): Malignancy of the ductal epithelial cells breaking through the basal membrane and into the supporting tissue of the breast. IDC may eventually spread elsewhere in the body.
- III. Lobular carcinoma in situ (LCIS): Malignancy arising in a single lobule of the breast that fail to extend through the lobule wall, it generally remains localized.

IV. Infiltrating lobular carcinoma (ILC): Malignancy arising in a single lobule of the breast and invading directly through the lobule wall into adjacent tissues.

By virtue of its invasion beyond the lobule wall, ILC may penetrate lymphatics and blood vessels and spread to distant sites.

5 For purpose of determining prognosis and treatment, these four breast cancer types have been staged according to the size of the primary tumor (T), the involvement of lymph nodes (N), and the presence of metastasis (M). Although DCIS by definition represents localized stage I disease, the other forms of breast cancer may range from stage II to stage IV. There are additional prognostic factors that further serve to guide surgical and medical
10 intervention. The most common ones are total number of lymph nodes involved, ER (estrogen receptor) status, Her2/neu receptor status and histologic grades.

Breast cancers are diagnosed into the appropriate stage categories recognizing that different treatments are more effective for different stages of cancer. Stage TX indicates that primary tumor cannot be assessed (i.e., tumor was removed or breast tissue was
15 removed). Stage T0 is characterized by abnormalities such as hyperplasia but with no evidence of primary tumor. Stage Tis is characterized by carcinoma in situ, intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the nipple with no tumor. Stage T1 (I) is characterized as having a tumor of 2 cm or less in the greatest dimension. Within stage T1, Tmic indicates microinvasion of 0.1 cm or less, T1a indicates a tumor of
20 between 0.1 to 0.5 cm, T1b indicates a tumor of between 0.5 to 1 cm, and T1c indicates tumors of between 1 cm to 2 cm. Stage T2 (II) is characterized by tumors from 2 cm to 5 cm in the greatest dimension. Tumors greater than 5 cm in size are classified as stage T3 (III). Stage T4 (IV) indicates a tumor of any size with extension to the chest wall or skin. Within stage T4, T4a indicates extension of the tumor to the chest wall, T4b indicates
25 edema or ulceration of the skin of the breast or satellite skin nodules confined to the same breast, T4c indicates a combination of T4a and T4b, and T4d indicates inflammatory carcinoma. AJCC Cancer Staging Handbook pp. 159-70 (Irvin D. Fleming *et al.* eds., 5th ed. 1998). In addition to standard staging, breast tumors may be classified according to their estrogen receptor and progesterone receptor protein status. Fisher *et al.*, *Breast
30 Cancer Research and Treatment* 7:147 (1986). Additional pathological status, such as HER2/neu status may also be useful. Thor *et al.*, *J.Nat'l.Cancer Inst.* 90:1346 (1998); Paik *et al.*, *J.Nat'l.Cancer Inst.* 90:1361 (1998); Hutchins *et al.*,

Proc.Am.Soc.Clin.Oncology 17:A2 (1998).; and Simpson *et al.*, *J.Clin.Oncology* 18:2059 (2000).

In addition to the staging of the primary tumor, breast cancer metastases to regional lymph nodes may be staged. Stage NX indicates that the lymph nodes cannot be assessed (e.g., previously removed). Stage N0 indicates no regional lymph node metastasis. Stage N1 indicates metastasis to movable ipsilateral axillary lymph nodes. Stage N2 indicates metastasis to ipsilateral axillary lymph nodes fixed to one another or to other structures. Stage N3 indicates metastasis to ipsilateral internal mammary lymph nodes. *Id.*

Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Simpson *et al.*, *J. Clin. Oncology* 18:2059 (2000). Generally, pathological staging of breast cancer is preferable to clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred if it were as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of breast cancer would be improved by detecting new markers in cells, tissues, or bodily fluids which could differentiate between different stages of invasion. Progress in this field will allow more rapid and reliable method for treating breast cancer patients.

Treatment of breast cancer is generally decided after an accurate staging of the primary tumor. Primary treatment options include breast conserving therapy (lumpectomy, breast irradiation, and surgical staging of the axilla), and modified radical mastectomy. Additional treatments include chemotherapy, regional irradiation, and, in extreme cases, terminating estrogen production by ovarian ablation.

Until recently, the customary treatment for all breast cancer was mastectomy. Fonseca *et al.*, *Annals of Internal Medicine* 127:1013 (1997). However, recent data indicate that less radical procedures may be equally effective, in terms of survival, for early stage breast cancer. Fisher *et al.*, *J. of Clinical Oncology* 16:441 (1998). The treatment options for a patient with early stage breast cancer (i.e., stage Tis) may be breast-sparing surgery followed by localized radiation therapy at the breast. Alternatively, mastectomy optionally coupled with radiation or breast reconstruction may be employed. These treatment methods are equally effective in the early stages of breast cancer.

Patients with stage I and stage II breast cancer require surgery with chemotherapy and/or hormonal therapy. Surgery is of limited use in stage III and stage IV patients.

Thus, these patients are better candidates for chemotherapy and radiation therapy with surgery limited to biopsy to permit initial staging or subsequent restaging because cancer is rarely curative at this stage of the disease. AJCC Cancer Staging Handbook 84, 164-65 (Irvin D. Fleming *et al.* eds., 5th ed.1998).

- 5 In an effort to provide more treatment options to patients, efforts are underway to define an earlier stage of breast cancer with low recurrence which could be treated with lumpectomy without postoperative radiation treatment. While a number of attempts have been made to classify early stage breast cancer, no consensus recommendation on postoperative radiation treatment has been obtained from these studies. Page *et al.*,
 10 *Cancer* 75:1219 (1995); Fisher *et al.*, *Cancer* 75:1223 (1995); Silverstein *et al.*, *Cancer* 77:2267 (1996).

- Cancer of the ovaries is the fourth most common cause of cancer death in women in the United States, with more than 23,000 new cases and roughly 14,000 deaths predicted for the year 2001. Shridhar, V. *et al.*, *Cancer Res.* 61(15):5895-904 (2001);
 15 Memarzadeh, S. & Berek, J. S., *J. Reprod. Med.* 46(7):621-29 (2001). The incidence of ovarian cancer is of serious concern worldwide, with an estimated 191,000 new cases predicted annually. Runnebaum, I. B. & Stickeler, E., *J.Cancer Res. Clin. Oncol.* 127(2):73-79 (2001). These numbers continue to rise today. In the United States alone, it is estimated there will be 25,400 new cases of ovarian cancer, and 14,300 deaths
 20 due to ovarian cancer in 2003. (American Cancer Society Website: <http://www.cancer.org>). Unfortunately, women with ovarian cancer are typically asymptomatic until the disease has metastasized. Because effective screening for ovarian cancer is not available, roughly 70% of women diagnosed have an advanced stage of the cancer with a five-year survival rate of ~25-30%. Memarzadeh, S. & Berek, J. S., *supra*;
 25 Nunns, D. *et al.*, *Obstet. Gynecol. Surv.* 55(12):746-51. Conversely, women diagnosed with early stage ovarian cancer enjoy considerably higher survival rates. Werness, B. A. & Eltabbakh, G. H., *Int'l. J. Gynecol. Pathol.* 20(1):48-63 (2001). Although our understanding of the etiology of ovarian cancer is incomplete, the results of extensive research in this area point to a combination of age, genetics, reproductive, and
 30 dietary/environmental factors. Age is a key risk factor in the development of ovarian cancer: while the risk for developing ovarian cancer before the age of 30 is slim, the incidence of ovarian cancer rises linearly between ages 30 to 50, increasing at a slower rate thereafter, with the highest incidence being among septagenarian women. Jeanne M.

Schilder *et al.*, Hereditary Ovarian Cancer: Clinical Syndromes and Management, in Ovarian Cancer 182 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001).

With respect to genetic factors, a family history of ovarian cancer is the most significant risk factor in the development of the disease, with that risk depending on the number of affected family members, the degree of their relationship to the woman, and which particular first degree relatives are affected by the disease. *Id.* Mutations in several genes have been associated with ovarian cancer, including BRCA1 and BRCA2, both of which play a key role in the development of breast cancer, as well as hMSH2 and hMLH1, both of which are associated with hereditary non-polyposis colon cancer. Katherine Y. Look, *Epidemiology, Etiology, and Screening of Ovarian Cancer*, in Ovarian Cancer 169, 171-73 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). BRCA1, located on chromosome 17, and BRCA2, located on chromosome 13, are tumor suppressor genes implicated in DNA repair; mutations in these genes are linked to roughly 10% of ovarian cancers. *Id.* at 171-72; Schilder *et al.*, *supra* at 185-86. hMSH2 and hMLH1 are associated with DNA mismatch repair, and are located on chromosomes 2 and 3, respectively; it has been reported that roughly 3% of hereditary ovarian carcinomas are due to mutations in these genes. Look, *supra* at 173; Schilder *et al.*, *supra* at 184, 188-89.

Reproductive factors have also been associated with an increased or reduced risk of ovarian cancer. Late menopause, nulliparity, and early age at menarche have all been linked with an elevated risk of ovarian cancer. Schilder *et al.*, *supra* at 182. One theory hypothesizes that these factors increase the number of ovulatory cycles over the course of a woman's life, leading to "incessant ovulation," which is thought to be the primary cause of mutations to the ovarian epithelium. *Id.*; Laura J. Havrilesky & Andrew Berchuck, *Molecular Alterations in Sporadic Ovarian Cancer*, in Ovarian Cancer 25 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). The mutations may be explained by the fact that ovulation results in the destruction and repair of that epithelium, necessitating increased cell division, thereby increasing the possibility that an undetected mutation will occur. *Id.* Support for this theory may be found in the fact that pregnancy, lactation, and the use of oral contraceptives, all of which suppress ovulation, confer a protective effect with respect to developing ovarian cancer. *Id.*

Among dietary/environmental factors, there would appear to be an association between high intake of animal fat or red meat and ovarian cancer, while the antioxidant Vitamin A, which prevents free radical formation and also assists in maintaining normal

cellular differentiation, may offer a protective effect. Look, *supra* at 169. Reports have also associated asbestos and hydrous magnesium trisilicate (talc), the latter of which may be present in diaphragms and sanitary napkins. *Id.* at 169-70.

Current screening procedures for ovarian cancer, while of some utility, are quite
5 limited in their diagnostic ability, a problem that is particularly acute at early stages of cancer progression when the disease is typically asymptomatic yet is most readily treatable. Walter J. Burdette, Cancer: Etiology, Diagnosis, and Treatment 166 (1998); Memarzadeh & Berek, *supra*; Runnebaum & Stickeler, *supra*; Werness & Eltabbakh, *supra*. Commonly used screening tests include biannual rectovaginal pelvic examination,
10 radioimmunoassay to detect the CA-125 serum tumor marker, and transvaginal ultrasonography. Burdette, *supra* at 166.

Pelvic examination has failed to yield adequate numbers of early diagnoses, and the other methods are not sufficiently accurate. *Id.* One study reported that only 15% of patients who suffered from ovarian cancer were diagnosed with the disease at the time of
15 their pelvic examination. Look, *supra* at 174. Moreover, the CA-125 test is prone to giving false positives in pre-menopausal women and has been reported to be of low predictive value in post-menopausal women. *Id.* at 174-75. Although transvaginal ultrasonography is now the preferred procedure for screening for ovarian cancer, it is unable to distinguish reliably between benign and malignant tumors, and also cannot
20 locate primary peritoneal malignancies or ovarian cancer if the ovary size is normal. Schilder *et al.*, *supra* at 194-95. While genetic testing for mutations of the BRCA1, BRCA2, hMSH2, and hMLH1 genes is now available, these tests may be too costly for some patients and may also yield false negative or indeterminate results. Schilder *et al.*, *supra* at 191-94.

25 The staging of ovarian cancer, which is accomplished through surgical exploration, is crucial in determining the course of treatment and management of the disease. AJCC Cancer Staging Handbook 187 (Irvin D. Fleming *et al.* eds., 5th ed. 1998); Burdette, *supra* at 170; Memarzadeh & Berek, *supra*; Shridhar *et al.*, *supra*. Staging is performed by reference to the classification system developed by the International Federation of
30 Gynecology and Obstetrics. David H. Moore, *Primary Surgical Management of Early Epithelial Ovarian Carcinoma*, in Ovarian Cancer 203 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001); Fleming *et al.* eds., *supra* at 188. Stage I ovarian cancer is characterized by tumor growth that is limited to the ovaries and is comprised of three

substages. *Id.* In substage IA, tumor growth is limited to one ovary, there is no tumor on the external surface of the ovary, the ovarian capsule is intact, and no malignant cells are present in ascites or peritoneal washings. *Id.* Substage IB is identical to A1, except that tumor growth is limited to both ovaries. *Id.* Substage IC refers to the presence of tumor growth limited to one or both ovaries, and also includes one or more of the following characteristics: capsule rupture, tumor growth on the surface of one or both ovaries, and malignant cells present in ascites or peritoneal washings. *Id.*

Stage II ovarian cancer refers to tumor growth involving one or both ovaries, along with pelvic extension. *Id.* Substage IIA involves extension and/or implants on the uterus and/or fallopian tubes, with no malignant cells in the ascites or peritoneal washings, while substage IIB involves extension into other pelvic organs and tissues, again with no malignant cells in the ascites or peritoneal washings. *Id.* Substage IIC involves pelvic extension as in IIA or IIB, but with malignant cells in the ascites or peritoneal washings. *Id.*

Stage III ovarian cancer involves tumor growth in one or both ovaries, with peritoneal metastasis beyond the pelvis confirmed by microscope and/or metastasis in the regional lymph nodes. *Id.* Substage IIIA is characterized by microscopic peritoneal metastasis outside the pelvis, with substage IIIB involving macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension. *Id.* Substage IIIC is identical to IIIB, except that the metastasis is greater than 2 cm in greatest dimension and may include regional lymph node metastasis. *Id.* Lastly, Stage IV refers to the presence of distant metastasis, excluding peritoneal metastasis. *Id.*

While surgical staging is currently the benchmark for assessing the management and treatment of ovarian cancer, it suffers from considerable drawbacks, including the invasiveness of the procedure, the potential for complications, as well as the potential for inaccuracy. Moore, *supra* at 206-208, 213. In view of these limitations, attention has turned to developing alternative staging methodologies through understanding differential gene expression in various stages of ovarian cancer and by obtaining various biomarkers to help better assess the progression of the disease. Vartiainen, J. *et al.*, *Int'l J. Cancer*, 95(5):313-16 (2001); Shridhar *et al. supra*; Baekelandt, M. *et al.*, *J. Clin. Oncol.* 18(22):3775-81.

The treatment of ovarian cancer typically involves a multiprong attack, with surgical intervention serving as the foundation of treatment. Dennis S. Chi & William J.

Hoskins, *Primary Surgical Management of Advanced Epithelial Ovarian Cancer*, in Ovarian Cancer 241 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). For example, in the case of epithelial ovarian cancer, which accounts for ~90% of cases of ovarian cancer, treatment typically consists of: (1) cytoreductive surgery, including total
5 abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy, followed by (2) adjuvant chemotherapy with paclitaxel and either cisplatin or carboplatin. Eltabbakh, G.H. & Awtrey, C.S., *Expert Op. Pharmacother.* 2(10):109-24. Despite a clinical response rate of 80% to the adjuvant therapy, most patients experience tumor recurrence within three years of treatment. *Id.* Certain patients
10 may undergo a second cytoreductive surgery and/or second-line chemotherapy. Memarzadeh & Berek, *supra*.

From the foregoing, it is clear that procedures used for detecting, diagnosing, monitoring, staging, prognosticating, and preventing the recurrence of ovarian cancer are of critical importance to the outcome of the patient. Moreover, current procedures, while
15 helpful in each of these analyses, are limited by their specificity, sensitivity, invasiveness, and/or their cost. As such, highly specific and sensitive procedures that would operate by way of detecting novel markers in cells, tissues, or bodily fluids, with minimal invasiveness and at a reasonable cost, would be highly desirable.

As discussed above, each of the methods for diagnosing and staging ovarian,
20 pancreatic or breast cancer is limited by the technology employed. Accordingly, there is need for sensitive molecular and cellular markers for the detection of ovarian, pancreatic or breast cancer. There is a need for molecular markers for the accurate staging, including clinical and pathological staging, of ovarian, pancreatic or breast cancers to optimize treatment methods. Finally, there is a need for sensitive molecular and cellular markers to
25 monitor the progress of cancer treatments, including markers that can detect recurrence of ovarian, pancreatic or breast cancers following remission.

The present invention provides alternative methods of treating ovarian, pancreatic or breast cancer that overcome the limitations of conventional therapeutic methods as well as offer additional advantages that will be apparent from the detailed description below.

30 Growth and metastasis of solid tumors are also dependent on angiogenesis. Folkman, J., 1986, *Cancer Research*, 46, 467-473; Folkman, J., 1989, *Journal of the National Cancer Institute*, 82, 4-6. It has been shown, for example, that tumors which enlarge to greater than 2 mm must obtain their own blood supply and do so by inducing

the growth of new capillary blood vessels. Once these new blood vessels become embedded in the tumor, they provide a means for tumor cells to enter the circulation and metastasize to distant sites such as liver, lung or bone. Weidner, N., *et al.*, 1991, *The New England Journal of Medicine*, 324(1), 1-8.

5 Angiogenesis, defined as the growth or sprouting of new blood vessels from existing vessels, is a complex process that primarily occurs during embryonic development. The process is distinct from vasculogenesis, in that the new endothelial cells lining the vessel arise from proliferation of existing cells, rather than differentiating from stem cells. The process is invasive and dependent upon proteolysis of the extracellular
10 matrix (ECM), migration of new endothelial cells, and synthesis of new matrix components. Angiogenesis occurs during embryogenic development of the circulatory system; however, in adult humans, angiogenesis only occurs as a response to a pathological condition (except during the reproductive cycle in women).

Under normal physiological conditions in adults, angiogenesis takes place only in
15 very restricted situations such as hair growth and wounding healing. Auerbach, W. and Auerbach, R., 1994, *Pharmacol Ther.* 63(3):265-311; Ribatti *et al.*, 1991, *Haematologica* 76(4):311-20; Risau, 1997, *Nature* 386(6626):671-4. Angiogenesis progresses by a stimulus which results in the formation of a migrating column of endothelial cells. Proteolytic activity is focused at the advancing tip of this "vascular sprout", which breaks
20 down the ECM sufficiently to permit the column of cells to infiltrate and migrate. Behind the advancing front, the endothelial cells differentiate and begin to adhere to each other, thus forming a new basement membrane. The cells then cease proliferation and finally define a lumen for the new arteriole or capillary.

Unregulated angiogenesis has gradually been recognized to be responsible for a
25 wide range of disorders, including, but not limited to, cancer, cardiovascular disease, rheumatoid arthritis, psoriasis and diabetic retinopathy. Folkman, 1995, *Nat Med* 1(1):27-31; Isner, 1999, *Circulation* 99(13):1653-5; Koch, 1998, *Arthritis Rheum* 41(6):951-62; Walsh, 1999, *Rheumatology* (Oxford) 38(2):103-12; Ware and Simons, 1997, *Nat Med* 3(2):158-64.

30 Of particular interest is the observation that angiogenesis is required by solid tumors for their growth and metastases. Folkman, 1986 *supra*; Folkman 1990, *J Natl. Cancer Inst.*, 82(1) 4-6; Folkman, 1992, *Semin Cancer Biol* 3(2):65-71; Zetter, 1998, *Annu Rev Med* 49:407-24. A tumor usually begins as a single aberrant cell which can proliferate

only to a size of a few cubic millimeters due to the distance from available capillary beds, and it can stay 'dormant' without further growth and dissemination for a long period of time. Some tumor cells then switch to the angiogenic phenotype to activate endothelial cells, which proliferate and mature into new capillary blood vessels. These newly formed blood vessels not only allow for continued growth of the primary tumor, but also for the dissemination and recolonization of metastatic tumor cells. The precise mechanisms that control the angiogenic switch is not well understood, but it is believed that neovascularization of tumor mass results from the net balance of a multitude of angiogenesis stimulators and inhibitors Folkman, 1995, *supra*.

One of the most potent angiogenesis inhibitors is endostatin identified by O'Reilly and Folkman. O'Reilly et al., 1997, *Cell* 88(2):277-85; O'Reilly et al., 1994, *Cell* 79(2):3 15-28. Its discovery was based on the phenomenon that certain primary tumors can inhibit the growth of distant metastases. O'Reilly and Folkman hypothesized that a primary tumor initiates angiogenesis by generating angiogenic stimulators in excess of inhibitors. However, angiogenic inhibitors, by virtue of their longer half life in the circulation, reach the site of a secondary tumor in excess of the stimulators. The net result is the growth of primary tumor and inhibition of secondary tumor. Endostatin is one of a growing list of such angiogenesis inhibitors produced by primary tumors. It is a proteolytic fragment of a larger protein: endostatin is a 20 kDa fragment of collagen XVIII (amino acid H1132- K1315 in murine collagen XVIII). Endostatin has been shown to specifically inhibit endothelial cell proliferation in vitro and block angiogenesis in vivo. More importantly, administration of endostatin to tumor-bearing mice leads to significant tumor regression, and no toxicity or drug resistance has been observed even after multiple treatment cycles. Boehm et al., 1997, *Nature* 390(6658):404-407. The fact that endostatin targets genetically stable endothelial cells and inhibits a variety of solid tumors makes it a very attractive candidate for anticancer therapy. Fidler and Ellis, 1994, *Cell* 79(2):185-8; Gastl et al., 1997, *Oncology* 54(3):177-84; Hinsbergh et al., 1999, *Ann Oncol* 10 Suppl 4:60-3. In addition, angiogenesis inhibitors have been shown to be more effective when combined with radiation and chemotherapeutic agents. Klement, 2000, *J. Clin Invest*, 105(8) R15- 24. Browder, 2000, *Cancer Res.* 6-(7) 1878-86, Arap et al., 1998, *Science* 279(5349):377- 80; Mauceri et al., 1998, *Nature* 394(6690):287-91.

SUMMARY OF THE INVENTION

The present invention solves many needs in the art by providing nucleic acid molecules, polypeptides and antibodies thereto, variants and derivatives of the nucleic acids and polypeptides, and agonists and antagonists thereto that may be used to identify, 5 diagnose, monitor, stage, image and treat breast cancer and/or non-cancerous disease states in breast; identify and monitor breast tissue; and identify and design agonists and antagonists of polypeptides of the invention. The invention also provides gene therapy, methods for producing transgenic animals and cells, and methods for producing 10 engineered breast tissue for treatment and research.

One aspect of the present invention relates to nucleic acid molecules that are specific to breast cells, breast tissue and/or the breast organ. These breast specific nucleic acids (BSNAs) may be a naturally occurring cDNA, genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally occurring nucleic acid molecule. 15 If the BSNA is genomic DNA, then the BSNA is a breast specific gene (BSG). If the BSNA is RNA, then it is a breast specific transcript encoded by a BSG. Due to alternative splicing and transcriptional modification one BSG may encode for multiple breast specific RNAs. In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to breast. More preferred is a nucleic acid molecule that encodes a polypeptide 20 comprising an amino acid sequence of SEQ ID NO: 73-179. In another preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1-72. For the BSNA sequences listed herein, DEX0451_001.nt.1 corresponds to SEQ ID NO: 1. For sequences with multiple splice variants, the parent sequence DEX0451_001.nt.1, will be followed by DEX0451_001.nt.2, etc. for each splice variant. 25 The sequences off the corresponding peptides are listed as DEX0451_001.aa.1, etc. For the mapping of all of the nucleotides and peptides, see the table in the Example 1 section below.

This aspect of the present invention also relates to nucleic acid molecules that selectively hybridize or exhibit substantial sequence similarity to nucleic acid molecules 30 encoding a breast Specific Protein (BSP), or that selectively hybridize or exhibit substantial sequence similarity to a BSNA. In one embodiment of the present invention the nucleic acid molecule comprises an allelic variant of a nucleic acid molecule encoding

a BSP, or an allelic variant of a BSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid sequence that encodes a BSP or a part of a nucleic acid sequence of a BSNA.

5 In addition, this aspect of the present invention relates to a nucleic acid molecule further comprising one or more expression control sequences controlling the transcription and/or translation of all or a part of a BSNA or the transcription and/or translation of a nucleic acid molecule that encodes all or a fragment of a BSP.

10 Another aspect of the present invention relates to vectors and/or host cells comprising a nucleic acid molecule of this invention. In a preferred embodiment, the nucleic acid molecule of the vector and/or host cell encodes all or a fragment of a BSP. In another preferred embodiment, the nucleic acid molecule of the vector and/or host cell comprises all or a part of a BSNA. Vectors and host cells of the present invention are useful in the recombinant production of polypeptides, particularly BSPs of the present invention.

15 Another aspect of the present invention relates to polypeptides encoded by a nucleic acid molecule of this invention. The polypeptide may comprise either a fragment or a full-length protein. In a preferred embodiment, the polypeptide is a BSP. However, this aspect of the present invention also relates to mutant proteins (muteins) of BSPs, fusion proteins of which a portion is a BSP, and proteins and polypeptides encoded by
20 allelic variants of a BSNA as provided herein.

A further aspect of the present invention is a novel splice variant which encodes an amino acid sequence that provides a novel region to be targeted for the generation of reagents that can be used in the detection and/or treatment of cancer. The novel amino acid sequence may lead to a unique protein structure, protein subcellular localization,
25 biochemical processing or function. This information can be used to directly or indirectly facilitate the generation of additional or novel therapeutics or diagnostics. The nucleotide sequence in this novel splice variant can be used as a nucleic acid probe for the diagnosis and/or treatment of cancer.

Another aspect of the present invention relates to antibodies and other binders that
30 specifically bind to a polypeptide of the instant invention. Accordingly antibodies or binders of the present invention specifically bind to BSPs, muteins, fusion proteins, and/or homologous proteins or polypeptides encoded by allelic variants of a BSNA as provided herein.

Another aspect of the present invention relates to agonists and antagonists of the nucleic acid molecules and polypeptides of this invention. The agonists and antagonists of the instant invention may be used to treat breast cancer and non-cancerous disease states in breast and to produce engineered breast tissue.

5 Another aspect of the present invention relates to methods for using the nucleic acid molecules to detect or amplify nucleic acid molecules that have similar or identical nucleic acid sequences compared to the nucleic acid molecules described herein. Such methods are useful in identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and/or non-cancerous disease states in breast. Such methods are also useful
10 in identifying and/or monitoring breast tissue. In addition, measurement of levels of one or more of the nucleic acid molecules of this invention may be useful as a diagnostic as part of a panel in combination with known other markers, particularly those described in the breast cancer background section above.

Another aspect of the present invention relates to use of the nucleic acid molecules
15 of this invention in gene therapy, for producing transgenic animals and cells, and for producing engineered breast tissue for treatment and research.

Another aspect of the present invention relates to methods for detecting polypeptides of this invention, preferably using antibodies thereto. Such methods are useful to identify, diagnose, monitor, stage, image and treat breast cancer and/or non-
20 cancerous disease states in breast. In addition, measurement of levels of one or more of the polypeptides of this invention may be useful to identify, diagnose, monitor, stage, and/or image breast cancer in combination with known other markers, particularly those described in the breast cancer background section above. The polypeptides of the present invention can also be used to identify and/or monitor breast tissue, and to produce
25 engineered breast tissue.

Yet another aspect of the present invention relates to a computer readable means of storing the nucleic acid and amino acid sequences of the invention. The records of the computer readable means can be accessed for reading and displaying of sequences for comparison, alignment and ordering of the sequences of the invention to other sequences.
30 In addition, the computer records regarding the nucleic acid and/or amino acid sequences and/or measurements of their levels may be used alone or in combination with other markers to diagnose breast related diseases.

DETAILED DESCRIPTION OF THE INVENTION

Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. *See, e.g.,* Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Press (2001); Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2000); Ausubel *et al.*, Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology – 4th Ed., Wiley & Sons (1999); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1990); and Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1999).

Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

The following terms, unless otherwise indicated, shall be understood to have the following meanings:

A "nucleic acid molecule" of this invention refers to a polymeric form of nucleotides and includes both sense and antisense strands of RNA, cDNA, genomic DNA,

and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A “nucleic acid molecule” as used herein is synonymous with “nucleic acid” and “polynucleotide.” The term “nucleic acid molecule” usually refers to a molecule of at least 10 bases in length, unless otherwise specified. The term includes single- and double-stranded forms of DNA. In addition, a polynucleotide may include either or both naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages.

Nucleotides are represented by single letter symbols in nucleic acid molecule sequences. The following table lists symbols identifying nucleotides or groups of nucleotides which may occupy the symbol position on a nucleic acid molecule. See Nomenclature Committee of the International Union of Biochemistry (NC-IUB), Nomenclature for incompletely specified bases in nucleic acid sequences, Recommendations 1984., *Eur J Biochem.* 150(1):1-5 (1985).

Symbol	Meaning	Group/Origin of Designation	Complementary Symbol
a	a	Adenine	t/u
g	g	Guanine	c
c	c	Cytosine	g
t	t	Thymine	a
u	u	Uracil	a
r	g or a	puRine	y
y	t/u or c	pYrimidine	r
m	a or c	aMino	k
k	g or t/u	Keto	m
s	g or c	Strong interactions 3H-bonds	w
w	a or t/u	Weak interactions 2H-bonds	s
b	g or c or t/u	not a	v
d	a or g or t/u	not c	h
h	a or c or t/u	not g	d
v	a or g or c	not t, not u	b
n	a or g or c or t/u, unknown, or other	aNy	n

15

The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g.,

20

phosphorothioates, phosphorodithioates, etc.), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen, etc.), chelators, alkylators, and modified linkages (*e.g.*, alpha anomeric nucleic acids, etc.) The term “nucleic acid molecule” also includes any topological conformation, including single-stranded, double-stranded, partially
5 duplexed, triplexed, hairpinned, circular and padlocked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

10 A “gene” is defined as a nucleic acid molecule that comprises a nucleic acid sequence that encodes a polypeptide and the expression control sequences that surround the nucleic acid sequence that encodes the polypeptide. For instance, a gene may comprise a promoter, one or more enhancers, a nucleic acid sequence that encodes a polypeptide, downstream regulatory sequences and, possibly, other nucleic acid sequences
15 involved in regulation of the expression of an RNA. As is well known in the art, eukaryotic genes usually contain both exons and introns. The term “exon” refers to a nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute contiguous sequence to a mature mRNA transcript. The term “intron” refers to a nucleic acid sequence found in genomic DNA that
20 is predicted and/or confirmed to not contribute to a mature mRNA transcript, but rather to be “spliced out” during processing of the transcript.

A nucleic acid molecule or polypeptide is “derived” from a particular species if the nucleic acid molecule or polypeptide has been isolated from the particular species, or if the nucleic acid molecule or polypeptide is homologous to a nucleic acid molecule or
25 polypeptide isolated from a particular species.

An “isolated” or “substantially pure” nucleic acid or polynucleotide (*e.g.*, an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, *e.g.*, ribosomes, polymerases, or genomic sequences with which it is naturally associated.
30 The term embraces a nucleic acid or polynucleotide that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a portion of a polynucleotide in which the “isolated polynucleotide” is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, (4) does not occur in nature

as part of a larger sequence or (5) includes nucleotides or internucleoside bonds that are not found in nature. The term “isolated” or “substantially pure” also can be used in reference to recombinant or cloned DNA isolates, chemically synthesized polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems. The term “isolated nucleic acid molecule” includes nucleic acid molecules that are integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.

A “part” of a nucleic acid molecule refers to a nucleic acid molecule that comprises a partial contiguous sequence of at least 10 bases of the reference nucleic acid molecule. Preferably, a part comprises at least 15 to 20 bases of a reference nucleic acid molecule. In theory, a nucleic acid sequence of 17 nucleotides is of sufficient length to occur at random less frequently than once in the three gigabase human genome, and thus provides a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. A preferred part is one that comprises a nucleic acid sequence that can encode at least 6 contiguous amino acid sequences (fragments of at least 18 nucleotides) because they are useful in directing the expression or synthesis of peptides that are useful in mapping the epitopes of the polypeptide encoded by the reference nucleic acid. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984); and U.S. Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. A part may also comprise at least 25, 30, 35 or 40 nucleotides of a reference nucleic acid molecule, or at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides of a reference nucleic acid molecule. A part of a nucleic acid molecule may comprise no other nucleic acid sequences. Alternatively, a part of a nucleic acid may comprise other nucleic acid sequences from other nucleic acid molecules.

The term “oligonucleotide” refers to a nucleic acid molecule generally comprising a length of 200 bases or fewer. The term often refers to single-stranded deoxyribonucleotides, but it can refer as well to single-or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other preferred oligonucleotides are 25, 30, 35, 40, 45, 50, 55 or 60 bases in length. Oligonucleotides may be single-stranded, *e.g.* for use as probes

or primers, or may be double-stranded, *e.g.* for use in the construction of a mutant gene. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. An oligonucleotide can be derivatized or modified as discussed above for nucleic acid molecules.

5 Oligonucleotides, such as single-stranded DNA probe oligonucleotides, often are synthesized by chemical methods, such as those implemented on automated oligonucleotide synthesizers. However, oligonucleotides can be made by a variety of other methods, including in vitro recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms. Initially, chemically synthesized DNAs
10 typically are obtained without a 5' phosphate. The 5' ends of such oligonucleotides are not substrates for phosphodiester bond formation by ligation reactions that employ DNA ligases typically used to form recombinant DNA molecules. Where ligation of such oligonucleotides is desired, a phosphate can be added by standard techniques, such as those that employ a kinase and ATP. The 3' end of a chemically synthesized
15 oligonucleotide generally has a free hydroxyl group and, in the presence of a ligase, such as T4 DNA ligase, readily will form a phosphodiester bond with a 5' phosphate of another polynucleotide, such as another oligonucleotide. As is well known, this reaction can be prevented selectively, where desired, by removing the 5' phosphates of the other polynucleotide(s) prior to ligation.

20 The term "naturally occurring nucleotide" referred to herein includes naturally occurring deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "nucleotide linkages" referred to herein includes nucleotide linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate,
25 phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. *See e.g.*, LaPlanche *et al. Nucl. Acids Res.* 14:9081-9093 (1986); Stein *et al. Nucl. Acids Res.* 16:3209-3221 (1988); Zon *et al. Anti-Cancer Drug Design* 6:539-568 (1991); Zon *et al.*, in Eckstein (ed.) Oligonucleotides and Analogues: A Practical Approach, pp. 87-108, Oxford University Press (1991); Uhlmann and Peyman *Chemical Reviews* 90:543 (1990),
30 and U.S. Patent No. 5,151,510, the disclosure of which is hereby incorporated by reference in its entirety.

Unless specified otherwise, the left hand end of a polynucleotide sequence in sense orientation is the 5' end and the right hand end of the sequence is the 3' end. In addition,

the left hand direction of a polynucleotide sequence in sense orientation is referred to as the 5' direction, while the right hand direction of the polynucleotide sequence is referred to as the 3' direction. Further, unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given
5 sequence be interpreted as would be appropriate to the polynucleotide composition: for example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

The term "allelic variant" refers to one of two or more alternative naturally occurring forms of a gene, wherein each gene possesses a unique nucleotide sequence. In
10 a preferred embodiment, different alleles of a given gene have similar or identical biological properties.

The term "percent sequence identity" in the context of nucleic acid sequences refers to the residues in two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at
15 least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or
20 Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA, which includes, *e.g.*, the programs FASTA2 and FASTA3, provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, *Methods Enzymol.* 183: 63-98 (1990); Pearson, *Methods Mol. Biol.* 132: 185-219 (2000); Pearson, *Methods Enzymol.*
25 266: 227-258 (1996); Pearson, *J. Mol. Biol.* 276: 71-84 (1998)). Unless otherwise specified, default parameters for a particular program or algorithm are used. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1.

30 A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, *e.g.*, for antisense

therapy, double-stranded RNA (dsRNA) inhibition (RNAi), combination of triplex and antisense, hybridization probes and PCR primers.

In the molecular biology art, researchers use the terms “percent sequence identity”, “percent sequence similarity” and “percent sequence homology” interchangeably. In this application, these terms shall have the same meaning with respect to nucleic acid sequences only.

The term “substantial similarity” or “substantial sequence similarity,” when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases, as measured by any well known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.

Alternatively, substantial similarity exists between a first and second nucleic acid sequence when the first nucleic acid sequence or fragment thereof hybridizes to an antisense strand of the second nucleic acid, under selective hybridization conditions. Typically, selective hybridization will occur between the first nucleic acid sequence and an antisense strand of the second nucleic acid sequence when there is at least about 55% sequence identity between the first and second nucleic acid sequences— preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90% — over a stretch of at least about 14 nucleotides, more preferably at least 17 nucleotides, even more preferably at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. “Stringent hybridization conditions” and “stringent wash conditions” in the context of nucleic acid hybridization experiments depend upon a number of different physical parameters. The most important parameters include temperature of hybridization, base composition of the nucleic acids, salt concentration and length of the nucleic acid. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization. In general, “stringent hybridization” is performed at about

25°C below the thermal melting point (T_m) for the specific DNA hybrid under a particular set of conditions. "Stringent washing" is performed at temperatures about 5°C lower than the T_m for the specific DNA hybrid under a particular set of conditions. The T_m is the temperature at which 50% of the target sequence hybridizes to a perfectly matched probe.

5 See Sambrook (1989), *supra*, p. 9.51.

The T_m for a particular DNA-DNA hybrid can be estimated by the formula:

$$T_m = 81.5^\circ\text{C} + 16.6 (\log_{10}[\text{Na}^+]) + 0.41 (\text{fraction G} + \text{C}) - 0.63 (\% \text{ formamide}) - (600/l) \text{ where } l \text{ is the length of the hybrid in base pairs.}$$

The T_m for a particular RNA-RNA hybrid can be estimated by the formula:

10
$$T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.35 (\% \text{ formamide}) - (820/l).$$

The T_m for a particular RNA-DNA hybrid can be estimated by the formula:

$$T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.50 (\% \text{ formamide}) - (820/l).$$

15 In general, the T_m decreases by 1-1.5°C for each 1% of mismatch between two nucleic acid sequences. Thus, one having ordinary skill in the art can alter hybridization and/or washing conditions to obtain sequences that have higher or lower degrees of sequence identity to the target nucleic acid. For instance, to obtain hybridizing nucleic acids that contain up to 10% mismatch from the target nucleic acid sequence, 10-15°C
20 would be subtracted from the calculated T_m of a perfectly matched hybrid, and then the hybridization and washing temperatures adjusted accordingly. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art.

25 An example of stringent hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 50% formamide/6X SSC at 42°C for at least ten hours and preferably overnight (approximately 16 hours). Another example of stringent hybridization conditions is 6X SSC at 68°C without formamide for at
30 least ten hours and preferably overnight. An example of moderate stringency hybridization conditions is 6X SSC at 55°C without formamide for at least ten hours and preferably overnight. An example of low stringency hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100

complementary residues on a filter in a Southern or northern blot or for screening a library is 6X SSC at 42°C for at least ten hours. Hybridization conditions to identify nucleic acid sequences that are similar but not identical can be identified by experimentally changing the hybridization temperature from 68°C to 42°C while keeping the salt concentration constant (6X SSC), or keeping the hybridization temperature and salt concentration constant (e.g. 42°C and 6X SSC) and varying the formamide concentration from 50% to 0%. Hybridization buffers may also include blocking agents to lower background. These agents are well known in the art. See Sambrook *et al.* (1989), *supra*, pages 8.46 and 9.46-9.58. See also Ausubel (1992), *supra*, Ausubel (1999), *supra*, and Sambrook (2001), *supra*.

Wash conditions also can be altered to change stringency conditions. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (see Sambrook (1989), *supra*, for SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove excess probe. An exemplary medium stringency wash for duplex DNA of more than 100 base pairs is 1x SSC at 45°C for 15 minutes. An exemplary low stringency wash for such a duplex is 4x SSC at 40°C for 15 minutes. In general, signal-to-noise ratio of 2x or higher than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

As defined herein, nucleic acids that do not hybridize to each other under stringent conditions are still substantially similar to one another if they encode polypeptides that are substantially identical to each other. This occurs, for example, when a nucleic acid is created synthetically or recombinantly using a high codon degeneracy as permitted by the redundancy of the genetic code.

Hybridization conditions for nucleic acid molecules that are shorter than 100 nucleotides in length (e.g., for oligonucleotide probes) may be calculated by the formula:

$$T_m = 81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\text{fraction G+C}) - (600/\text{N})$$
, wherein N is change length and the $[\text{Na}^+]$ is 1 M or less. See Sambrook (1989), *supra*, p. 11.46. For hybridization of probes shorter than 100 nucleotides, hybridization is usually performed under stringent conditions (5-10°C below the T_m) using high concentrations (0.1-1.0 pmol/ml) of probe. *Id.* at p. 11.45. Determination of hybridization using mismatched probes, pools of degenerate probes or “guessmers,” as well as hybridization solutions and methods for empirically determining hybridization conditions are well known in the art. See, e.g., Ausubel (1999), *supra*; Sambrook (1989), *supra*, pp. 11.45-11.57.

The term "digestion" or "digestion of DNA" refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes referred to herein are commercially available and their reaction conditions, cofactors and other requirements for use are known and routine to the skilled artisan. For analytical purposes, typically, 1 μ g of plasmid or DNA fragment is digested with about 2 units of enzyme in about 20 μ l of reaction buffer. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 μ g of DNA are digested with 20 to 250 units of enzyme in proportionately larger volumes. Appropriate buffers and substrate amounts for particular restriction enzymes are described in standard laboratory manuals, such as those referenced below, and are specified by commercial suppliers. Incubation times of about 1 hour at 37°C are ordinarily used, but conditions may vary in accordance with standard procedures, the supplier's instructions and the particulars of the reaction. After digestion, reactions may be analyzed, and fragments may be purified by electrophoresis through an agarose or polyacrylamide gel, using well known methods that are routine for those skilled in the art.

The term "ligation" refers to the process of forming phosphodiester bonds between two or more polynucleotides, which most often are double-stranded DNAs. Techniques for ligation are well known to the art and protocols for ligation are described in standard laboratory manuals and references, such as, *e.g.*, Sambrook (1989), *supra*.

Genome-derived "single exon probes," are probes that comprise at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon but do not hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon. Single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome, and may contain a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. The minimum length of genome-derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids, as discussed above. The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one exon. The single exon probes may contain priming sequences not found in contiguity with the rest of the probe sequence in the genome, which priming sequences are useful for PCR

and other amplification-based technologies. In another aspect, the invention is directed to single exon probes based on the BSNAs disclosed herein.

In one embodiment, the term "microarray" refers to a "nucleic acid microarray" having a substrate-bound plurality of nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. Nucleic acid microarrays include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999); *Nature Genet.* 21(1)(suppl.):1 - 60 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000). Additionally, these nucleic acid microarrays include a substrate-bound plurality of nucleic acids in which the plurality of nucleic acids are disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):1665-1670 (2000). Examples of nucleic acid microarrays may be found in U.S. Patent Nos. 6,391,623, 6,383,754, 6,383,749, 6,380,377, 6,379,897, 6,376,191, 6,372,431, 6,351,712, 6,344,316, 6,316,193, 6,312,906, 6,309,828, 6,309,824, 6,306,643, 6,300,063, 6,287,850, 6,284,497, 6,284,465, 6,280,954, 6,262,216, 6,251,601, 6,245,518, 6,263,287, 6,251,601, 6,238,866, 6,228,575, 6,214,587, 6,203,989, 6,171,797, 6,103,474, 6,083,726, 6,054,274, 6,040,138, 6,083,726, 6,004,755, 6,001,309, 5,958,342, 5,952,180, 5,936,731, 5,843,655, 5,814,454, 5,837,196, 5,436,327, 5,412,087, and 5,405,783, the disclosures of which are incorporated herein by reference in their entireties.

In an alternative embodiment, a "microarray" may also refer to a "peptide microarray" or "protein microarray" having a substrate-bound collection or plurality of polypeptides, the binding to each of the plurality of bound polypeptides being separately detectable. Alternatively, the peptide microarray may have a plurality of binders, including but not limited to monoclonal antibodies, polyclonal antibodies, phage display binders, yeast 2 hybrid binders, and aptamers, which can specifically detect the binding of the polypeptides of this invention. The array may be based on autoantibody detection to the polypeptides of this invention, see Robinson *et al.*, *Nature Medicine* 8(3):295-301 (2002). Examples of peptide arrays may be found in WO 02/31463, WO 02/25288, WO 01/94946, WO 01/88162, WO 01/68671, WO 01/57259, WO 00/61806, WO 00/54046, WO 00/47774, WO 99/40434, WO 99/39210, and WO 97/42507 and U.S. Patent Nos.

6,268,210, 5,766,960, and 5,143,854, the disclosures of which are incorporated herein by reference in their entireties.

In addition, determination of the levels of the BSNA or BSP may be made in a multiplex manner using techniques described in WO 02/29109, WO 02/24959, WO 5 01/83502, WO01/73113, WO 01/59432, WO 01/57269, and WO 99/67641, the disclosures of which are incorporated herein by reference in their entireties.

The term “mutant”, “mutated”, or “mutation” when applied to nucleic acid sequences means that nucleotides in a nucleic acid sequence may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration may be made 10 at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleic acid sequence. In a preferred embodiment of the present invention, the nucleic acid sequence is the wild type nucleic acid sequence encoding a BSP or is a BSNA. The nucleic acid sequence may be mutated by any method known in the art 15 including those mutagenesis techniques described *infra*.

The term “error-prone PCR” refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. *See, e.g., Leung et al., Technique 1: 11-15 (1989) and Caldwell et al., PCR Methods Applic. 2: 28-33 20 (1992).*

The term “oligonucleotide-directed mutagenesis” refers to a process which enables the generation of site-specific mutations in any cloned DNA segment of interest. *See, e.g., Reidhaar-Olson et al., Science 241: 53-57 (1988).*

The term “assembly PCR” refers to a process which involves the assembly of a 25 PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.

The term “sexual PCR mutagenesis” or “DNA shuffling” refers to a method of error-prone PCR coupled with forced homologous recombination between DNA 30 molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence similarity, followed by fixation of the crossover by primer extension in an error-prone PCR reaction. *See, e.g., Stemmer,*

Proc. Natl. Acad. Sci. U.S.A. 91: 10747-10751 (1994). DNA shuffling can be carried out between several related genes ("Family shuffling").

The term "*in vivo* mutagenesis" refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of
5 bacteria such as *E. coli* that carries mutations in one or more of the DNA repair pathways. These "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in a mutator strain will eventually generate random mutations within the DNA.

The term "cassette mutagenesis" refers to any process for replacing a small region
10 of a double-stranded DNA molecule with a synthetic oligonucleotide "cassette" that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

The term "recursive ensemble mutagenesis" refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of
15 phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. See, e.g., Arkin *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89: 7811-7815 (1992).

The term "exponential ensemble mutagenesis" refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein
20 small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. See, e.g., Delegrave *et al.*, *Biotechnology Research* 11: 1548-1552 (1993); Arnold, *Current Opinion in Biotechnology* 4: 450-455 (1993).

"Operatively linked" expression control sequences refers to a linkage in which the
25 expression control sequence is either contiguous with the gene of interest to control the gene of interest, or acts in *trans* or at a distance to control the gene of interest.

The term "expression control sequence" as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the
30 transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that

enhance translation efficiency (*e.g.*, ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription
5 termination sequence. The term “control sequences” is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

The term “vector,” as used herein, is intended to refer to a nucleic acid molecule
10 capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral
15 genome. Viral vectors that infect bacterial cells are referred to as bacteriophages. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of
20 directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” may be used interchangeably as the plasmid is the most commonly used form of vector. However, the
25 invention is intended to include other forms of expression vectors that serve equivalent functions.

The term “recombinant host cell” (or simply “host cell”), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular
30 subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein.

As used herein, the phrase "open reading frame" and the equivalent acronym "ORF" refers to that portion of a transcript-derived nucleic acid that can be translated in its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

As used herein, the phrase "ORF-encoded peptide" refers to the predicted or actual translation of an ORF.

As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence is meant to be inclusive of all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.

The term "polypeptide" encompasses both naturally occurring and non-naturally occurring proteins and polypeptides, as well as polypeptide fragments and polypeptide mutants, derivatives and analogs thereof. A polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different modules within a single polypeptide each of which has one or more distinct activities. A preferred polypeptide in accordance with the invention comprises a BSP encoded by a nucleic acid molecule of the instant invention, or a fragment, mutant, analog or derivative thereof.

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.

A protein or polypeptide is "substantially pure," "substantially homogeneous" or "substantially purified" when at least about 60% to 75% of a sample exhibits a single species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure. Protein purity or homogeneity may be determined by a number of means

well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel with a stain well known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well known in the art for purification.

5 The term “fragment” when used herein with respect to polypeptides of the present invention refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion compared to a full-length BSP. In a preferred embodiment, the fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally occurring polypeptide. Fragments typically are at
10 least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40 or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

 A “derivative” when used herein with respect to polypeptides of the present
15 invention refers to a polypeptide which is substantially similar in primary structural sequence to a BSP but which includes, *e.g.*, *in vivo* or *in vitro* chemical and biochemical modifications that are not found in the BSP. Such modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide
20 derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing,
25 phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. Other modifications include, *e.g.*, labeling with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes
30 are well known in the art, and include radioactive isotopes such as ^{125}I , ^{32}P , ^{35}S , ^{14}C and ^3H , ligands which bind to labeled antiligands (*e.g.*, antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required,

ease of conjugation with the primer, stability requirements, and available instrumentation. Methods for labeling polypeptides are well known in the art. *See* Ausubel (1992), *supra*; Ausubel (1999), *supra*.

5 The term "fusion protein" refers to polypeptides of the present invention coupled to a heterologous amino acid sequence. Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125
10 amino acids. Fusion proteins can be produced recombinantly by constructing a nucleic acid sequence that encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

15 The term "analog" refers to both polypeptide analogs and non-peptide analogs. The term "polypeptide analog" as used herein refers to a polypeptide that is comprised of a segment of at least 25 amino acids that has substantial identity to a portion of an amino acid sequence but which contains non-natural amino acids or non-natural inter-residue bonds. In a preferred embodiment, the analog has the same or similar biological activity
20 as the native polypeptide. Typically, polypeptide analogs comprise a conservative amino acid substitution (or insertion or deletion) with respect to the naturally occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally occurring polypeptide.

The term "non-peptide analog" refers to a compound with properties that are
25 analogous to those of a reference polypeptide. A non-peptide compound may also be termed a "peptide mimetic" or a "peptidomimetic." Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to useful peptides may be used to produce an equivalent effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that
30 has a desired biochemical property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of:
--CH₂NH--, --CH₂S--, --CH₂-CH₂--, --CH=CH--(cis and trans), --COCH₂--,
--CH(OH)CH₂--, and --CH₂SO--, by methods well known in the art. Systematic

substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (*e.g.*, D-lysine in place of L-lysine) may also be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known
5 in the art (Rizo *et al.*, *Ann. Rev. Biochem.* 61:387-418 (1992)). For example, one may add internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

The term "mutant" or "mutein" when referring to a polypeptide of the present invention relates to an amino acid sequence containing substitutions, insertions or
10 deletions of one or more amino acids compared to the amino acid sequence of a BSP. A mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally occurring protein, and/or truncations of the amino acid sequence
15 at either or both the amino or carboxy termini. Further, a mutein may have the same or different biological activity as the naturally occurring protein. For instance, a mutein may have an increased or decreased biological activity. A mutein has at least 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are muteins having 80%, 85% or 90%
20 sequence similarity to a BSP. In an even more preferred embodiment, a mutein exhibits 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99%. Sequence similarity may be measured by any common sequence analysis algorithm, such as GAP or BESTFIT or other variation Smith-Waterman alignment. *See*, T. F. Smith and M. S. Waterman, *J. Mol. Biol.* 147:195-197 (1981) and
25 W.R. Pearson, *Genomics* 11:635-650 (1991).

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs. For example,
30 single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. In a preferred embodiment, the amino acid substitutions are moderately conservative substitutions or

conservative substitutions. In a more preferred embodiment, the amino acid substitutions are conservative substitutions. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (*e.g.*, a replacement amino acid should not tend to disrupt a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterize the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton (ed.), Proteins, Structures and Molecular Principles, W. H. Freeman and Company (1984); Branden *et al.* (ed.), Introduction to Protein Structure, Garland Publishing (1991); Thornton *et al.*, *Nature* 354:105-106 (1991).

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Golub *et al.* (eds.), Immunology - A Synthesis 2nd Ed., Sinauer Associates (1991). Stereoisomers (*e.g.*, D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (*e.g.*, 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

By "homology" or "homologous" when referring to a polypeptide of the present invention it is meant polypeptides from different organisms with a similar sequence to the encoded amino acid sequence of a BSP and a similar biological activity or function. Although two polypeptides are said to be "homologous," this does not imply that there is necessarily an evolutionary relationship between the polypeptides. Instead, the term "homologous" is defined to mean that the two polypeptides have similar amino acid sequences and similar biological activities or functions. In a preferred embodiment, a homologous polypeptide is one that exhibits 50% sequence similarity to BSP, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are homologous polypeptides that exhibit 80%, 85% or 90% sequence similarity to a BSP. In yet a more preferred embodiment, a homologous polypeptide exhibits 95%, 97%, 98% or 99% sequence similarity.

When “sequence similarity” is used in reference to polypeptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. In a preferred embodiment, a polypeptide that has “sequence similarity” comprises conservative or moderately conservative amino acid substitutions. A

5 “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (*e.g.*, charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative
10 substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. *See, e.g.*, Pearson, *Methods Mol. Biol.* 24: 307-31 (1994).

For instance, the following six groups each contain amino acids that are
15 conservative substitutions for one another:

- 1) Serine (S), Threonine (T);
- 2) Aspartic Acid (D), Glutamic Acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 20 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet *et al.*, *Science* 256: 1443-45 (1992). A “moderately conservative” replacement is any change having a nonnegative
25 value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides, which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For
30 instance, GCG contains programs such as “Gap” and “Bestfit” which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of

organisms or between a wild type protein and a mutein thereof. *See, e.g.*, GCG Version 6.1. Other programs include FASTA, discussed *supra*.

A preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program
 5 BLAST, especially blastp or tblastn. *See, e.g.*, Altschul *et al.*, *J. Mol. Biol.* 215: 403-410 (1990); Altschul *et al.*, *Nucleic Acids Res.* 25:3389-402 (1997). Preferred parameters for blastp are:

	Expectation value:	10 (default)
	Filter:	seg (default)
10	Cost to open a gap:	11 (default)
	Cost to extend a gap:	1 (default)
	Max. alignments:	100 (default)
	Word size:	11 (default)
	No. of descriptions:	100 (default)
15	Penalty Matrix:	BLOSUM62

The length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues. When searching a database containing sequences from a large number of
 20 different organisms, it is preferable to compare amino acid sequences.

Algorithms other than blastp for database searching using amino acid sequences are known in the art. For instance, polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1. FASTA (*e.g.*, FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best overlap between the
 25 query and search sequences (Pearson (1990), *supra*; Pearson (2000), *supra*. For example, percent sequence identity between amino acid sequences can be determined using FASTA with its default or recommended parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1.

An "antibody" refers to an intact immunoglobulin, or to an antigen-binding portion
 30 thereof that competes with the intact antibody for specific binding to a molecular species, *e.g.*, a polypeptide of the instant invention. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')₂, Fv, dAb, and

complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide. A Fab fragment is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; a F(ab')₂ fragment is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consists of the VH and CH1 domains; a Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment consists of a VH domain. *See, e.g., Ward et al., Nature* 341: 544-546 (1989).

By "bind specifically" and "specific binding" as used herein it is meant the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said to "recognize" a first molecular species when it can bind specifically to that first molecular species.

A single-chain antibody (scFv) is an antibody in which VL and VH regions are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain. *See, e.g., Bird et al., Science* 242: 423-426 (1988); Huston *et al., Proc. Natl. Acad. Sci. USA* 85: 5879-5883 (1988). Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites. *See e.g., Holliger et al., Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); Poljak *et al., Structure* 2: 1121-1123 (1994). One or more CDRs may be incorporated into a molecule either covalently or noncovalently to make it an immunoadhesin. An immunoadhesin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoadhesin to specifically bind to a particular antigen of interest. A chimeric antibody is an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodies.

An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally occurring immunoglobulin has two identical binding sites, a single-chain

antibody or Fab fragment has one binding site, while a “bispecific” or “bifunctional” antibody has two different binding sites.

An “isolated antibody” is an antibody that (1) is not associated with naturally-associated components, including other naturally-associated antibodies, that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature. It is known that purified proteins, including purified antibodies, may be stabilized with non-naturally-associated components. The non-naturally-associated component may be a protein, such as albumin (e.g., BSA) or a chemical such as polyethylene glycol (PEG).

A “neutralizing antibody” or “an inhibitory antibody” is an antibody that inhibits the activity of a polypeptide or blocks the binding of a polypeptide to a ligand that normally binds to it. An “activating antibody” is an antibody that increases the activity of a polypeptide.

The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is less than $1\ \mu\text{M}$, preferably less than $100\ \text{nM}$ and most preferably less than $10\ \text{nM}$.

The term “patient” includes human and veterinary subjects.

Throughout this specification and claims, the word “comprise,” or variations such as “comprises” or “comprising,” will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

The term “breast specific” refers to a nucleic acid molecule or polypeptide that is expressed predominantly in the breast as compared to other tissues in the body. In a preferred embodiment, a “breast specific” nucleic acid molecule or polypeptide is detected at a level that is 1.5-fold higher than any other tissue in the body. In a more preferred embodiment, the “breast specific” nucleic acid molecule or polypeptide is detected at a level that is 2-fold higher than any other tissue in the body, more preferably 5-fold higher, still more preferably at least 10-fold, 15-fold, 20-fold, 25-fold, 50-fold or 100-fold higher than any other tissue in the body. Nucleic acid molecule levels may be measured by nucleic acid hybridization, such as Northern blot hybridization, or quantitative PCR.

Polypeptide levels may be measured by any method known to accurately quantitate protein levels, such as Western blot analysis.

Nucleic Acid Molecules, Regulatory Sequences, Vectors, Host Cells and Recombinant Methods of Making Polypeptides

5 *Nucleic Acid Molecules*

One aspect of the invention provides isolated nucleic acid molecules that are specific to the breast or to breast cells or tissue or that are derived from such nucleic acid molecules. These isolated breast specific nucleic acids (BSNAs) may comprise cDNA genomic DNA, RNA, or a combination thereof, a fragment of one of these nucleic acids, 10 or may be a non-naturally occurring nucleic acid molecule. A BSNA may be derived from an animal. In a preferred embodiment, the BSNA is derived from a human or other mammal. In a more preferred embodiment, the BSNA is derived from a human or other primate. In an even more preferred embodiment, the BSNA is derived from a human.

In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that 15 is specific to breast, a breast-specific polypeptide (BSP). In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 73-179. In another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1-72. Nucleotide sequences of the instantly-described nucleic acid molecules were determined by assembling several DNA 20 molecules from either public or proprietary databases. Some of the underlying DNA sequences are the result, directly or indirectly, of at least one enzymatic polymerization reaction (*e.g.*, reverse transcription and/or polymerase chain reaction) using an automated sequencer (such as the MegaBACE™ 1000, Amersham Biosciences, Sunnyvale, CA, USA).

25 Nucleic acid molecules of the present invention may also comprise sequences that selectively hybridize to a nucleic acid molecule encoding a BSNA or a complement or antisense thereof. The hybridizing nucleic acid molecule may or may not encode a polypeptide or may or may not encode a BSP. However, in a preferred embodiment, the hybridizing nucleic acid molecule encodes a BSP. In a more preferred embodiment, the 30 invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 73-179. In an even more preferred

embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1-72 or the antisense sequence thereof. Preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a
5 BSP under low stringency conditions. More preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a BSP under moderate stringency conditions. Most preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a BSP under high stringency conditions. In
10 a preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 73-179. In a more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule or the antisense
15 sequence of a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO: 1-72.

Nucleic acid molecules of the present invention may also comprise nucleic acid sequences that exhibit substantial sequence similarity to a nucleic acid encoding a BSP or a complement of the encoding nucleic acid molecule. In this embodiment, it is preferred
20 that the nucleic acid molecule exhibit substantial sequence similarity to a nucleic acid molecule encoding human BSP. More preferred is a nucleic acid molecule exhibiting substantial sequence similarity to a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 73-179. By substantial sequence similarity it is meant a nucleic acid molecule having at least 60%, more preferably at least 70%, even
25 more preferably at least 80% and even more preferably at least 85% sequence identity with a nucleic acid molecule encoding a BSP, such as a polypeptide having an amino acid sequence of SEQ ID NO: 73-179. In a more preferred embodiment, the similar nucleic acid molecule is one that has at least 90%, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%
30 sequence identity with a nucleic acid molecule encoding a BSP. Most preferred in this embodiment is a nucleic acid molecule that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a nucleic acid molecule encoding a BSP.

The nucleic acid molecules of the present invention are also inclusive of those exhibiting substantial sequence similarity to a BSNA or its complement. In this embodiment, it is preferred that the nucleic acid molecule exhibit substantial sequence similarity to a nucleic acid molecule having a nucleic acid sequence of SEQ ID NO: 1-72.

5 By substantial sequence similarity it is meant a nucleic acid molecule that has at least 60%, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85% sequence identity with a BSNA, such as one having a nucleic acid sequence of SEQ ID NO: 1-72. More preferred is a nucleic acid molecule that has at least 90%, more preferably at least 95%, more preferably at least 97%, even more preferably at
10 least 98%, and still more preferably at least 99% sequence identity with a BSNA. Most preferred is a nucleic acid molecule that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a BSNA.

Nucleic acid molecules that exhibit substantial sequence similarity are inclusive of sequences that exhibit sequence identity over their entire length to a BSNA or to a nucleic
15 acid molecule encoding a BSP, as well as sequences that are similar over only a part of its length. In this case, the part is at least 50 nucleotides of the BSNA or the nucleic acid molecule encoding a BSP, preferably at least 100 nucleotides, more preferably at least 150 or 200 nucleotides, even more preferably at least 250 or 300 nucleotides, still more preferably at least 400 or 500 nucleotides.

20 The substantially similar nucleic acid molecule may be a naturally occurring one that is derived from another species, especially one derived from another primate, wherein the similar nucleic acid molecule encodes an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 73-179 or demonstrates significant sequence identity to the nucleotide sequence of SEQ ID NO: 1-72. The similar nucleic acid
25 molecule may also be a naturally occurring nucleic acid molecule from a human, when the BSNA is a member of a gene family. The similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, hamster, cow, horse and pig; and wild animals, *e.g.*, monkey, fox, lions, tigers,
30 bears, giraffes, zebras, etc. The substantially similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule derived from a non-mammalian species, such as birds or reptiles. The naturally occurring substantially similar nucleic acid molecule may be isolated directly from humans or other species. In another embodiment, the

substantially similar nucleic acid molecule may be one that is experimentally produced by random mutation of a nucleic acid molecule. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by directed mutation of a BSNA. In a preferred embodiment, the substantially similar nucleic acid molecule is a BSNA.

The nucleic acid molecules of the present invention are also inclusive of allelic variants of a BSNA or a nucleic acid encoding a BSP. For example, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes and the sequence determined from one individual of a species may differ from other allelic forms present within the population. More than 1.4 million SNPs have already been identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409: 860-921 (2001) – Variants with small deletions and insertions of more than a single nucleotide are also found in the general population, and often do not alter the function of the protein. In addition, amino acid substitutions occur frequently among natural allelic variants, and often do not substantially change protein function.

In a preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into a mRNA that encodes a BSP. In a more preferred embodiment, the gene is transcribed into a mRNA that encodes a BSP comprising an amino acid sequence of SEQ ID NO: 73-179. In another preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into a mRNA that is a BSNA. In a more preferred embodiment, the gene is transcribed into a mRNA that comprises the nucleic acid sequence of SEQ ID NO: 1-72. Also preferred is that the allelic variant be a naturally occurring allelic variant in the species of interest, particularly human.

Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences comprising a part of a nucleic acid sequence of the instant invention. The part may or may not encode a polypeptide, and may or may not encode a polypeptide that is a BSP. In a preferred embodiment, the part encodes a BSP. In one embodiment, the nucleic acid molecule comprises a part of a BSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that hybridizes or exhibits substantial sequence similarity to a BSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that is an allelic variant of a BSNA. In yet another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that encodes a BSP. A part comprises at least 10 nucleotides, more preferably at

least 15, 17, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides. The maximum size of a nucleic acid part is one nucleotide shorter than the sequence of the nucleic acid molecule encoding the full-length protein.

5 Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences that encode fusion proteins, homologous proteins, polypeptide fragments, muteins and polypeptide analogs, as described *infra*.

10 Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences containing modifications of the native nucleic acid molecule. Examples of such modifications include, but are not limited to, nonnative internucleoside bonds, post-synthetic modifications or altered nucleotide analogues. One having ordinary skill in the art would recognize that the type of modification that may be made will depend upon the intended use of the nucleic acid molecule. For instance, when the nucleic acid molecule is used as a hybridization probe, the range of such modifications will be limited to those that permit sequence-discriminating base pairing of the resulting nucleic acid. When used to
15 direct expression of RNA or protein *in vitro* or *in vivo*, the range of such modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent, the modifications will be limited to those that do not confer toxicity upon the isolated nucleic acid.

20 Accordingly, in one embodiment, a nucleic acid molecule may include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens. The labeled nucleic acid molecules are particularly useful as hybridization probes.

25 Common radiolabeled analogues include those labeled with ^{33}P , ^{32}P , and ^{35}S , such as α - ^{32}P -dATP, α - ^{32}P -dCTP, α - ^{32}P -dGTP, α - ^{32}P -dTTP, α - ^{32}P -3'dATP, α - ^{32}P -ATP, α - ^{32}P -CTP, α - ^{32}P -GTP, α - ^{32}P -UTP, α - ^{35}S -dATP, γ - ^{35}S -GTP, γ - ^{33}P -dATP, and the like.

Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy3-dUTP (Amersham Biosciences, Piscataway, New Jersey, USA), fluorescein-12-dUTP,
30 tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP,

BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, 5 BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, OR, USA). One may also custom synthesize nucleotides having other fluorophores. *See Henegariu et al., Nature Biotechnol.* 18: 345-348 (2000).

Haptens that are commonly conjugated to nucleotides for subsequent labeling 10 include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA; biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA).

15 Nucleic acid molecules of the present invention can be labeled by incorporation of labeled nucleotide analogues into the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation, random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules, and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3, 20 and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach. Analogues can also be incorporated during automated solid phase chemical synthesis. Labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3' hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

25 Other post-synthetic approaches also permit internal labeling of nucleic acids. For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and Peptide Nucleic Acids (PNA) to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); *see Alers et al., Genes, Chromosomes & Cancer* 25: 301- 305 (1999); Jelsma *et al.*, *J. NIH Res.* 5: 82 (1994); Van Belkum *et al.*, *BioTechniques* 16: 148-153 (1994). Alternatively, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector

Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally coupled to the target nucleic acid using aryl azide chemistry; after reduction, a free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

One or more independent or interacting labels can be incorporated into the nucleic acid molecules of the present invention. For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report specific hybridization through release of fluorescence quenching or to report exonucleotidic excision. *See, e.g., Tyagi et al., Nature Biotechnol.* 14: 303-308 (1996); Tyagi et al., *Nature Biotechnol.* 16: 49-53 (1998); Sokol et al., *Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); Kostrikis et al., *Science* 279: 1228-1229 (1998); Marras et al., *Genet. Anal.* 14: 151-156 (1999); Holland et al., *Proc. Natl. Acad. Sci. USA* 88: 7276-7280 (1991); Heid et al., *Genome Res.* 6(10): 986-94 (1996); Kuimelis et al., *Nucleic Acids Symp. Ser.* (37): 255-6 (1997); and U.S. Patent Nos. 5,846,726, 5,925,517, 5,925,517, 5,723,591 and 5,538,848, the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules of the present invention may also be modified by altering one or more native phosphodiester internucleoside bonds to more nuclease-resistant, internucleoside bonds. *See Hartmann et al. (eds.), Manual of Antisense Methodology: Perspectives in Antisense Science*, Kluwer Law International (1999); Stein et al. (eds.), *Applied Antisense Oligonucleotide Technology*, Wiley-Liss (1998); Chadwick et al. (eds.), *Oligonucleotides as Therapeutic Agents – Symposium No. 209*, John Wiley & Son Ltd (1997). Such altered internucleoside bonds are often desired for techniques or for targeted gene correction, Gamper et al., *Nucl. Acids Res.* 28(21): 4332-4339 (2000). For double-stranded RNA inhibition which may utilize either natural ds RNA or ds RNA modified in its, sugar, phosphate or base, *see Hannon, Nature* 418(11): 244-251 (2002); Fire et al. in WO 99/32619; Tuschl et al. in US2002/0086356; Kruetzer et al. in WO 00/44895, the disclosures of which are incorporated herein by reference in their entirety. For circular antisense, *see Kool* in U.S. Patent No. 5,426,180, the disclosure of which is incorporated herein by reference in its entirety.

Modified oligonucleotide backbones include, without limitation, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including

3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'.

5 Representative U.S. Patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Patent Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of
10 which are incorporated herein by reference in their entireties. In a preferred embodiment, the modified internucleoside linkages may be used for antisense techniques.

Other modified oligonucleotide backbones do not include a phosphorus atom, but have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or
15 more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino
20 backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S. Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086;
25 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437 and 5,677,439; the disclosures of which are incorporated herein by reference in their entireties.

In other preferred nucleic acid molecules, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA). In PNA
30 compounds, the phosphodiester backbone of the nucleic acid is replaced with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages. PNA can be

synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference in its entirety. Automated PNA synthesis is readily achievable on commercial synthesizers (see, e.g., "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA). PNA molecules are advantageous for a number of reasons. First, because the PNA backbone is uncharged, PNA/DNA and PNA/RNA duplexes have a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes. The T_m of a PNA/DNA or PNA/RNA duplex is generally 1°C higher per base pair than the T_m of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl). Second, PNA molecules can also form stable PNA/DNA complexes at low ionic strength, under conditions in which DNA/DNA duplex formation does not occur. Third, PNA also demonstrates greater specificity in binding to complementary DNA because a PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the T_m by 8–20°C (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the T_m by 4–16°C (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater. Fourth, PNA oligomers are resistant to degradation by enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro* because nucleases and proteases do not recognize the PNA polyamide backbone with nucleobase sidechains. See, e.g., Ray *et al.*, *FASEB J.* 14(9): 1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1): 3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1): 159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3): 353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1): 71-5 (1999).

Nucleic acid molecules may be modified compared to their native structure throughout the length of the nucleic acid molecule or can be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and that can be used for targeted gene repair and modified PCR reactions, as further described in, Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); and Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), and U.S. Patent Nos. 5,760,012 and 5,731,181, the disclosures of which are incorporated herein by reference in their entireties.

Unless otherwise specified, nucleic acid molecules of the present invention can include any topological conformation appropriate to the desired use; the term thus explicitly comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, 5 branched, hairpinned, circular, and padlocked conformations. Padlocked conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12: 11-15 (2001); Escude *et al.*, *Proc. Natl. Acad. Sci. USA* 14: 96(19):10603-7 (1999); and Nilsson *et al.*, *Science* 265(5181): 2085-8 (1994). Triplexed and quadruplexed conformations, and their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1): 181-206 10 (1999); Fox, *Curr. Med. Chem.* 7(1): 17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130: 189-201 (2000); Chan *et al.*, *J. Mol. Med.* 75(4): 267-82 (1997); Rowley *et al.*, *Mol Med* 5(10): 693-700 (1999); Kool, *Annu Rev Biophys Biomol Struct.* 25: 1-28 (1996).

SNP Polymorphisms

Commonly, sequence differences between individuals involve differences in single 15 nucleotide positions. SNPs may account for 90% of human DNA polymorphism. Collins *et al.*, 8 *Genome Res.* 1229-31 (1998). SNPs include single base pair positions in genomic DNA at which different sequence alternatives (alleles) exist in a population. In addition, the least frequent allele generally must occur at a frequency of 1% or greater. DNA sequence variants with a reasonably high population frequency are observed 20 approximately every 1,000 nucleotide across the genome, with estimates as high as 1 SNP per 350 base pairs. Wang *et al.*, 280 *Science* 1077-82 (1998); Harding *et al.*, 60 *Am. J. Human Genet.* 772-89 (1997); Taillon-Miller *et al.*, 8 *Genome Res.* 748-54 (1998); Cargill *et al.*, 22 *Nat. Genet.* 231-38 (1999); and Semple *et al.*, 16 *Bioinform. Disc. Note* 735-38 (2000). The frequency of SNPs varies with the type and location of the change. In base 25 substitutions, two-thirds of the substitutions involve the C-T and G-A type. This variation in frequency can be related to 5-methylcytosine deamination reactions that occur frequently, particularly at CpG dinucleotides. Regarding location, SNPs occur at a much higher frequency in non-coding regions than in coding regions. Information on over one million variable sequences is already publicly available via the Internet and more such 30 markers are available from commercial providers of genetic information. Kwok and Gu, 5 *Med. Today* 538-53 (1999).

Several definitions of SNPs exist. See, e.g., Brooks, 235 *Gene* 177-86 (1999). As used herein, the term "single nucleotide polymorphism" or "SNP" includes all single base variants, thus including nucleotide insertions and deletions in addition to single nucleotide substitutions. There are two types of nucleotide substitutions. A transition is the
5 replacement of one purine by another purine or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine for a pyrimidine, or vice versa.

Numerous methods exist for detecting SNPs within a nucleotide sequence. A review of many of these methods can be found in Landegren *et al.*, 8 *Genome Res.* 769-76 (1998). For example, a SNP in a genomic sample can be detected by preparing a Reduced
10 Complexity Genome (RCG) from the genomic sample, then analyzing the RCG for the presence or absence of a SNP. See, e.g., WO 00/18960 which is herein incorporated by reference in its entirety. Multiple SNPs in a population of target polynucleotides in parallel can be detected using, for example, the methods of WO 00/50869 which is herein incorporated by reference in its entirety. Other SNP detection methods include the
15 methods of U.S. Pat. Nos. 6,297,018 and 6,322,980 which are herein incorporated by reference in their entirety. Furthermore, SNPs can be detected by restriction fragment length polymorphism (RFLP) analysis. See, e.g., U.S. Pat. Nos. 5,324,631; 5,645,995 which are herein incorporated by reference in their entirety. RFLP analysis of SNPs, however, is limited to cases where the SNP either creates or destroys a restriction enzyme
20 cleavage site. SNPs can also be detected by direct sequencing of the nucleotide sequence of interest. In addition, numerous assays based on hybridization have also been developed to detect SNPs and mismatch distinction by polymerases and ligases. Several web sites provide information about SNPs including Ensembl on the World Wide Web at ensembl.org, Sanger Institute on the World Wide Web at sanger.ac.uk/genetics/exon/,
25 National Center for Biotechnology Information (NCBI) on the World Wide Web at ncbi.nlm.nih.gov/SNP/, The SNP Consortium Ltd. on the World Wide Web at snp.cshl.org. The chromosomal locations for the compositions disclosed herein are provided below. In addition, one of ordinary skill in the art could use a BLAST against the genome or any of the databases cited above to find the chromosomal location.
30 Another a preferred method to find the genomic coordinates and associated SNPs would be to use the BLAT tool (genome.ucsc.edu, Kent et al. 2001, The Human Genome Browser at UCSC, Genome Research 996-1006 or Kent 2002 BLAT —The BLAST -Like

Alignment Tool Genome Research, 1-9). All web sites above were accessed December 3, 2003.

RNA interference

RNA interference refers to the process of sequence-specific post transcriptional
5 gene silencing in animals mediated by short interfering RNAs (siRNA). Fire *et al.*, 1998, *Nature*, 391, 806. The corresponding process in plants is commonly referred to as post transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post transcriptional gene silencing is thought to be an evolutionarily conserved cellular defense mechanism used to prevent the expression of foreign genes
10 which is commonly shared by diverse flora and phyla. Fire *et al.*, 1999, *Trends Genet.*, 15, 358. Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNA) derived from viral infection or the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA. The
15 presence of dsRNA in cells triggers the RNAi response though a mechanism that has yet to be fully characterized. This mechanism appears to be different from the interferon response that results from dsRNA mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III
20 enzyme referred to as dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNA). Berstein *et al.*, 2001, *Nature*, 409, 363. Short interfering RNAs derived from dicer activity are typically about 21-23 nucleotides in length and comprise about 19 base pair duplexes. Dicer has also been implicated in the excision of 21 and 22 nucleotide small temporal RNAs (stRNA) from
25 precursor RNA of conserved structure that are implicated in translational control. Hutvagner *et al.*, 2001, *Science*, 293, 834. The RNAi response also features an endonuclease complex containing a siRNA, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the
30 target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex. Elbashir *et al.*, 2001, *Genes Dev.*, 15, 188.

Short interfering RNA mediated RNAi has been studied in a variety of systems. Fire *et al.*, 1998, *Nature*, 391, 806, were the first to observe RNAi in *C. Elegans*. Wianny and Goetz, 1999, *Nature Cell Biol.*, 2, 70, describe RNAi mediated by dsRNA in mouse embryos. Hammond *et al.*, 2000, *Nature*, 404, 293, describe RNAi in *Drosophila* cells
5 transfected with dsRNA. Elbashir *et al.*, 2001, *Nature*, 411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in *Drosophila* embryonic lysates (Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877) has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate
10 efficient RNAi activity. These studies have shown that 21 nucleotide siRNA duplexes are most active when containing two nucleotide 3'-overhangs. Furthermore, complete substitution of one or both siRNA strands with 2'-deoxy (2'-H) or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of the 3'-terminal siRNA overhang nucleotides with deoxy nucleotides (2'-H) was shown to be tolerated. Single mismatch
15 sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end. Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877. Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that
20 ATP is utilized to maintain the 5'-phosphate moiety on the siRNA. Nykanen *et al.*, 2001, *Cell*, 107, 309.

Studies have shown that replacing the 3'-overhanging segments of a 21-mer siRNA duplex having 2 nucleotide 3' overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to 4 nucleotides on each end of the siRNA
25 with deoxyribonucleotides has been reported to be well tolerated whereas complete substitution with deoxyribonucleotides results in no RNAi activity. Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877. In addition, Elbashir *et al.*, *supra*, also report that substitution of siRNA with 2'-O-methyl nucleotides completely abolishes RNAi activity. Li *et al.*, WO 00/44914, and Beach *et al.*, WO 01/68836 both suggest that siRNA "may include
30 modifications to either the phosphate-sugar back bone or the nucleoside to include at least one of a nitrogen or sulfur heteroatom", however neither application teaches to what extent these modifications are tolerated in siRNA molecules nor provide any examples of such modified siRNA. Kreutzer and Limmer, Canadian Patent Application No. 2,359,180, also

describe certain chemical modifications for use in dsRNA constructs in order to counteract activation of double-stranded RNA-dependent protein kinase PKR, specifically 2'-amino or 2'-O-methyl nucleotides, and nucleotides containing a 2'-O or 4'-C methylene bridge. However, Kreutzer and Limmer similarly fail to show to what extent these modifications are tolerated in siRNA molecules nor do they provide any examples of such modified siRNA.

Parrish et al., 2000, *Molecular Cell*, 6, 1977-1087, tested certain chemical modifications targeting the *unc-22* gene in *C. elegans* using long (>25 nt) siRNA transcripts. The authors describe the introduction of thiophosphate residues into these siRNA transcripts by incorporating thiophosphate nucleotide analogs with T7 and T3 RNA polymerase and observed that "RNAs with two [phosphorothioate] modified bases also had substantial decreases in effectiveness as RNAi triggers; [phosphorothioate] modification of more than two residues greatly destabilized the RNAs in vitro and we were not able to assay interference activities." Parrish et al. at 1081. The authors also tested certain modifications at the 2'-position of the nucleotide sugar in the long siRNA transcripts and observed that substituting deoxynucleotides for ribonucleotides "produced a substantial decrease in interference activity", especially in the case of Uridine to Thymidine and/or Cytidine to deoxy-Cytidine substitutions. Parrish et al. In addition, the authors tested certain base modifications, including substituting 4-thiouracil, 5-bromouracil, 5-iodouracil, 3-(aminoallyl)uracil for uracil, and inosine for guanosine in sense and antisense strands of the siRNA, and found that whereas 4-thiouracil and 5-bromouracil were all well tolerated, inosine "produced a substantial decrease in interference activity" when incorporated in either strand. Incorporation of 5-iodouracil and 3-(aminoallyl)uracil in the antisense strand resulted in substantial decrease in RNAi activity as well.

Beach et al., WO 01/68836, describes specific methods for attenuating gene expression using endogenously derived dsRNA. Tuschl et al., WO 01/75164, describes a *Drosophila* in vitro RNAi system and the use of specific siRNA molecules for certain functional genomic and certain therapeutic applications; although Tuschl, 2001, *Chem. Biochem.*, 2, 239-245, doubts that RNAi can be used to cure genetic diseases or viral infection due "to the danger of activating interferon response". Li et al., WO 00/44914, describes the use of specific dsRNAs for use in attenuating the expression of certain target

genes. Zernicka-Goetz et al., WO 01/36646, describes certain methods for inhibiting the expression of particular genes in mammalian cells using certain dsRNA molecules. Fire et al., WO 99/32619, U.S. Patent No. 6,506,559, the contents of which are hereby incorporated by reference in their entirety, describes particular methods for introducing
5 certain dsRNA molecules into cells for use in inhibiting gene expression. Plaetinck et al., WO 00/01846, describes certain methods for identifying specific genes responsible for conferring a particular phenotype in a cell using specific dsRNA molecules. Mello et al., WO 01/29058, describes the identification of specific genes involved in dsRNA mediated RNAi. Deschamps Depaillette et al., International PCT Publication No. WO 99/07409,
10 describes specific compositions consisting of particular dsRNA molecules combined with certain anti-viral agents. Driscoll et al., International PCT Publication No. WO 01/49844, describes specific DNA constructs for use in facilitating gene silencing in targeted organisms. Parrish et al., 2000, Molecular Cell, 6, 1977-1087, describes specific chemically modified siRNA constructs targeting the unc-22 gene of *C. elegans*. Tuschl et al.,
15 International PCT Publication No. WO 02/44321, describe certain synthetic siRNA constructs.

Methods for Using Nucleic Acid Molecules as Probes and Primers

The isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize, and quantify hybridizing nucleic acids in, and
20 isolate hybridizing nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably, detectably labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

In one embodiment, the isolated nucleic acid molecules of the present invention
25 can be used as probes to detect and characterize gross alterations in the gene of a BSNA, such as deletions, insertions, translocations, and duplications of the BSNA genomic locus through fluorescence *in situ* hybridization (FISH) to chromosome spreads. *See, e.g.,* Andreeff *et al.* (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications, John Wiley & Sons (1999). The isolated nucleic acid molecules of
30 the present invention can be used as probes to assess smaller genomic alterations using, *e.g.,* Southern blot detection of restriction fragment length polymorphisms. The isolated nucleic acid molecules of the present invention can be used as probes to isolate genomic

clones that include a nucleic acid molecule of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

Alternatively, detection techniques such as molecular beacons may be used, see Kostrikis
5 *et al. Science* 279:1228-1229 (1998).

The isolated nucleic acid molecules of the present invention can also be used as probes to detect, characterize, and quantify BSNA in, and isolate BSNA from, transcript-derived nucleic acid samples. In one embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by length,
10 and quantify mRNA by Northern blot of total or poly-A⁺-selected RNA samples. In another embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by location, and quantify mRNA by *in situ* hybridization to tissue sections. See, e.g., Schwarczacher *et al.*, In Situ Hybridization, Springer-Verlag New York (2000). In another preferred embodiment, the
15 isolated nucleic acid molecules of the present invention can be used as hybridization probes to measure the representation of clones in a cDNA library or to isolate hybridizing nucleic acid molecules acids from cDNA libraries, permitting sequence level characterization of mRNAs that hybridize to BSNA, including, without limitations, identification of deletions, insertions, substitutions, truncations, alternatively spliced forms
20 and single nucleotide polymorphisms. In yet another preferred embodiment, the nucleic acid molecules of the instant invention may be used in microarrays.

All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook (2001), *supra*; Ausubel (1999), *supra*; and Walker *et al.* (eds.), The Nucleic Acids Protocols Handbook, Humana
25 Press (2000).

In another embodiment, a nucleic acid molecule of the invention may be used as a probe or primer to identify and/or amplify a second nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of the invention. In this embodiment, it is preferred that the probe or primer be derived from a nucleic acid molecule encoding a
30 BSP. More preferably, the probe or primer is derived from a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 73-179. Also preferred are probes or primers derived from a BSNA. More preferred are probes or

primers derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-72.

In general, a probe or primer is at least 10 nucleotides in length, more preferably at least 12, more preferably at least 14 and even more preferably at least 16 or 17 nucleotides in length. In an even more preferred embodiment, the probe or primer is at least 18 nucleotides in length, even more preferably at least 20 nucleotides and even more preferably at least 22 nucleotides in length. Primers and probes may also be longer in length. For instance, a probe or primer may be 25 nucleotides in length, or may be 30, 40 or 50 nucleotides in length. Methods of performing nucleic acid hybridization using oligonucleotide probes are well known in the art. *See, e.g.*, Sambrook *et al.*, 1989, *supra*, Chapter 11 and pp. 11.31-11.32 and 11.40-11.44, which describes radiolabeling of short probes, and pp. 11.45-11.53, which describe hybridization conditions for oligonucleotide probes, including specific conditions for probe hybridization (pp. 11.50-11.51).

Methods of performing primer-directed amplification are also well known in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR Basics: From Background to Bench, Springer Verlag (2000); Innis *et al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic Press (1999); Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998); Newton *et al.*, PCR, Springer-Verlag New York (1997); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996); White (ed.), PCR Cloning Protocols: From Molecular Cloning to Genetic Engineering, Vol. 67, Humana Press (1996); and McPherson *et al.* (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995). Methods for performing RT-PCR are collected, *e.g.*, in Siebert *et al.* (eds.), Gene Cloning and Analysis by RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998; and Siebert (ed.), PCR Technique: RT-PCR, Eaton Publishing Company/ BioTechniques Books (1995).

PCR and hybridization methods may be used to identify and/or isolate nucleic acid molecules of the present invention including allelic variants, homologous nucleic acid molecules and fragments. PCR and hybridization methods may also be used to identify, amplify and/or isolate nucleic acid molecules of the present invention that encode homologous proteins, analogs, fusion proteins or muteins of the invention. Nucleic acid primers as described herein can be used to prime amplification of nucleic acid molecules of the invention, using transcript-derived or genomic DNA as the template.

These nucleic acid primers can also be used, for example, to prime single base extension (SBE) for SNP detection (*See, e.g.*, U.S. Pat. No. 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

Isothermal amplification approaches, such as rolling circle amplification, are also
5 now well-described. *See, e.g.*, Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1): 21-7
(2001); International Patent publications WO 97/19193 and WO 00/15779, and U.S.
Patent Nos. 5,854,033 and 5,714,320, the disclosures of which are incorporated herein by
reference in their entireties. Rolling circle amplification can be combined with other
techniques to facilitate SNP detection. *See, e.g.*, Lizardi *et al.*, *Nature Genet.* 19(3):
10 225-32 (1998).

Nucleic acid molecules of the present invention may be bound to a substrate either
covalently or noncovalently. The substrate can be porous or solid, planar or non-planar,
unitary or distributed. The bound nucleic acid molecules may be used as hybridization
probes, and may be labeled or unlabeled. In a preferred embodiment, the bound nucleic
15 acid molecules are unlabeled.

In one embodiment, the nucleic acid molecule of the present invention is bound to
a porous substrate, *e.g.*, a membrane, typically comprising nitrocellulose, nylon, or
positively charged derivatized nylon. The nucleic acid molecule of the present invention
can be used to detect a hybridizing nucleic acid molecule that is present within a labeled
20 nucleic acid sample, *e.g.*, a sample of transcript-derived nucleic acids. In another
embodiment, the nucleic acid molecule is bound to a solid substrate, including, without
limitation, glass, amorphous silicon, crystalline silicon or plastics. Examples of plastics
include, without limitation, polymethylacrylic, polyethylene, polypropylene, polyacrylate,
polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene,
25 polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or
mixtures thereof. The solid substrate may be any shape, including rectangular, disk-like
and spherical. In a preferred embodiment, the solid substrate is a microscope slide or
slide-shaped substrate.

The nucleic acid molecule of the present invention can be attached covalently to a
30 surface of the support substrate or applied to a derivatized surface in a chaotropic agent
that facilitates denaturation and adherence by presumed noncovalent interactions, or some
combination thereof. The nucleic acid molecule of the present invention can be bound to a
substrate to which a plurality of other nucleic acids are concurrently bound, hybridization

to each of the plurality of bound nucleic acids being separately detectable. At low density, *e.g.* on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such as glass, these substrate bound collections of plural nucleic acids are colloquially termed microarrays. As used
5 herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that comprise one or more of the nucleic acid molecules of the present invention.

In yet another embodiment, the invention is directed to single exon probes based on the BSNA's disclosed herein.

10 *Expression Vectors, Host Cells and Recombinant Methods of Producing Polypeptides*

Another aspect of the present invention provides vectors that comprise one or more of the isolated nucleic acid molecules of the present invention, and host cells in which such vectors have been introduced.

15 The vectors can be used, *inter alia*, for propagating the nucleic acid molecules of the present invention in host cells (cloning vectors), for shuttling the nucleic acid molecules of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acid molecules of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of
20 the nucleic acid molecules of the present invention *in vitro* or within a host cell, and for expressing polypeptides encoded by the nucleic acid molecules of the present invention, alone or as fusion proteins with heterologous polypeptides (expression vectors). Vectors are by now well known in the art, and are described, *inter alia*, in Jones *et al.* (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John
25 Wiley & Son Ltd. (1998); Jones *et al.* (eds.), Vectors: Expression Systems: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Gacesa *et al.*, Vectors: Essential Data, John Wiley & Sons Ltd. (1995); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co. (2000); Sambrook (2001), *supra*; Ausubel (1999), *supra*. Furthermore, a variety of vectors are available
30 commercially. Use of existing vectors and modifications thereof are well within the skill in the art. Thus, only basic features need be described here.

Nucleic acid sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Expression control sequences are sequences that control the transcription, post-transcriptional events and translation of nucleic acid sequences. Such operative linking of a nucleic acid sequence of this invention to an expression control sequence, of course, includes, if not already part of the nucleic acid sequence, the provision of a translation initiation codon, ATG or GTG, in the correct reading frame upstream of the nucleic acid sequence.

A wide variety of host/expression vector combinations may be employed in expressing the nucleic acid sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic nucleic acid sequences.

In one embodiment, prokaryotic cells may be used with an appropriate vector. Prokaryotic host cells are often used for cloning and expression. In a preferred embodiment, prokaryotic host cells include *E. coli*, *Pseudomonas*, *Bacillus* and *Streptomyces*. In a preferred embodiment, bacterial host cells are used to express the nucleic acid molecules of the instant invention. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, *Bacillus* or *Streptomyces*, including pBluescript, pGEX-2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their derivatives, wider host range plasmids, such as RP4, phage DNAs, *e.g.*, the numerous derivatives of phage lambda, *e.g.*, NM989, λ GT10 and λ GT11, and other phages, *e.g.*, M13 and filamentous single stranded phage DNA. Where *E. coli* is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: *e.g.*, typical markers confer resistance to antibiotics, such as ampicillin, tetracycline, chloramphenicol, kanamycin, streptomycin and zeocin; auxotrophic markers can also be used.

In other embodiments, eukaryotic host cells, such as yeast, insect, mammalian or plant cells, may be used. Yeast cells, typically *S. cerevisiae*, are useful for eukaryotic genetic studies, due to the ease of targeting genetic changes by homologous recombination and the ability to easily complement genetic defects using recombinantly expressed proteins. Yeast cells are useful for identifying interacting protein components, *e.g.* through use of a two-hybrid system. In a preferred embodiment, yeast cells are useful for protein expression. Vectors of the present invention for use in yeast will typically, but not

invariably, contain an origin of replication suitable for use in yeast and a selectable marker that is functional in yeast. Yeast vectors include Yeast Integrating plasmids (*e.g.*, YIp5) and Yeast Replicating plasmids (the YRp and YEplac series plasmids), Yeast Centromere plasmids (the YCp series plasmids), Yeast Artificial Chromosomes (YACs) which are
5 based on yeast linear plasmids, denoted YLp, pGPD-2, 2 μ plasmids and derivatives thereof, and improved shuttle vectors such as those described in Gietz *et al.*, *Gene*, 74: 527-34 (1988) (YIplac, YEplac and YCplac). Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific
10 auxotrophic mutations, such as *ura3-52*, *his3-D1*, *leu2-D1*, *trp1-D1* and *lys2-201*.

Insect cells may be chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda*, *e.g.*, Sf9 and Sf21 cell lines, and expresSFTM cells (Protein Sciences Corp., Meriden, CT, USA), the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors are used to
15 replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following co-transfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10
20 promoter. Selection can be based upon visual screening for lacZ fusion activity.

The host cells may also be mammalian cells, which are particularly useful for expression of proteins intended as pharmaceutical agents, and for screening of potential agonists and antagonists of a protein or a physiological pathway. Mammalian vectors intended for autonomous extrachromosomal replication will typically include a viral
25 origin, such as the SV40' origin (for replication in cell lines expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, *e.g.*, in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A). Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an
30 origin of replication functional in mammalian cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy. Selectable markers for use in mammalian cells include, but are not limited to,

resistance to neomycin (G418), blasticidin, hygromycin and zeocin, and selection based upon the purine salvage pathway using HAT medium.

Expression in mammalian cells can be achieved using a variety of plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (*e.g.*, vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (*e.g.*, bovine papillomavirus), and retroviral vectors (*e.g.*, murine retroviruses). Useful vectors for insect cells include baculoviral vectors and pVL 941.

Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

It is known that codon usage of different host cells may be different. For example, a plant cell and a human cell may exhibit a difference in codon preference for encoding a particular amino acid. As a result, human mRNA may not be efficiently translated in a plant, bacteria or insect host cell. Therefore, another embodiment of this invention is directed to codon optimization. The codons of the nucleic acid molecules of the invention may be modified to resemble, as much as possible, genes naturally contained within the host cell without altering the amino acid sequence encoded by the nucleic acid molecule.

Any of a wide variety of expression control sequences may be used in these vectors to express the nucleic acid molecules of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Expression control sequences that control transcription include, *e.g.*, promoters, enhancers and transcription termination sites. Expression control sequences in eukaryotic cells that control post-transcriptional events include splice donor and acceptor sites and sequences that modify the half-life of the transcribed RNA, *e.g.*, sequences that direct poly(A) addition or binding sites for RNA-binding proteins. Expression control sequences that control translation include ribosome binding sites, sequences which direct targeted expression of the polypeptide to or within particular cellular compartments, and sequences in the 5' and 3' untranslated regions that modify the rate or efficiency of translation.

Examples of useful expression control sequences for a prokaryote, *e.g.*, *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the *trc* promoter, a hybrid derived from the *trp* and *lac* promoters, the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), the TAC or TRC

system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, and the araBAD operon. Prokaryotic expression vectors may further include transcription terminators, such as the aspA terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon, Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8506-8510 (1986).

Expression control sequences for yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the CYC1 promoter, the GAL1 promoter, the GAL10 promoter, ADH1 promoter, the promoters of the yeast α -mating system, or the GPD promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the CYC1 or ADH1 gene.

Expression vectors useful for expressing proteins in mammalian cells will include a promoter active in mammalian cells. These promoters include, but are not limited to, those derived from mammalian viruses, such as the enhancer-promoter sequences from the immediate early gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), the enhancer-promoter from SV40 and the early and late promoters of adenovirus. Other expression control sequences include the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase. Other expression control sequences include those from the gene comprising the BSNA of interest. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include introns, such as intron II of rabbit β -globin gene and the SV40 splice elements.

Preferred nucleic acid vectors also include a selectable or amplifiable marker gene and means for amplifying the copy number of the gene of interest. Such marker genes are well known in the art. Nucleic acid vectors may also comprise stabilizing sequences (*e.g.*, ori- or ARS-like sequences and telomere-like sequences), or may alternatively be designed to favor directed or non-directed integration into the host cell genome. In a preferred embodiment, nucleic acid sequences of this invention are inserted in frame into an expression vector that allows a high level expression of an RNA which encodes a protein comprising the encoded nucleic acid sequence of interest. Nucleic acid cloning and sequencing methods are well known to those of skill in the art and are described in an assortment of laboratory manuals, including Sambrook (1989), *supra*, Sambrook (2000),

supra; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. Product information from manufacturers of biological, chemical and immunological reagents also provide useful information.

Expression vectors may be either constitutive or inducible. Inducible vectors
5 include either naturally inducible promoters, such as the *trc* promoter, which is regulated by the *lac* operon, and the *pL* promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid *Plac/ara-1* promoter and the
10 *PLtetO-1* promoter. The *PLtetO-1* promoter takes advantage of the high expression levels from the *PL* promoter of phage lambda, but replaces the lambda repressor sites with two copies of operator 2 of the *Tn10* tetracycline resistance operon, causing this promoter to be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline. Vectors may also be inducible
15 because they contain hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), which can confer hormone inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

20 In one embodiment of the invention, expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or visualization. Such tags include a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography
25 medium, Clontech Labs, Palo Alto, CA, USA). The fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverly, MA, USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically
30 excisable fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, WI, USA). As another useful alternative, the polypeptides of the present invention can be expressed as a fusion to glutathione-S-transferase, the affinity and

specificity of binding to glutathione permitting purification using glutathione affinity resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione. Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a
5 myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, CA, USA), and the HA epitope, detectable by anti-HA antibody.

For secretion of expressed polypeptides, vectors can include appropriate sequences
10 that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2 kb mammalian expression vectors that carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

Expression vectors can also be designed to fuse proteins encoded by the
15 heterologous nucleic acid insert to polypeptides that are larger than purification and/or identification tags. Useful protein fusions include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusions for use in two hybrid systems.

20 Vectors for phage display fuse the encoded polypeptide to, *e.g.*, the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. *See* Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc., (1996); Abelson *et al.* (eds.), Combinatorial
25 Chemistry (Methods in Enzymology, Vol. 267) Academic Press (1996). Vectors for yeast display, *e.g.* the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the α -agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S. cerevisiae*. Vectors for mammalian display, *e.g.*, the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface
30 targeting signal and a C-terminal transmembrane anchoring domain of platelet derived growth factor receptor.

A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent

green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), 5 FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. *See Li et al., J. Biol. Chem.* 272: 28545-28549 (1997). Alternatively, the GFP-like chromophore can be 10 selected from GFP-like chromophores modified from those found in nature. The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of protein fusions, are well known in the art. *See Heim et al., Curr. Biol.* 6: 178-182 (1996) and Palm *et al., Methods Enzymol.* 302: 378-394 (1999). A variety of such modified chromophores are now commercially available and can readily 15 be used in the fusion proteins of the present invention. These include EGFP ("enhanced GFP"), EBFP ("enhanced blue fluorescent protein"), BFP2, EYFP ("enhanced yellow fluorescent protein"), ECFP ("enhanced cyan fluorescent protein") or Citrine. EGFP (*see, e.g., Cormack et al., Gene* 173: 33-38 (1996); U.S. Patent Nos. 6,090,919 and 5,804,387, the disclosures of which are incorporated herein by reference in their entireties) is found 20 on a variety of vectors, both plasmid and viral, which are available commercially (Clontech Labs, Palo Alto, CA, USA); EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria (*see, e.g., Heim et al., Curr. Biol.* 6: 178-182 (1996) and Cormack *et al., Gene* 173: 33-38 (1996)). Vectors containing these blue-shifted variants are available from 25 Clontech Labs (Palo Alto, CA, USA). Vectors containing EYFP, ECFP (*see, e.g., Heim et al., Curr. Biol.* 6: 178-182 (1996); Miyawaki *et al., Nature* 388: 882-887 (1997)) and Citrine (*see, e.g., Heikal et al., Proc. Natl. Acad. Sci. USA* 97: 11996-12001 (2000)) are also available from Clontech Labs. The GFP-like chromophore can also be drawn from other modified GFPs, including those described in U.S. Patent Nos. 6,124,128; 6,096,865; 30 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. *See also Conn (ed.), Green Fluorescent Protein* (Methods in Enzymology, Vol. 302), Academic Press, Inc. (1999); Yang, *et al., J Biol Chem*, 273: 8212-6 (1998);

Bevis *et al.*, *Nature Biotechnology*, 20:83-7 (2002). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

5 Fusions to the IgG Fc region increase serum half-life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in International Patent Application Nos. WO 97/43316, WO 97/34631, WO 96/32478, and WO 96/18412, the disclosures of which are incorporated herein by reference in their entireties.

10 For long-term, high-yield recombinant production of the polypeptides of the present invention, stable expression is preferred. Stable expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection of these integrants. Vectors such as pUB6/V5-His A, B, and C (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and cell lines. pUB6/V5-His uses the
15 promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The bsd gene permits rapid selection of stably transfected mammalian cells with the potent antibiotic blasticidin.

Replication incompetent retroviral vectors, typically derived from Moloney murine
20 leukemia virus, also are useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines such as RetroPack™ PT 67, EcoPack2™-293, AmphoPack-293, and GP2-293 cell lines (all available from Clontech Laboratories, Palo Alto, CA, USA) allow a wide host range to be infected with high efficiency; varying the
25 multiplicity of infection readily adjusts the copy number of the integrated provirus.

Of course, not all vectors and expression control sequences will function equally well to express the nucleic acid molecules of this invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue
30 experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must be replicated in it. The vector's copy number, the ability to control that copy number, the ability to control integration, if any, and the expression of any other proteins encoded by the vector, such as

an antibiotic or other selection marker, should also be considered. The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into the host cell chromosome. Among other considerations, some of which are described above, a host cell strain may be
5 chosen for its ability to process the expressed polypeptide in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation, and it is an aspect of the present invention to provide BSPs with such post-translational modifications.

10 In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the nucleic acid molecules of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the
15 product coded for by the nucleic acid sequences of this invention, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the nucleic acid molecules of this invention.

The recombinant nucleic acid molecules and more particularly, the expression
20 vectors of this invention may be used to express the polypeptides of this invention as recombinant polypeptides in a heterologous host cell. The polypeptides of this invention may be full-length or less than full-length polypeptide fragments recombinantly expressed from the nucleic acid molecules according to this invention. Such polypeptides include analogs, derivatives and muteins that may or may not have biological activity.

25 Vectors of the present invention will also often include elements that permit *in vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

30 Transformation and other methods of introducing nucleic acids into a host cell (*e.g.*, conjugation, protoplast transformation or fusion, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion) can be accomplished by a variety of methods which are

well known in the art (*See*, for instance, Ausubel, *supra*, and Sambrook *et al.*, *supra*). Bacterial, yeast, plant or mammalian cells are transformed or transfected with an expression vector, such as a plasmid, a cosmid, or the like, wherein the expression vector comprises the nucleic acid of interest. Alternatively, the cells may be infected by a viral expression vector comprising the nucleic acid of interest. Depending upon the host cell, vector, and method of transformation used, transient or stable expression of the polypeptide will be constitutive or inducible. One having ordinary skill in the art will be able to decide whether to express a polypeptide transiently or stably, and whether to express the protein constitutively or inducibly.

10 A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of, fungi, yeast, insect cells such as *Spodoptera frugiperda* (SF9), animal cells such as CHO, as well as plant cells in tissue culture. Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from *Spodoptera frugiperda*, *e.g.*, Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA), *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells
15 (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include BHK cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, COS1 cells, COS7 cells, Chinese hamster ovary (CHO) cells, 3T3 cells, NIH 3T3 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, MDCK cells, HEK293 cells, WI38 cells, murine ES cell lines (*e.g.*, from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562 cells, Jurkat cells, and
20 BW5147 cells. Other mammalian cell lines are well known and readily available from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA). Cells or cell lines derived from breast are particularly preferred because they may provide a more native post-translational
25 processing. Particularly preferred are human breast cells.

Particular details of the transfection, expression and purification of recombinant proteins are well documented and are understood by those of skill in the art. Further details on the various technical aspects of each of the steps used in recombinant

production of foreign genes in bacterial cell expression systems can be found in a number of texts and laboratory manuals in the art. *See, e.g.*, Ausubel (1992), *supra*, Ausubel (1999), *supra*, Sambrook (1989), *supra*, and Sambrook (2001), *supra*.

5 Methods for introducing the vectors and nucleic acid molecules of the present invention into the host cells are well known in the art; the choice of technique will depend primarily upon the specific vector to be introduced and the host cell chosen.

Nucleic acid molecules and vectors may be introduced into prokaryotes, such as *E. coli*, in a number of ways. For instance, phage lambda vectors will typically be packaged using a packaging extract (*e.g.*, Gigapack® packaging extract, Stratagene, La Jolla, CA, USA), and the packaged virus used to infect *E. coli*.

10 Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells. *E. coli* cells can be rendered chemically competent by treatment, *e.g.*, with CaCl_2 , or a solution of Mg^{2+} , Mn^{2+} , Ca^{2+} , Rb^+ or K^+ , dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent strains are also available commercially (*e.g.*, Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5α competent cells (Clontech Laboratories, Palo Alto, CA, USA); and TOP10 Chemically Competent *E. coli* Kit (Invitrogen, Carlsbad, CA, USA)). Bacterial cells can be rendered electrocompetent to take up exogenous DNA by electroporation by various pre-pulse treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided by BioRad (Richmond, CA, USA).

25 Vectors can be introduced into yeast cells by spheroplasting, treatment with lithium salts, electroporation, or protoplast fusion. Spheroplasts are prepared by the action of hydrolytic enzymes such as a snail-gut extract, usually denoted Glusulase or Zymolyase, or an enzyme from *Arthrobacter luteus* to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol (PEG) and Ca^{2+} . Subsequently, the cells are resuspended in a solution of sorbitol, mixed with molten agar and then layered on the surface of a selective plate containing sorbitol.

30 For lithium-mediated transformation, yeast cells are treated with lithium acetate to permeabilize the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of PEG and lithium acetate, and

subsequently spread on plates containing ordinary selective medium. Increased frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6): 339-46 (1989).

5 For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194: 182-187 (1991). The efficiency of transformation by electroporation can be increased over 100-fold by
10 using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means. For chemical transfection, DNA can be coprecipitated with CaPO₄ or introduced using liposomal and nonliposomal lipid-based
15 agents. Commercial kits are available for CaPO₄ transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN® Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent,
20 FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA). Protocols for electroporating mammalian cells can be found in, for example, ; Norton *et al.* (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000). Other transfection techniques
25 include transfection by particle bombardment and microinjection. See, e.g., Cheng *et al.*, *Proc. Natl. Acad. Sci. USA* 90(10): 4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA* 87(24): 9568-72 (1990).

Production of the recombinantly produced proteins of the present invention can optionally be followed by purification.

30 Purification of recombinantly expressed proteins is now well within the skill in the art and thus need not be detailed here. See, e.g., Thorner *et al.* (eds.), Applications of Chimeric Genes and Hybrid Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Vol. 326), Academic Press (2000); Harbin (ed.), Cloning, Gene

Expression and Protein Purification : Experimental Procedures and Process Rationale, Oxford Univ. Press (2001); Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996); and Roe (ed.), Protein Purification Applications, Oxford University Press (2001).

5 Briefly, however, if purification tags have been fused through use of an expression vector that appends such tag, purification can be effected, at least in part, by means appropriate to the tags, such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high
10 performance liquid chromatography (HPLC), and preparative gel electrophoresis.

Polypeptides, including Fragments Muteins, Homologous Proteins, Allelic Variants, Analogs and Derivatives

Another aspect of the invention relates to polypeptides encoded by the nucleic acid molecules described herein. In a preferred embodiment, the polypeptide is a breast
15 specific polypeptide (BSP). In an even more preferred embodiment, the polypeptide comprises an amino acid sequence of SEQ ID NO: 73-179 or is derived from a polypeptide having the amino acid sequence of SEQ ID NO: 73-179. A polypeptide as defined herein may be produced recombinantly, as discussed *supra*, may be isolated from a cell that naturally expresses the protein, or may be chemically synthesized following the teachings
20 of the specification and using methods well known to those having ordinary skill in the art.

Polypeptides of the present invention may also comprise a part or fragment of a BSP. In a preferred embodiment, the fragment is derived from a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 73-179. Polypeptides of the present invention comprising a part or fragment of an entire BSP may
25 or may not be BSPs. For example, a full-length polypeptide may be breast-specific, while a fragment thereof may be found in other tissues as well as in breast. A polypeptide that is not a BSP, whether it is a fragment, analog, mutein, homologous protein or derivative, is nevertheless useful, especially for immunizing animals to prepare anti-BSP antibodies. In a preferred embodiment, the part or fragment is a BSP. Methods of determining whether a
30 polypeptide of the present invention is a BSP are described *infra*.

Polypeptides of the present invention comprising fragments of at least 6 contiguous amino acids are also useful in mapping B cell and T cell epitopes of the

reference protein. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA* 81: 3998-4002 (1984) and U.S. Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native
5 antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of a polypeptide of the present invention have utility in such a study.

Polypeptides of the present invention comprising fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, are useful as immunogens for raising antibodies that recognize polypeptides of the present invention.
10 *See, e.g., Lerner, Nature* 299: 592-596 (1982); Shinnick *et al., Annu. Rev. Microbiol.* 37: 425-46 (1983); Sutcliffe *et al., Science* 219: 660-6 (1983). As further described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein, prove immunogenic and are capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the polypeptides of the present
15 invention have utility as immunogens.

Polypeptides comprising fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as competitive inhibitors of binding of the entire polypeptide, or a portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein;
20 this competitive inhibition permits identification and separation of molecules that bind specifically to the polypeptide of interest. *See* U.S. Patent Nos. 5,539,084 and 5,783,674, incorporated herein by reference in their entireties.

The polypeptide of the present invention thus preferably is at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15 amino
25 acids in length. Often, the polypeptide of the present invention is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids, or 50 amino acids or more in length. Of course, larger polypeptides having at least 75 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

One having ordinary skill in the art can produce fragments by truncating the
30 nucleic acid molecule, *e.g.,* a BSNA, encoding the polypeptide and then expressing it recombinantly. Alternatively, one can produce a fragment by chemically synthesizing a portion of the full-length polypeptide. One may also produce a fragment by enzymatically cleaving either a recombinant polypeptide or an isolated naturally occurring polypeptide.

Methods of producing polypeptide fragments are well known in the art. *See, e.g.*, Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. In one embodiment, a polypeptide comprising only a fragment, preferably a fragment of a BSP, may be produced by chemical or enzymatic cleavage of a BSP polypeptide. In a preferred embodiment, a polypeptide fragment is produced by expressing a nucleic acid molecule of the present invention encoding a fragment, preferably of a BSP, in a host cell.

Polypeptides of the present invention are also inclusive of mutants, fusion proteins, homologous proteins and allelic variants.

10 A mutant protein, or mutein, may have the same or different properties compared to a naturally occurring polypeptide and comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of a native polypeptide. Small deletions and insertions can often be found that do not alter the function of a protein. Muteins may or may not be breast-specific. Preferably, the
15 mutein is breast-specific. More preferably the mutein is a polypeptide that comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of SEQ ID NO: 73-179. Accordingly, in a preferred embodiment, the mutein is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more
20 preferably at least 80% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 73-179. In a yet more preferred embodiment, the mutein exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97%, 98%, 99% or 99.5% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 73-179.

25 A mutein may be produced by isolation from a naturally occurring mutant cell, tissue or organism. A mutein may be produced by isolation from a cell, tissue or organism that has been experimentally mutagenized. Alternatively, a mutein may be produced by chemical manipulation of a polypeptide, such as by altering the amino acid residue to another amino acid residue using synthetic or semi-synthetic chemical techniques. In a
30 preferred embodiment, a mutein is produced from a host cell comprising a mutated nucleic acid molecule compared to the naturally occurring nucleic acid molecule. For instance, one may produce a mutein of a polypeptide by introducing one or more mutations into a nucleic acid molecule of the invention and then expressing it recombinantly. These

mutations may be targeted, in which particular encoded amino acids are altered, or may be untargeted, in which random encoded amino acids within the polypeptide are altered. Muteins with random amino acid alterations can be screened for a particular biological activity or property, particularly whether the polypeptide is breast-specific, as described below. Multiple random mutations can be introduced into the gene by methods well known to the art, *e.g.*, by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis and site-specific mutagenesis. Methods of producing muteins with targeted or random amino acid alterations are well known in the art. *See, e.g.*, Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), as well as U.S. Patent No. 5,223,408, which is herein incorporated by reference in its entirety.

The invention also contemplates polypeptides that are homologous to a polypeptide of the invention. In a preferred embodiment, the polypeptide is homologous to a BSP. In an even more preferred embodiment, the polypeptide is homologous to a BSP selected from the group having an amino acid sequence of SEQ ID NO: 73-179. By homologous polypeptide it is meant one that exhibits significant sequence identity to a BSP, preferably a BSP having an amino acid sequence of SEQ ID NO: 73-179. By significant sequence identity it is meant that the homologous polypeptide exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 73-179. More preferred are homologous polypeptides exhibiting at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97% or 98% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 73-179. Most preferably, the homologous polypeptide exhibits at least 99%, more preferably 99.5%, even more preferably 99.6%, 99.7%, 99.8% or 99.9% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 73-179. In a preferred embodiment, the amino acid substitutions of the homologous polypeptide are conservative amino acid substitutions as discussed *supra*.

Homologous polypeptides of the present invention also comprise polypeptides encoded by a nucleic acid molecule that selectively hybridizes to a BSNA or an antisense sequence thereof. In this embodiment, it is preferred that the homologous polypeptide be

encoded by a nucleic acid molecule that hybridizes to a BSNA under low stringency, moderate stringency or high stringency conditions, as defined herein. More preferred is a homologous polypeptide encoded by a nucleic acid sequence which hybridizes to a BSNA selected from the group consisting of SEQ ID NO: 1-72 or a homologous polypeptide
5 encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule that encodes a BSP, preferably a BSP of SEQ ID NO:73-179 under low stringency, moderate stringency or high stringency conditions, as defined herein.

Homologous polypeptides of the present invention may be naturally occurring and derived from another species, especially one derived from another primate, such as
10 chimpanzee, gorilla, rhesus macaque, or baboon, wherein the homologous polypeptide comprises an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 73-179. The homologous polypeptide may also be a naturally occurring polypeptide from a human, when the BSP is a member of a family of polypeptides. The homologous polypeptide may also be a naturally occurring polypeptide derived from a
15 non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, guinea pig, hamster, cow, horse, goat or pig. The homologous polypeptide may also be a naturally occurring polypeptide derived from a non-mammalian species, such as birds or reptiles. The naturally occurring homologous protein may be isolated directly from humans or other species. Alternatively, the nucleic acid molecule
20 encoding the naturally occurring homologous polypeptide may be isolated and used to express the homologous polypeptide recombinantly. The homologous polypeptide may also be one that is experimentally produced by random mutation of a nucleic acid molecule and subsequent expression of the nucleic acid molecule. Alternatively, the homologous polypeptide may be one that is experimentally produced by directed mutation
25 of one or more codons to alter the encoded amino acid of a BSP. In a preferred embodiment, the homologous polypeptide encodes a polypeptide that is a BSP.

Relatedness of proteins can also be characterized using a second functional test, such as the ability of a first protein competitively to inhibit the binding of a second protein to an antibody. It is, therefore, another aspect of the present invention to provide isolated
30 polypeptides not only identical in sequence to those described with particularity herein, but also to provide isolated polypeptides ("cross-reactive proteins") that competitively inhibit the binding of antibodies to all or to a portion of the isolated polypeptides of the

present invention. Such competitive inhibition can readily be determined using immunoassays well known in the art.

As discussed above, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes, and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Thus, polypeptides of the present invention are also inclusive of those encoded by an allelic variant of a nucleic acid molecule encoding a BSP. In this embodiment, it is preferred that the polypeptide be encoded by an allelic variant of a gene that encodes a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 73-179. More preferred is that the polypeptide be encoded by an allelic variant of a gene that has the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-72.

Polypeptides of the present invention are also inclusive of derivative polypeptides encoded by a nucleic acid molecule according to the instant invention. In this embodiment, it is preferred that the polypeptide be a BSP. Also preferred are derivative polypeptides having an amino acid sequence selected from the group consisting of SEQ ID NO: 73-179 and which has been acetylated, carboxylated, phosphorylated, glycosylated, ubiquitinated or post-translationally modified in another manner. In another preferred embodiment, the derivative has been labeled with, *e.g.*, radioactive isotopes such as ^{125}I , ^{32}P , ^{35}S , and ^3H . In another preferred embodiment, the derivative has been labeled with fluorophores, chemiluminescent agents, enzymes, and antiligands that can serve as specific binding pair members for a labeled ligand.

Polypeptide modifications are well known to those of skill and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as, for instance Creighton, Protein Structure and Molecular Properties, 2nd ed., W. H. Freeman and Company (1993). Many detailed reviews are available on this subject, such as, for example, those provided by Wold, in Johnson (ed.), Posttranslational Covalent Modification of Proteins, pgs. 1-12, Academic Press (1983); Seifter *et al.*, *Meth. Enzymol.* 182: 626-646 (1990) and Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663: 48-62 (1992).

One may determine whether a polypeptide of the invention is likely to be post-translationally modified by analyzing the sequence of the polypeptide to determine if there

are peptide motifs indicative of sites for post-translational modification. There are a number of computer programs that permit prediction of post-translational modifications. See, e.g., expasy.org (accessed November 11, 2002) of the world wide web, which includes PSORT, for prediction of protein sorting signals and localization sites, SignalP, for prediction of signal peptide cleavage sites, MITOPROT and Predotar, for prediction of mitochondrial targeting sequences, NetOGlyc, for prediction of type O-glycosylation sites in mammalian proteins, big-PI Predictor and DGPI, for prediction of prenylation-anchor and cleavage sites, and NetPhos, for prediction of Ser, Thr and Tyr phosphorylation sites in eukaryotic proteins. Other computer programs, such as those included in GCG, also may be used to determine post-translational modification peptide motifs.

General examples of types of post-translational modifications include, but are not limited to: (Z)-dehydrobutyrine; 1-chondroitin sulfate-L-aspartic acid ester; 1'-glycosyl-L-tryptophan; 1'-phospho-L-histidine; 1-thioglycine; 2'-(S-L-cysteinyl)-L-histidine; 2'-[3-carboxamido (trimethylammonio)propyl]-L-histidine; 2'-alpha-mannosyl-L-tryptophan; 2-methyl-L-glutamine; 2-oxobutanoic acid; 2-pyrrolidone carboxylic acid; 3'-(1'-L-histidyl)-L-tyrosine; 3'-(8alpha-FAD)-L-histidine; 3'-(S-L-cysteinyl)-L-tyrosine; 3', 3'', 5'-triiodo-L-thyronine; 3'-4'-phospho-L-tyrosine; 3-hydroxy-L-proline; 3'-methyl-L-histidine; 3-methyl-L-lanthionine; 3'-phospho-L-histidine; 4'-(L-tryptophan)-L-tryptophyl quinone; 42 N-cysteinyl-glycosylphosphatidylinositoethanolamine; 43 -(T-L-histidyl)-L-tyrosine; 4-hydroxy-L-arginine; 4-hydroxy-L-lysine; 4-hydroxy-L-proline; 5'-(N6-L-lysine)-L-topaquinone; 5-hydroxy-L-lysine; 5-methyl-L-arginine; alpha-I-microglobulin-Ig alpha complex chromophore; bis-L-cysteinyl bis-L-histidino diiron disulfide; bis-L--cysteinyl-L-N3'-histidino-L-serinyI tetrairon' tetrasulfide; chondroitin sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; D-alanine; D-allo-isoleucine; D-asparagine; 25 dehydroalanine; dehydrotyrosine; dermatan 4-sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; D-glucuronyl-N-glycine; dipyrrolylmethanemethyl-L-cysteine; D-leucine; D-methionine; D-phenylalanine; D-serine; D-tryptophan; glycine amide; glycine oxazolecarboxylic acid; glycine thiazolecarboxylic acid; heme P450-bis-L-cysteine-L-tyrosine; heme-bis-L-cysteine; hemediol-L-aspartyl ester-L-glutamyl ester; 30 hemediol-L-aspartyl ester-L-glutamyl ester-L-methionine sulfonium; heme-L-cysteine; heme-L-histidine; heparan sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; heme P450-bis-L-cysteine-L-lysine; hexakis-L-cysteinyl hexairon hexasulfide; keratan sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-threonine; L

oxoalanine- lactic acid; L phenyllactic acid; l'-(8alpha-FAD)-L-histidine; L-2'.4',5'-
 topaquinone; L-3',4'-dihydroxyphenylalanine; L-3'.4'.5'-trihydroxyphenylalanine; L-4'-
 bromophenylalanine; L-6'-bromotryptophan; L-alanine amide; L-alanyl imidazolinone
 glycine; L-allysine; L-arginine amide; L-asparagine amide; L-aspartic 4-phosphoric
 5 anhydride; L-aspartic acid 1-amide; L-beta-methylthioaspartic acid; L-bromohistidine; L-
 citrulline; L-cysteine amide; L-cysteine glutathione disulfide; L-cysteine methyl disulfide;
 L-cysteine methyl ester; L-cysteine oxazolecarboxylic acid; L-cysteine
 oxazolinecarboxylic acid; L-cysteine persulfide; L-cysteine sulfenic acid; L-cysteine
 sulfinic acid; L-cysteine thiazolecarboxylic acid; L-cysteinyl homocitryl molybdenum-
 10 heptairon-nonasulfide; L-cysteinyl imidazolinone glycine; L-cysteinyl molybdopterin; L-
 cysteinyl molybdopterin guanine dinucleotide; L-cystine; L-erythro-beta-
 hydroxyasparagine; L-erythro-beta-hydroxyaspartic acid; L-gamma-carboxyglutamic acid;
 L-glutamic acid 1-amide; L-glutamic acid 5-methyl ester; L-glutamine amide; L-glutamyl
 5-glycerylphosphorylethanolamine; L-histidine amide; L-isoglutamyl-polyglutamic acid;
 15 L-isoglutamyl-polyglycine; L-isoleucine amide; L-lanthionine; L-leucine amide; L-lysine
 amide; L-lysine thiazolecarboxylic acid; L-lysinoalanine; L-methionine amide; L-
 methionine sulfone; L-phenylalanine thiazolecarboxylic acid; L-phenylalanine amide; L-
 proline amide; L-selenocysteine; L-selenocysteinyl molybdopterin guanine dinucleotide;
 L-serine amide; L-serine thiazolecarboxylic acid; L-seryl imidazolinone glycine; L-T-
 20 bromophenylalanine; L-T-bromophenylalanine; L-threonine amide; L-thyroxine; L-
 tryptophan amide; L-tryptophyl quinone; L-tyrosine amide; L-valine amide; meso-
 lanthionine; N-(L-glutamyl)-L-tyrosine; N-(L-isoaspartyl)-glycine; N-(L-isoaspartyl)-L-
 cysteine; N,N,N-trimethyl-L-alanine; N,N-dimethyl-L-proline; N2-acetyl-L-lysine; N2-
 succinyl-L-tryptophan; N4-(ADP-ribosyl)-L-asparagine; N4-glycosyl-L-asparagine; N4-
 25 hydroxymethyl-L-asparagine; N4-methyl-L-asparagine; N5-methyl-L-glutamine; N6- 1 -
 carboxyethyl-L-lysine; N6-(4-amino hydroxybutyl)-L-lysine; N6-(L-isoglutamyl)-L-
 lysine; N6-(phospho-5'-adenosine)-L-lysine; N6-(phospho-5'-guanosine)-L-lysine;
 N6,N6,N6-trimethyl-L-lysine; N6,N6-dimethyl-L-lysine; N6-acetyl-L-lysine; N6-biotinyl-
 L-lysine; N6-carboxy-L-lysine; N6-formyl-L-lysine; N6-glycyl-L-lysine; N6-lipoyl-L-
 30 lysine; N6-methyl-L-lysine; N6-methyl-N6-poly(N-methyl-propylamine)-L-lysine; N6-
 mureinyl-L-lysine; N6-myristoyl-L-lysine; N6-palmitoyl-L-lysine; N6-pyridoxal
 phosphate-L-lysine; N6-pyruvic acid 2-iminyl-L-lysine; N6-retinal-L-lysine; N-
 acetyl glycine; N-acetyl-L-glutamine; N-acetyl-L-alanine; N-acetyl-L-aspartic acid; N-

acetyl-L-cysteine; N-acetyl-L-glutamic acid; N-acetyl-L-isoleucine; N-acetyl-L-methionine; N-acetyl-L-proline; N-acetyl-L-serine; N-acetyl-L-threonine; N-acetyl-L-tyrosine; N-acetyl-L-valine; N-alanyl-glycosylphosphatidylinositoethanolamine; N-asparaginyl-glycosylphosphatidylinositoethanolamine; N-aspartyl-

5 glycosylphosphatidylinositoethanolamine; N-formylglycine; N-formyl-L-methionine; N-glycyl-glycosylphosphatidylinositoethanolamine; N-L-glutamyl-poly-L-glutamic acid; N-methylglycine; N-methyl-L-alanine; N-methyl-L-methionine; N-methyl-L-phenylalanine; N-myristoyl-glycine; N-palmitoyl-L-cysteine; N-pyruvic acid 2-iminyl-L-cysteine; N-pyruvic acid 2-iminyl-L-valine; N-seryl-glycosylphosphatidylinositoethanolamine; N-

10 seryl-glycosylphosphatidylinositoethanolamine; O-(ADP-ribosyl)-L-serine; O-(phospho-5'-adenosine)-L-threonine; O-(phospho-5'-DNA)-L-serine; O-(phospho-5'-DNA)-L-threonine; O-(phospho-5'rRNA)-L-serine; O-(phosphoribosyl dephospho-coenzyme A)-L-serine; O-(sn-1-glycerophosphoryl)-L-serine; O4'-(8alpha-FAD)-L-tyrosine; O4'-(phospho-5'-adenosine)-L-tyrosine; O4'-(phospho-5'-DNA)-L-tyrosine; O4'-(phospho-5'-RNA)-L-

15 tyrosine; O4'-(phospho-5'-uridine)-L-tyrosine; O4-glycosyl-L-hydroxyproline; O4'-glycosyl-L-tyrosine; O4'-sulfo-L-tyrosine; O5-glycosyl-L-hydroxylysine; O-glycosyl-L-serine; O-glycosyl-L-threonine; omega-N-(ADP-ribosyl)-L-arginine; omega-N-omega-N'-dimethyl-L-arginine; omega-N-methyl-L-arginine; omega-N-omega-N-dimethyl-L-arginine; omega-N-phospho-L-arginine; O-octanoyl-L-serine; O-palmitoyl-L-serine; O-

20 palmitoyl-L-threonine; O-phospho-L-serine; O-phospho-L-threonine; O-phosphopantetheine-L-serine; phycoerythrobilin-bis-L-cysteine; phycourobilin-bis-L-cysteine; pyrroloquinoline quinone; pyruvic acid; S-hydroxycinnamyl-L-cysteine; S-(2-aminovinyl)-methyl-D-cysteine; S-(2-aminovinyl)-D-cysteine; S-(6-FW)-L-cysteine; S-(8alpha-FAD)-L-cysteine; S-(ADP-ribosyl)-L-cysteine; S-(L-isoglutamyl)-L-cysteine; S-

25 12-hydroxyfarnesyl-L-cysteine; S-acetyl-L-cysteine; S-diacylglycerol-L-cysteine; S-diphytanylglycerol diether-L-cysteine; S-farnesyl-L-cysteine; S-geranylgeranyl-L-cysteine; S-glycosyl-L-cysteine; S-glycyl-L-cysteine; S-methyl-L-cysteine; S-nitrosyl-L-cysteine; S-palmitoyl-L-cysteine; S-phospho-L-cysteine; S-phycobiliviolin-L-cysteine; S-phycocyanobilin-L-cysteine; S-phycoerythrobilin-L-cysteine; S-phytochromobilin-L-

30 cysteine; S-selenyl-L-cysteine; S-sulfo-L-cysteine; tetrakis-L-cysteinyl diiron disulfide; tetrakis-L-cysteinyl iron; tetrakis-L-cysteinyl tetrairon tetrasulfide; trans-2,3-cis 4-dihydroxy-L-proline; tris-L-cysteinyl triiron tetrasulfide; tris-L-cysteinyl triiron trisulfide; tris-L-cysteinyl-L-aspartato tetrairon tetrasulfide; tris-L-cysteinyl-L-cysteine persulfido-

bis-L-glutamato-L-histidino tetrairon disulfide trioxide; tris-L-cysteinyl-L-N³'-histidino tetrairon tetrasulfide; tris-L-cysteinyl-L-N¹'-histidino tetrairon tetrasulfide; and tris-L-cysteinyl-L-serinyl tetrairon tetrasulfide.

Additional examples of PTMs may be found in web sites such as the Delta Mass
5 database based on Krishna, R. G. and F. Wold (1998). Posttranslational Modifications.
Proteins - Analysis and Design. R. H. Angeletti. San Diego, Academic Press. 1: 121-206;
Methods in Enzymology, 193, J.A. McClosky (ed) (1990), pages 647-660; Methods in
Protein Sequence Analysis edited by Kazutomo Imahori and Fumio Sakiyama, Plenum
Press, (1993) "Post-translational modifications of proteins" R.G. Krishna and F. Wold
10 pages 167-172; "GlycoSuiteDB: a new curated relational database of glycoprotein glycan
structures and their biological sources" Cooper et al. Nucleic Acids Res. 29; 332-335
(2001) "O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins" Gupta
et al. Nucleic Acids Research, 27: 370-372 (1999); and "PhosphoBase, a database of
phosphorylation sites: release 2.0.", Kreegipuu et al. Nucleic Acids Res 27(1):237-239
15 (1999) see also, WO 02/21139A2, the disclosure of which is incorporated herein by
reference in its entirety.

Tumorigenesis is often accompanied by alterations in the post-translational
modifications of proteins. Thus, in another embodiment, the invention provides
polypeptides from cancerous cells or tissues that have altered post-translational
20 modifications compared to the post-translational modifications of polypeptides from
normal cells or tissues. A number of altered post-translational modifications are known.
One common alteration is a change in phosphorylation state, wherein the polypeptide from
the cancerous cell or tissue is hyperphosphorylated or hypophosphorylated compared to
the polypeptide from a normal tissue, or wherein the polypeptide is phosphorylated on
25 different residues than the polypeptide from a normal cell. Another common alteration is
a change in glycosylation state, wherein the polypeptide from the cancerous cell or tissue
has more or less glycosylation than the polypeptide from a normal tissue, and/or wherein
the polypeptide from the cancerous cell or tissue has a different type of glycosylation than
the polypeptide from a noncancerous cell or tissue. Changes in glycosylation may be
30 critical because carbohydrate-protein and carbohydrate-carbohydrate interactions are
important in cancer cell progression, dissemination and invasion. See, e.g., Barchi, *Curr.*
Pharm. Des. 6: 485-501 (2000), Verma, *Cancer Biochem. Biophys.* 14: 151-162 (1994)
and Dennis et al., *Bioessays* 5: 412-421 (1999).

Another post-translational modification that may be altered in cancer cells is prenylation. Prenylation is the covalent attachment of a hydrophobic prenyl group (either farnesyl or geranylgeranyl) to a polypeptide. Prenylation is required for localizing a protein to a cell membrane and is often required for polypeptide function. For instance, the Ras superfamily of GTPase signalling proteins must be prenylated for function in a cell. See, e.g., Prendergast et al., *Semin. Cancer Biol.* 10: 443-452 (2000) and Khwaja et al., *Lancet* 355: 741-744 (2000).

Other post-translation modifications that may be altered in cancer cells include, without limitation, polypeptide methylation, acetylation, arginylation or racemization of amino acid residues. In these cases, the polypeptide from the cancerous cell may exhibit either increased or decreased amounts of the post-translational modification compared to the corresponding polypeptides from noncancerous cells.

Other polypeptide alterations in cancer cells include abnormal polypeptide cleavage of proteins and aberrant protein-protein interactions. Abnormal polypeptide cleavage may be cleavage of a polypeptide in a cancerous cell that does not usually occur in a normal cell, or a lack of cleavage in a cancerous cell, wherein the polypeptide is cleaved in a normal cell. Aberrant protein-protein interactions may be either covalent cross-linking or non-covalent binding between proteins that do not normally bind to each other. Alternatively, in a cancerous cell, a protein may fail to bind to another protein to which it is bound in a noncancerous cell. Alterations in cleavage or in protein-protein interactions may be due to over- or underproduction of a polypeptide in a cancerous cell compared to that in a normal cell, or may be due to alterations in post-translational modifications (see above) of one or more proteins in the cancerous cell. See, e.g., Henschen-Edman, *Ann. N.Y. Acad. Sci.* 936: 580-593 (2001).

Alterations in polypeptide post-translational modifications, as well as changes in polypeptide cleavage and protein-protein interactions, may be determined by any method known in the art. For instance, alterations in phosphorylation may be determined by using anti-phosphoserine, anti-phosphothreonine or anti-phosphotyrosine antibodies or by amino acid analysis. Glycosylation alterations may be determined using antibodies specific for different sugar residues, by carbohydrate sequencing, or by alterations in the size of the glycoprotein, which can be determined by, e.g., SDS polyacrylamide gel electrophoresis (PAGE). Other alterations of post-translational modifications, such as prenylation, racemization, methylation, acetylation and arginylation, may be determined by chemical

analysis, protein sequencing, amino acid analysis, or by using antibodies specific for the particular post-translational modifications. Changes in protein-protein interactions and in polypeptide cleavage may be analyzed by any method known in the art including, without limitation, non-denaturing PAGE (for non-covalent protein-protein interactions), SDS
5 PAGE (for covalent protein-protein interactions and protein cleavage), chemical cleavage, protein sequencing or immunoassays.

In another embodiment, the invention provides polypeptides that have been post-translationally modified. In one embodiment, polypeptides may be modified enzymatically or chemically, by addition or removal of a post-translational modification.
10 For example, a polypeptide may be glycosylated or deglycosylated enzymatically. Similarly, polypeptides may be phosphorylated using a purified kinase, such as a MAP kinase (e.g., p38, ERK, or JNK) or a tyrosine kinase (e.g., Src or erbB2). A polypeptide may also be modified through synthetic chemistry. Alternatively, one may isolate the polypeptide of interest from a cell or tissue that expresses the polypeptide with the desired
15 post-translational modification. In another embodiment, a nucleic acid molecule encoding the polypeptide of interest is introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide in the desired fashion. If the polypeptide does not contain a motif for a desired post-translational modification, one may alter the post-translational modification by mutating the nucleic acid sequence of a nucleic
20 acid molecule encoding the polypeptide so that it contains a site for the desired post-translational modification. Amino acid sequences that may be post-translationally modified are known in the art. See, e.g., the programs described above on the website expasy.org of the world wide web. The nucleic acid molecule may also be introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide.
25 Similarly, one may delete sites that are post-translationally modified by either mutating the nucleic acid sequence so that the encoded polypeptide does not contain the post-translational modification motif, or by introducing the native nucleic acid molecule into a host cell that is not capable of post-translationally modifying the encoded polypeptide.

It will be appreciated, as is well known and as noted above, that polypeptides are
30 not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslation events, including natural processing events and events brought about by human manipulation which do not occur naturally. Circular, branched and branched

circular polypeptides may be synthesized by non-translation natural processes and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well. For instance, the amino terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores. A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA), *e.g.*, offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA).

The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents. Common homobifunctional reagents include, *e.g.*, APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB,

DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA); common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMPA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available
10 Pierce, Rockford, IL, USA).

Polypeptides of the present invention, including full length polypeptides, fragments and fusion proteins, can be conjugated, using such cross-linking reagents, to fluorophores that are not amine- or thiol-reactive. Other labels that usefully can be conjugated to polypeptides of the present invention include radioactive labels,
15 echosonographic contrast reagents, and MRI contrast agents.

Polypeptides of the present invention, including full length polypeptides, fragments and fusion proteins, can also usefully be conjugated using cross-linking agents to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-BSP antibodies.

20 Polypeptides of the present invention, including full length polypeptides, fragments and fusion proteins, can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum half life of proteins administered intravenously for replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4): 249-304 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6): 423-38 (1998); DeSantis *et al.*, *Curr. Opin. Biotechnol.* 10(4): 324-30 (1999). PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild
25 conditions.

Polypeptides of the present invention are also inclusive of analogs of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred
30 embodiment, this polypeptide is a BSP. In a more preferred embodiment, this polypeptide is derived from a polypeptide having part or all of the amino acid sequence of SEQ ID NO: 73-179. Also preferred is an analog polypeptide comprising one or more

substitutions of non-natural amino acids or non-native inter-residue bonds compared to the naturally occurring polypeptide. In one embodiment, the analog is structurally similar to a BSP, but one or more peptide linkages is replaced by a linkage selected from the group consisting of --CH₂NH--, --CH₂S--, --CH₂-CH₂--, --CH=CH--(cis and trans), --COCH₂--,
5 --CH(OH)CH₂-- and --CH₂SO--. In another embodiment, the analog comprises substitution of one or more amino acids of a BSP with a D-amino acid of the same type or other non-natural amino acid in order to generate more stable peptides. D-amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-amino acids can
10 also be used to confer specific three-dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (*see, e.g., Kole et al., Biochem. Biophys. Res. Com.* 209: 817-821 (1995)), and various
15 halogenated phenylalanine derivatives.

Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common. Solid phase chemical synthesis of peptides is well established in the art. Procedures are described, *inter alia*, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A
20 Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000); Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (1992); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (1993).

Amino acid analogues having detectable labels are also usefully incorporated
25 during synthesis to provide derivatives and analogs. Biotin, for example can be added using biotinoyl-(9-fluorenylmethoxycarbonyl)-L-lysine (Fmoc biocytin) (Molecular Probes, Eugene, OR, USA). Biotin can also be added enzymatically by incorporation into a fusion protein of an *E. coli* BirA substrate peptide. The Fmoc and *t*BOC derivatives of dabcyL-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate
30 the dabcyL chromophore at selected sites in the peptide sequence during synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyL quencher in fluorescence resonance energy transfer (FRET) systems, can be

introduced during automated synthesis of peptides by using EDANS-FMOC-L-glutamic acid or the corresponding *t*BOC derivative (both from Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be incorporated during automated FMOC synthesis of peptides using (FMOC)-TMR-L-lysine (Molecular Probes, Inc.

5 Eugene, OR, USA).

Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and

10 phosphorylated peptides.

A large number of other FMOC-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially, including, *e.g.*, Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-

15 aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-bicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-

20 cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-aminobenzoyl)- β -alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-

25 aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-

30 methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmoc-3-amino-2-naphtioic acid, Fmoc-D,L-3-amino-3-phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-

pyridinecarboxylic acid, Fmoc-D,L-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid, all
5 available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical aminoacylation with the desired unnatural amino acid. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the
10 protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9): 4780-5 (1999); Wang *et al.*, *Science* 292(5516): 498-500 (2001).

15 *Fusion Proteins*

Another aspect of the present invention relates to the fusion of a polypeptide of the present invention to heterologous polypeptides. In a preferred embodiment, the polypeptide of the present invention is a BSP. In a more preferred embodiment, the polypeptide of the present invention that is fused to a heterologous polypeptide which
20 comprises part or all of the amino acid sequence of SEQ ID NO: 73-179, or is a mutein, homologous polypeptide, analog or derivative thereof. In an even more preferred embodiment, the fusion protein is encoded by a nucleic acid molecule comprising all or part of the nucleic acid sequence of SEQ ID NO: 1-72, or comprises all or part of a nucleic acid sequence that selectively hybridizes or is homologous to a nucleic acid molecule
25 comprising a nucleic acid sequence of SEQ ID NO: 1-72.

The fusion proteins of the present invention will include at least one fragment of a polypeptide of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the polypeptide of the present to be included in the fusion can usefully be at least 25
30 amino acids long, at least 50 amino acids long; and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of a polypeptide of the present invention have particular utility.

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and preferably at least 15, 20, or 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP
5 chromophore-containing proteins) are particularly useful.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated here by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of
10 recombinantly-expressed proteins. *See, e.g.,* Ausubel, Chapter 16, (1992), *supra*. Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so included
15 render the fusion proteins of the present invention useful as directly detectable markers of the presence of a polypeptide of the invention.

As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins into the periplasmic space or extracellular milieu for
20 prokaryotic hosts or into the culture medium for eukaryotic cells through incorporation of secretion signals and/or leader sequences. For example, a His⁶ tagged protein can be purified on a Ni affinity column and a GST fusion protein can be purified on a glutathione affinity column. Similarly, a fusion protein comprising the Fc domain of IgG can be purified on a Protein A or Protein G column and a fusion protein comprising an epitope
25 tag such as myc can be purified using an immunoaffinity column containing an anti-c-myc antibody. It is preferable that the epitope tag be separated from the protein encoded by the essential gene by an enzymatic cleavage site that can be cleaved after purification. See also the discussion of nucleic acid molecules encoding fusion proteins that may be expressed on the surface of a cell.

30 Other useful fusion proteins of the present invention include those that permit use of the polypeptide of the present invention as bait in a yeast two-hybrid system. *See* Bartel *et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997); Zhu *et al.*, Yeast Hybrid Technologies, Eaton Publishing (2000); Fields *et al.*, *Trends Genet.*

10(8): 286-92 (1994); Mendelsohn *et al.*, *Curr. Opin. Biotechnol.* 5(5): 482-6 (1994); Luban *et al.*, *Curr. Opin. Biotechnol.* 6(1): 59-64 (1995); Allen *et al.*, *Trends Biochem. Sci.* 20(12): 511-6 (1995); Drees, *Curr. Opin. Chem. Biol.* 3(1): 64-70 (1999); Topcu *et al.*, *Pharm. Res.* 17(9): 1049-55 (2000); Fashena *et al.*, *Gene* 250(1-2): 1-14 (2000); Colas
5 *et al.*, *Nature* 380, 548-550 (1996); Norman, T. *et al.*, *Science* 285, 591-595 (1999); Fabbrizio *et al.*, *Oncogene* 18, 4357-4363 (1999); Xu *et al.*, *Proc Natl Acad Sci U S A.* 94, 12473-12478 (1997); Yang, *et al.*, *Nuc. Acids Res.* 23, 1152-1156 (1995); Kolonin *et al.*, *Proc Natl Acad Sci U S A* 95, 14266-14271 (1998); Cohen *et al.*, *Proc Natl Acad Sci U S A* 95, 14272-14277 (1998); Uetz, *et al.* *Nature* 403, 623-627(2000); Ito, *et al.*, *Proc Natl*
10 *Acad Sci U S A* 98, 4569-4574 (2001). Typically, such fusion is to either *E. coli* LexA or yeast GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful fusion proteins include those that permit display of the encoded polypeptide on the surface of a phage or cell, fusions to intrinsically fluorescent proteins,
15 such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above.

The polypeptides of the present invention can also usefully be fused to protein toxins, such as Pseudomonas exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin, in order to effect ablation of cells that bind or take up the proteins of
20 the present invention.

Fusion partners include, *inter alia*, myc, hemagglutinin (HA), GST, immunoglobulins, β -galactosidase, biotin trpE, protein A, β -lactamase, α -amylase, maltose binding protein, alcohol dehydrogenase, polyhistidine (for example, six histidine at the amino and/or carboxyl terminus of the polypeptide), lacZ, green fluorescent protein
25 (GFP), yeast α mating factor, GAL4 transcription activation or DNA binding domain, luciferase, and serum proteins such as ovalbumin, albumin and the constant domain of IgG. *See, e.g.*, Ausubel (1992), *supra* and Ausubel (1999), *supra*. Fusion proteins may also contain sites for specific enzymatic cleavage, such as a site that is recognized by enzymes such as Factor XIII, trypsin, pepsin, or any other enzyme known in the art.
30 Fusion proteins will typically be made by either recombinant nucleic acid methods, as described above, chemically synthesized using techniques well known in the art (*e.g.*, a Merrifield synthesis), or produced by chemical cross-linking.

Another advantage of fusion proteins is that the epitope tag can be used to bind the fusion protein to a plate or column through an affinity linkage for screening binding proteins or other molecules that bind to the BSP.

As further described below, the polypeptides of the present invention can readily
5 be used as specific immunogens to raise antibodies that specifically recognize polypeptides of the present invention including BSPs and their allelic variants and homologues. The antibodies, in turn, can be used, *inter alia*, specifically to assay for the polypeptides of the present invention, particularly BSPs, *e.g.* by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning
10 cytometry, for detection of protein in tissue samples, or by flow cytometry, for detection of intracellular protein in cell suspensions, for specific antibody-mediated isolation and/or purification of BSPs, as for example by immunoprecipitation, and for use as specific agonists or antagonists of BSPs.

One may determine whether polypeptides of the present invention including BSPs,
15 muteins, homologous proteins or allelic variants or fusion proteins of the present invention are functional by methods known in the art. For instance, residues that are tolerant of change while retaining function can be identified by altering the polypeptide at known residues using methods known in the art, such as alanine scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908): 1081-5 (1989); transposon linker scanning
20 mutagenesis, Chen *et al.*, *Gene* 263(1-2): 39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin *et al.*, *J. Mol. Biol.* 226(3): 851-65 (1992); and combinatorial alanine scanning, Weiss *et al.*, *Proc. Natl. Acad. Sci USA* 97(16): 8950-4 (2000), followed by functional assay. Transposon linker scanning kits are available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-102S;
25 EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, (Epicentre Technologies Corporation, Madison, WI, USA).

Purification of the polypeptides or fusion proteins of the present invention is well known and within the skill of one having ordinary skill in the art. *See, e.g.*, Scopes, Protein Purification, 2d ed. (1987). Purification of recombinantly expressed polypeptides
30 is described above. Purification of chemically-synthesized peptides can readily be effected, *e.g.*, by HPLC.

Accordingly, it is an aspect of the present invention to provide the isolated polypeptides or fusion proteins of the present invention in pure or substantially pure form

in the presence or absence of a stabilizing agent. Stabilizing agents include both proteinaceous and non-proteinaceous material and are well known in the art. Stabilizing agents, such as albumin and polyethylene glycol (PEG) are known and are commercially available.

5 Although high levels of purity are preferred when the isolated polypeptide or fusion protein of the present invention are used as therapeutic agents, such as in vaccines and replacement therapy, the isolated polypeptides of the present invention are also useful at lower purity. For example, partially purified polypeptides of the present invention can be used as immunogens to raise antibodies in laboratory animals.

10 In a preferred embodiment, the purified and substantially purified polypeptides of the present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

 The polypeptides or fusion proteins of the present invention can usefully be attached to a substrate. The substrate can be porous or solid, planar or non-planar; the
15 bond can be covalent or noncovalent. For example, the peptides of the invention may be stabilized by covalent linkage to albumin. See, U.S. Patent No. 5,876,969, the contents of which are hereby incorporated in its entirety.

 The polypeptides or fusion proteins of the present invention can also be usefully bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose,
20 polyvinylidene fluoride (PVDF), or cationically derivatized, hydrophilic PVDF; so bound, the polypeptides or fusion proteins of the present invention can be used to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized polypeptide or fusion protein of the present invention.

 As another example, the polypeptides or fusion proteins of the present invention
25 can usefully be bound to a substantially nonporous substrate, such as plastic, to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate,
30 nitrocellulose, or mixtures thereof; when the assay is performed in a standard microtiter dish, the plastic is typically polystyrene.

 The polypeptides and fusion proteins of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so

attached, the polypeptide or fusion protein of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound polypeptide or fusion protein to indicate biologic interaction there between. The polypeptides or fusion proteins of the present invention can also be attached to a
5 substrate suitable for use in surface plasmon resonance detection; so attached, the polypeptide or fusion protein of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound polypeptide or fusion protein to indicate biological interaction there between.

Alternative Transcripts

10 In another aspect, the present invention provides splice variants of genes and proteins encoded thereby. The identification of a novel splice variant which encodes an amino acid sequence with a novel region can be targeted for the generation of reagents for use in detection and/or treatment of cancer. The novel amino acid sequence may lead to a unique protein structure, protein subcellular localization, biochemical processing or
15 function of the splice variant. This information can be used to directly or indirectly facilitate the generation of additional or novel therapeutics or diagnostics. The nucleotide sequence in this novel splice variant can be used as a nucleic acid probe for the diagnosis and/or treatment of cancer.

Specifically, the newly identified sequences may enable the production of new
20 antibodies or compounds directed against the novel region for use as a therapeutic or diagnostic. Alternatively, the newly identified sequences may alter the biochemical or biological properties of the encoded protein in such a way as to enable the generation of improved or different therapeutics targeting this protein.

Antibodies

25 In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to polypeptides encoded by the nucleic acid molecules of the invention. In a preferred embodiment, the antibodies are specific for a polypeptide that is a BSP, or a fragment, mutein, derivative, analog or fusion protein thereof. In a more preferred embodiment, the antibodies are specific for a polypeptide that
30 comprises SEQ ID NO: 73-179, or a fragment, mutein, derivative, analog or fusion protein thereof.

The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, *e.g.*, by solubilization in SDS. New epitopes may also be
5 due to a difference in post translational modifications (PTMs) in disease versus normal tissue. For example, a particular site on a BSP may be glycosylated in cancerous cells, but not glycosylated in normal cells or vice versa. In addition, alternative splice forms of a BSP may be indicative of cancer. Differential degradation of the C or N-terminus of a BSP may also be a marker or target for anticancer therapy. For example, a BSP may be
10 N-terminal degraded in cancer cells exposing new epitopes to antibodies which may selectively bind for diagnostic or therapeutic uses.

As is well known in the art, the degree to which an antibody can discriminate among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention
15 will discriminate over adventitious binding to non-BSP polypeptides by at least two-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine
20 the presence of the polypeptide of the present invention in samples derived from human breast.

Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the present invention will be at least about 1×10^{-6} molar (M), typically at least about 5×10^{-7}
25 M, 1×10^{-7} M, with affinities and avidities of at least 1×10^{-8} M, 5×10^{-9} M, 1×10^{-10} M and up to 1×10^{-13} M proving especially useful.

The antibodies of the present invention can be naturally occurring forms, such as IgG, IgM, IgD, IgE, IgY, and IgA, from any avian, reptilian, or mammalian species.

Human antibodies can, but will infrequently, be drawn directly from human donors
30 or human cells. In such case, antibodies to the polypeptides of the present invention will typically have resulted from fortuitous immunization, such as autoimmune immunization, with the polypeptide of the present invention. Such antibodies will typically, but will not

invariably, be polyclonal. In addition, individual polyclonal antibodies may be isolated and cloned to generate monoclonals.

Human antibodies are more frequently obtained using transgenic animals that express human immunoglobulin genes, which transgenic animals can be affirmatively immunized with the protein immunogen of the present invention. Human Ig-transgenic mice capable of producing human antibodies and methods of producing human antibodies therefrom upon specific immunization are described, *inter alia*, in U.S. Patent Nos. 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318; 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically produced using techniques developed for production of murine antibodies.

Human antibodies are particularly useful, and often preferred, when the antibodies of the present invention are to be administered to human beings as *in vivo* diagnostic or therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by administration of an antibody derived from another species, such as mouse.

IgG, IgM, IgD, IgE, IgY, and IgA antibodies of the present invention are also usefully obtained from other species, including mammals such as rodents (typically mouse, but also rat, guinea pig, and hamster), lagomorphs (typically rabbits), and also larger mammals, such as sheep, goats, cows, and horses; or egg laying birds or reptiles such as chickens or alligators. In such cases, as with the transgenic human-antibody-producing non-human mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the polypeptide of the present invention. One form of avian antibodies may be generated using techniques described in WO 00/29444, published 25 May 2000, which is herein incorporated by reference in its entirety.

As discussed above, virtually all fragments of 8 or more contiguous amino acids of a polypeptide of the present invention can be used effectively as immunogens when conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

Immunogenicity can also be conferred by fusion of the polypeptides of the present invention to other moieties. For example, polypeptides of the present invention can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical
5 definition and improved safety in vaccine development. Tam *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5409-5413 (1988); Posnett *et al.*, *J. Biol. Chem.* 263: 1719-1725 (1988).

Protocols for immunizing non-human mammals or avian species are well-established in the art. See Harlow *et al.* (eds.), Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998); Coligan *et al.* (eds.), Current Protocols in
10 Immunology, John Wiley & Sons, Inc. (2001); Zola, Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000); Gross M, Speck *J.Dtsch. Tierarztl. Wochenschr.* 103: 417-422 (1996). Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and
15 Freund's incomplete adjuvant, and may include naked DNA immunization. Moss, *Semin. Immunol.* 2: 317-327 (1990).

Antibodies from non-human mammals and avian species can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the polypeptides of the present invention and
20 monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the polypeptides of the present invention. Antibodies from avian species may have particular advantage in detection of the polypeptides of the present invention, in human serum or tissues. Vikinge *et al.*, *Biosens. Bioelectron.* 13: 1257-1262 (1998). Following immunization, the antibodies of the present invention can be obtained using any
25 art-accepted technique. Such techniques are well known in the art and are described in detail in references such as Coligan, *supra*; Zola, *supra*; Howard *et al.* (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000); Harlow, *supra*; Davis (ed.), Monoclonal Antibody Protocols, Vol. 45, Humana Press (1995); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997); and Kenney,
30 Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997).

Briefly, such techniques include, *inter alia*, production of monoclonal antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two

methods of production are not mutually exclusive: genes encoding antibodies specific for the polypeptides of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two necessarily be performed together: *e.g.*, genes encoding antibodies specific for the polypeptides of the present invention can be
5 cloned directly from B cells known to be specific for the desired protein, as further described in U.S. Patent No. 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

10 Host cells for recombinant antibody production of whole antibodies, antibody fragments, or antibody derivatives can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies of the present invention.

The technology of phage-displayed antibodies, in which antibody variable region
15 fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established. *See, e.g.*, Sidhu, *Curr. Opin. Biotechnol.* 11(6): 610-6 (2000); Griffiths *et al.*, *Curr. Opin. Biotechnol.* 9(1): 102-8 (1998); Hoogenboom *et al.*, *Immunotechnology*, 4(1): 1-20 (1998); Rader *et al.*, *Current Opinion in Biotechnology* 8: 503-508 (1997); Aujame *et al.*, *Human*
20 *Antibodies* 8: 155-168 (1997); Hoogenboom, *Trends in Biotechnol.* 15: 62-70 (1997); de Kruif *et al.*, 17: 453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14: 230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994). Techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled. *See, e.g.*, Barbas (2001), *supra*; Kay, *supra*; and Abelson, *supra*.

25 Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length antibody in a further prokaryotic or a eukaryotic host cell. Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the
30 present invention. For example, antibody fragments of the present invention can be produced in *Pichia pastoris* and in *Saccharomyces cerevisiae*. *See, e.g.*, Takahashi *et al.*, *Biosci. Biotechnol. Biochem.* 64(10): 2138-44 (2000); Freyre *et al.*, *J. Biotechnol.* 76(2-3):1 57-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 117-20

(1999); Pennell *et al.*, *Res. Immunol.* 149(6): 599-603 (1998); Eldin *et al.*, *J. Immunol. Methods*. 201(1): 67-75 (1997);, Frenken *et al.*, *Res. Immunol.* 149(6): 589-99 (1998); and Shusta *et al.*, *Nature Biotechnol.* 16(8): 773-7 (1998).

Antibodies, including antibody fragments and derivatives, of the present invention
5 can also be produced in insect cells. *See, e.g.*, Li *et al.*, *Protein Expr. Purif.* 21(1): 121-8 (2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3): 196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1): 96-104 (1997); Edelman *et al.*, *Immunology* 91(1): 13-9 (1997); and Nesbit *et al.*, *J. Immunol. Methods* 151(1-2): 201-8 (1992).

Antibodies and fragments and derivatives thereof of the present invention can also
10 be produced in plant cells, particularly maize or tobacco, Giddings *et al.*, *Nature Biotechnol.* 18(11): 1151-5 (2000); Gavilondo *et al.*, *Biotechniques* 29(1): 128-38 (2000); Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2): 83-92 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 113-6 (1999); Fischer *et al.*, *Biol. Chem.* 380(7-8): 825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240: 119-38 (1999); and Ma *et al.*, *Plant Physiol.* 109(2): 341-6 (1995).

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in transgenic, non-human, mammalian milk. *See, e.g.* Pollock *et al.*, *J. Immunol Methods*. 231: 147-57 (1999); Young *et al.*, *Res. Immunol.* 149: 609-10 (1998); and Limonta *et al.*, *Immunotechnology* 1: 107-13 (1995).

20 Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS cells, 293 cells, and myeloma cells. Verma *et al.*, *J. Immunol. Methods* 216(1-2):165-81 (1998) review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies. Antibodies of the present invention can also be prepared by cell
25 free translation, as further described in Merk *et al.*, *J. Biochem. (Tokyo)* 125(2): 328-33 (1999) and Ryabova *et al.*, *Nature Biotechnol.* 15(1): 79-84 (1997), and in the milk of transgenic animals, as further described in Pollock *et al.*, *J. Immunol. Methods* 231(1-2): 147-57 (1999).

The invention further provides antibody fragments that bind specifically to one or
30 more of the polypeptides of the present invention or to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid

molecules of the present invention. Among such useful fragments are Fab, Fab', Fv, F(ab)'₂, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4): 395-402 (1998).

5 The present invention also relates to antibody derivatives that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention.

10 Among such useful derivatives are chimeric, primatized, and humanized antibodies; such derivatives are less immunogenic in human beings, and thus are more suitable for *in vivo* administration, than are unmodified antibodies from non-human mammalian species. Another useful method is PEGylation to increase the serum half life of the antibodies.

15 Chimeric antibodies typically include heavy and/or light chain variable regions (including both CDR and framework residues) of immunoglobulins of one species, typically mouse, fused to constant regions of another species, typically human. *See, e.g., Morrison et al., Proc. Natl. Acad. Sci USA* 81(21): 6851-5 (1984); Sharon *et al., Nature* 309(5966): 364-7 (1984); Takeda *et al., Nature* 314(6010): 452-4 (1985); and U.S. Patent
20 No. 5,807,715 the disclosure of which is incorporated herein by reference in its entirety. Primatized and humanized antibodies typically include heavy and/or light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al., Nature* 332(6162): 323-7 (1988); Co *et al., Nature* 351(6326): 501-2 (1991); and U.S. Patent Nos.
25 6,054,297; 5,821,337; 5,770,196; 5,766,886; 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of which are incorporated herein by reference in their entireties. Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

30 It is contemplated that the nucleic acids encoding the antibodies of the present invention can be operably joined to other nucleic acids forming a recombinant vector for cloning or for expression of the antibodies of the invention. Accordingly, the present invention includes any recombinant vector containing the coding sequences, or part

thereof, whether for eukaryotic transduction, transfection or gene therapy. Such vectors may be prepared using conventional molecular biology techniques, known to those with skill in the art, and would comprise DNA encoding sequences for the immunoglobulin V-regions including framework and CDRs or parts thereof, and a suitable promoter either
5 with or without a signal sequence for intracellular transport. Such vectors may be transduced or transfected into eukaryotic cells or used for gene therapy (Marasco et al., *Proc. Natl. Acad. Sci. (USA)* 90: 7889-7893 (1993); Duan et al., *Proc. Natl. Acad. Sci. (USA)* 91: 5075-5079 (1994), by conventional techniques, known to those with skill in the art.

10 The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to provide labeled antibodies that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited
15 by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention. The choice of label depends, in part, upon the desired use.

For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label can usefully be an enzyme that
20 catalyzes production and local deposition of a detectable product. Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well known, and include alkaline phosphatase, β -galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG);
25 o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl phosphate (PNPP); p-nitrophenyl-beta-D-galactopyranoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN);
5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BlueGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS);
30 phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide (H₂O₂), horseradish

peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic compounds. Advantages
5 include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. See, e.g., Thorpe *et al.*, *Methods Enzymol.* 133: 331-53 (1986); Kricka *et al.*, *J. Immunoassay* 17(1): 67-83 (1996); and Lundqvist *et al.*, *J. Biolumin. Chemilumin.* 10(6): 353-9 (1995). Kits for such enhanced chemiluminescent detection (ECL) are available commercially. The antibodies can also be labeled using
10 colloidal gold.

As another example, when the antibodies of the present invention are used, e.g., for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent immunoassay, they can usefully be labeled with fluorophores. There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention.
15 For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY
25 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, all of
30 which are also useful for fluorescently labeling the antibodies of the present invention. For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.

When the antibodies of the present invention are used, *e.g.*, for western blotting applications, they can usefully be labeled with radioisotopes, such as ^{33}P , ^{32}P , ^{35}S , ^3H , and ^{125}I . As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be ^{228}Th , ^{227}Ac , ^{225}Ac , ^{223}Ra , ^{213}Bi , ^{212}Pb ,
5 ^{212}Bi , ^{211}At , ^{203}Pb , ^{194}Os , ^{188}Re , ^{186}Re , ^{153}Sm , ^{149}Tb , ^{131}I , ^{125}I , ^{111}In , ^{105}Rh , $^{99\text{m}}\text{Tc}$, ^{97}Ru , ^{90}Y ,
 ^{90}Sr , ^{88}Y , ^{72}Se , ^{67}Cu , or ^{47}Sc .

As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*,
10 *Radiology* 207(2): 529-38 (1998), or by radioisotopic labeling.

As would be understood, use of the labels described above is not restricted to the application as for which they were mentioned.

The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to
15 cells that display and/or express the polypeptides of the present invention. Commonly, the antibody in such immunotoxins is conjugated to *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. *See* Hall (ed.), Immunotoxin Methods and Protocols (Methods in Molecular Biology, vol. 166), Humana Press (2000); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag (1998).

20 The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of
25 the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, attached to a substrate. Substrates can be porous or nonporous, planar or nonplanar. For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography. For example, the
30 antibodies of the present invention can usefully be attached to paramagnetic microspheres, typically by biotin-streptavidin interaction, which microsphere can then be used for isolation of cells that express or display the polypeptides of the present invention. As

another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

As noted above, the antibodies of the present invention can be produced in prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to
5 provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind specifically to one or more of the BSPs of the present invention or to polypeptides
10 encoded by the BSNA of the invention.

In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody
15 molecule, or to alter it in any other way that may render it more suitable for a particular application.

Transgenic Animals and Cells

In another aspect, the invention provides transgenic cells and non-human organisms comprising nucleic acid molecules of the invention. In a preferred
20 embodiment, the transgenic cells and non-human organisms comprise a nucleic acid molecule encoding a BSP. In a preferred embodiment, the BSP comprises an amino acid sequence selected from SEQ ID NO: 73-179, or a fragment, mutein, homologous protein or allelic variant thereof. In another preferred embodiment, the transgenic cells and non-human organism comprise a BSNA of the invention, preferably a BSNA comprising a
25 nucleotide sequence selected from the group consisting of SEQ ID NO: 1-72, or a part, substantially similar nucleic acid molecule, allelic variant or hybridizing nucleic acid molecule thereof.

In another embodiment, the transgenic cells and non-human organisms have a targeted disruption or replacement of the endogenous orthologue of the human BSG. The
30 transgenic cells can be embryonic stem cells or somatic cells. The transgenic non-human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes. Methods of producing transgenic animals are well known in the art. *See, e.g., Hogan et*

al., Manipulating the Mouse Embryo: A Laboratory Manual, 2d ed., Cold Spring Harbor Press (1999); Jackson *et al.*, Mouse Genetics and Transgenics: A Practical Approach, Oxford University Press (2000); and Pinkert, Transgenic Animal Technology: A Laboratory Handbook, Academic Press (1999).

5 Any technique known in the art may be used to introduce a nucleic acid molecule of the invention into an animal to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection. (*see, e.g.*, Paterson *et al.*, *Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver *et al.*, *Biotechnology* 11: 1263-1270 (1993); Wright *et al.*, *Biotechnology* 9: 830-834 (1991); and U.S. Patent No.
10 4,873,191, herein incorporated by reference in its entirety); retrovirus-mediated gene transfer into germ lines, blastocysts or embryos (*see, e.g.*, Van der Putten *et al.*, *Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)); gene targeting in embryonic stem cells (*see, e.g.*, Thompson *et al.*, *Cell* 56: 313-321 (1989)); electroporation of cells or embryos (*see, e.g.*, Lo, 1983, *Mol. Cell. Biol.* 3: 1803-1814 (1983)); introduction using a gene gun (*see,*
15 *e.g.*, Ulmer *et al.*, *Science* 259: 1745-49 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (*see, e.g.*, Lavitrano *et al.*, *Cell* 57: 717-723 (1989)).

Other techniques include, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (*see, e.g.*,
20 Campell *et al.*, *Nature* 380: 64-66 (1996); Wilmut *et al.*, *Nature* 385: 810-813 (1997)). The present invention provides for transgenic animals that carry the transgene (*i.e.*, a nucleic acid molecule of the invention) in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.* *e.*, mosaic animals or chimeric animals.

The transgene may be integrated as a single transgene or as multiple copies, such
25 as in concatamers, *e. g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, *e.g.*, the teaching of Lasko *et al. et al.*, *Proc. Natl. Acad. Sci. USA* 89: 6232- 6236 (1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

30 Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the

transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (RT-PCR). Samples of transgenic gene-expressing tissue may also be evaluated

5 immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than

10 one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA

15 analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of

20 the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Methods for creating a transgenic animal with a disruption of a targeted gene are also well known in the art. In general, a vector is designed to comprise some nucleotide

25 sequences homologous to the endogenous targeted gene. The vector is introduced into a cell so that it may integrate, via homologous recombination with chromosomal sequences, into the endogenous gene, thereby disrupting the function of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type. *See, e.g., Gu et al., Science* 265: 103-106

30 (1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. *See, e.g., Smithies et al., Nature* 317: 230-234 (1985); Thomas *et al., Cell* 51: 503-512 (1987); Thompson *et al., Cell* 5: 313-321 (1989).

In one embodiment, a mutant, non-functional nucleic acid molecule of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous nucleic acid sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable
5 marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications
10 to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene. *See, e.g.,* Thomas, *supra* and Thompson, *supra*. However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

15 In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient in vivo. Such cells may be obtained from an animal or patient or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells,
20 blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably
25 vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve
30 expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. *See, e.g.*, U.S. Patent Nos. 5,399,349 and 5,460,959, each of which is
5 incorporated by reference herein in its entirety.

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of
10 components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with
15 aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Computer Readable Means

A further aspect of the invention is a computer readable means for storing the nucleic acid and amino acid sequences of the instant invention. In a preferred
20 embodiment, the invention provides a computer readable means for storing SEQ ID NO: 73-179 and SEQ ID NO: 1-72 as described herein, as the complete set of sequences or in any combination. The records of the computer readable means can be accessed for reading and display and for interface with a computer system for the application of programs allowing for the location of data upon a query for data meeting certain criteria,
25 the comparison of sequences, the alignment or ordering of sequences meeting a set of criteria, and the like.

The nucleic acid and amino acid sequences of the invention are particularly useful as components in databases useful for search analyses as well as in sequence analysis algorithms. As used herein, the terms "nucleic acid sequences of the invention" and
30 "amino acid sequences of the invention" mean any detectable chemical or physical characteristic of a polynucleotide or polypeptide of the invention that is or may be reduced to or stored in a computer readable form. These include, without limitation,

chromatographic scan data or peak data, photographic data or scan data therefrom, and mass spectrographic data.

This invention provides computer readable media having stored thereon sequences of the invention. A computer readable medium may comprise one or more of the following: a nucleic acid sequence comprising a sequence of a nucleic acid sequence of the invention; an amino acid sequence comprising an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of one or more nucleic acid sequences of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of a nucleic acid sequence of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention. The computer readable medium can be any composition of matter used to store information or data, including, for example, commercially available floppy disks, tapes, hard drives, compact disks, and video disks.

Also provided by the invention are methods for the analysis of character sequences, particularly genetic sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis, RNA structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, and sequencing chromatogram peak analysis.

A computer-based method is provided for performing nucleic acid sequence identity or similarity identification. This method comprises the steps of providing a nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and comparing said nucleic acid sequence to at least one nucleic acid or amino acid sequence to identify sequence identity or similarity.

A computer-based method is also provided for performing amino acid homology identification, said method comprising the steps of: providing an amino acid sequence comprising the sequence of an amino acid of the invention in a computer readable medium; and comparing said amino acid sequence to at least one nucleic acid or an amino acid sequence to identify homology.

A computer-based method is still further provided for assembly of overlapping nucleic acid sequences into a single nucleic acid sequence, said method comprising the steps of: providing a first nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and screening for at least one overlapping region between said first nucleic acid sequence and a second nucleic acid sequence. In addition, the invention includes a method of using patterns of expression associated with either the nucleic acids or proteins in a computer-based method to diagnose disease.

Diagnostic Methods for Breast Cancer

The present invention also relates to quantitative and qualitative diagnostic assays and methods for detecting, diagnosing, monitoring, staging and predicting cancers by comparing expression of a BSNA or a BSP in a human patient that has or may have breast cancer, or who is at risk of developing breast cancer, with the expression of a BSNA or a BSP in a normal human control. For purposes of the present invention, "expression of a BSNA" or "BSNA expression" means the quantity of BSNA mRNA that can be measured by any method known in the art or the level of transcription that can be measured by any method known in the art in a cell, tissue, organ or whole patient. Similarly, the term "expression of a BSP" or "BSP expression" means the amount of BSP that can be measured by any method known in the art or the level of translation of a BSNA that can be measured by any method known in the art.

The present invention provides methods for diagnosing breast cancer in a patient, by analyzing for changes in levels of BSNA or BSP in cells, tissues, organs or bodily fluids compared with levels of BSNA or BSP in cells, tissues, organs or bodily fluids of preferably the same type from a normal human control, wherein an increase, or decrease in certain cases, in levels of a BSNA or BSP in the patient versus the normal human control is associated with the presence of breast cancer or with a predilection to the disease. In another preferred embodiment, the present invention provides methods for diagnosing

breast cancer in a patient by analyzing changes in the structure of the mRNA of a BSG compared to the mRNA from a normal control. These changes include, without limitation, aberrant splicing, alterations in polyadenylation and/or alterations in 5' nucleotide capping. In yet another preferred embodiment, the present invention provides methods for
5 diagnosing breast cancer in a patient by analyzing changes in a BSP compared to a BSP from a normal patient. These changes include, *e.g.*, alterations, including post translational modifications such as glycosylation and/or phosphorylation of the BSP or changes in the subcellular BSP localization.

For purposes of the present invention, diagnosing means that BSNA or BSP levels
10 are used to determine the presence or absence of disease in a patient. As will be understood by those of skill in the art, measurement of other diagnostic parameters may be required for definitive diagnosis or determination of the appropriate treatment for the disease. The determination may be made by a clinician, a doctor, a testing laboratory, or a patient using an over the counter test. The patient may have symptoms of disease or may
15 be asymptomatic. In addition, the BSNA or BSP levels of the present invention may be used as screening marker to determine whether further tests or biopsies are warranted. In addition, the BSNA or BSP levels may be used to determine the vulnerability or susceptibility to disease.

In a preferred embodiment, the expression of a BSNA is measured by determining
20 the amount of a mRNA that encodes an amino acid sequence selected from SEQ ID NO: 73-179, a homolog, an allelic variant, or a fragment thereof. In a more preferred embodiment, the BSNA expression that is measured is the level of expression of a BSNA mRNA selected from SEQ ID NO: 1-72, or a hybridizing nucleic acid, homologous nucleic acid or allelic variant thereof, or a part of any of these nucleic acid molecules.
25 BSNA expression may be measured by any method known in the art, such as those described *supra*, including measuring mRNA expression by Northern blot, quantitative or qualitative reverse transcriptase PCR (RT-PCR), microarray, dot or slot blots or *in situ* hybridization. *See, e.g.*, Ausubel (1992), *supra*; Ausubel (1999), *supra*; Sambrook (1989), *supra*; and Sambrook (2001), *supra*. BSNA transcription may be measured by any
30 method known in the art including using a reporter gene hooked up to the promoter of a BSG of interest or doing nuclear run-off assays. Alterations in mRNA structure, *e.g.*, aberrant splicing variants, may be determined by any method known in the art, including, RT-PCR followed by sequencing or restriction analysis. As necessary, BSNA expression

may be compared to a known control, such as normal breast nucleic acid, to detect a change in expression.

In another preferred embodiment, the expression of a BSP is measured by determining the level of a BSP having an amino acid sequence selected from the group consisting of SEQ ID NO: 73-179, a homolog, an allelic variant, or a fragment thereof. Such levels are preferably determined in at least one of cells, tissues, organs and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over- or underexpression of a BSNA or BSP compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of breast cancer. The expression level of a BSP may be determined by any method known in the art, such as those described *supra*. In a preferred embodiment, the BSP expression level may be determined by radioimmunoassays, competitive-binding assays, ELISA, Western blot, FACS, immunohistochemistry, immunoprecipitation, proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel-based approaches such as mass spectrometry or protein interaction profiling. *See, e.g.*, Harlow (1999), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. Alterations in the BSP structure may be determined by any method known in the art, including, *e.g.*, using antibodies that specifically recognize phosphoserine, phosphothreonine or phosphotyrosine residues, two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and/or chemical analysis of amino acid residues of the protein. *Id.*

In a preferred embodiment, a radioimmunoassay (RIA) or an ELISA is used. An antibody specific to a BSP is prepared if one is not already available. In a preferred embodiment, the antibody is a monoclonal antibody. The anti-BSP antibody is bound to a solid support and any free protein binding sites on the solid support are blocked with a protein such as bovine serum albumin. A sample of interest is incubated with the antibody on the solid support under conditions in which the BSP will bind to the anti-BSP antibody. The sample is removed, the solid support is washed to remove unbound material, and an anti-BSP antibody that is linked to a detectable reagent (a radioactive substance for RIA and an enzyme for ELISA) is added to the solid support and incubated under conditions in which binding of the BSP to the labeled antibody will occur. After binding, the unbound labeled antibody is removed by washing. For an ELISA, one or more substrates are added to produce a colored reaction product that is based upon the amount of a BSP in the

sample. For an RIA, the solid support is counted for radioactive decay signals by any method known in the art. Quantitative results for both RIA and ELISA typically are obtained by reference to a standard curve.

Other methods to measure BSP levels are known in the art. For instance, a
5 competition assay may be employed wherein an anti-BSP antibody is attached to a solid support and an allocated amount of a labeled BSP and a sample of interest are incubated with the solid support. The amount of labeled BSP attached to the solid support can be correlated to the quantity of a BSP in the sample.

Of the proteomic approaches, 2D PAGE is a well known technique. Isolation of
10 individual proteins from a sample such as serum is accomplished using sequential separation of proteins by isoelectric point and molecular weight. Typically, polypeptides are first separated by isoelectric point (the first dimension) and then separated by size using an electric current (the second dimension). In general, the second dimension is perpendicular to the first dimension. Because no two proteins with different sequences are
15 identical on the basis of both size and charge, the result of 2D PAGE is a roughly square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

Expression levels of a BSNA can be determined by any method known in the art,
20 including PCR and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In
25 RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.

Hybridization to specific DNA molecules (*e.g.*, oligonucleotides) arrayed on a solid support can be used to both detect the expression of and quantitate the level of
30 expression of one or more BSNAs of interest. In this approach, all or a portion of one or more BSNAs is fixed to a substrate. A sample of interest, which may comprise RNA, *e.g.*, total RNA or polyA-selected mRNA, or a complementary DNA (cDNA) copy of the RNA is incubated with the solid support under conditions in which hybridization will occur

between the DNA on the solid support and the nucleic acid molecules in the sample of interest. Hybridization between the substrate-bound DNA and the nucleic acid molecules in the sample can be detected and quantitated by several means, including, without limitation, radioactive labeling or fluorescent labeling of the nucleic acid molecule or a
5 secondary molecule designed to detect the hybrid.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any
10 other bodily secretion or derivative thereof. As used herein "blood" includes whole blood, plasma, serum, circulating epithelial cells, constituents, or any derivative of blood.

In addition to detection in bodily fluids, the proteins and nucleic acids of the invention are suitable to detection by cell capture technology. Whole cells may be captured by a variety of methods for example magnetic separation, such as described in U.S.
15 Patent Nos. 5,200,084; 5,186,827; 5,108,933; and 4,925,788, the disclosures of which are incorporated herein by reference in their entireties. Epithelial cells may be captured using such products as Dynabeads® or CELlection™ (Dynal Biotech, Oslo, Norway). Alternatively, fractions of blood may be captured, e.g., the buffy coat fraction (50mm cells isolated from 5ml of blood) containing epithelial cells. In addition, cancer cells may be
20 captured using the techniques described in WO 00/47998, the disclosure of which is incorporated herein by reference in its entirety. Once the cells are captured or concentrated, the proteins or nucleic acids are detected by the means described in the subject application. Alternatively, nucleic acids may be captured directly from blood samples, see U.S. Patent Nos. 6,156,504, 5,501,963; or WO 01/42504, the disclosures of
25 which are incorporated herein by reference in their entireties.

In a preferred embodiment, the specimen tested for expression of BSNA or BSP includes without limitation breast tissue, breast cells grown in cell culture, blood, serum, lymph node tissue, and lymphatic fluid. In another preferred embodiment, especially when metastasis of a primary breast cancer is known or suspected, specimens include,
30 without limitation, tissues from brain, bone, bone marrow, liver, lungs, colon, and adrenal glands. In general, the tissues may be sampled by biopsy, including, without limitation, needle biopsy, e.g., transthoracic needle aspiration, cervical mediastinoscopy, endoscopic

lymph node biopsy, video-assisted thoracoscopy, exploratory thoracotomy, bone marrow biopsy and bone marrow aspiration.

All the methods of the present invention may optionally include determining the expression levels of one or more other cancer markers in addition to determining the expression level of a BSNA or BSP. In many cases, the use of another cancer marker will decrease the likelihood of false positives or false negatives. In one embodiment, the one or more other cancer markers include other BSNAs or BSPs as disclosed herein. Other cancer markers useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. In a preferred embodiment, at least one other cancer marker in addition to a particular BSNA or BSP is measured. In a more preferred embodiment, at least two other additional cancer markers are used. In an even more preferred embodiment, at least three, more preferably at least five, even more preferably at least ten additional cancer markers are used.

Diagnosing

In one aspect, the invention provides a method for determining the expression levels and/or structural alterations of one or more BSNA and/or BSP in a sample from a patient suspected of having breast cancer. In general, the method comprises the steps of obtaining the sample from the patient, determining the expression level or structural alterations of a BSNA and/or BSP and then ascertaining whether the patient has breast cancer from the expression level of the BSNA or BSP. In general, if high expression relative to a control of a BSNA or BSP is indicative of breast cancer, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least one and a half times higher, and more preferably are at least two times higher, still more preferably five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of breast cancer, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least one and a half times lower, and more preferably are at least two times lower, still more preferably five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

The present invention also provides a method of determining whether breast cancer has metastasized in a patient. One may identify whether the breast cancer has metastasized by measuring the expression levels and/or structural alterations of one or more BSNA and/or BSPs in a variety of tissues. The presence of a BSNA or BSP in a tissue other than breast at levels higher than that of corresponding noncancerous tissue (e.g., the same tissue from another individual) is indicative of metastasis if high level expression of a BSNA or BSP is associated with breast cancer. Similarly, the presence of a BSNA or BSP in a tissue other than breast at levels lower than that of corresponding noncancerous tissue is indicative of metastasis if low level expression of a BSNA or BSP is associated with breast cancer. Further, the presence of a structurally altered BSNA or BSP that is associated with breast cancer is also indicative of metastasis.

In general, if high expression relative to a control of a BSNA or BSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the BSNA or BSP is at least one and a half times higher, and more preferably are at least two times higher, still more preferably five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the BSNA or BSP is at least one and a half times lower, and more preferably are at least two times lower, still more preferably five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control.

Staging

The invention also provides a method of staging breast cancer in a human patient. The method comprises identifying a human patient having breast cancer and analyzing cells, tissues or bodily fluids from such human patient for expression levels and/or structural alterations of one or more BSNA and/or BSPs. First, one or more tumors from a variety of patients are staged according to procedures well known in the art, and the expression levels of one or more BSNA and/or BSPs is determined for each stage to obtain a standard expression level for each BSNA and BSP. Then, the BSNA or BSP expression levels of the BSNA or BSP are determined in a biological sample from a patient whose stage of cancer is not known. The BSNA or BSP expression levels from the patient are

then compared to the standard expression level. By comparing the expression level of the BSNAs and BSPs from the patient to the standard expression levels, one may determine the stage of the tumor. The same procedure may be followed using structural alterations of a BSNA or BSP to determine the stage of a breast cancer.

5 *Monitoring*

Further provided is a method of monitoring breast cancer in a human patient. One may monitor a human patient to determine whether there has been metastasis and, if there has been, when metastasis began to occur. One may also monitor a human patient to determine whether a preneoplastic lesion has become cancerous. One may also monitor a
10 human patient to determine whether a therapy, *e.g.*, chemotherapy, radiotherapy or surgery, has decreased or eliminated the breast cancer. The monitoring may determine if there has been a reoccurrence and, if so, determine its nature. The method comprises identifying a human patient that one wants to monitor for breast cancer, periodically analyzing cells, tissues or bodily fluids from such human patient for expression levels of
15 one or more BSNAs or BSPs, and comparing the BSNA or BSP levels over time to those BSNA or BSP expression levels obtained previously. Patients may also be monitored by measuring one or more structural alterations in a BSNA or BSP that are associated with breast cancer.

If increased expression of a BSNA or BSP is associated with metastasis, treatment
20 failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an increase in the expression level of a BSNA or BSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. One having ordinary skill in the art would recognize that if this were the case, then a decreased expression level would be indicative of no metastasis, effective therapy or failure to
25 progress to a neoplastic lesion. If decreased expression of a BSNA or BSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting a decrease in the expression level of a BSNA or BSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. In a preferred embodiment, the levels of BSNAs or BSPs are determined
30 from the same cell type, tissue or bodily fluid as prior patient samples. Monitoring a patient for onset of breast cancer metastasis is periodic and preferably is done on a quarterly basis, but may be done more or less frequently.

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased or decreased expression levels of a BSNA and/or BSP. The present invention provides a method in which a test sample is obtained from a human patient and one or more BSNAs and/or BSPs are detected. The presence of higher (or lower) BSNA or BSP levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly breast cancer. The effectiveness of therapeutic agents to decrease (or increase) expression or activity of one or more BSNAs and/or BSPs of the invention can also be monitored by analyzing levels of expression of the BSNAs and/or BSPs in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the human patient or cells, as the case may be, to the agent being tested.

Detection of Genetic Lesions or Mutations

The methods of the present invention can also be used to detect genetic lesions or mutations in a BSG, thereby determining if a human with the genetic lesion is susceptible to developing breast cancer or to determine what genetic lesions are responsible, or are partly responsible, for a person's existing breast cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion, insertion and/or substitution of one or more nucleotides from the BSGs of this invention, a chromosomal rearrangement of a BSG, an aberrant modification of a BSG (such as of the methylation pattern of the genomic DNA), or allelic loss of a BSG. Methods to detect such lesions in the BSG of this invention are known to those having ordinary skill in the art following the teachings of the specification.

25 Methods of Detecting Noncancerous Breast Diseases

The present invention also provides methods for determining the expression levels and/or structural alterations of one or more BSNAs and/or BSPs in a sample from a patient suspected of having or known to have a noncancerous breast disease. In general, the method comprises the steps of obtaining a sample from the patient, determining the expression level or structural alterations of a BSNA and/or BSP, comparing the expression level or structural alteration of the BSNA or BSP to a normal breast control, and then ascertaining whether the patient has a noncancerous breast disease. In general, if high

expression relative to a control of a BSNA or BSP is indicative of a particular noncancerous breast disease, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of a noncancerous breast disease, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

One having ordinary skill in the art may determine whether a BSNA and/or BSP is associated with a particular noncancerous breast disease by obtaining breast tissue from a patient having a noncancerous breast disease of interest and determining which BSNAs and/or BSPs are expressed in the tissue at either a higher or a lower level than in normal breast tissue. In another embodiment, one may determine whether a BSNA or BSP exhibits structural alterations in a particular noncancerous breast disease state by obtaining breast tissue from a patient having a noncancerous breast disease of interest and determining the structural alterations in one or more BSNAs and/or BSPs relative to normal breast tissue.

Methods for Identifying Breast Tissue

In another aspect, the invention provides methods for identifying breast tissue. These methods are particularly useful in, *e.g.*, forensic science, breast cell differentiation and development, and in tissue engineering.

In one embodiment, the invention provides a method for determining whether a sample is breast tissue or has breast tissue-like characteristics. The method comprises the steps of providing a sample suspected of comprising breast tissue or having breast tissue-like characteristics, determining whether the sample expresses one or more BSNAs and/or BSPs, and, if the sample expresses one or more BSNAs and/or BSPs, concluding that the sample comprises breast tissue. In a preferred embodiment, the BSNA encodes a polypeptide having an amino acid sequence selected from SEQ ID NO: 73-179, or a homolog, allelic variant or fragment thereof. In a more preferred embodiment, the BSNA

has a nucleotide sequence selected from SEQ ID NO: 1-72, or a hybridizing nucleic acid, an allelic variant or a part thereof. Determining whether a sample expresses a BSNA can be accomplished by any method known in the art. Preferred methods include hybridization to microarrays, Northern blot hybridization, and quantitative or qualitative
5 RT-PCR. In another preferred embodiment, the method can be practiced by determining whether a BSP is expressed. Determining whether a sample expresses a BSP can be accomplished by any method known in the art. Preferred methods include Western blot, ELISA, RIA and 2D PAGE. In one embodiment, the BSP has an amino acid sequence selected from SEQ ID NO: 73-179, or a homolog, allelic variant or fragment thereof. In
10 another preferred embodiment, the expression of at least two BSNA and/or BSPs is determined. In a more preferred embodiment, the expression of at least three, more preferably four and even more preferably five BSNA and/or BSPs are determined.

In one embodiment, the method can be used to determine whether an unknown tissue is breast tissue. This is particularly useful in forensic science, in which small,
15 damaged pieces of tissues that are not identifiable by microscopic or other means are recovered from a crime or accident scene. In another embodiment, the method can be used to determine whether a tissue is differentiating or developing into breast tissue. This is important in monitoring the effects of the addition of various agents to cell or tissue culture, *e.g.*, in producing new breast tissue by tissue engineering. These agents include,
20 *e.g.*, growth and differentiation factors, extracellular matrix proteins and culture medium. Other factors that may be measured for effects on tissue development and differentiation include gene transfer into the cells or tissues, alterations in pH, aqueous:air interface and various other culture conditions.

Methods for Producing and Modifying Breast Tissue

25 In another aspect, the invention provides methods for producing engineered breast tissue or cells. In one embodiment, the method comprises the steps of providing cells, introducing a BSNA or a BSG into the cells, and growing the cells under conditions in which they exhibit one or more properties of breast tissue cells. In a preferred embodiment, the cells are pluripotent. As is well known in the art, normal breast tissue
30 comprises a large number of different cell types. Thus, in one embodiment, the engineered breast tissue or cells comprises one of these cell types. In another embodiment, the engineered breast tissue or cells comprises more than one breast cell

type. Further, the culture conditions of the cells or tissue may require manipulation in order to achieve full differentiation and development of the breast cell tissue. Methods for manipulating culture conditions are well known in the art.

Nucleic acid molecules encoding one or more BSPs are introduced into cells,
5 preferably pluripotent cells. In a preferred embodiment, the nucleic acid molecules encode BSPs having amino acid sequences selected from SEQ ID NO: 73-179, or homologous proteins, analogs, allelic variants or fragments thereof. In a more preferred embodiment, the nucleic acid molecules have a nucleotide sequence selected from SEQ ID NO: 1-72, or hybridizing nucleic acids, allelic variants or parts thereof. In another highly
10 preferred embodiment, a BSG is introduced into the cells. Expression vectors and methods of introducing nucleic acid molecules into cells are well known in the art and are described in detail, *supra*.

Artificial breast tissue may be used to treat patients who have lost some or all of their breast function.

15 Pharmaceutical Compositions

In another aspect, the invention provides pharmaceutical compositions comprising the nucleic acid molecules, polypeptides, fusion proteins, antibodies, antibody derivatives, antibody fragments, agonists, antagonists, or inhibitors of the present invention. In a preferred embodiment, the pharmaceutical composition comprises a BSNA or part thereof.
20 In a more preferred embodiment, the BSNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-72, a nucleic acid that hybridizes thereto, an allelic variant thereof, or a nucleic acid that has substantial sequence identity thereto. In another preferred embodiment, the pharmaceutical composition comprises a BSP or fragment thereof. In a more preferred embodiment, the pharmaceutical composition comprises a
25 BSP having an amino acid sequence that is selected from the group consisting of SEQ ID NO: 73-179, a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof. In another preferred embodiment, the pharmaceutical composition comprises an anti-BSP antibody, preferably an antibody that specifically binds to a BSP having an amino acid that is selected from the
30 group consisting of SEQ ID NO: 73-179, or an antibody that binds to a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof.

Due to the association of angiogenesis with cancer vascularization there is great need of new markers and methods for diagnosing angiogenesis activity to identify developing tumors and angiogenesis related diseases. Furthermore, great need is also present for new molecular targets useful in the treatment of angiogenesis and angiogenesis related diseases such as cancer. In addition known modulators of angiogenesis such as endostatin or vascular endothelial growth factor (VEGF). Use of the methods and compositions disclosed herein in combination with anti-angiogenesis drugs, drugs that block the matrix breakdown (such as BMS-275291, Dalteparin (Fragmin®), Suramin), drugs that inhibit endothelial cells (2-methoxyestradiol (2-ME), CC-5013 (Thalidomide Analog), Combretastatin A4 Phosphate, LY317615 (Protein Kinase C Beta Inhibitor), Soy Isoflavone (Genistein; Soy Protein Isolate), Thalidomide), drugs that block activators of angiogenesis (AE-941 (Neovastat™; GW786034), Anti-VEGF Antibody (Bevacizumab; Avastin™), Interferon-alpha, PTK787/ZK 222584, VEGF-Trap, ZD6474), Drugs that inhibit endothelial-specific integrin/survival signaling (EMD 121974, Anti-Anb3 Integrin Antibody (Medi-522; Vitaxin™)).

Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable carrier or excipient.

Pharmaceutical formulation is a well-established art that is further described in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20th ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippincott Williams & Wilkins (1999); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3rd ed. (2000) and thus need not be described in detail herein.

Briefly, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation, topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Solid formulations of the compositions for oral administration can contain suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and alginic acid.

Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, cornstarch, sodium starch glycolate, and alginic acid.

Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone™), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

Solid oral dosage forms need not be uniform throughout. For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Liquid formulations of the pharmaceutical compositions for oral (enteral) administration are prepared in water or other aqueous vehicles and can contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.

The pharmaceutical compositions of the present invention can also be formulated for parenteral administration. Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

For intravenous injection, water soluble versions of the compounds of the present invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline, 0.9% saline, Hanks' solution, or Ringer's solution. Intravenous formulations may include carriers, excipients or stabilizers including, without limitation, calcium, human serum albumin, citrate, acetate, calcium chloride, carbonate, and other salts.

Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.

Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).

Aqueous injection suspensions can also contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition. Injectable depot forms may be made by forming

microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot
5 injectable formulations are also prepared by entrapping the drug in microemulsions that are compatible with body tissues.

The pharmaceutical compositions of the present invention can be administered topically. For topical use the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and
10 can take the form of lotions, creams, ointments, liquid sprays or inhalants, drops, tinctures, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin
15 penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone. A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, *e.g.*, 5 to 10%, in a carrier such as a pharmaceutical cream base.

For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as
20 ointments, creams, lotions, paints or powders.

For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.

Inhalation formulations can also readily be formulated. For inhalation, various
25 powder and liquid formulations can be prepared. For aerosol preparations, a sterile formulation of the compound or salt form of the compound may be used in inhalers, such as metered dose inhalers, and nebulizers. Aerosolized forms may be especially useful for treating respiratory disorders.

Alternatively, the compounds of the present invention can be in powder form for
30 reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery.

The pharmaceutically active compound in the pharmaceutical compositions of the present invention can be provided as the salt of a variety of acids, including but not limited

to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

The active compound will be present in an amount effective to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

A "therapeutically effective dose" refers to that amount of active ingredient, for example BSP polypeptide, fusion protein, or fragments thereof, antibodies specific for BSP, agonists, antagonists or inhibitors of BSP, which ameliorates the signs or symptoms of the disease or prevent progression thereof; as would be understood in the medical arts, cure, although desired, is not required.

The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine an initial preferred concentration range and route of administration.

For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in one or more cell culture or animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies are used in formulating an initial dosage range for human use, and preferably provide a range of circulating concentrations that includes the ED50 with little or no toxicity. After administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age,

weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

5 Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (*e.g.*, 1mg/kg to 5 mg/kg). The pharmaceutical formulation can be
10 administered in multiple doses per day, if desired, to achieve the total desired daily dose.

Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells,
15 conditions, locations, etc.

Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to the patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

20 Therapeutic Methods

The present invention further provides methods of treating subjects having defects in a gene of the invention, *e.g.*, in expression, activity, distribution, localization, and/or solubility, which can manifest as a disorder of breast function. As used herein, "treating" includes all medically-acceptable types of therapeutic intervention, including palliation
25 and prophylaxis (prevention) of disease. The term "treating" encompasses any improvement of a disease, including minor improvements. These methods are discussed below.

Gene Therapy and Vaccines

The isolated nucleic acids of the present invention can also be used to drive *in vivo*
30 expression of the polypeptides of the present invention. *In vivo* expression can be driven from a vector, typically a viral vector, often a vector based upon a replication incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV), for the purpose of gene

therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, CA, USA), for purpose of “naked” nucleic acid vaccination, as further described in U.S. Patent Nos. 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5 5,985,847; 6,017,897; 6,110,898; 6,204,250, the disclosures of which are incorporated herein by reference in their entireties. For cancer therapy, it is preferred that the vector also be tumor-selective. *See, e.g., Doronin et al., J. Virol.* 75: 3314-24 (2001).

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid molecule of the present invention is administered. The nucleic acid molecule can be delivered in a vector that drives expression of a BSP, fusion protein, or fragment thereof, or without such vector. Nucleic acid compositions that can drive expression of a BSP are administered, for example, to complement a deficiency in the native BSP, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, 15 adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used as can plasmids. *See, e.g., Cid-Arregui, supra.* In a preferred embodiment, the nucleic acid molecule encodes a BSP having the amino acid sequence of SEQ ID NO: 73-179, or a fragment, fusion protein, allelic variant or homolog thereof.

In still other therapeutic methods of the present invention, pharmaceutical 20 compositions comprising host cells that express a BSP, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement defects in BSP production or activity. In a preferred embodiment, the nucleic acid molecules in the cells encode a BSP having the amino acid sequence of SEQ ID NO: 73-179, or a fragment, 25 fusion protein, allelic variant or homolog thereof.

Antisense Administration

Antisense nucleic acid compositions, or vectors that drive expression of a BSG antisense nucleic acid, are administered to downregulate transcription and/or translation of a BSG in circumstances in which excessive production, or production of aberrant protein, 30 is the pathophysiologic basis of disease.

Antisense compositions useful in therapy can have a sequence that is complementary to coding or to noncoding regions of a BSG. For example,

oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred.

Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to BSG transcripts, are also useful in therapy. *See, e.g.*,
5 Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3): 97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10): 1649-53 (1998); Rossi, *Ciba Found. Symp.* 209: 195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8): 286-9 (1995).

Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the BSG genomic locus. Such
10 triplexing oligonucleotides are able to inhibit transcription. *See, e.g.*, Intody *et al.*, *Nucleic Acids Res.* 28(21): 4283-90 (2000); and McGuffie *et al.*, *Cancer Res.* 60(14): 3790-9 (2000). Pharmaceutical compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

15 In a preferred embodiment, the antisense molecule is derived from a nucleic acid molecule encoding a BSP, preferably a BSP comprising an amino acid sequence of SEQ ID NO: 73-179, or a fragment, allelic variant or homolog thereof. In a more preferred embodiment, the antisense molecule is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-72, or a part, allelic variant, substantially similar or
20 hybridizing nucleic acid thereof.

Polypeptide Administration

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a BSP, a
25 fusion protein, fragment, analog or derivative thereof is administered to a subject with a clinically-significant BSP defect.

Protein compositions are administered, for example, to complement a deficiency in native BSP. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to BSP. The immune response can be used to modulate activity of BSP or, depending on the immunogen, to immunize against
30 aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate BSP.

In a preferred embodiment, the polypeptide administered is a BSP comprising an amino acid sequence of SEQ ID NO: 73-179, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the polypeptide is encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-72, or a part,
5 allelic variant, substantially similar or hybridizing nucleic acid thereof.

Antibody, Agonist and Antagonist Administration

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is administered. As is
10 well known, antibody compositions are administered, for example, to antagonize activity of BSP, or to target therapeutic agents to sites of BSP presence and/or accumulation. In a preferred embodiment, the antibody specifically binds to a BSP comprising an amino acid sequence of SEQ ID NO: 73-179, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antibody specifically binds to a
15 BSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-72, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

The present invention also provides methods for identifying modulators which bind to a BSP or have a modulatory effect on the expression or activity of a BSP. Modulators which decrease the expression or activity of BSP (antagonists) are believed to
20 be useful in treating breast cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell-free assays. Small molecules predicted via computer imaging to specifically bind to regions of a BSP can also be designed, synthesized and tested for use in the imaging and treatment of breast cancer. Further, libraries of molecules can be screened for potential anticancer agents by
25 assessing the ability of the molecule to bind to the BSPs identified herein. Molecules identified in the library as being capable of binding to a BSP are key candidates for further evaluation for use in the treatment of breast cancer. In a preferred embodiment, these molecules will downregulate expression and/or activity of a BSP in cells.

In another embodiment of the therapeutic methods of the present invention, a
30 pharmaceutical composition comprising a non-antibody antagonist of BSP is administered. Antagonists of BSP can be produced using methods generally known in the art. In particular, purified BSP can be used to screen libraries of pharmaceutical agents, often

combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of a BSP.

In other embodiments a pharmaceutical composition comprising an agonist of a BSP is administered. Agonists can be identified using methods analogous to those used to
5 identify antagonists.

In a preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a BSP comprising an amino acid sequence of SEQ ID NO: 73-179, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antagonist or agonist specifically binds to and
10 antagonizes or agonizes, respectively, a BSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-72, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

Targeting Breast Tissue

15 The invention also provides a method in which a polypeptide of the invention, or an antibody thereto, is linked to a therapeutic agent such that it can be delivered to the breast or to specific cells in the breast. In a preferred embodiment, an anti-BSP antibody is linked to a therapeutic agent and is administered to a patient in need of such therapeutic agent. The therapeutic agent may be a toxin, if breast tissue needs to be selectively
20 destroyed. This would be useful for targeting and killing breast cancer cells. In another embodiment, the therapeutic agent may be a growth or differentiation factor, which would be useful for promoting breast cell function.

In another embodiment, an anti-BSP antibody may be linked to an imaging agent that can be detected using, *e.g.*, magnetic resonance imaging, CT or PET. This would be
25 useful for determining and monitoring breast function, identifying breast cancer tumors, and identifying noncancerous breast diseases.

EXAMPLES

Example 1a: Alternative Splice Variants

We identified gene transcripts using the Gencarta™ tools (Compugen Ltd., Tel Aviv, Israel) and a variety of public and proprietary databases. These splice variants are
30 either sequences which differ from a previously defined sequence or new uses of known sequences. In general related variants are annotated as DEX0451_XXX.nt.1,

DEX0451_XXX.nt.2, DEX0451_XXX.nt.3, etc. The variant DNA sequences encode proteins which differ from a previously defined protein sequence. In relation to the nucleotide sequence naming convention, protein variants are annotated as DEX0451_XXX.aa.1, DEX0451_XXX.aa.2, etc., wherein transcript DEX0451_XXX.nt.1
 5 encodes protein DEX0451_XXX.aa.1. A single transcript may encode a protein from an alternate Open Reading Fram (ORF) which is designated DEX0451_XXX.orf.1. Additionally, multiple transcripts may encode for a single protein. In this case, DEX0451_XXX.nt.1 and DEX0451_XXX.nt.2 will both be associated with DEX0451_XXX.aa.1.

10 The mapping of the nucleic acid ("NT") SEQ ID NO; DEX ID; chromosomal location (if known); open reading frame (ORF) location; amino acid ("AA") SEQ ID NO; AA DEX ID; are shown in the table below.

SEQ ID NO	DEX ID	Chromo Map	ORF Loc	SEQ ID NO	DEX ID
1	DEX0451_001.nt.1	7q32.2	338-609	73	DEX0451_001.aa.1
1	DEX0451_001.nt.1	7q32.2	219-569	74	DEX0451_001.orf.1
2	DEX0451_001.nt.2	7q32.2	444-913	75	DEX0451_001.aa.2
2	DEX0451_001.nt.2	7q32.2	415-873	76	DEX0451_001.orf.2
3	DEX0451_002.nt.1	19p13.12	255-473	77	DEX0451_002.aa.1
4	DEX0451_003.nt.1	17q12	1-602	78	DEX0451_003.aa.1
5	DEX0451_004.nt.1	17q24.3	1-399	79	DEX0451_004.aa.1
5	DEX0451_004.nt.1	17q24.3	417-614	80	DEX0451_004.orf.1
6	DEX0451_005.nt.1	15	96-620	81	DEX0451_005.aa.1
7	DEX0451_006.nt.1	8q22.2	19-255	82	DEX0451_006.aa.1
8	DEX0451_006.nt.2	8q22.2	4-267	83	DEX0451_006.aa.2
9	DEX0451_006.nt.3	8q22.2	5-283	84	DEX0451_006.aa.3
10	DEX0451_006.nt.4	8q22.2	10-249	85	DEX0451_006.aa.4
11	DEX0451_006.nt.5	8q22.2	21-224	86	DEX0451_006.aa.5
12	DEX0451_006.nt.6	8q22.2	67-225	87	DEX0451_006.aa.6
13	DEX0451_006.nt.7	8q22.2	29-244	88	DEX0451_006.orf.7
13	DEX0451_006.nt.7	8q22.2	6-249	89	DEX0451_006.aa.7
14	DEX0451_006.nt.8	8q22.2	442-963	90	DEX0451_006.orf.8
14	DEX0451_006.nt.8	8q22.2	10-315	91	DEX0451_006.aa.8
15	DEX0451_007.nt.1	8q13.1	188-839	92	DEX0451_007.aa.1
15	DEX0451_007.nt.1	8q13.1	221-1276	93	DEX0451_007.orf.1
16	DEX0451_007.nt.2	8q13.1	574-793	94	DEX0451_007.aa.2
16	DEX0451_007.nt.2	8q13.1	905-1780	95	DEX0451_007.orf.2
17	DEX0451_007.nt.3	8q13.1	188-665	96	DEX0451_007.aa.3
17	DEX0451_007.nt.3	8q13.1	221-1105	97	DEX0451_007.orf.3
18	DEX0451_007.nt.4	8q13.1	710-1169	98	DEX0451_007.aa.4
18	DEX0451_007.nt.4	8q13.1	530-1162	99	DEX0451_007.orf.4

19	DEX0451_007.nt.5	8q13.1	1-447	100	DEX0451_007.aa.5
20	DEX0451_008.nt.1	1p34.1	63-659	101	DEX0451_008.aa.1
21	DEX0451_009.nt.1	17q12	1-152	102	DEX0451_009.aa.1
21	DEX0451_009.nt.1	17q12	3525-3920	103	DEX0451_009.orf.1
22	DEX0451_010.nt.1	2q35	5-217	104	DEX0451_010.aa.1
23	DEX0451_011.nt.1	12q13.11	179-709	105	DEX0451_011.aa.1
24	DEX0451_012.nt.1	20q13.33	150-678	106	DEX0451_012.aa.1
25	DEX0451_013.nt.1	6p12.3	707-2209	107	DEX0451_013.aa.1
26	DEX0451_013.nt.2	6p12.3	204-1581	108	DEX0451_013.aa.2
26	DEX0451_013.nt.2	6p12.3	172-1578	109	DEX0451_013.orf.2
27	DEX0451_014.nt.1	8p11.22	640-1242	110	DEX0451_014.aa.1
28	DEX0451_015.nt.1	10p12.1	388-790	111	DEX0451_015.aa.1
28	DEX0451_015.nt.1	10p12.1	1135-1605	112	DEX0451_015.orf.1
29	DEX0451_015.nt.2	10p12.1	389-751	113	DEX0451_015.aa.2
30	DEX0451_016.nt.1	12q13.13	824-1270	114	DEX0451_016.aa.1
30	DEX0451_016.nt.1	12q13.13	1568-2179	115	DEX0451_016.orf.1
31	DEX0451_016.nt.2	12q13.13	823-1273	114	DEX0451_016.aa.1
32	DEX0451_017.nt.1	17q12	74-655	116	DEX0451_017.aa.1
33	DEX0451_018.nt.1	X;53439399 -53447815	236-1651	117	DEX0451_018.aa.1
34	DEX0451_018.nt.2	X;53439399 -53447815	235-1822	118	DEX0451_018.aa.2
34	DEX0451_018.nt.2	X;53439399 -53447815	233-1174	119	DEX0451_018.orf.2
35	DEX0451_019.nt.1	17q12	1-108	120	DEX0451_019.aa.1
35	DEX0451_019.nt.1	17q12	652-891	121	DEX0451_019.orf.1
36	DEX0451_019.nt.2	17q12	1-102	122	DEX0451_019.aa.2
36	DEX0451_019.nt.2	17q12	633-872	123	DEX0451_019.orf.2
37	DEX0451_020.nt.1	18p11.22	178-400	124	DEX0451_020.aa.1
37	DEX0451_020.nt.1	18p11.22	3508-3789	125	DEX0451_020.orf.1
38	DEX0451_020.nt.2	18p11.22	1-165	126	DEX0451_020.aa.2
38	DEX0451_020.nt.2	18p11.22	3090-3371	127	DEX0451_020.orf.2
39	DEX0451_021.nt.1	10q26.2	139-990	128	DEX0451_021.aa.1
40	DEX0451_021.nt.2	10q26.2	139-798	129	DEX0451_021.aa.2
41	DEX0451_021.nt.3	10q26.2	139-708	130	DEX0451_021.aa.3
42	DEX0451_022.nt.1	8q21.11	263-1177	131	DEX0451_022.aa.1
43	DEX0451_023.nt.1	8q22.1	351-2100	132	DEX0451_023.aa.1
44	DEX0451_024.nt.1	X;75410607 -75423029	4-1170	133	DEX0451_024.aa.1
45	DEX0451_025.nt.1	1p36.11	176-538	134	DEX0451_025.aa.1
46	DEX0451_026.nt.1	7q22.1	13-376	135	DEX0451_026.aa.1
47	DEX0451_026.nt.2	7q22.1	121-816	136	DEX0451_026.aa.2
48	DEX0451_027.nt.1	14q12	1328-3077	137	DEX0451_027.aa.1
48	DEX0451_027.nt.1	14q12	1314-2681	138	DEX0451_027.orf.1
49	DEX0451_028.nt.1	22q13.31	990-2064	139	DEX0451_028.aa.1
49	DEX0451_028.nt.1	22q13.31	1049-2059	140	DEX0451_028.orf.1
50	DEX0451_028.nt.2	22q13.31	50-764	141	DEX0451_028.aa.2
50	DEX0451_028.nt.2	22q13.31	18-761	142	DEX0451_028.orf.2

51	DEX0451_029.nt.1	4q31.1	24-362	143	DEX0451_029.aa.1
52	DEX0451_030.nt.1	2q33.1	480-726	144	DEX0451_030.aa.1
52	DEX0451_030.nt.1	2q33.1	40-417	145	DEX0451_030.orf.1
53	DEX0451_030.nt.2	2q33.1	913-1290	146	DEX0451_030.aa.2
54	DEX0451_031.nt.1	6p21.33	142-630	147	DEX0451_031.aa.1
54	DEX0451_031.nt.1	6p21.33	26-628	148	DEX0451_031.orf.1
55	DEX0451_032.nt.1	17q12	136-644	149	DEX0451_032.aa.1
55	DEX0451_032.nt.1	17q12	3-584	150	DEX0451_032.orf.1
56	DEX0451_032.nt.2	17q12	155-949	151	DEX0451_032.aa.2
57	DEX0451_032.nt.3	17q12	1-210	152	DEX0451_032.aa.3
57	DEX0451_032.nt.3	17q12	21-257	153	DEX0451_032.orf.3
58	DEX0451_032.nt.4	17q12	1-172	154	DEX0451_032.aa.4
58	DEX0451_032.nt.4	17q12	2-271	155	DEX0451_032.orf.4
59	DEX0451_032.nt.5	17q12	88-1028	156	DEX0451_032.aa.5
59	DEX0451_032.nt.5	17q12	14-1027	157	DEX0451_032.orf.5
60	DEX0451_032.nt.6	17q12	518-1319	158	DEX0451_032.aa.6
60	DEX0451_032.nt.6	17q12	471-1259	159	DEX0451_032.orf.6
61	DEX0451_033.nt.1	15q21.1	163-483	160	DEX0451_033.aa.1
62	DEX0451_033.nt.2	15q21.1	16-142	161	DEX0451_033.aa.2
62	DEX0451_033.nt.2	15q21.1	143-283	162	DEX0451_033.orf.2
63	DEX0451_034.nt.1	19q13.32	491-1265	163	DEX0451_034.aa.1
64	DEX0451_035.nt.1	2p13.1	58-933	164	DEX0451_035.aa.1
64	DEX0451_035.nt.1	2p13.1	2-922	165	DEX0451_035.orf.1
65	DEX0451_036.nt.1	8q21.13	203-823	166	DEX0451_036.aa.1
66	DEX0451_036.nt.2	8q21.13	1-247	167	DEX0451_036.aa.2
66	DEX0451_036.nt.2	8q21.13	278-739	168	DEX0451_036.orf.2
67	DEX0451_036.nt.3	8q21.13	2-535	169	DEX0451_036.aa.3
68	DEX0451_037.nt.1	11q13.4	151-564	170	DEX0451_037.aa.1
68	DEX0451_037.nt.1	11q13.4	2-562	171	DEX0451_037.orf.1
69	DEX0451_037.nt.2	11q13.4	289-895	172	DEX0451_037.aa.2
69	DEX0451_037.nt.2	11q13.4	2-1162	173	DEX0451_037.orf.2
70	DEX0451_037.nt.3	11q13.4	150-825	174	DEX0451_037.aa.3
70	DEX0451_037.nt.3	11q13.4	151-1092	175	DEX0451_037.orf.3
71	DEX0451_037.nt.4	11q13.4	908-1932	176	DEX0451_037.aa.4
71	DEX0451_037.nt.4	11q13.4	729-1664	177	DEX0451_037.orf.4
72	DEX0451_037.nt.5	11q13.4	71-569	178	DEX0451_037.aa.5
72	DEX0451_037.nt.5	11q13.4	101-565	179	DEX0451_037.orf.5

The polypeptides of the present invention were analyzed and the following attributes were identified; specifically, epitopes, post translational modifications, signal peptides and transmembrane domains. Antigenicity (Epitope) prediction was performed through the antigenic module in the EMBOSS package. Rice, P., EMBOSS: The European Molecular Biology Open Software Suite, *Trends in Genetics* 16(6): 276-277 (2000). The antigenic module predicts potentially antigenic regions of a protein sequence, using the method of Kolaskar and Tongaonkar. Kolaskar, AS and Tongaonkar, PC., A

semi-empirical method for prediction of antigenic determinants on protein antigens, *FEBS Letters* 276: 172-174 (1990). Examples of post-translational modifications (PTMs) and other motifs of the BSPs of this invention are listed below. In addition, antibodies that specifically bind such post-translational modifications may be useful as a diagnostic or as
 5 therapeutic. The PTMs and other motifs were predicted by using the ProSite Dictionary of Proteins Sites and Patterns (Bairoch *et al.*, *Nucleic Acids Res.* 25(1):217-221 (1997)), the following motifs, including PTMs, were predicted for the BSPs of the invention. The signal peptides were detected by using the SignalP 2.0, *see* Nielsen *et al.*, *Protein Engineering* 12, 3-9 (1999). Prediction of transmembrane helices in proteins was
 10 performed by the application TMHMM 2.0, "currently the best performing transmembrane prediction program", according to authors (Krogh *et al.*, *Journal of Molecular Biology*, 305(3):567-580, (2001); Moller *et al.*, *Bioinformatics*, 17(7):646-653, (2001); Sonnhammer, *et al.*, *A hidden Markov model for predicting transmembrane helices in protein sequences* in Glasgow, *et al.* Ed. Proceedings of the Sixth International
 15 Conference on Intelligent Systems for Molecular Biology, pages 175-182, Menlo Park, CA, 1998. AAAI Press. The PSORT II program may also be used to predict cellular localizations. Horton *et al.*, *Intelligent Systems for Molecular Biology* 5: 147-152 (1997). The table below includes the following sequence annotations: Signal peptide presence; TM (number of membrane domain, topology in orientation and position); Amino acid
 20 location and antigenic index (location, AI score); PTM and other motifs (type, amino acid residue locations); and functional domains (type, amino acid residue locations).

DEX ID	Sig P	TMHMM	Antigenicity	PTM	Domains
DEX0451_001.aa.1	N	0 - 01- 91;	49-55,1.065; 61-72,1.291;	PKC_PHOSPHO_SITE 8-10; MYRISTYL 74-79; CK2_PHOSPHO_SITE 6-9; MYRISTYL 45-50; CAMP_PHOSPHO_SITE 80-83; CAMP_PHOSPHO_SITE 27-30;	
DEX0451_001.orf.1	N	0 - 01- 117;	101- 112,1.291; 6-12,1.037; 89-95,1.065; 24-48,1.15;	PKC_PHOSPHO_SITE 48-50; MYRISTYL 85-90; CAMP_PHOSPHO_SITE 67-70; CK2_PHOSPHO_SITE 46-49;	
DEX0451_001.aa.2	N	0 - 01- 157;	115- 121,1.065; 22-29,1.069; 50-74,1.15; 32-38,1.037; 127- 138.1.291;	CAMP_PHOSPHO_SITE 146- 149; MYRISTYL 140-145; MYRISTYL 111-116; PKC_PHOSPHO_SITE 3-5; CK2_PHOSPHO_SITE 72-75; PKC_PHOSPHO_SITE 74-76; CAMP_PHOSPHO_SITE 93-96;	

			8-14,1.029;		
DEX0451_001.orf.2	N	0 - 01-153;	125- 131,1.065; 60-84,1.15; 42-48,1.037; 18-24,1.029; 137- 148,1.291; 32-39,1.069;	PKC_PHOSPHO_SITE 84-86; CAMP_PHOSPHO_SITE 103-106; PKC_PHOSPHO_SITE 13-15; MYRISTYL 121-126; CK2_PHOSPHO_SITE 82-85;	
DEX0451_002.aa.1	N	0 - 01-73;	50-58,1.118; 4-12,1.151; 62-70,1.098; 27-44,1.213; 14-20,1.074;	MYRISTYL 19-24; PKC_PHOSPHO_SITE 6-8; MYRISTYL 15-20; MYRISTYL 2-7;	
DEX0451_003.aa.1	N	0 - 01-199;	123- 143,1.128; 164- 171,1.07; 112- 121,1.149; 15-21,1.074; 150- 156,1.101; 95- 110,1.163; 72-78,1.104; 39-46,1.1;	PKC_PHOSPHO_SITE 54-56; MYRISTYL 53-58; PKC_PHOSPHO_SITE 60-62; CK2_PHOSPHO_SITE 179-182; MYRISTYL 160-165; MYRISTYL 175-180; PKC_PHOSPHO_SITE 33-35; CAMP_PHOSPHO_SITE 111-114; MYRISTYL 26-31; AMIDATION 29-32; ASN_GLYCOSYLATION 188-191; PKC_PHOSPHO_SITE 179-181;	
DEX0451_004.aa.1	N	0 - 01-132;	29-36,1.087; 77-98,1.184; 39-52,1.073; 122- 129,1.163; 8-15,1.118;	ASN_GLYCOSYLATION 88-91; PKC_PHOSPHO_SITE 73-75; CK2_PHOSPHO_SITE 62-65; PKC_PHOSPHO_SITE 96-98; PKC_PHOSPHO_SITE 106-108; CK2_PHOSPHO_SITE 16-19; PKC_PHOSPHO_SITE 115-117; MYRISTYL 102-107; CK2_PHOSPHO_SITE 2-5; PKC_PHOSPHO_SITE 36-38;	
DEX0451_004.orf.1	N	0 - 01-66;	7-32,1.133; 48-54,1.11; 37-43,1.074;	PKC_PHOSPHO_SITE 41-43; PKC_PHOSPHO_SITE 4-6; CK2_PHOSPHO_SITE 28-31; CK2_PHOSPHO_SITE 41-44; PKC_PHOSPHO_SITE 35-37; PKC_PHOSPHO_SITE 53-55; CK2_PHOSPHO_SITE 35-38;	
DEX0451_005.aa.1	N	0 - 01-175;	100- 124,1.141; 59-72,1.121; 84-94,1.153; 4-18,1.091; 130- 172,1.242; 26-36,1.102;	PKC_PHOSPHO_SITE 126-128; MYRISTYL 82-87; CK2_PHOSPHO_SITE 50-53; ASN_GLYCOSYLATION 97-100; CK2_PHOSPHO_SITE 99-102; PKC_PHOSPHO_SITE 111-113; TYR_PHOSPHO_SITE 22-29;	LEURICHRPT 44-57; LRR 89-113; LRRcap 128-146; LEURICHRPT 87-100; LRR_SDS22 50-120; LRR 65-88;
DEX0451_006.aa.1	N	1 - 01-26:tm	16-21,1.062; 4-12,1.14; 26-48,1.205;	MYRISTYL 73-78; PKC_PHOSPHO_SITE 77-79;	COX6C 5-79;

		27-46;i47-79;			
DEX0451_006.aa.2	N	1 - o1-34;tm35-52;i53-88;	25-30,1.062; 7-21,1.22; 35-57,1.205;	PKC_PHOSPHO_SITE 86-88; MYRISTYL 82-87; MYRISTYL 9-14;	COX6C 14-88;
DEX0451_006.aa.3	N	1 - o1-39;tm40-57;i58-93;	40-62,1.205; 17-26,1.087; 30-35,1.062;	CK2_PHOSPHO_SITE 6-9; PKC_PHOSPHO_SITE 91-93; MYRISTYL 87-92;	COX6C 19-93;
DEX0451_006.aa.4	N	1 - o1-27;tm28-47;i48-80;	17-22,1.062; 7-13,1.132; 27-49,1.205;	PKC_PHOSPHO_SITE 78-80; MYRISTYL 74-79;	COX6C 6-80;
DEX0451_006.aa.5	Y	1 - o1-14;tm15-32;i33-68;	15-37,1.205; 5-10,1.039;	MYRISTYL 62-67; PKC_PHOSPHO_SITE 66-68;	COX6C 1-68;
DEX0451_006.aa.6	Y	0 - o1-53;	4-22,1.205;	PKC_PHOSPHO_SITE 51-53; MYRISTYL 47-52;	COX6C 1-53;
DEX0451_006.orf.7	N	0 - o1-72;	20-41,1.155; 9-17,1.114;	MYRISTYL 66-71; PKC_PHOSPHO_SITE 13-15; PKC_PHOSPHO_SITE 70-72;	COX6C 4-72;
DEX0451_006.aa.7	N	0 - o1-80;	28-49,1.155; 4-10,1.075; 15-21,1.057;	MYRISTYL 15-20; MYRISTYL 74-79; PKC_PHOSPHO_SITE 78-80;	COX6C 13-80;
DEX0451_006.orf.8	N	0 - i1-174;		PKC_PHOSPHO_SITE 14-16; PKC_PHOSPHO_SITE 156-158; PKC_PHOSPHO_SITE 13-15; AMIDATION 13-16; PKC_PHOSPHO_SITE 146-148; CAMP_PHOSPHO_SITE 11-14; MYRISTYL 132-137; PKC_PHOSPHO_SITE 145-147; AMIDATION 45-48; PKC_PHOSPHO_SITE 71-73; CK2_PHOSPHO_SITE 107-110; PKC_PHOSPHO_SITE 99-101; CAMP_PHOSPHO_SITE 10-13; MYRISTYL 128-133; MYRISTYL 26-31; PKC_PHOSPHO_SITE 18-20; MYRISTYL 13-18; MYRISTYL 54-59; MYRISTYL 112-117; CAMP_PHOSPHO_SITE 15-18; PKC PHOSPHO SITE 107-	LYS_RICH 3-24;

				109; PKC_PHOSPHO_SITE 115-117;	
DEX0451_006.aa.8	N	1 - 01- 47;tm 48- 65;16 6- 101;	38-43,1.062; 48-70,1.205; 26-34,1.087; 10-23,1.195;	PKC_PHOSPHO_SITE 99-101; PKC_PHOSPHO_SITE 9-11; MYRISTYL 95-100;	COX6C 27-101;
DEX0451_007.aa.1	N	0 - 01- 216;	9-18,1.116; 124- 131,1.104; 192- 202,1.217; 48-54,1.105; 165- 185,1.078; 138- 149,1.061; 33-39,1.039; 76-99,1.149;	PKC_PHOSPHO_SITE 60-62; ASN_GLYCOSYLATION 5-8; ASN_GLYCOSYLATION 63-66; MYRISTYL 14-19; MYRISTYL 74-79; PKC_PHOSPHO_SITE 65-67; MYRISTYL 179-184; PKC_PHOSPHO_SITE 68-70; MYRISTYL 42-47; ASN_GLYCOSYLATION 59-62; PKC_PHOSPHO_SITE 213- 215; MYRISTYL 174-179; PKC_PHOSPHO_SITE 64-66; PKC_PHOSPHO_SITE 47-49; MYRISTYL 109-114; PKC_PHOSPHO_SITE 54-56; CK2_PHOSPHO_SITE 178- 181;	Mov34 80-194; JAB_MPN 84- 216; MPN_DOMAIN 83-173;
DEX0451_007.orf.1	N	0 - 01- 352;	55-61,1.06; 196- 202,1.053; 112- 119,1.104; 153- 173,1.078; 67-87,1.149; 331- 343,1.086; 180- 190,1.217; 221- 227,1.057; 252- 262,1.096; 281- 290,1.07; 270- 276,1.114; 231- 250,1.167; 126- 137,1.061;	CK2_PHOSPHO_SITE 166- 169; MYRISTYL 202-207; CK2_PHOSPHO_SITE 249- 252; ASN_GLYCOSYLATION 12-15; MYRISTYL 23-28; CK2_PHOSPHO_SITE 8-11; CK2_PHOSPHO_SITE 328- 331; CK2_PHOSPHO_SITE 42-45; PKC_PHOSPHO_SITE 325-327; MYRISTYL 167- 172; PKC_PHOSPHO_SITE 288-290; MYRISTYL 162- 167; CK2_PHOSPHO_SITE 275-278; MYRISTYL 97- 102;	JAB_MPN 72- 209; MPN_DOMAIN 71-161; Mov34 68-182;
DEX0451_007.aa.2	N	0 - 11- 72;	30-36,1.06; 49-67,1.107;	CK2_PHOSPHO_SITE 39-42; CK2_PHOSPHO_SITE 17-20; MICROBODIES_CTER 70-72; PKC_PHOSPHO_SITE 39-41; CK2_PHOSPHO_SITE 51-54; PKC_PHOSPHO_SITE 69-71;	
DEX0451_007.orf.	N	0 - 01-	161- 167.1.057;	CK2_PHOSPHO_SITE 106- 109; MYRISTYL 102-107;	Mov34 8-122; JAB MPN 12-

2		292;	120- 130,1.217; 66-77,1.061; 93- 113,1.078; 271- 283,1.086; 52-59,1.104; 171- 190,1.167; 221- 230,1.07; 192- 202,1.096; 4-27,1.149; 210- 216,1.114; 136- 142,1.053;	PKC_PHOSPHO_SITE 265- 267; MYRISTYL 107-112; PKC_PHOSPHO_SITE 228- 230; MYRISTYL 142-147; CK2_PHOSPHO_SITE 189- 192; CK2_PHOSPHO_SITE 268-271; MYRISTYL 37-42; CK2_PHOSPHO_SITE 215- 218;	149; MPN_DOMAIN 11-101;
DEX0451_007.aa.3	N	0 - o1- 158;	134- 144,1.217; 66-73,1.104; 80-91,1.061; 9-41,1.149; 107- 127,1.078;	ASN_GLYCOSYLATION 5-8; MYRISTYL 121-126; MYRISTYL 51-56; MYRISTYL 116-121; MYRISTYL 14-19; PKC_PHOSPHO_SITE 155- 157; CK2_PHOSPHO_SITE 120-123;	MPN_DOMAIN 25-115; Mov34 22-136; JAB_MPN 26- 158;
DEX0451_007.orf.3	N	0 - o1- 295;	96- 116,1.078; 224- 233,1.07; 164- 170,1.057; 213- 219,1.114; 69-80,1.061; 123- 133,1.217; 55-62,1.104; 174- 193,1.167; 274- 286,1.086; 139- 145,1.053; 4-30,1.149; 195- 205,1.096;	CK2_PHOSPHO_SITE 109- 112; PKC_PHOSPHO_SITE 231-233; CK2_PHOSPHO_SITE 271- 274; MYRISTYL 110-115; PKC_PHOSPHO_SITE 268- 270; MYRISTYL 105-110; MYRISTYL 40-45; MYRISTYL 145-150; CK2_PHOSPHO_SITE 218- 221; CK2_PHOSPHO_SITE 192-195;	Mov34 11-125; MPN_DOMAIN 14-104; JAB_MPN 15- 152;
DEX0451_007.aa.4	N	0 - i1- 152;	111- 131,1.078; 138- 149,1.25; 84-95,1.061; 22-45,1.149; 70-77,1.104;	MYRISTYL 55-60; ASN_GLYCOSYLATION 5-8; PKC_PHOSPHO_SITE 10-12; MYRISTYL 20-25; PKC_PHOSPHO_SITE 6-8; MYRISTYL 125-130; PKC_PHOSPHO_SITE 14-16; PKC_PHOSPHO_SITE 11-13; CK2_PHOSPHO_SITE 124- 127; ASN_GLYCOSYLATION 9-12; MYRISTYL 120-125;	Mov34 26-140; JAB_MPN 30- 151; MPN_DOMAIN 29-119;

DEX0451_007.orf.4	N	0 - 01-211;	129- 136,1.104; 143- 154,1.061; 16-25,1.139; 4-12,1.192; 170- 190,1.078; 72-78,1.06; 84- 104,1.149; 197- 208,1.25;	CK2_PHOSPHO_SITE 59-62; PKC_PHOSPHO_SITE 13-15; CK2_PHOSPHO_SITE 183-186; ASN_GLYCOSYLATION 29-32; MYRISTYL 184-189; MYRISTYL 40-45; MYRISTYL 179-184; CAMP_PHOSPHO_SITE 14-17; MYRISTYL 114-119;	Mov34 85-199; MPN_DOMAIN 88-178; JAB_MPN 89-210;
DEX0451_007.aa.5	Y	0 - 01-149;	67-73,1.114; 49-59,1.096; 128- 140,1.086; 7-18,1.211; 78-87,1.07; 28-47,1.167;	CK2_PHOSPHO_SITE 125-128; CK2_PHOSPHO_SITE 46-49; CK2_PHOSPHO_SITE 72-75; PKC_PHOSPHO_SITE 85-87; PKC_PHOSPHO_SITE 122-124;	
DEX0451_008.aa.1	N	0 - 01-199;	170- 176,1.108; 28-34,1.055; 36-60,1.194; 9-14,1.036; 127- 133,1.069; 100- 108,1.113; 68-89,1.171; 144- 152,1.12; 154- 164,1.132; 113- 121,1.088;	PKC_PHOSPHO_SITE 183-185; MYRISTYL 117-122; PKC_PHOSPHO_SITE 126-128; CK2_PHOSPHO_SITE 30-33; CK2_PHOSPHO_SITE 143-146; PKC_PHOSPHO_SITE 166-168; PKC_PHOSPHO_SITE 90-92; PKC_PHOSPHO_SITE 60-62; CK2_PHOSPHO_SITE 152-155; PKC_PHOSPHO_SITE 156-158;	AhpC-TSA 8-158;
DEX0451_009.aa.1	N	0 - 01-49;	17-26,1.171; 28-34,1.037;	PKC_PHOSPHO_SITE 37-39; CK2_PHOSPHO_SITE 13-16; MYRISTYL 25-30;	
DEX0451_009.orf.1	N	0 - 01-132;	15-33,1.114; 52-66,1.136; 111- 129,1.106; 72-87,1.19; 4-11,1.094; 36-49,1.126; 89- 101,1.132;	PKC_PHOSPHO_SITE 50-52; PKC_PHOSPHO_SITE 2-4; CK2_PHOSPHO_SITE 62-65; CAMP_PHOSPHO_SITE 71-74; CK2_PHOSPHO_SITE 34-37; CK2_PHOSPHO_SITE 98-101; PKC_PHOSPHO_SITE 125-127; AMIDATION 68-71;	
DEX0451_010.aa.1	N	0 - 01-71;	49-65,1.15; 35-43,1.049;	PKC_PHOSPHO_SITE 39-41; MYRISTYL 32-37; MYRISTYL 8-13;	
DEX0451_011.aa.1	N	0 - 01-177;	120- 131,1.045; 98- 104,1.118; 147-155,1.1; 64-73,1.091; 79-92,1.078;	PKC_PHOSPHO_SITE 28-30; CK2_PHOSPHO_SITE 50-53; PKC_PHOSPHO_SITE 132-134; PKC_PHOSPHO_SITE 144-146; PKC_PHOSPHO_SITE 147-149; ASN_GLYCOSYLATION	COLFI 1-177; COLFI 1-176; sp_Q14047_Q14047_HUMAN 1-176;

			168- 174,1.175; 11-21,1.132;	78-81; CK2_PHOSPHO_SITE 138-141;	
DEX0451_012.aa.1	N	0 - o1- 175;	4-10,1.052; 114- 128,1.183; 153- 159,1.056; 14-44,1.142; 55-64,1.127;	PKC_PHOSPHO_SITE 143- 145; PKC_PHOSPHO_SITE 40-42; ASN_GLYCOSYLATION 102-105; PKC_PHOSPHO_SITE 94-96; TYR_PHOSPHO_SITE 96-103; PKC_PHOSPHO_SITE 114- 116; MYRISTYL 78-83; AMIDATION 49-52; CK2_PHOSPHO_SITE 94-97; CK2_PHOSPHO_SITE 26-29; CAMP_PHOSPHO_SITE 172- 175; PKC_PHOSPHO_SITE 6- 8; PKC_PHOSPHO_SITE 68- 70; CK2_PHOSPHO_SITE 6- 9; MYRISTYL 19-24;	proteasome 1- 138; PROTEASOME_PR OTEASE 31- 126;
DEX0451_013.aa.1	Y	1 - il- 30;tm 31- 53;o5 4- 501;	286- 298,1.114; 160- 176,1.103; 12-22,1.168; 135- 145,1.088; 206- 213,1.108; 398- 415,1.119; 26-66,1.25; 235- 251,1.175; 72- 101,1.114; 374- 380,1.093; 425- 445,1.147; 300- 315,1.145; 331- 337,1.061; 267- 284,1.174; 345- 371,1.138; 182- 199,1.167; 105- 133,1.117; 447- 465,1.153;	ASN_GLYCOSYLATION 305- 308; PKC_PHOSPHO_SITE 184-186; MYRISTYL 202- 207; CK2_PHOSPHO_SITE 222-225; PKC_PHOSPHO_SITE 78-80; CK2_PHOSPHO_SITE 324- 327; CK2_PHOSPHO_SITE 290-293; PKC_PHOSPHO_SITE 64-66; PKC_PHOSPHO_SITE 479- 481; PKC_PHOSPHO_SITE 284-286; MYRISTYL 198- 203; ASN_GLYCOSYLATION 227-230; CK2_PHOSPHO_SITE 483- 486; PKC_PHOSPHO_SITE 324-326; ASN_GLYCOSYLATION 476- 479; PKC_PHOSPHO_SITE 393-395; MYRISTYL 431- 436; MYRISTYL 262-267; MYRISTYL 489-494; ASN_GLYCOSYLATION 475- 478; CK2_PHOSPHO_SITE 351-354; ASN_GLYCOSYLATION 345- 348; AMIDATION 338-341; CK2_PHOSPHO_SITE 299- 302; MYRISTYL 156-161; CK2_PHOSPHO_SITE 174- 177; CAMP_PHOSPHO_SITE 296-299;	TF AP-2 267- 474;
DEX0451_013.aa.2	N	0 - o1- 458;	331- 337,1.093; 163- 170,1.108; 139- 156.1.167;	ASN_GLYCOSYLATION 262- 265; PKC_PHOSPHO_SITE 436-438; ASN_GLYCOSYLATION 184- 187; CK2_PHOSPHO_SITE 179-182; MYRISTYL 388-	TF AP-2 224- 431;

			117- 133,1.103; 192- 208,1.175; 4-9,1.105; 224- 241,1.174; 29-58,1.114; 92- 102,1.088; 243- 255,1.114; 288- 294,1.061; 257- 272,1.145; 16-22,1.119; 302- 328,1.138; 355- 372,1.119; 404- 422,1.153; 62-90,1.117; 382- 402,1.147;	393; CK2_PHOSPHO_SITE 131-134; TYR_PHOSPHO_SITE 4-11; PKC_PHOSPHO_SITE 141- 143; MYRISTYL 446-451; MYRISTYL 113-118; CK2_PHOSPHO_SITE 308- 311; ASN_GLYCOSYLATION 432-435; MYRISTYL 159- 164; CK2_PHOSPHO_SITE 256-259; AMIDATION 295- 298; CK2_PHOSPHO_SITE 281-284; PKC_PHOSPHO_SITE 241- 243; MYRISTYL 219-224; PKC_PHOSPHO_SITE 35-37; CK2_PHOSPHO_SITE 440- 443; MYRISTYL 155-160; ASN_GLYCOSYLATION 302- 305; CK2_PHOSPHO_SITE 23-26; CK2_PHOSPHO_SITE 247-250; ASN_GLYCOSYLATION 433- 436; PKC_PHOSPHO_SITE 350-352; PKC_PHOSPHO_SITE 281- 283; CAMP_PHOSPHO_SITE 253-256;	
DEX0451_ 013.orf. 2	N	0 - 01- 469;	128- 144,1.103; 10-20,1.105; 415- 433,1.153; 299- 305,1.061; 342- 348,1.093; 268- 283,1.145; 27-33,1.119; 203- 219,1.175; 103- 113,1.088; 174- 181,1.108; 150- 167,1.167; 393- 413,1.147; 40-69,1.114; 73- 101,1.117; 235- 252,1.174; 313- 339,1.138; 254- 266.1.114:	CK2_PHOSPHO_SITE 292- 295; ASN_GLYCOSYLATION 313-316; CK2_PHOSPHO_SITE 319- 322; AMIDATION 306-309; CK2_PHOSPHO_SITE 34-37; CK2_PHOSPHO_SITE 190- 193; MYRISTYL 124-129; CK2_PHOSPHO_SITE 258- 261; CK2_PHOSPHO_SITE 267-270; ASN_GLYCOSYLATION 195- 198; PKC_PHOSPHO_SITE 447-449; PKC_PHOSPHO_SITE 361- 363; ASN_GLYCOSYLATION 444-447; MYRISTYL 399- 404; ASN_GLYCOSYLATION 273-276; PKC_PHOSPHO_SITE 292- 294; ASN_GLYCOSYLATION 443-446; MYRISTYL 457- 462; PKC_PHOSPHO_SITE 152-154; TYR_PHOSPHO_SITE 15-22; CK2_PHOSPHO_SITE 142- 145; PKC_PHOSPHO_SITE 46-48; MYRISTYL 230-235; PKC_PHOSPHO_SITE 252- 254; MYRISTYL 170-175; CK2 PHOSPHO SITE 451-	TF_AP-2 235- 442;

			366- 383,1.119;	454; CAMP_PHOSPHO_SITE 264-267; MYRISTYL 166- 171;	
DEX0451_ 014.aa.1	N	0 - 01- 201;	160- 193,1.231; 22-27,1.082; 75-93,1.176; 42-53,1.094; 99- 133,1.217; 148- 154,1.081; 67-73,1.078;	CK2_PHOSPHO_SITE 153- 156; PKC_PHOSPHO_SITE 75-77; PKC_PHOSPHO_SITE 115-117; CAMP_PHOSPHO_SITE 193- 196; PKC_PHOSPHO_SITE 153-155;	IDO 8-201;
DEX0451_ 015.aa.1	Y	0 - 01- 133;	109- 115,1.133; 27-58,1.187; 66-83,1.124; 93-102,1.15; 5-25,1.178;	PKC_PHOSPHO_SITE 121- 123; CK2_PHOSPHO_SITE 75-78; MYRISTYL 68-73; CK2_PHOSPHO_SITE 24-27; ASN_GLYCOSYLATION 87-90;	
DEX0451_ 015.orf. 1	N	1 - 01- 48;tm 49- 71;i7 2- 157;	139- 146,1.155; 47-72,1.241; 88-99,1.095; 102- 127,1.17; 11-18,1.154; 33-39,1.07;	CK2_PHOSPHO_SITE 117- 120; PKC_PHOSPHO_SITE 100-102; PKC_PHOSPHO_SITE 41-43; MYRISTYL 146-151; CK2_PHOSPHO_SITE 41-44;	
DEX0451_ 015.aa.2	Y	0 - 01- 121;	93-101,1.15; 112- 118,1.076; 5-25,1.178; 27-58,1.187; 66-83,1.124;	CK2_PHOSPHO_SITE 24-27; CK2_PHOSPHO_SITE 75-78; ASN_GLYCOSYLATION 87-90; MYRISTYL 68-73; PKC_PHOSPHO_SITE 116- 118;	
DEX0451_ 016.aa.1	N	0 - 01- 149;	10-33,1.159; 70-80,1.164; 39-66,1.223; 102- 119,1.147; 123- 139,1.095; 86-95,1.116;	MYRISTYL 70-75; PKC_PHOSPHO_SITE 74-76; CK2_PHOSPHO_SITE 129- 132; PKC_PHOSPHO_SITE 100-102; ASN_GLYCOSYLATION 9-12; CK2_PHOSPHO_SITE 96-99; ASN_GLYCOSYLATION 146- 149; PKC_PHOSPHO_SITE 115-117; PKC_PHOSPHO_SITE 16-18;	
DEX0451_ 016.orf. 1	Y	0 - 01- 204;	81-93,1.148; 162- 182,1.143; 37-46,1.089; 23-34,1.198; 64-79,1.082; 147- 157,1.231; 102- 140,1.154; 51-57,1.068; 4-20,1.231;	MYRISTYL 161-166; PKC_PHOSPHO_SITE 91-93; PKC_PHOSPHO_SITE 127- 129; CK2_PHOSPHO_SITE 91-94; MYRISTYL 160-165; MYRISTYL 135-140; ASN_GLYCOSYLATION 147- 150; CAMP_PHOSPHO_SITE 143-146; MYRISTYL 178- 183; CK2_PHOSPHO_SITE 47-50; MYRISTYL 157-162; MYRISTYL 119-124; MICROBODIES_CTER 202- 204; PKC PHOSPHO SITE	

				142-144; CK2_PHOSPHO_SITE 164-167; AMIDATION 95-98; MYRISTYL 185-190; MYRISTYL 56-61; MYRISTYL 57-62;	
DEX0451_017.aa.1	N	0 - 01-194;	130- 136,1.101; 52-58,1.104; 92- 101,1.149; 75-90,1.163; 103- 123,1.128; 144- 151,1.07; 162- 169,1.129;	CK2_PHOSPHO_SITE 159-162; MYRISTYL 172-177; PKC_PHOSPHO_SITE 34-36; PKC_PHOSPHO_SITE 40-42; CAMP_PHOSPHO_SITE 91-94; MYRISTYL 15-20; MYRISTYL 155-160; PKC_PHOSPHO_SITE 159-161; MYRISTYL 33-38; PKC_PHOSPHO_SITE 169-171; PKC_PHOSPHO_SITE 173-175; MYRISTYL 140-145;	
DEX0451_018.aa.1	N	0 - 01-472;	260- 265,1.05; 220- 225,1.029; 30-42,1.1; 307- 321,1.09; 177- 183,1.076; 239- 248,1.102; 402- 432,1.247; 344- 352,1.169; 273- 281,1.107; 46-70,1.115; 113- 119,1.052; 125- 132,1.115; 91-97,1.083; 284- 293,1.184; 325- 337,1.099; 436- 469,1.227; 368- 379,1.184;	PKC_PHOSPHO_SITE 247-249; CK2_PHOSPHO_SITE 350-353; CAMP_PHOSPHO_SITE 124-127; AMIDATION 201-204; PKC_PHOSPHO_SITE 123-125; MYRISTYL 62-67; PKC_PHOSPHO_SITE 106-108; MYRISTYL 383-388; TYR_PHOSPHO_SITE 282-289; PKC_PHOSPHO_SITE 19-21; PKC_PHOSPHO_SITE 362-364; CAMP_PHOSPHO_SITE 227-230; CAMP_PHOSPHO_SITE 215-218; ASN_GLYCOSYLATION 384-387; CK2_PHOSPHO_SITE 19-22; CK2_PHOSPHO_SITE 362-365; PKC_PHOSPHO_SITE 244-246; MYRISTYL 358-363; MYRISTYL 393-398; MYRISTYL 198-203; CAMP_PHOSPHO_SITE 203-206; CK2_PHOSPHO_SITE 264-267; MYRISTYL 456-461; CK2_PHOSPHO_SITE 387-390; PKC_PHOSPHO_SITE 366-368; ASN_GLYCOSYLATION 99-102; PKC_PHOSPHO_SITE 42-44; MYRISTYL 8-13; MYRISTYL 430-435;	ARG_RICH 215-258; MAGE 279-390; MAGE 88-395;
DEX0451_018.aa.2	N	0 - 01-528;	412- 424,1.099; 431- 439,1.169; 239- 248.1.102:	PKC_PHOSPHO_SITE 380-382; PKC_PHOSPHO_SITE 106-108; PKC_PHOSPHO_SITE 449-451; ASN_GLYCOSYLATION 471-474; MYRISTYL 470-	MAGE 88-488; ARG_RICH 215-258; MAGE 390-490;

			273- 281,1.107; 125- 132,1.115; 455- 466,1.184; 177- 183,1.076; 492- 525,1.227; 475- 488,1.139; 91-97,1.083; 46-70,1.115; 358- 367,1.146; 284- 293,1.184; 113- 119,1.052; 260- 265,1.05; 220- 225,1.029; 30-42,1.1; 375- 392,1.124; 394- 408,1.09; 303- 355,1.194;	475; PKC_PHOSPHO_SITE 42-44; MYRISTYL 327-332; CK2_PHOSPHO_SITE 449- 452; CK2_PHOSPHO_SITE 437-440; PKC_PHOSPHO_SITE 19-21; MYRISTYL 445-450; CK2_PHOSPHO_SITE 264- 267; TYR_PHOSPHO_SITE 282-289; PKC_PHOSPHO_SITE 453- 455; MYRISTYL 62-67; CAMP_PHOSPHO_SITE 215- 218; ASN_GLYCOSYLATION 99-102; MYRISTYL 512- 517; MYRISTYL 8-13; AMIDATION 201-204; PKC_PHOSPHO_SITE 247- 249; CAMP_PHOSPHO_SITE 203-206; CK2_PHOSPHO_SITE 19-22; PKC_PHOSPHO_SITE 123- 125; PKC_PHOSPHO_SITE 244-246; CAMP_PHOSPHO_SITE 124- 127; CAMP_PHOSPHO_SITE 227-230; MYRISTYL 486- 491; MYRISTYL 198-203; PKC_PHOSPHO_SITE 303- 305;	
DEX0451_018.orf.2	N	0 - 01- 314;	274- 282,1.107; 92-98,1.083; 47-71,1.115; 261- 266,1.05; 126- 133,1.115; 114- 120,1.052; 285- 294,1.184; 178- 184,1.076; 221- 226,1.029; 31-43,1.1; 240- 249,1.102; 304- 311,1.202;	CAMP_PHOSPHO_SITE 125- 128; PKC_PHOSPHO_SITE 245-247; PKC_PHOSPHO_SITE 43-45; PKC_PHOSPHO_SITE 107- 109; TYR_PHOSPHO_SITE 283-290; CK2_PHOSPHO_SITE 20-23; CAMP_PHOSPHO_SITE 228- 231; PKC_PHOSPHO_SITE 304-306; AMIDATION 202- 205; PKC_PHOSPHO_SITE 248-250; CAMP_PHOSPHO_SITE 204- 207; MYRISTYL 199-204; CAMP_PHOSPHO_SITE 216- 219; PKC_PHOSPHO_SITE 124-126; CK2_PHOSPHO_SITE 265- 268; MYRISTYL 63-68; PKC_PHOSPHO_SITE 20-22; MYRISTYL 9-14; ASN_GLYCOSYLATION 100- 103;	ARG_RICH 216-259;
DEX0451_019.aa.1	N	0 - 01- 35;		MYRISTYL 7-12; AMIDATION 21-24;	
DEX0451	Y	0 -	7-37.1.162:	PKC PHOSPHO SITE 36-38;	

019.orf. 1		01- 80;	41-77,1.204;	PKC_PHOSPHO_SITE 46-48; PKC_PHOSPHO_SITE 76-78; PKC_PHOSPHO_SITE 72-74;	
DEX0451_ 019.aa.2	N	0 - 01- 33;		CAMP_PHOSPHO_SITE 29-32; AMIDATION 21-24; MYRISTYL 7-12;	
DEX0451_ 019.orf. 2	Y	0 - 01- 80;	41-77,1.204; 7-37,1.162;	PKC_PHOSPHO_SITE 72-74; PKC_PHOSPHO_SITE 36-38; PKC_PHOSPHO_SITE 46-48; PKC_PHOSPHO_SITE 76-78;	
DEX0451_ 020.aa.1	N	0 - 01- 73;	5-14,1.193; 44-52,1.087; 54-60,1.096; 18-29,1.187;	MYRISTYL 68-73; MYRISTYL 15-20; MYRISTYL 63-68;	ATP_GTP_A 12- 19; RAB 6-73; RASTRNSFRMNG 47-69; RASTRNSFRMNG 6-27; RASTRNSFRMNG 29-45;
DEX0451_ 020.orf. 1	N	0 - 01- 94;	4-89,1.281;	CK2_PHOSPHO_SITE 89-92; MYRISTYL 87-92; ASN_GLYCOSYLATION 32-35; CK2_PHOSPHO_SITE 45-48;	
DEX0451_ 020.aa.2	N	0 - 01- 54;	4-18,1.148;	MYRISTYL 10-15; PKC_PHOSPHO_SITE 20-22; PKC_PHOSPHO_SITE 39-41; ASN_GLYCOSYLATION 37-40; PKC_PHOSPHO_SITE 50-52; MYRISTYL 35-40;	
DEX0451_ 020.orf. 2	N	0 - 01- 94;	4-89,1.281;	CK2_PHOSPHO_SITE 45-48; MYRISTYL 87-92; CK2_PHOSPHO_SITE 89-92; ASN_GLYCOSYLATION 32-35;	
DEX0451_ 021.aa.1	N	0 - 01- 284;	122- 129,1.091; 159- 176,1.159; 112- 120,1.099; 182- 188,1.055; 276- 281,1.152; 233- 248,1.211; 94-110,1.16; 195- 226,1.155; 31-43,1.09; 144- 153,1.122;	PKC_PHOSPHO_SITE 62-64; CK2_PHOSPHO_SITE 245- 248; PKC_PHOSPHO_SITE 254-256; CK2_PHOSPHO_SITE 85-88; PKC_PHOSPHO_SITE 201- 203; CAMP_PHOSPHO_SITE 156-159; ASN_GLYCOSYLATION 252- 255; MYRISTYL 197-202; PKC_PHOSPHO_SITE 7-9; CK2_PHOSPHO_SITE 180- 183; PKC_PHOSPHO_SITE 4- 6; ASN_GLYCOSYLATION 152-155; CK2_PHOSPHO_SITE 62-65; CK2_PHOSPHO_SITE 135- 138; CAMP_PHOSPHO_SITE 256-259; ASN_GLYCOSYLATION 190- 193; MYRISTYL 225-230; PKC_PHOSPHO_SITE 25-27; PKC_PHOSPHO_SITE 259- 261; PKC_PHOSPHO_SITE 229-231; CK2 PHOSPHO SITE 87-90;	

				MYRISTYL 19-24; PKC_PHOSPHO_SITE 154-156; CAMP_PHOSPHO_SITE 13-16; PKC_PHOSPHO_SITE 192-194;	
DEX0451_021.aa.2	N	0 - o1- 220;	182- 188,1.055; 195- 217,1.155; 122- 129,1.091; 112- 120,1.099; 159- 176,1.159; 94-110,1.16; 144- 153,1.122; 31-43,1.09;	CAMP_PHOSPHO_SITE 156-159; CK2_PHOSPHO_SITE 135-138; CK2_PHOSPHO_SITE 62-65; PKC_PHOSPHO_SITE 154-156; ASN_GLYCOSYLATION 190-193; CK2_PHOSPHO_SITE 85-88; CK2_PHOSPHO_SITE 87-90; PKC_PHOSPHO_SITE 4-6; PKC_PHOSPHO_SITE 62-64; PKC_PHOSPHO_SITE 192-194; PKC_PHOSPHO_SITE 7-9; CK2_PHOSPHO_SITE 180-183; MYRISTYL 19-24; PKC_PHOSPHO_SITE 201-203; ASN_GLYCOSYLATION 152-155; CAMP_PHOSPHO_SITE 13-16; MYRISTYL 197-202; PKC_PHOSPHO_SITE 25-27;	
DEX0451_021.aa.3	N	0 - o1- 190;	31-43,1.09; 94-110,1.16; 152- 158,1.055; 165- 187,1.155; 122- 146,1.159; 112- 120,1.099;	PKC_PHOSPHO_SITE 4-6; MYRISTYL 19-24; CK2_PHOSPHO_SITE 87-90; CK2_PHOSPHO_SITE 62-65; CK2_PHOSPHO_SITE 150-153; PKC_PHOSPHO_SITE 25-27; CK2_PHOSPHO_SITE 85-88; MYRISTYL 167-172; ASN_GLYCOSYLATION 160-163; CAMP_PHOSPHO_SITE 13-16; PKC_PHOSPHO_SITE 162-164; PKC_PHOSPHO_SITE 171-173; PKC_PHOSPHO_SITE 7-9; PKC_PHOSPHO_SITE 62-64;	
DEX0451_022.aa.1	N	1 - i1- 137;t m138- 157;o 158- 305;	105- 111,1.142; 28-73,1.192; 256- 295,1.203; 11-23,1.134; 76-83,1.118; 92-98,1.063; 167- 181,1.155; 241- 249,1.113; 201- 229,1.187; 117- 161,1.173;	PKC_PHOSPHO_SITE 240-242; CK2_PHOSPHO_SITE 165-168; MYRISTYL 229-234; MYRISTYL 149-154; CK2_PHOSPHO_SITE 240-243; PKC_PHOSPHO_SITE 167-169; TYR_PHOSPHO_SITE 114-121; MYRISTYL 296-301; CK2_PHOSPHO_SITE 3-6; PKC_PHOSPHO_SITE 3-5; CK2_PHOSPHO_SITE 18-21; CK2_PHOSPHO_SITE 295-298; ASN_GLYCOSYLATION 73-76;	Pex2_Pex12 12-228; zf- C3HC4 244- 283; sp_Q9M9Z9_Q9M 9Z9_ARATH 1- 119; RING 244-283; ZF_RING_2 244-283; ZF_RING_1 259-268;

				123; PKC_PHOSPHO_SITE 148-150; CK2_PHOSPHO_SITE 560- 563; PKC_PHOSPHO_SITE 489-491; MYRISTYL 435- 440; PKC_PHOSPHO_SITE 123-125; MYRISTYL 190- 195; PKC_PHOSPHO_SITE 568-570;	
DEX0451_024.aa.1	N	0 - 01- 389;	349-354,1.1; 235- 241,1.082; 41-83,1.169; 328- 342,1.089; 146- 154,1.106; 119- 136,1.121; 360- 366,1.105; 272- 279,1.088; 8-36,1.251; 371- 386,1.126; 214- 220,1.129; 178- 195,1.106; 296- 317,1.077; 167- 174,1.059; 85-99,1.141; 251- 262,1.153;	MYRISTYL 211-216; MYRISTYL 186-191; PKC_PHOSPHO_SITE 335- 337; PKC_PHOSPHO_SITE 293-295; PKC_PHOSPHO_SITE 292- 294; MYRISTYL 278-283; MYRISTYL 249-254; CK2_PHOSPHO_SITE 228- 231; MYRISTYL 345-350; MYRISTYL 209-214; MYRISTYL 367-372; CK2_PHOSPHO_SITE 243- 246; MYRISTYL 344-349;	PHGLYCKINASE 129-151; PHGLYCKINASE 158-180; PGK 20-389; PHGLYCKINASE 86-101; PHGLYCKINASE 341-352; PHGLYCKINASE 305-330; PHGLYCKINASE 181-200; PHGLYCKINASE 364-381;
DEX0451_025.aa.1	N	0 - 01- 121;	80-86,1.092; 19-26,1.096; 44-49,1.054; 65-72,1.106; 5-11,1.072; 29-40,1.102; 106- 118,1.186;	PKC_PHOSPHO_SITE 102- 104; PKC_PHOSPHO_SITE 25-27; ASN_GLYCOSYLATION 92-95; CAMP_PHOSPHO_SITE 60-63; CAMP_PHOSPHO_SITE 13-16; CK2_PHOSPHO_SITE 46-49; CK2_PHOSPHO_SITE 31-34;	Stathmin 4- 121; STATHMIN 37-65; STATHMIN 8- 26; STATHMIN_1 40-49; STATHMIN_2 73-82; STATHMIN 90- 113; STATHMIN 66-89;
DEX0451_026.aa.1	N	0 - 01- 121;	8-19,1.09; 63-69,1.077; 49-55,1.116; 83-97,1.205; 102- 118,1.131; 27-38,1.166;	ASN_GLYCOSYLATION 59-62; PKC_PHOSPHO_SITE 67-69; MYRISTYL 57-62; CK2_PHOSPHO_SITE 26-29; MYRISTYL 76-81; PKC_PHOSPHO_SITE 62-64; MYRISTYL 43-48;	ZINC_FINGER_C 2H2_1 86-108;
DEX0451_026.aa.2	N	0 - 01-	4-16,1.161; 22-37,1.111;	MYRISTYL 214-219; MYRISTYL 207-212;	GPROTEINB 48- 64; WD40 41-

		232;	112- 126,1.195; 88-96,1.138; 153- 175,1.132; 43-48,1.068; 98-104,1.08; 131- 140,1.12; 214- 229,1.147; 199- 212,1.18; 75-81,1.084; 142- 149,1.108;	PKC_PHOSPHO_SITE 80-82; PKC_PHOSPHO_SITE 219- 221; MYRISTYL 53-58; MYRISTYL 39-44; PKC_PHOSPHO_SITE 64-66; CK2_PHOSPHO_SITE 56-59; MYRISTYL 71-76; PKC_PHOSPHO_SITE 85-87; PKC_PHOSPHO_SITE 72-74;	80; WD40 132- 170; GPROTEINB 67- 81; WD40 86- 124; GPROTEINB 106-123; WD40 85-124; WD_REPEATS_RE GION 48-89; WD_REPEATS_2 48-82; WD40 130-170; WD40 42-80;
DEX0451_027.aa.1	N	0 - 01- 582;	143- 162,1.105; 278- 285,1.09; 500- 526,1.16; 183- 200,1.172; 26- 107,1.207; 465- 471,1.081; 221- 226,1.098; 443- 457,1.167; 547- 567,1.253; 351- 356,1.073; 231- 248,1.112; 114- 122,1.163; 479- 497,1.182; 164- 175,1.07; 429- 441,1.099; 533- 541,1.148; 325- 338,1.12; 371- 411,1.232; 4-21,1.127; 267- 273,1.076; 570- 579,1.096; 290- 296,1.11;	CK2_PHOSPHO_SITE 433- 436; CK2_PHOSPHO_SITE 128-131; CK2_PHOSPHO_SITE 148- 151; TYR_PHOSPHO_SITE 40-48; ASN_GLYCOSYLATION 369-372; PKC_PHOSPHO_SITE 541- 543; CK2_PHOSPHO_SITE 195-198; CK2_PHOSPHO_SITE 262- 265; PKC_PHOSPHO_SITE 217-219; PKC_PHOSPHO_SITE 341- 343; CK2_PHOSPHO_SITE 274-277; MYRISTYL 13-18; MYRISTYL 358-363; CK2_PHOSPHO_SITE 217- 220; MYRISTYL 249-254; CK2_PHOSPHO_SITE 41-44;	PRO_RICH 237- 297; Rad21_Rec8 527-581; Rad21_Rec8_N 1-120; GLU_RICH 160- 278;

DEX0451_027.orf.1	N	0 - 01-456;	188-205,1.172; 226-231,1.098; 356-361,1.073; 330-343,1.12; 31-112,1.207; 283-290,1.09; 376-415,1.236; 295-301,1.11; 169-180,1.07; 236-253,1.112; 148-167,1.105; 447-453,1.192; 435-441,1.113; 418-425,1.105; 9-26,1.127; 272-278,1.076; 119-127,1.163;	CK2_PHOSPHO_SITE 46-49; PKC_PHOSPHO_SITE 346-348; ASN_GLYCOSYLATION 374-377; MYRISTYL 254-259; CK2_PHOSPHO_SITE 153-156; MYRISTYL 18-23; CK2_PHOSPHO_SITE 267-270; CK2_PHOSPHO_SITE 200-203; CK2_PHOSPHO_SITE 222-225; TYR_PHOSPHO_SITE 45-53; MYRISTYL 363-368; PKC_PHOSPHO_SITE 222-224; CK2_PHOSPHO_SITE 279-282; CK2_PHOSPHO_SITE 133-136;	PRO_RICH 242-302; GLU_RICH 165-283; Rad21_Rec8_N 6-125;
DEX0451_028.aa.1	N	0 - 01-357;	184-234,1.167; 325-335,1.099; 108-124,1.143; 132-144,1.148; 156-170,1.111; 28-55,1.203; 6-20,1.183; 236-255,1.209; 295-308,1.097; 313-319,1.014; 265-291,1.189; 57-88,1.164; 342-352,1.088;	PKC_PHOSPHO_SITE 3-5; CK2_PHOSPHO_SITE 163-166; MYRISTYL 8-13; TYR_PHOSPHO_SITE 232-239; ASN_GLYCOSYLATION 262-265; PKC_PHOSPHO_SITE 19-21; CK2_PHOSPHO_SITE 216-219; MYRISTYL 6-11; PKC_PHOSPHO_SITE 221-223; PKC_PHOSPHO_SITE 53-55; CK2_PHOSPHO_SITE 233-236; CK2_PHOSPHO_SITE 93-96; PKC_PHOSPHO_SITE 163-165; AMIDATION 56-59; CK2_PHOSPHO_SITE 306-309;	RHO_GAP 134-276; RhoGAP 134-284; CRAL_TRIO 1-92; RhoGAP 131-302;
DEX0451_028.orf.1	N	0 - 01-337;	216-235,1.209; 112-	CK2_PHOSPHO_SITE 213-216; PKC_PHOSPHO_SITE 33-35; PKC PHOSPHO SITE	RHO_GAP 114-256; CRAL TRIO 1-

			124,1.148; 293- 299,1.014; 88- 104,1.143; 136- 150,1.111; 245- 271,1.189; 37-68,1.164; 275- 288,1.097; 164- 214,1.167; 322- 332,1.088; 305- 315,1.099; 8-35,1.203;	2-4; AMIDATION 36-39; PKC_PHOSPHO_SITE 143- 145; ASN_GLYCOSYLATION 242-245; CK2_PHOSPHO_SITE 286- 289; CK2_PHOSPHO_SITE 143-146; TYR_PHOSPHO_SITE 212- 219; CK2_PHOSPHO_SITE 73-76; PKC_PHOSPHO_SITE 201-203; CK2_PHOSPHO_SITE 196- 199;	72; RhoGAP 111-282; RhoGAP 114- 264;
DEX0451_028.aa.2	N	0 - 01- 237;	222- 232,1.088; 116- 135,1.209; 64- 114,1.167; 175- 188,1.097; 145- 171,1.189; 205- 215,1.099; 193- 199,1.014; 36-50,1.111; 6-13,1.12;	CK2_PHOSPHO_SITE 113- 116; CK2_PHOSPHO_SITE 186-189; PKC_PHOSPHO_SITE 43-45; CK2_PHOSPHO_SITE 43-46; ASN_GLYCOSYLATION 142- 145; MYRISTYL 4-9; CK2_PHOSPHO_SITE 96-99; PKC_PHOSPHO_SITE 101- 103; TYR_PHOSPHO_SITE 112-119;	RHO_GAP 28- 156; RhoGAP 7-182; RhoGAP 27-164;
DEX0451_028.orf.2	N	0 - 01- 248;	216- 226,1.099; 4-9,1.091; 17-24,1.12; 204- 210,1.014; 186- 199,1.097; 233- 243,1.088; 127- 146,1.209; 75- 125,1.167; 47-61,1.111; 156- 182,1.189;	CK2_PHOSPHO_SITE 54-57; TYR_PHOSPHO_SITE 123- 130; PKC_PHOSPHO_SITE 112-114; CK2_PHOSPHO_SITE 197- 200; ASN_GLYCOSYLATION 153-156; PKC_PHOSPHO_SITE 54-56; CK2_PHOSPHO_SITE 124- 127; CK2_PHOSPHO_SITE 107-110; MYRISTYL 15-20;	RhoGAP 38- 175; RhoGAP 18-193; RHO_GAP 39- 167;
DEX0451_029.aa.1	N	0 - 01- 113;	18-39,1.14; 99- 105,1.084; 46-58,1.081; 69-75,1.092; 85-95,1.121;	PKC_PHOSPHO_SITE 5-7; PKC_PHOSPHO_SITE 16-18; CK2_PHOSPHO_SITE 25-28; PKC_PHOSPHO_SITE 45-47; PKC_PHOSPHO_SITE 13-15; PKC_PHOSPHO_SITE 69-71; PKC_PHOSPHO_SITE 110-	

				112;	
DEX0451_030.aa.1	N	0 - 01- 81;	10-29,1.25; 37-62,1.214;	PKC_PHOSPHO_SITE 5-7; MYRISTYL 35-40; MYRISTYL 46-51; MYRISTYL 49-54; PKC_PHOSPHO_SITE 14-16;	
DEX0451_030.orf.1	N	0 - 01- 126;	109- 114,1.055; 61-90,1.137; 24-40,1.166;	CK2_PHOSPHO_SITE 99-102; AMIDATION 4-7; MYRISTYL 57-62; MYRISTYL 46-51; CAMP_PHOSPHO_SITE 90-93; ASN_GLYCOSYLATION 22-25; MYRISTYL 8-13; MYRISTYL 118-123; MYRISTYL 84-89; PKC_PHOSPHO_SITE 31-33; PKC_PHOSPHO_SITE 88-90; CK2_PHOSPHO_SITE 93-96; CAMP_PHOSPHO_SITE 6-9; MYRISTYL 61-66; MYRISTYL 42-47; RGD 49-51;	
DEX0451_030.aa.2	N	0 - 01- 126;	4-28,1.152; 104- 116,1.156; 32-46,1.157; 85- 100,1.167; 64-76,1.198;	PKC_PHOSPHO_SITE 118- 120; PKC_PHOSPHO_SITE 89-91; ASN_GLYCOSYLATION 116-119; CK2_PHOSPHO_SITE 46-49; CAMP_PHOSPHO_SITE 119- 122;	sp_Q04984_CH1 O_HUMAN 33- 111; cpn10 32-116; CHAPERONIN10 34-49; CHAPERONINS_C PN10 34-58; CHAPERONIN10 56-77; CHAPERONIN10 91-103;
DEX0451_031.aa.1	N	0 - 01- 162;	132- 153,1.246; 4-55,1.227; 115- 122,1.089; 69- 113,1.256;	PKC_PHOSPHO_SITE 113- 115; MYRISTYL 24-29; PKC_PHOSPHO_SITE 12-14;	
DEX0451_031.orf.1	N	0 - 01- 201;	108- 152,1.256; 171- 192,1.246; 154- 161,1.089; 4-11,1.122; 36-94,1.227;	CK2_PHOSPHO_SITE 30-33; PKC_PHOSPHO_SITE 51-53; PKC_PHOSPHO_SITE 152- 154; MYRISTYL 63-68;	
DEX0451_032.aa.1	N	0 - 01- 168;	50-66,1.078; 158- 165,1.123; 127- 137,1.118; 81- 101,1.129; 142- 149,1.118;	PKC_PHOSPHO_SITE 21-23; CK2_PHOSPHO_SITE 41-44; PKC_PHOSPHO_SITE 125- 127; MYRISTYL 116-121; PKC_PHOSPHO_SITE 64-66; MYRISTYL 81-86; CK2_PHOSPHO_SITE 3-6; PKC_PHOSPHO_SITE 105- 107; CAMP_PHOSPHO_SITE 138-141; CK2_PHOSPHO_SITE 92-95; CK2_PHOSPHO_SITE 22-25; MYRISTYL 155-160;	TYPE1KERATIN 54-69; TYPE1KERATIN 80-106;

				CK2_PHOSPHO_SITE 72-75; PKC_PHOSPHO_SITE 120-122;	
DEX0451_032.orf.1	N	0 - 01- 194;	168- 179,1.074; 95- 111,1.078; 24-34,1.132; 4-17,1.226; 126- 146,1.129;	PKC_PHOSPHO_SITE 150-152; PKC_PHOSPHO_SITE 109-111; PKC_PHOSPHO_SITE 18-20; MYRISTYL 126-131; TYR_PHOSPHO_SITE 166-174; CK2_PHOSPHO_SITE 48-51; MYRISTYL 9-14; CK2_PHOSPHO_SITE 176-179; CK2_PHOSPHO_SITE 117-120; ASN_GLYCOSYLATION 187-190; MYRISTYL 36-41; CK2_PHOSPHO_SITE 86-89; CK2_PHOSPHO_SITE 67-70; CK2_PHOSPHO_SITE 165-168; PKC_PHOSPHO_SITE 66-68; MYRISTYL 21-26; CK2_PHOSPHO_SITE 137-140; MYRISTYL 24-29; PKC_PHOSPHO_SITE 173-175;	TROPOMYOSIN 89-106; filament 1-184; TROPOMYOSIN 151-179; TYPE1KERATIN 27-47; IF 171-179; TYPE1KERATIN 99-114; TYPE1KERATIN 125-151;
DEX0451_032.aa.2	N	0 - 01- 265;	139- 144,1.047; 149- 155,1.12; 126- 134,1.06; 239- 256,1.131; 209- 216,1.062; 90- 101,1.095; 44-56,1.117; 24-37,1.079; 66-75,1.074; 186- 198,1.108;	LEUCINE_ZIPPER 193-214; MYRISTYL 44-49; PKC_PHOSPHO_SITE 5-7; MYRISTYL 74-79; CK2_PHOSPHO_SITE 133-136; MYRISTYL 63-68; CK2_PHOSPHO_SITE 198-201; CK2_PHOSPHO_SITE 93-96; MYRISTYL 17-22; MYRISTYL 59-64; CK2_PHOSPHO_SITE 167-170; LEUCINE_ZIPPER 186-90; PKC_PHOSPHO_SITE 49-51; PKC_PHOSPHO_SITE 224-226; MYRISTYL 62-67; CK2_PHOSPHO_SITE 70-73; MYRISTYL 38-43; PKC_PHOSPHO_SITE 22-24; MYRISTYL 66-71; MYRISTYL 16-21; MYRISTYL 67-72;	filament 79-265; GLY_RICH 16-78; TYPE1KERATIN 179-202; TYPE1KERATIN 158-171;
DEX0451_032.aa.3	N	0 - 11- 69;	28-38,1.118; 43-50,1.118; 59-66,1.123; 4-9,1.101;	CAMP_PHOSPHO_SITE 39-42; MYRISTYL 56-61; PKC_PHOSPHO_SITE 21-23; MYRISTYL 14-19; MYRISTYL 17-22; PKC_PHOSPHO_SITE 26-28;	
DEX0451_032.orf.3	N	0 - 01- 79;	10-26,1.139; 69-76,1.171; 34-61,1.202;	MYRISTYL 17-22; AMIDATION 64-67; MYRISTYL 50-55; MYRISTYL 57-62; MYRISTYL 29-34; PKC_PHOSPHO_SITE 30-32;	
DEX0451_032.aa.4	N	0 - 11-	30-41,1.074;	PKC_PHOSPHO_SITE 7-9; CK2 PHOSPHO SITE 38-41;	IF 33-41;

		56;		PKC_PHOSPHO_SITE 35-37; TYR_PHOSPHO_SITE 28-36; ASN_GLYCOSYLATION 49-52; CK2_PHOSPHO_SITE 27-30;	
DEX0451_032.orf.4	N	0 - 11-90;	45-72,1.202; 21-37,1.139; 80-87,1.171;	MYRISTYL 18-23; MYRISTYL 28-33; MYRISTYL 68-73; PKC_PHOSPHO_SITE 7-9; MYRISTYL 61-66; PKC_PHOSPHO_SITE 41-43; MYRISTYL 40-45; AMIDATION 75-78;	
DEX0451_032.aa.5	N	0 - 01-315;	149-155,1.12; 66-75,1.074; 139-144,1.047; 44-56,1.117; 186-198,1.108; 294-299,1.082; 274-285,1.122; 90-101,1.095; 24-37,1.079; 126-134,1.06; 230-240,1.132; 209-216,1.062;	CK2_PHOSPHO_SITE 167-170; PKC_PHOSPHO_SITE 49-51; LEUCINE_ZIPPER 193-214; CK2_PHOSPHO_SITE 70-73; MYRISTYL 301-306; MYRISTYL 38-43; MYRISTYL 44-49; MYRISTYL 67-72; MYRISTYL 62-67; PKC_PHOSPHO_SITE 224-226; CK2_PHOSPHO_SITE 254-257; MYRISTYL 59-64; MYRISTYL 16-21; MYRISTYL 230-235; MYRISTYL 227-232; MYRISTYL 17-22; MYRISTYL 63-68; MYRISTYL 242-247; MYRISTYL 74-79; CK2_PHOSPHO_SITE 198-201; PKC_PHOSPHO_SITE 22-24; PKC_PHOSPHO_SITE 272-274; CK2_PHOSPHO_SITE 93-96; PKC_PHOSPHO_SITE 5-7; CK2_PHOSPHO_SITE 133-136; MYRISTYL 66-71; CAMP_PHOSPHO_SITE 299-302; LEUCINE_ZIPPER 186-207;	TYPE1KERATIN 158-171; TYPE1KERATIN 179-202; TYPE1KERATIN 233-253; filament 79-313; GLY_RICH 16-78;
DEX0451_032.orf.5	N	0 - 01-338;		MYRISTYL 40-45; PKC_PHOSPHO_SITE 296-298; LEUCINE_ZIPPER 210-231; MYRISTYL 68-73; CK2_PHOSPHO_SITE 94-97; MYRISTYL 90-95; MYRISTYL 266-271; CK2_PHOSPHO_SITE 157-160; PKC_PHOSPHO_SITE 73-75; MYRISTYL 62-67; CK2_PHOSPHO_SITE 117-120; MYRISTYL 251-256; PKC_PHOSPHO_SITE 46-48; MYRISTYL 41-46; MYRISTYL 98-103; MYRISTYL 83-88; PKC_PHOSPHO_SITE 335-337; CK2_PHOSPHO_SITE 222-225; PKC_PHOSPHO_SITE 29-31; MYRISTYL 254-259;	filament 103-338; TYPE1KERATIN 203-226; TYPE1KERATIN 182-195; TYPE1KERATIN 257-277; GLY_RICH 40-102;

				MYRISTYL 4-9; CK2_PHOSPHO_SITE 278-281; PKC_PHOSPHO_SITE 329-331; PKC_PHOSPHO_SITE 248-250; PKC_PHOSPHO_SITE 312-314; ASN_GLYCOSYLATION 6-9; MYRISTYL 323-328; MYRISTYL 91-96; MYRISTYL 86-91; LEUCINE_ZIPPER 217-238; MYRISTYL 87-92; PKC_PHOSPHO_SITE 309-311; TYR_PHOSPHO_SITE 298-305; CK2_PHOSPHO_SITE 191-194;	
DEX0451_032.aa.6	N	0 - 01- 266;	240- 247,1.118; 148- 164,1.078; 56-63,1.062; 179- 199,1.129; 4-11,1.157; 256- 263,1.123; 77-87,1.132; 33-45,1.108; 225- 235,1.118;	CK2_PHOSPHO_SITE 120-123; PKC_PHOSPHO_SITE 218-220; MYRISTYL 77-82; MYRISTYL 214-219; PKC_PHOSPHO_SITE 203-205; CK2_PHOSPHO_SITE 170-173; LEUCINE_ZIPPER 40-61; CAMP_PHOSPHO_SITE 236-239; CK2_PHOSPHO_SITE 190-193; LEUCINE_ZIPPER 33-54; PKC_PHOSPHO_SITE 119-121; MYRISTYL 74-79; CK2_PHOSPHO_SITE 139-142; PKC_PHOSPHO_SITE 71-73; MYRISTYL 253-258; CK2_PHOSPHO_SITE 45-48; PKC_PHOSPHO_SITE 162-164; MYRISTYL 179-184; PKC_PHOSPHO_SITE 223-225; CK2_PHOSPHO_SITE 101-104; MYRISTYL 89-94;	filament 2-213; TYPE1KERATIN 178-204; TYPE1KERATIN 26-49; TYPE1KERATIN 80-100; TYPE1KERATIN 152-167;
DEX0451_032.orf.6	N	0 - 01- 263;	237- 248,1.074; 49-61,1.108; 19-27,1.157; 195- 215,1.129; 72-79,1.062; 93- 103,1.132; 164- 180,1.078;	TYR_PHOSPHO_SITE 235-243; PKC_PHOSPHO_SITE 242-244; CK2_PHOSPHO_SITE 245-248; CK2_PHOSPHO_SITE 61-64; CK2_PHOSPHO_SITE 206-209; ASN_GLYCOSYLATION 256-259; CK2_PHOSPHO_SITE 117-120; LEUCINE_ZIPPER 49-70; MYRISTYL 4-9; PKC_PHOSPHO_SITE 135-137; CK2_PHOSPHO_SITE 234-237; PKC_PHOSPHO_SITE 87-89; PKC_PHOSPHO_SITE 219-221; MYRISTYL 105-110; MYRISTYL 93-98; CK2_PHOSPHO_SITE 186-189; LEUCINE_ZIPPER 56-	TYPE1KERATIN 96-116; TYPE1KERATIN 194-220; filament 5-253; IF 240-248; TYPE1KERATIN 168-183; TYPE1KERATIN 42-65;

				77; PKC_PHOSPHO_SITE 178-180; CK2_PHOSPHO_SITE 136-139; MYRISTYL 90-95; MYRISTYL 195-200; CK2_PHOSPHO_SITE 155-158;	
DEX0451_033.aa.1	Y	0 - 01-107;	98-104,1.088; 71-77,1.068; 26-33,1.102; 81-89,1.155; 4-21,1.216; 42-60,1.155;	CK2_PHOSPHO_SITE 91-94; PKC_PHOSPHO_SITE 24-26; CK2_PHOSPHO_SITE 53-56; CK2_PHOSPHO_SITE 103-106; PKC_PHOSPHO_SITE 93-95; CK2_PHOSPHO_SITE 16-19; CK2_PHOSPHO_SITE 93-96;	IG LIKE 25-102; IGc1 40-106;
DEX0451_033.aa.2	N	0 - 11-41;	19-36,1.142;	CK2_PHOSPHO_SITE 15-18; PKC_PHOSPHO_SITE 15-17; CK2_PHOSPHO_SITE 13-16;	IG_MHC 20-26;
DEX0451_033.orf.2	Y	1 - 01-14;tm 15-34;i3 5-47;	10-44,1.246;	PKC_PHOSPHO_SITE 3-5;	
DEX0451_034.aa.1	N	0 - 01-257;	10-17,1.098; 144-152,1.168; 182-208,1.135; 156-168,1.253; 77-83,1.11; 91-127,1.227; 39-58,1.144; 216-245,1.17; 249-254,1.087; 60-70,1.119; 25-34,1.124;	MYRISTYL 98-103; MYRISTYL 73-78; CK2_PHOSPHO_SITE 212-215; MYRISTYL 141-146; CK2_PHOSPHO_SITE 2-5;	sp_Q15102_PA1 G_HUMAN 6-246;
DEX0451_035.aa.1	Y	0 - 01-292;	68-78,1.219; 242-265,1.146; 193-200,1.14; 271-278,1.123; 206-216,1.102; 127-138,1.209; 5-52,1.146; 155-178,1.122; 81-88,1.141; 227-234.1.085;	MYRISTYL 223-228; CK2_PHOSPHO_SITE 107-110; PKC_PHOSPHO_SITE 41-43; PKC_PHOSPHO_SITE 231-233; MICROBODIES_CTER 290-292; AMIDATION 41-44; PKC_PHOSPHO_SITE 235-237; CK2_PHOSPHO_SITE 109-112; PKC_PHOSPHO_SITE 22-24; MYRISTYL 206-211; ASN_GLYCOSYLATION 87-90; CK2_PHOSPHO_SITE 264-267; CAMP_PHOSPHO_SITE 241-244; CK2 PHOSPHO SITE 235-	THFDHDRGNASE 189-209; THF_DHG_CYH 35-155; THF_DHG_CYH_C 157-285; sp_P13995_MTD C_HUMAN 49-290; THFDHDRGNASE 144-165; THFDHDRGNASE 68-90; THFDHDRGNASE 109-136; THF_DHG_CYH_1 110-135;

			91-97,1.141; 144- 151,1.123; 282- 289,1.128;	238;	
DEX0451_035.orf.1	Y	0 - 01- 307;	146- 157,1.209; 24-71,1.146; 246- 253,1.085; 261- 284,1.146; 174- 197,1.122; 225- 235,1.102; 110- 116,1.141; 6-16,1.076; 87-97,1.219; 212- 219,1.14; 163- 170,1.123; 100- 107,1.141; 292- 297,1.073;	MYRISTYL 225-230; CAMP_PHOSPHO_SITE 260-263; PKC_PHOSPHO_SITE 250-252; CK2_PHOSPHO_SITE 128-131; CK2_PHOSPHO_SITE 126-129; PKC_PHOSPHO_SITE 254-256; CK2_PHOSPHO_SITE 254-257; PKC_PHOSPHO_SITE 41-43; AMIDATION 60-63; PKC_PHOSPHO_SITE 60-62; MYRISTYL 242-247; ASN_GLYCOSYLATION 106-109;	THF_DHG_CYH_C 176-305; THF_DHG_CYH 54-174; THF_DHG_CYH_1 129-154; sp_P13995_MTD C_HUMAN 68-293; THFDHDRGNASE 163-184; THFDHDRGNASE 128-155; THFDHDRGNASE 208-228; THFDHDRGNASE 87-109;
DEX0451_036.aa.1	N	0 - 01- 207;	89-95,1.072; 109- 123,1.118; 41-49,1.032; 125- 147,1.106; 8-13,1.085; 182- 188,1.057; 51-62,1.148;	CK2_PHOSPHO_SITE 75-78; ASN_GLYCOSYLATION 190-193; CK2_PHOSPHO_SITE 32-35; MYRISTYL 178-183; MYRISTYL 173-178; CAMP_PHOSPHO_SITE 97-100; CK2_PHOSPHO_SITE 30-33; CK2_PHOSPHO_SITE 159-162; PKC_PHOSPHO_SITE 138-140; MYRISTYL 107-112; PKC_PHOSPHO_SITE 156-158; MYRISTYL 7-12; CK2_PHOSPHO_SITE 26-29; MYRISTYL 118-123; CK2_PHOSPHO_SITE 194-197; PKC_PHOSPHO_SITE 122-124;	TPD52 4-194;
DEX0451_036.aa.2	N	0 - 01- 81;	8-19,1.076; 50-59,1.082; 32-44,1.202; 65-71,1.092;	MYRISTYL 61-66; MYRISTYL 55-60; MYRISTYL 74-79; AMIDATION 3-6; MYRISTYL 25-30;	
DEX0451_036.orf.2	N	0 - 01- 154;	109- 123,1.118; 51-62,1.148; 41-49,1.032; 89-95,1.072; 4-13,1.162;	MYRISTYL 107-112; CAMP_PHOSPHO_SITE 97-100; MYRISTYL 7-12; CK2_PHOSPHO_SITE 32-35; PKC_PHOSPHO_SITE 122-124; CK2_PHOSPHO_SITE 75-78; CK2_PHOSPHO_SITE 26-29; PKC PHOSPHO SITE	TPD52 7-149;

				133-135; MYRISTYL 118-123; CK2_PHOSPHO_SITE 30-33; CK2_PHOSPHO_SITE 136-139;	
DEX0451_036.aa.3	N	0 - 01-178;	118-135,1.148; 73-81,1.085; 18-27,1.06; 108-116,1.032; 163-175,1.203; 143-149,1.046;	CK2_PHOSPHO_SITE 5-8; CK2_PHOSPHO_SITE 28-31; CAMP_PHOSPHO_SITE 37-40; PKC_PHOSPHO_SITE 161-163; MYRISTYL 25-30; CK2_PHOSPHO_SITE 99-102; PKC_PHOSPHO_SITE 61-63; CK2_PHOSPHO_SITE 97-100; MYRISTYL 74-79; CK2_PHOSPHO_SITE 93-96; MYRISTYL 54-59; PKC_PHOSPHO_SITE 40-42; CK2_PHOSPHO_SITE 32-35; CK2_PHOSPHO_SITE 142-145; PKC_PHOSPHO_SITE 28-30;	PRENYLATION 175-178; TPD52 71-176;
DEX0451_037.aa.1	N	0 - 01-138;	71-89,1.15; 13-27,1.089; 47-59,1.162; 105-135,1.091;	ASN_GLYCOSYLATION 44-47; PKC_PHOSPHO_SITE 133-135; CK2_PHOSPHO_SITE 35-38; PKC_PHOSPHO_SITE 32-34; CK2_PHOSPHO_SITE 81-84; PKC_PHOSPHO_SITE 118-120;	START 42-117; sp_Q9Y365_Q9Y365_HUMAN 43-130;
DEX0451_037.orf.1	N	0 - 01-187;		CK2_PHOSPHO_SITE 131-134; PKC_PHOSPHO_SITE 13-15; ASN_GLYCOSYLATION 94-97; CK2_PHOSPHO_SITE 26-29; PKC_PHOSPHO_SITE 82-84; CK2_PHOSPHO_SITE 85-88; CK2_PHOSPHO_SITE 173-176;	START 92-167; sp_Q9Y365_Q9Y365_HUMAN 93-181;
DEX0451_037.aa.2	N	0 - 01-201;	145-156,1.091; 178-189,1.183; 105-124,1.09; 47-59,1.162; 13-27,1.089; 158-175,1.16; 191-198,1.099; 130-136,1.067; 71-89,1.15;	PKC_PHOSPHO_SITE 118-120; ASN_GLYCOSYLATION 147-150; CK2_PHOSPHO_SITE 35-38; PKC_PHOSPHO_SITE 149-151; PKC_PHOSPHO_SITE 132-134; PKC_PHOSPHO_SITE 32-34; ASN_GLYCOSYLATION 44-47; CK2_PHOSPHO_SITE 81-84;	START 42-201; sp_Q9Y365_Q9Y365_HUMAN 43-192;
DEX0451_037.orf.2	N	0 - 01-387;	109-123,1.089; 254-271,1.16; 292-306,1.131; 201-220,1.09;	MYRISTYL 373-378; PKC_PHOSPHO_SITE 14-16; CK2_PHOSPHO_SITE 380-383; PKC_PHOSPHO_SITE 214-216; ASN_GLYCOSYLATION 243-246; MYRISTYL 376-381; CK2 PHOSPHO SITE 131-	ARG_RICH 23-90; sp_Q9Y365_Q9Y365_HUMAN 139-318; START 117-322; START 117-322;

			143- 155,1.162; 48-63,1.091; 312- 319,1.13; 226- 232,1.067; 81-86,1.051; 324- 354,1.136; 274- 290,1.19; 15-22,1.056; 89-95,1.11; 241- 252,1.091; 167- 185,1.15; 361- 366,1.056;	134; PKC_PHOSPHO_SITE 245-247; ASN_GLYCOSYLATION 140- 143; CK2_PHOSPHO_SITE 367-370; PKC_PHOSPHO_SITE 228- 230; CK2_PHOSPHO_SITE 177-180; PKC_PHOSPHO_SITE 128- 130; ASN_GLYCOSYLATION 297-300;	START 138- 320;
DEX0451_037.aa.3	N	0 - 01- 224;	128- 147,1.09; 168- 179,1.091; 181- 198,1.16; 36-50,1.089; 70-82,1.162; 16-22,1.11; 153- 159,1.067; 214- 221,1.099; 94-112,1.15; 201- 212,1.183; 8-13,1.051;	CK2_PHOSPHO_SITE 104- 107; PKC_PHOSPHO_SITE 55-57; CK2_PHOSPHO_SITE 58-61; ASN_GLYCOSYLATION 170-173; PKC_PHOSPHO_SITE 141- 143; PKC_PHOSPHO_SITE 172-174; ASN_GLYCOSYLATION 67-70; PKC_PHOSPHO_SITE 155- 157;	sp_Q9Y365_Q9Y 365_HUMAN 66- 215; START 65-224;
DEX0451_037.orf.3	N	0 - 01- 314;	288- 293,1.056; 70-82,1.162; 153- 159,1.067; 239- 246,1.13; 94-112,1.15; 128- 147,1.09; 251- 281,1.136; 168- 179,1.091; 219- 233,1.131; 181- 198,1.16; 36-50,1.089; 8-13,1.051; 201- 217.1.19;	PKC_PHOSPHO_SITE 55-57; MYRISTYL 303-308; ASN_GLYCOSYLATION 224- 227; PKC_PHOSPHO_SITE 141-143; CK2_PHOSPHO_SITE 294- 297; MYRISTYL 300-305; CK2_PHOSPHO_SITE 307- 310; ASN_GLYCOSYLATION 67-70; PKC_PHOSPHO_SITE 172-174; CK2_PHOSPHO_SITE 58-61; CK2_PHOSPHO_SITE 104- 107; ASN_GLYCOSYLATION 170-173; PKC_PHOSPHO_SITE 155- 157;	START 44-249; START 44-249; sp_Q9Y365_Q9Y 365_HUMAN 66- 245; START 65-247;

			16-22,1.11;		
DEX0451_037.aa.4	N	0 - 01-341;	192- 227,1.187; 258- 275,1.115; 145- 156,1.091; 326- 338,1.221; 105- 124,1.09; 178- 189,1.183; 71-89,1.15; 47-59,1.162; 130- 136,1.067; 242- 250,1.163; 297- 307,1.172; 13-27,1.089; 158- 175,1.16; 314- 320,1.072;	PKC_PHOSPHO_SITE 290-292; PKC_PHOSPHO_SITE 32-34; CK2_PHOSPHO_SITE 290-293; CK2_PHOSPHO_SITE 35-38; MYRISTYL 265-270; CK2_PHOSPHO_SITE 81-84; PKC_PHOSPHO_SITE 132-134; MYRISTYL 273-278; ASN_GLYCOSYLATION 306-309; CK2_PHOSPHO_SITE 294-297; PKC_PHOSPHO_SITE 284-286; ASN_GLYCOSYLATION 44-47; CK2_PHOSPHO_SITE 248-251; ASN_GLYCOSYLATION 147-150; PKC_PHOSPHO_SITE 149-151; CK2_PHOSPHO_SITE 308-311; PKC_PHOSPHO_SITE 248-250; CK2_PHOSPHO_SITE 236-239; PKC_PHOSPHO_SITE 118-120; MYRISTYL 189-194;	ig 240-319; IG 232-335; IG LIKE 224-331; sp_Q9Y365_Q9Y365_HUMAN 43-210; START 42-201;
DEX0451_037.orf.4	N	0 - 01-312;	190- 196,1.067; 131- 149,1.15; 205- 216,1.091; 218- 235,1.16; 10-39,1.145; 165- 184,1.09; 300- 308,1.183; 73-87,1.089; 238- 286,1.245; 53-59,1.094; 107- 119,1.162;	PKC_PHOSPHO_SITE 92-94; ASN_GLYCOSYLATION 104-107; CK2_PHOSPHO_SITE 36-39; PKC_PHOSPHO_SITE 192-194; PKC_PHOSPHO_SITE 209-211; PKC_PHOSPHO_SITE 309-311; MYRISTYL 297-302; MYRISTYL 278-283; PKC_PHOSPHO_SITE 178-180; CK2_PHOSPHO_SITE 95-98; CK2_PHOSPHO_SITE 141-144; ASN_GLYCOSYLATION 207-210;	sp_Q9Y365_Q9Y365_HUMAN 103-261; START 102-261; START 81-288;
DEX0451_037.aa.5	N	0 - 01-165;	90-97,1.13; 4-9,1.079; 60-68,1.054; 70-84,1.131; 11-18,1.057; 102- 132,1.136; 139- 144,1.056;	CK2_PHOSPHO_SITE 145-148; MYRISTYL 154-159; ASN_GLYCOSYLATION 25-28; ASN_GLYCOSYLATION 75-78; ASN_GLYCOSYLATION 17-20; MYRISTYL 151-156; ASN_GLYCOSYLATION 41-44; CK2_PHOSPHO_SITE 158-161; ASN_GLYCOSYLATION 33-36;	sp_Q9Y365_Q9Y365_HUMAN 51-96;
DEX0451_037.orf.	Y	0 - 01-	4-11,1.132; 13-19,1.03;	MYRISTYL 141-146; CK2 PHOSPHO SITE 148-	START 30-88; so Q9Y365 Q9Y

5		155;	21-27, 1.03; 80-87, 1.13; 29-35, 1.03; 60-74, 1.131; 42-58, 1.19; 129- 134, 1.056; 92- 122, 1.136;	151; CK2_PHOSPHO_SITE 135-138; ASN_GLYCOSYLATION 65-68; MYRISTYL 144-149;	365_HUMAN 42- 86;
---	--	------	--	--	----------------------

Example 1b: Sequence Alignment Support

Alignments between previously identified sequences and splice variant sequences are performed to confirm unique portions of splice variant nucleic acid and amino acid sequences. The alignments are done using the Needle program in the European Molecular Biology Open Software Suite (EMBOSS) version 2.2.0 available at www.emboss.org from EMBnet (<http://www.embn.net.org>). Default settings are used unless otherwise noted. The Needle program in EMBOSS implements the Needleman-Wunsch algorithm. Needleman, S. B., Wunsch, C. D., *J. Mol. Biol.* 48:443-453 (1970).

It is well known to those skilled in the art that implication of alignment algorithms by various programs may result in minor changes in the generated output. These changes include but are not limited to: alignment scores (percent identity, similarity, and gap), display of nonaligned flanking sequence regions, and number assignment to residues. These minor changes in the output of an alignment do not alter the physical characteristics of the sequences or the differences between the sequences, e.g. regions of homology, insertions, or deletions.

Example 1c: RT-PCR Analysis

To detect the presence and tissue distribution of a particular splice variant Reverse Transcription-Polymerase Chain Reaction (RT-PCR) is performed using cDNA generated from a panel of tissue RNAs. See, e.g., Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and; Kawasaki ES *et al.*, *PNAS* 85(15):5698 (1988). Total RNA is extracted from a variety of tissues and first strand cDNA is prepared with reverse transcriptase (RT). Each panel includes 23 cDNAs from five cancer types (lung, ovary, breast, colon, and prostate) and normal samples of testis, placenta and fetal brain. Each cancer set is composed of three cancer cDNAs from different donors and one normal pooled sample. Using a standard enzyme kit from BD Bioscience Clontech (Mountain View, CA), the target transcript is detected with

sequence-specific primers designed to only amplify the particular splice variant. The PCR reaction is run on the GeneAmp PCR system 9700 (Applied Biosystem, Foster City, CA) thermocycler under optimal conditions. One of ordinary skill can design appropriate primers and determine optimal conditions. The amplified product is resolved on an agarose gel to detect a band of equivalent size to the predicted RT-PCR product. A band indicated the presence of the splice variant in a sample. The relation of the amplified product to the splice variant was subsequently confirmed by DNA sequencing.

After subcloning, all positively screened clones are sequence verified. The DNA sequence verification results show the splice variant contains the predicted sequence differences in comparison with the reference sequence.

Results for RT-PCR analysis include the sequence DEX ID, Lead Name, Cancer Tissue(s) the transcript was detected in, Normal Tissue(s) the transcript was detected in, the predicted length of the RT-PCR product, and the Confirmed Length of the RT-PCR product.

RT-PCR results confirm the presence SEQ ID NO: 1-72 in biologic samples and distinguish between related transcripts.

Example 1d: Secretion Assay

To determine if a protein encoded by a splice variant is secreted from cells a secretion assay is preformed. A pcDNA3.1 clone containing the gene transcript which encodes the variant protein is transfected into 293T cells using the Superfect transfection reagent (Qiagen, Valencia CA). Transfected cells are incubated for 28 hours before the media is collected and immediately spun down to remove any detached cells. The adherent cells are solubilized with lysis buffer (1% NP40, 10mM sodium phosphate pH7.0, and 0.15M NaCl). The lysed cells are collected and spun down and the supernatant extracted as cell lysate. Western immunoblot is carried out in the following manner: 15µl of the cell lysate and media are run on 4-12% NuPage Bis-Tris gel (Invitrogen, Carlsbad CA), and blotted onto a PVDF membrane (Invitrogen, Carlsbad CA). The blot is incubated with a polyclonal primary antibody which binds to the variant protein (Imgenex, San Diego CA) and polyclonal goat anti-rabbit-peroxidase secondary antibody (Sigma=Aldrich, St. Louis MO). The blot is developed with the ECL Plus chemiluminescent detection reagent (Amersham BioSciences, Piscataway NJ).

Secretion assay results are indicative of SEQ ID NO: 73-179 being a diagnostic marker and/or therapeutic target for cancer.

Example 2a: Gene Expression Analysis

Custom Microarray Experiment - Cancer

5 Custom oligonucleotide microarrays were provided by Agilent Technologies, Inc. (Palo Alto, CA). The microarrays were fabricated by Agilent using their technology for the *in-situ* synthesis of 60mer oligonucleotides (Hughes, et al. 2001, Nature Biotechnology 19:342-347). The 60mer microarray probes were designed by Agilent, from gene sequences provided by diaDexus, using Agilent proprietary algorithms. Whenever
10 possible two different 60mers were designed for each gene of interest.

All microarray experiments were two-color experiments and were preformed using Agilent-recommended protocols and reagents. Briefly, each microarray was hybridized with cRNAs synthesized from RNA (total RNA for ovarian and prostate, polyA+ RNA for lung, breast and colon samples), isolated from cancer and normal tissues, labeled with
15 fluorescent dyes Cyanine3 (Cy3) or Cyanine5 (Cy5) (NEN Life Science Products, Inc., Boston, MA) using a linear amplification method (Agilent). In each experiment the experimental sample was RNA isolated from cancer tissue from a single individual and the reference sample was a pool of RNA isolated from normal tissues of the same organ as the cancerous tissue (*i.e.* normal ovarian tissue in experiments with ovarian cancer
20 samples). Hybridizations were carried out at 60°C, overnight using Agilent *in-situ* hybridization buffer. Following washing, arrays were scanned with a GenePix 4000B Microarray Scanner (Axon Instruments, Inc., Union City, CA). The resulting images were analyzed with GenePix Pro 3.0 Microarray Acquisition and Analysis Software (Axon).

Data normalization and expression profiling were done with Expressionist
25 software from GeneData Inc. (Daly City, CA/Basel, Switzerland). Gene expression analysis was performed using only experiments that met certain quality criteria. The quality criteria that experiments must meet are a combination of evaluations performed by the Expressionist software and evaluations performed manually using raw and normalized data. To evaluate raw data quality, detection limits (the mean signal for a replicated
30 negative control + 2 Standard Deviations (SD)) for each channel were calculated. The detection limit is a measure of non-specific hybridization. Acceptable detection limits were defined for each dye (<80 for Cy5 and <150 for Cy3). Arrays with poor detection

limits in one or both channels were not analyzed and the experiments were repeated. To evaluate normalized data quality, positive control elements included in the array were utilized. These array features should have a mean ratio of 1 (no differential expression). If these features have a mean ratio of greater than 1.5-fold up or down, the experiments
5 were not analyzed further and were repeated. In addition to traditional scatter plots demonstrating the distribution of signal in each experiment, the Expressionist software also has minimum thresholding criteria that employ user defined parameters to identify quality data. These thresholds include two distinct quality measurements: 1) minimum area percentage, which is a measure of the integrity of each spot and 2) signal to noise
10 ratio, which ensures that the signal being measured is significantly above any background (nonspecific) signal present. Only those features that met the threshold criteria were included in the filtering and analyses carried out by Expressionist. The thresholding settings employed require a minimum area percentage of 60% [(% pixels > background + 2SD)-(% pixels saturated)], and a minimum signal to noise ratio of 2.0 in both channels.
15 By these criteria, very low expressors, saturated features and spots with abnormally high local background were not included in analysis.

Relative expression data was collected from Expressionist based on filtering and clustering analyses. Up-regulated genes were identified using criteria for the percentage of experiments in which the gene is up-regulated by at least 2-fold. In general, up-
20 regulation in ~30% of samples tested was used as a cutoff for filtering.

Two microarray experiments were performed for each normal and cancer tissue pair. The tissue specific Array Chip for each cancer tissue is a unique microarray specific to that tissue and cancer. The Multi-Cancer Array Chip is a universal microarray that was hybridized with samples from each of the cancers (ovarian, breast, colon, lung, and
25 prostate). See the description below for the experiments specific to the different cancers.

Microarray Experiments and Data Tables

BREAST CANCER CHIPS

For breast cancer two different chip designs were evaluated with overlapping sets of a total of 36 samples, comparing the expression patterns of breast cancer derived
30 polyA+ RNA to polyA+ RNA isolated from a pool of 10 normal breast tissues. For the Breast Array Chip, all 36 samples (9 stage I cancers, 23 stage II cancers, 4 stage III cancers) were analyzed. These samples also represented 10 Grade 1/2 and 26 Grade 3

cancers. The histopathologic grades for cancer are classified as follows: GX, cannot be assessed; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; and G4, undifferentiated. AJCC Cancer Staging Handbook, pp. 9, (5th Ed, 1998).

Samples were further grouped based on the expression patterns of the known breast cancer associated genes Her2 and ER α (10 HER2 up, 26 HER2 not up, 20 ER up and 16 ER not up) and for the Multi-Cancer Array Chip, a subset of 20 of these samples (9 stage I cancers, 8 stage II cancers, 3 stage III cancers) were assessed.

The results for the statistically significant up-regulated genes on the Breast Array Chip are shown in Tables 1 and 2. No results for the statistically significant up-regulated genes on the Multi-Cancer Array Chip are shown. The first two columns of each table contain information about the sequence itself (Seq ID, Oligo Name), the next columns show the results obtained for all ("ALL") breast cancer samples, cancers corresponding to stage I ("ST1"), stages II and III ("ST2,3"), grades 1 and 2 ("GR1,2"), grade 3 ("GR3"), cancers exhibiting up-regulation of Her2 ("HER2up") or ER α ("ERup") or those not exhibiting up-regulation of Her2 ("NOT HER2up") or ER α ("NOT ERup"). '%up' indicates the percentage of all experiments in which up-regulation of at least 2-fold was observed (n=36 for Colon Array Chip, n=20 for the Multi-Cancer Array Chip), '%valid up' indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

Table 1.

DEX ID	Oligo Name	Mam ALL %up n=36	Mam ALL %valid up n=36	Mam ST1 %up n=9	Mam ST1 %valid up n=9	Mam ST2,3 %up n=27	Mam ST2,3 %valid up n=27	Mam GR1,2 %up n=10	Mam GR1,2 %valid up n=10	Mam GR3 %up n=26	Mam GR3 %valid up n=26
DEX0451_001.nt.1	22403.0	22.2	22.2	22.2	22.2	22.2	22.2	10.0	10.0	26.9	26.9
DEX0451_002.nt.1	19368.0	44.4	45.7	44.4	44.4	44.4	46.2	60.0	60.0	38.5	40.0
DEX0451_002.nt.1	19369.0	22.2	22.2	33.3	33.3	18.5	18.5	30.0	30.0	19.2	19.2
DEX0451_003.nt.1	20531.0	36.1	36.1	11.1	11.1	44.4	44.4	50.0	50.0	30.8	30.8
DEX0451_003.nt.1	20532.0	25.0	26.5	11.1	11.1	29.6	32.0	30.0	30.0	23.1	25.0
DEX0451_004.nt.1	40416.0	2.8	2.8	0.0	0.0	3.7	3.7	0.0	0.0	3.8	3.8
DEX0451_005.nt.1	10310.0	19.4	19.4	11.1	11.1	22.2	22.2	10.0	10.0	23.1	23.1
DEX0451_006.nt.1	12495.0	50.0	52.9	66.7	75.0	44.4	46.2	60.0	66.7	46.2	48.0

DEX0451_007.nt.1	16882.0	27.8	27.8	33.3	33.3	25.9	25.9	40.0	40.0	23.1	23.1
DEX0451_007.nt.1	33254.0	38.9	40.0	55.6	55.6	33.3	34.6	60.0	60.0	30.8	32.0
DEX0451_007.nt.1	33255.0	30.6	30.6	33.3	33.3	29.6	29.6	40.0	40.0	26.9	26.9
DEX0451_007.nt.2	16882.0	27.8	27.8	33.3	33.3	25.9	25.9	40.0	40.0	23.1	23.1
DEX0451_007.nt.2	33254.0	38.9	40.0	55.6	55.6	33.3	34.6	60.0	60.0	30.8	32.0
DEX0451_007.nt.2	33255.0	30.6	30.6	33.3	33.3	29.6	29.6	40.0	40.0	26.9	26.9
DEX0451_007.nt.3	16882.0	27.8	27.8	33.3	33.3	25.9	25.9	40.0	40.0	23.1	23.1
DEX0451_007.nt.3	16883.0	22.2	22.2	33.3	33.3	18.5	18.5	40.0	40.0	15.4	15.4
DEX0451_007.nt.3	33254.0	38.9	40.0	55.6	55.6	33.3	34.6	60.0	60.0	30.8	32.0
DEX0451_007.nt.3	33255.0	30.6	30.6	33.3	33.3	29.6	29.6	40.0	40.0	26.9	26.9
DEX0451_007.nt.4	16882.0	27.8	27.8	33.3	33.3	25.9	25.9	40.0	40.0	23.1	23.1
DEX0451_007.nt.5	33254.0	38.9	40.0	55.6	55.6	33.3	34.6	60.0	60.0	30.8	32.0
DEX0451_007.nt.5	33255.0	30.6	30.6	33.3	33.3	29.6	29.6	40.0	40.0	26.9	26.9
DEX0451_008.nt.1	18463.0	25.0	25.0	22.2	22.2	25.9	25.9	10.0	10.0	30.8	30.8
DEX0451_008.nt.1	19444.0	36.1	36.1	33.3	33.3	37.0	37.0	30.0	30.0	38.5	38.5
DEX0451_008.nt.1	19445.0	33.3	33.3	22.2	22.2	37.0	37.0	30.0	30.0	34.6	34.6
DEX0451_008.nt.1	19448.0	27.8	27.8	22.2	22.2	29.6	29.6	10.0	10.0	34.6	34.6
DEX0451_008.nt.1	31908.0	27.8	27.8	22.2	22.2	29.6	29.6	10.0	10.0	34.6	34.6
DEX0451_009.nt.1	12219.0	8.3	8.3	0.0	0.0	11.1	11.1	0.0	0.0	11.5	11.5
DEX0451_009.nt.1	12220.0	8.3	8.3	0.0	0.0	11.1	11.1	0.0	0.0	11.5	11.5
DEX0451_009.nt.1	13615.0	5.6	5.9	0.0	0.0	7.4	8.0	0.0	0.0	7.7	8.3
DEX0451_011.nt.1	28011.0	27.8	30.3	22.2	28.6	29.6	30.8	20.0	20.0	30.8	34.8
DEX0451_012.nt.1	22451.0	22.2	22.2	22.2	22.2	22.2	22.2	0.0	0.0	30.8	30.8
DEX0451_012.nt.1	22452.0	11.1	11.1	11.1	11.1	11.1	11.1	0.0	0.0	15.4	15.4
DEX0451_013.nt.1	28395.0	13.9	14.7	0.0	0.0	18.5	19.2	30.0	33.3	7.7	8.0
DEX0451_013.nt.1	28396.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_013.nt.2	28395.0	13.9	14.7	0.0	0.0	18.5	19.2	30.0	33.3	7.7	8.0
DEX0451_013.nt.2	28396.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_014.nt.1	16523.0	16.7	17.6	11.1	12.5	18.5	19.2	0.0	0.0	23.1	24.0

DEX0451_015.nt.1	15187.0	30.6	31.4	11.1	11.1	37.0	38.5	40.0	40.0	26.9	28.0
DEX0451_015.nt.1	27235.0	33.3	33.3	11.1	11.1	40.7	40.7	40.0	40.0	30.8	30.8
DEX0451_015.nt.1	27236.0	30.6	30.6	11.1	11.1	37.0	37.0	40.0	40.0	26.9	26.9
DEX0451_015.nt.2	15187.0	30.6	31.4	11.1	11.1	37.0	38.5	40.0	40.0	26.9	28.0
DEX0451_015.nt.2	27235.0	33.3	33.3	11.1	11.1	40.7	40.7	40.0	40.0	30.8	30.8
DEX0451_015.nt.2	27236.0	30.6	30.6	11.1	11.1	37.0	37.0	40.0	40.0	26.9	26.9
DEX0451_016.nt.1	40554.0	13.9	14.3	22.2	22.2	11.1	11.5	50.0	50.0	0.0	0.0
DEX0451_017.nt.1	20531.0	36.1	36.1	11.1	11.1	44.4	44.4	50.0	50.0	30.8	30.8
DEX0451_017.nt.1	20532.0	25.0	26.5	11.1	11.1	29.6	32.0	30.0	30.0	23.1	25.0
DEX0451_018.nt.1	15234.0	25.0	25.0	33.3	33.3	22.2	22.2	50.0	50.0	15.4	15.4
DEX0451_018.nt.1	15980.0	25.0	25.7	33.3	33.3	22.2	23.1	50.0	50.0	15.4	16.0
DEX0451_018.nt.1	15987.0	30.6	30.6	33.3	33.3	29.6	29.6	80.0	80.0	11.5	11.5
DEX0451_018.nt.1	16050.0	25.0	25.0	33.3	33.3	22.2	22.2	50.0	50.0	15.4	15.4
DEX0451_018.nt.1	16055.0	30.6	30.6	33.3	33.3	29.6	29.6	70.0	70.0	15.4	15.4
DEX0451_018.nt.1	16056.0	25.0	25.0	33.3	33.3	22.2	22.2	60.0	60.0	11.5	11.5
DEX0451_018.nt.1	33563.0	25.0	25.0	33.3	33.3	22.2	22.2	60.0	60.0	11.5	11.5
DEX0451_018.nt.2	15234.0	25.0	25.0	33.3	33.3	22.2	22.2	50.0	50.0	15.4	15.4
DEX0451_018.nt.2	15980.0	25.0	25.7	33.3	33.3	22.2	23.1	50.0	50.0	15.4	16.0
DEX0451_018.nt.2	15987.0	30.6	30.6	33.3	33.3	29.6	29.6	80.0	80.0	11.5	11.5
DEX0451_018.nt.2	16050.0	25.0	25.0	33.3	33.3	22.2	22.2	50.0	50.0	15.4	15.4
DEX0451_018.nt.2	16055.0	30.6	30.6	33.3	33.3	29.6	29.6	70.0	70.0	15.4	15.4
DEX0451_018.nt.2	16056.0	25.0	25.0	33.3	33.3	22.2	22.2	60.0	60.0	11.5	11.5
DEX0451_018.nt.2	33563.0	25.0	25.0	33.3	33.3	22.2	22.2	60.0	60.0	11.5	11.5
DEX0451_020.nt.1	32801.0	30.6	30.6	22.2	22.2	33.3	33.3	50.0	50.0	23.1	23.1
DEX0451_021.nt.1	19436.0	2.8	2.9	0.0	0.0	3.7	3.8	0.0	0.0	3.8	4.0
DEX0451_021.nt.1	19437.0	13.9	13.9	22.2	22.2	11.1	11.1	40.0	40.0	3.8	3.8
DEX0451_021.nt.2	19436.0	2.8	2.9	0.0	0.0	3.7	3.8	0.0	0.0	3.8	4.0
DEX0451_021.nt.2	19437.0	13.9	13.9	22.2	22.2	11.1	11.1	40.0	40.0	3.8	3.8
DEX0451_021.nt.3	19436.0	2.8	2.9	0.0	0.0	3.7	3.8	0.0	0.0	3.8	4.0

DEX0451_021.nt.3	19437.0	13.9	13.9	22.2	22.2	11.1	11.1	40.0	40.0	3.8	3.8
DEX0451_022.nt.1	20617.0	30.6	30.6	11.1	11.1	37.0	37.0	40.0	40.0	26.9	26.9
DEX0451_022.nt.1	20618.0	11.1	11.1	0.0	0.0	14.8	14.8	20.0	20.0	7.7	7.7
DEX0451_023.nt.1	18012.0	30.6	31.4	22.2	22.2	33.3	34.6	20.0	20.0	34.6	36.0
DEX0451_023.nt.1	18013.0	27.8	28.6	22.2	22.2	29.6	30.8	20.0	20.0	30.8	32.0
DEX0451_023.nt.1	18016.0	22.2	22.9	22.2	22.2	22.2	23.1	30.0	30.0	19.2	20.0
DEX0451_023.nt.1	18017.0	27.8	28.6	22.2	22.2	29.6	30.8	30.0	30.0	26.9	28.0
DEX0451_023.nt.1	18018.0	27.8	27.8	11.1	11.1	33.3	33.3	10.0	10.0	34.6	34.6
DEX0451_023.nt.1	18019.0	33.3	33.3	11.1	11.1	40.7	40.7	20.0	20.0	38.5	38.5
DEX0451_023.nt.1	28313.0	2.8	3.0	0.0	0.0	3.7	3.8	10.0	10.0	0.0	0.0
DEX0451_023.nt.1	28314.0	2.8	5.0	11.1	25.0	0.0	0.0	0.0	0.0	3.8	7.1
DEX0451_024.nt.1	36510.0	27.8	27.8	22.2	22.2	29.6	29.6	10.0	10.0	34.6	34.6
DEX0451_025.nt.1	21189.0	38.9	40.0	44.4	44.4	37.0	38.5	20.0	20.0	46.2	48.0
DEX0451_026.nt.1	30171.0	33.3	33.3	22.2	22.2	37.0	37.0	30.0	30.0	34.6	34.6
DEX0451_026.nt.1	30172.0	19.4	19.4	11.1	11.1	22.2	22.2	10.0	10.0	23.1	23.1
DEX0451_026.nt.2	30171.0	33.3	33.3	22.2	22.2	37.0	37.0	30.0	30.0	34.6	34.6
DEX0451_026.nt.2	30172.0	19.4	19.4	11.1	11.1	22.2	22.2	10.0	10.0	23.1	23.1
DEX0451_027.nt.1	13999.0	2.8	2.9	0.0	0.0	3.7	3.8	0.0	0.0	3.8	3.8
DEX0451_027.nt.1	14001.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_027.nt.1	20396.0	5.6	5.6	11.1	11.1	3.7	3.7	0.0	0.0	7.7	7.7
DEX0451_027.nt.1	31768.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_027.nt.1	31769.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_028.nt.1	9670.0	11.1	11.4	11.1	11.1	11.1	11.5	10.0	10.0	11.5	12.0
DEX0451_029.nt.1	37563.0	19.4	19.4	11.1	11.1	22.2	22.2	40.0	40.0	11.5	11.5
DEX0451_030.nt.1	34949.0	27.8	27.8	33.3	33.3	25.9	25.9	30.0	30.0	26.9	26.9
DEX0451_032.nt.1	19190.0	19.4	19.4	22.2	22.2	18.5	18.5	40.0	40.0	11.5	11.5
DEX0451_032.nt.1	19191.0	19.4	19.4	22.2	22.2	18.5	18.5	40.0	40.0	11.5	11.5
DEX0451_032.nt.1	19246.0	11.1	13.8	22.2	22.2	7.4	10.0	30.0	37.5	3.8	4.8
DEX0451_032.nt.1	19247.0	5.6	20.0	0.0	0.0	7.4	28.6	10.0	50.0	3.8	12.5

DEX0451_032.nt.1	19262.0	5.6	25.0	0.0	0.0	7.4	25.0	10.0	50.0	3.8	16.7
DEX0451_032.nt.1	19332.0	8.3	13.6	11.1	14.3	7.4	13.3	20.0	33.3	3.8	6.2
DEX0451_032.nt.1	19333.0	11.1	17.4	22.2	25.0	7.4	13.3	30.0	42.9	3.8	6.2
DEX0451_032.nt.1	19387.0	19.4	19.4	22.2	22.2	18.5	18.5	40.0	40.0	11.5	11.5
DEX0451_032.nt.2	19248.0	19.4	19.4	22.2	22.2	18.5	18.5	30.0	30.0	15.4	15.4
DEX0451_032.nt.2	19250.0	16.7	16.7	22.2	22.2	14.8	14.8	30.0	30.0	11.5	11.5
DEX0451_032.nt.2	19260.0	16.7	16.7	22.2	22.2	14.8	14.8	30.0	30.0	11.5	11.5
DEX0451_032.nt.2	19265.0	19.4	19.4	22.2	22.2	18.5	18.5	30.0	30.0	15.4	15.4
DEX0451_032.nt.3	19246.0	11.1	13.8	22.2	22.2	7.4	10.0	30.0	37.5	3.8	4.8
DEX0451_032.nt.3	19247.0	5.6	20.0	0.0	0.0	7.4	28.6	10.0	50.0	3.8	12.5
DEX0451_032.nt.3	19262.0	5.6	25.0	0.0	0.0	7.4	25.0	10.0	50.0	3.8	16.7
DEX0451_032.nt.3	19332.0	8.3	13.6	11.1	14.3	7.4	13.3	20.0	33.3	3.8	6.2
DEX0451_032.nt.3	19333.0	11.1	17.4	22.2	25.0	7.4	13.3	30.0	42.9	3.8	6.2
DEX0451_032.nt.4	19246.0	11.1	13.8	22.2	22.2	7.4	10.0	30.0	37.5	3.8	4.8
DEX0451_032.nt.4	19247.0	5.6	20.0	0.0	0.0	7.4	28.6	10.0	50.0	3.8	12.5
DEX0451_032.nt.4	19262.0	5.6	25.0	0.0	0.0	7.4	25.0	10.0	50.0	3.8	16.7
DEX0451_032.nt.4	19332.0	8.3	13.6	11.1	14.3	7.4	13.3	20.0	33.3	3.8	6.2
DEX0451_032.nt.4	19333.0	11.1	17.4	22.2	25.0	7.4	13.3	30.0	42.9	3.8	6.2
DEX0451_032.nt.5	19191.0	19.4	19.4	22.2	22.2	18.5	18.5	40.0	40.0	11.5	11.5
DEX0451_032.nt.5	19194.0	8.3	8.3	0.0	0.0	11.1	11.1	0.0	0.0	11.5	11.5
DEX0451_032.nt.5	19248.0	19.4	19.4	22.2	22.2	18.5	18.5	30.0	30.0	15.4	15.4
DEX0451_032.nt.5	19250.0	16.7	16.7	22.2	22.2	14.8	14.8	30.0	30.0	11.5	11.5
DEX0451_032.nt.5	19260.0	16.7	16.7	22.2	22.2	14.8	14.8	30.0	30.0	11.5	11.5
DEX0451_032.nt.5	19265.0	19.4	19.4	22.2	22.2	18.5	18.5	30.0	30.0	15.4	15.4
DEX0451_032.nt.6	19190.0	19.4	19.4	22.2	22.2	18.5	18.5	40.0	40.0	11.5	11.5
DEX0451_032.nt.6	19191.0	19.4	19.4	22.2	22.2	18.5	18.5	40.0	40.0	11.5	11.5
DEX0451_032.nt.6	19194.0	8.3	8.3	0.0	0.0	11.1	11.1	0.0	0.0	11.5	11.5
DEX0451_032.nt.6	19246.0	11.1	13.8	22.2	22.2	7.4	10.0	30.0	37.5	3.8	4.8
DEX0451_032.nt.6	19247.0	5.6	20.0	0.0	0.0	7.4	28.6	10.0	50.0	3.8	12.5

DEX0451_032.nt.6	19262.0	5.6	25.0	0.0	0.0	7.4	25.0	10.0	50.0	3.8	16.7
DEX0451_032.nt.6	19332.0	8.3	13.6	11.1	14.3	7.4	13.3	20.0	33.3	3.8	6.2
DEX0451_032.nt.6	19333.0	11.1	17.4	22.2	25.0	7.4	13.3	30.0	42.9	3.8	6.2
DEX0451_032.nt.6	19387.0	19.4	19.4	22.2	22.2	18.5	18.5	40.0	40.0	11.5	11.5
DEX0451_033.nt.1	12500.0	19.4	29.2	22.2	28.6	18.5	29.4	0.0	0.0	26.9	38.9
DEX0451_033.nt.1	12505.0	19.4	19.4	11.1	11.1	22.2	22.2	10.0	10.0	23.1	23.1
DEX0451_033.nt.1	12506.0	19.4	19.4	11.1	11.1	22.2	22.2	20.0	20.0	19.2	19.2
DEX0451_033.nt.1	33560.0	25.0	29.0	22.2	25.0	25.9	30.4	10.0	12.5	30.8	34.8
DEX0451_033.nt.1	33561.0	13.9	38.5	22.2	66.7	11.1	30.0	10.0	50.0	15.4	36.4
DEX0451_033.nt.2	12500.0	19.4	29.2	22.2	28.6	18.5	29.4	0.0	0.0	26.9	38.9
DEX0451_033.nt.2	33560.0	25.0	29.0	22.2	25.0	25.9	30.4	10.0	12.5	30.8	34.8
DEX0451_033.nt.2	33561.0	13.9	38.5	22.2	66.7	11.1	30.0	10.0	50.0	15.4	36.4
DEX0451_034.nt.1	14003.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_034.nt.1	14004.0	25.0	25.0	44.4	44.4	18.5	18.5	20.0	20.0	26.9	26.9
DEX0451_034.nt.1	27151.0	22.2	22.2	44.4	44.4	14.8	14.8	20.0	20.0	23.1	23.1
DEX0451_034.nt.1	27152.0	22.2	22.2	44.4	44.4	14.8	14.8	30.0	30.0	19.2	19.2
DEX0451_036.nt.1	23858.0	61.1	61.1	55.6	55.6	63.0	63.0	70.0	70.0	57.7	57.7
DEX0451_036.nt.1	23859.0	61.1	61.1	55.6	55.6	63.0	63.0	70.0	70.0	57.7	57.7
DEX0451_036.nt.1	37858.0	58.3	58.3	44.4	44.4	63.0	63.0	70.0	70.0	53.8	53.8
DEX0451_036.nt.2	23858.0	61.1	61.1	55.6	55.6	63.0	63.0	70.0	70.0	57.7	57.7
DEX0451_036.nt.2	23859.0	61.1	61.1	55.6	55.6	63.0	63.0	70.0	70.0	57.7	57.7
DEX0451_036.nt.2	37858.0	58.3	58.3	44.4	44.4	63.0	63.0	70.0	70.0	53.8	53.8
DEX0451_036.nt.3	23858.0	61.1	61.1	55.6	55.6	63.0	63.0	70.0	70.0	57.7	57.7
DEX0451_036.nt.3	23859.0	61.1	61.1	55.6	55.6	63.0	63.0	70.0	70.0	57.7	57.7
DEX0451_036.nt.3	37858.0	58.3	58.3	44.4	44.4	63.0	63.0	70.0	70.0	53.8	53.8
DEX0451_037.nt.1	15045.0	30.6	30.6	33.3	33.3	29.6	29.6	40.0	40.0	26.9	26.9
DEX0451_037.nt.1	15066.0	33.3	33.3	22.2	22.2	37.0	37.0	40.0	40.0	30.8	30.8
DEX0451_037.nt.2	15044.0	25.0	25.0	22.2	22.2	25.9	25.9	30.0	30.0	23.1	23.1
DEX0451_037.nt.2	15045.0	30.6	30.6	33.3	33.3	29.6	29.6	40.0	40.0	26.9	26.9

DEX0451_037.nt.2	15062.0	33.3	33.3	22.2	22.2	37.0	37.0	40.0	40.0	30.8	30.8
DEX0451_037.nt.2	15063.0	27.8	30.3	22.2	25.0	29.6	32.0	40.0	40.0	23.1	26.1
DEX0451_037.nt.2	15066.0	33.3	33.3	22.2	22.2	37.0	37.0	40.0	40.0	30.8	30.8
DEX0451_037.nt.2	33432.0	27.8	27.8	22.2	22.2	29.6	29.6	30.0	30.0	26.9	26.9
DEX0451_037.nt.3	15044.0	25.0	25.0	22.2	22.2	25.9	25.9	30.0	30.0	23.1	23.1
DEX0451_037.nt.3	15045.0	30.6	30.6	33.3	33.3	29.6	29.6	40.0	40.0	26.9	26.9
DEX0451_037.nt.3	15062.0	33.3	33.3	22.2	22.2	37.0	37.0	40.0	40.0	30.8	30.8
DEX0451_037.nt.3	15063.0	27.8	30.3	22.2	25.0	29.6	32.0	40.0	40.0	23.1	26.1
DEX0451_037.nt.3	15066.0	33.3	33.3	22.2	22.2	37.0	37.0	40.0	40.0	30.8	30.8
DEX0451_037.nt.3	33432.0	27.8	27.8	22.2	22.2	29.6	29.6	30.0	30.0	26.9	26.9
DEX0451_037.nt.4	15044.0	25.0	25.0	22.2	22.2	25.9	25.9	30.0	30.0	23.1	23.1
DEX0451_037.nt.4	15045.0	30.6	30.6	33.3	33.3	29.6	29.6	40.0	40.0	26.9	26.9
DEX0451_037.nt.4	15066.0	33.3	33.3	22.2	22.2	37.0	37.0	40.0	40.0	30.8	30.8
DEX0451_037.nt.4	15071.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_037.nt.4	33432.0	27.8	27.8	22.2	22.2	29.6	29.6	30.0	30.0	26.9	26.9
DEX0451_037.nt.5	15062.0	33.3	33.3	22.2	22.2	37.0	37.0	40.0	40.0	30.8	30.8
DEX0451_037.nt.5	15063.0	27.8	30.3	22.2	25.0	29.6	32.0	40.0	40.0	23.1	26.1

Table 2.

DEX ID	Oligo Name	Mam HER2up %up n=10	Mam HER2up %valid up n=10	Mam NOT HER2up %up n=26	Mam NOT HER2up %valid up n=26	Mam ERup %up n=20	Mam ERup %valid up n=20	Mam NOT ERup %up n=16	Mam NOT ERup %valid up n=16
DEX0451_001.nt.1	22403.0	20.0	20.0	23.1	23.1	5.0	5.0	43.8	43.8
DEX0451_002.nt.1	19368.0	60.0	66.7	38.5	38.5	60.0	60.0	25.0	26.7
DEX0451_002.nt.1	19369.0	30.0	30.0	19.2	19.2	30.0	30.0	12.5	12.5
DEX0451_003.nt.1	20531.0	30.0	30.0	38.5	38.5	60.0	60.0	6.2	6.2
DEX0451_003.nt.1	20532.0	10.0	11.1	30.8	32.0	40.0	42.1	6.2	6.7
DEX0451_004.nt.1	40416.0	0.0	0.0	3.8	3.8	5.0	5.0	0.0	0.0
DEX0451_005.nt.1	10310.0	30.0	30.0	15.4	15.4	10.0	10.0	31.2	31.2
DEX0451_006.nt.1	12495.0	30.0	30.0	57.7	62.5	60.0	66.7	37.5	37.5
DEX0451_007.nt.1	16882.0	10.0	10.0	34.6	34.6	30.0	30.0	25.0	25.0
DEX0451_007.nt.1	33254.0	20.0	20.0	46.2	48.0	40.0	42.1	37.5	37.5
DEX0451_007.nt.1	33255.0	10.0	10.0	38.5	38.5	30.0	30.0	31.2	31.2
DEX0451_007.nt.2	16882.0	10.0	10.0	34.6	34.6	30.0	30.0	25.0	25.0
DEX0451_007.nt.2	33254.0	20.0	20.0	46.2	48.0	40.0	42.1	37.5	37.5
DEX0451_007.nt.2	33255.0	10.0	10.0	38.5	38.5	30.0	30.0	31.2	31.2
DEX0451_007.nt.3	16882.0	10.0	10.0	34.6	34.6	30.0	30.0	25.0	25.0
DEX0451_007.nt.3	16883.0	10.0	10.0	26.9	26.9	25.0	25.0	18.8	18.8

DEX0451_007.nt.3	33254.0	20.0	20.0	46.2	48.0	40.0	42.1	37.5	37.5
DEX0451_007.nt.3	33255.0	10.0	10.0	38.5	38.5	30.0	30.0	31.2	31.2
DEX0451_007.nt.4	16882.0	10.0	10.0	34.6	34.6	30.0	30.0	25.0	25.0
DEX0451_007.nt.5	33254.0	20.0	20.0	46.2	48.0	40.0	42.1	37.5	37.5
DEX0451_007.nt.5	33255.0	10.0	10.0	38.5	38.5	30.0	30.0	31.2	31.2
DEX0451_008.nt.1	18463.0	10.0	10.0	30.8	30.8	15.0	15.0	37.5	37.5
DEX0451_008.nt.1	19444.0	20.0	20.0	42.3	42.3	30.0	30.0	43.8	43.8
DEX0451_008.nt.1	19445.0	20.0	20.0	38.5	38.5	30.0	30.0	37.5	37.5
DEX0451_008.nt.1	19448.0	20.0	20.0	30.8	30.8	10.0	10.0	50.0	50.0
DEX0451_008.nt.1	31908.0	10.0	10.0	34.6	34.6	15.0	15.0	43.8	43.8
DEX0451_009.nt.1	12219.0	30.0	30.0	0.0	0.0	10.0	10.0	6.2	6.2
DEX0451_009.nt.1	12220.0	30.0	30.0	0.0	0.0	10.0	10.0	6.2	6.2
DEX0451_009.nt.1	13615.0	20.0	22.2	0.0	0.0	5.0	5.0	6.2	7.1
DEX0451_011.nt.1	28011.0	10.0	11.1	34.6	37.5	30.0	31.6	25.0	28.6
DEX0451_012.nt.1	22451.0	10.0	10.0	26.9	26.9	15.0	15.0	31.2	31.2
DEX0451_012.nt.1	22452.0	10.0	10.0	11.5	11.5	5.0	5.0	18.8	18.8
DEX0451_013.nt.1	28395.0	40.0	44.4	3.8	4.0	20.0	21.1	6.2	6.7
DEX0451_013.nt.1	28396.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_013.nt.2	28395.0	40.0	44.4	3.8	4.0	20.0	21.1	6.2	6.7
DEX0451_013.nt.2	28396.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_014.nt.1	16523.0	20.0	20.0	15.4	16.7	0.0	0.0	37.5	40.0
DEX0451_015.nt.1	15187.0	50.0	50.0	23.1	24.0	35.0	36.8	25.0	25.0
DEX0451_015.nt.1	27235.0	60.0	60.0	23.1	23.1	40.0	40.0	25.0	25.0
DEX0451_015.nt.1	27236.0	60.0	60.0	19.2	19.2	35.0	35.0	25.0	25.0
DEX0451_015.nt.2	15187.0	50.0	50.0	23.1	24.0	35.0	36.8	25.0	25.0
DEX0451_015.nt.2	27235.0	60.0	60.0	23.1	23.1	40.0	40.0	25.0	25.0
DEX0451_015.nt.2	27236.0	60.0	60.0	19.2	19.2	35.0	35.0	25.0	25.0
DEX0451_016.nt.1	40554.0	20.0	20.0	11.5	12.0	25.0	26.3	0.0	0.0
DEX0451_017.nt.1	20531.0	30.0	30.0	38.5	38.5	60.0	60.0	6.2	6.2
DEX0451_017.nt.1	20532.0	10.0	11.1	30.8	32.0	40.0	42.1	6.2	6.7
DEX0451_018.nt.1	15234.0	40.0	40.0	19.2	19.2	40.0	40.0	6.2	6.2
DEX0451_018.nt.1	15980.0	40.0	40.0	19.2	20.0	40.0	40.0	6.2	6.7
DEX0451_018.nt.1	15987.0	50.0	50.0	23.1	23.1	55.0	55.0	0.0	0.0
DEX0451_018.nt.1	16050.0	40.0	40.0	19.2	19.2	40.0	40.0	6.2	6.2
DEX0451_018.nt.1	16055.0	50.0	50.0	23.1	23.1	50.0	50.0	6.2	6.2
DEX0451_018.nt.1	16056.0	40.0	40.0	19.2	19.2	45.0	45.0	0.0	0.0
DEX0451_018.nt.1	33563.0	40.0	40.0	19.2	19.2	45.0	45.0	0.0	0.0
DEX0451_018.nt.2	15234.0	40.0	40.0	19.2	19.2	40.0	40.0	6.2	6.2
DEX0451_018.nt.2	15980.0	40.0	40.0	19.2	20.0	40.0	40.0	6.2	6.7
DEX0451_018.nt.2	15987.0	50.0	50.0	23.1	23.1	55.0	55.0	0.0	0.0
DEX0451_018.nt.2	16050.0	40.0	40.0	19.2	19.2	40.0	40.0	6.2	6.2
DEX0451_018.nt.2	16055.0	50.0	50.0	23.1	23.1	50.0	50.0	6.2	6.2
DEX0451_018.nt.2	16056.0	40.0	40.0	19.2	19.2	45.0	45.0	0.0	0.0
DEX0451_018.nt.2	33563.0	40.0	40.0	19.2	19.2	45.0	45.0	0.0	0.0
DEX0451_020.nt.1	32801.0	20.0	20.0	34.6	34.6	40.0	40.0	18.8	18.8
DEX0451_021.nt.1	19436.0	0.0	0.0	3.8	4.0	0.0	0.0	6.2	6.7
DEX0451_021.nt.1	19437.0	20.0	20.0	11.5	11.5	20.0	20.0	6.2	6.2
DEX0451_021.nt.2	19436.0	0.0	0.0	3.8	4.0	0.0	0.0	6.2	6.7
DEX0451_021.nt.2	19437.0	20.0	20.0	11.5	11.5	20.0	20.0	6.2	6.2
DEX0451_021.nt.3	19436.0	0.0	0.0	3.8	4.0	0.0	0.0	6.2	6.7
DEX0451_021.nt.3	19437.0	20.0	20.0	11.5	11.5	20.0	20.0	6.2	6.2
DEX0451_022.nt.1	20617.0	20.0	20.0	34.6	34.6	30.0	30.0	31.2	31.2
DEX0451_022.nt.1	20618.0	10.0	10.0	11.5	11.5	10.0	10.0	12.5	12.5
DEX0451_023.nt.1	18012.0	20.0	22.2	34.6	34.6	20.0	21.1	43.8	43.8
DEX0451_023.nt.1	18013.0	20.0	22.2	30.8	30.8	20.0	21.1	37.5	37.5
DEX0451_023.nt.1	18016.0	20.0	20.0	23.1	24.0	15.0	15.8	31.2	31.2
DEX0451_023.nt.1	18017.0	20.0	22.2	30.8	30.8	25.0	26.3	31.2	31.2

DEX0451 023.nt.1	18018.0	20.0	20.0	30.8	30.8	15.0	15.0	43.8	43.8
DEX0451 023.nt.1	18019.0	20.0	20.0	38.5	38.5	20.0	20.0	50.0	50.0
DEX0451 023.nt.1	28313.0	10.0	11.1	0.0	0.0	5.0	5.6	0.0	0.0
DEX0451 023.nt.1	28314.0	0.0	0.0	3.8	5.9	0.0	0.0	6.2	10.0
DEX0451 024.nt.1	36510.0	30.0	30.0	26.9	26.9	25.0	25.0	31.2	31.2
DEX0451 025.nt.1	21189.0	30.0	33.3	42.3	42.3	20.0	21.1	62.5	62.5
DEX0451 026.nt.1	30171.0	40.0	40.0	30.8	30.8	30.0	30.0	37.5	37.5
DEX0451 026.nt.1	30172.0	30.0	30.0	15.4	15.4	10.0	10.0	31.2	31.2
DEX0451 026.nt.2	30171.0	40.0	40.0	30.8	30.8	30.0	30.0	37.5	37.5
DEX0451 026.nt.2	30172.0	30.0	30.0	15.4	15.4	10.0	10.0	31.2	31.2
DEX0451 027.nt.1	13999.0	10.0	10.0	0.0	0.0	0.0	0.0	6.2	6.2
DEX0451 027.nt.1	14001.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451 027.nt.1	20396.0	10.0	10.0	3.8	3.8	0.0	0.0	12.5	12.5
DEX0451 027.nt.1	31768.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451 027.nt.1	31769.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451 028.nt.1	9670.0	40.0	40.0	0.0	0.0	15.0	15.8	6.2	6.2
DEX0451 029.nt.1	37563.0	30.0	30.0	15.4	15.4	25.0	25.0	12.5	12.5
DEX0451 030.nt.1	34949.0	30.0	30.0	26.9	26.9	20.0	20.0	37.5	37.5
DEX0451 032.nt.1	19190.0	10.0	10.0	23.1	23.1	35.0	35.0	0.0	0.0
DEX0451 032.nt.1	19191.0	10.0	10.0	23.1	23.1	35.0	35.0	0.0	0.0
DEX0451 032.nt.1	19246.0	10.0	12.5	11.5	14.3	20.0	26.7	0.0	0.0
DEX0451 032.nt.1	19247.0	10.0	33.3	3.8	14.3	10.0	28.6	0.0	0.0
DEX0451 032.nt.1	19262.0	10.0	50.0	3.8	16.7	10.0	28.6	0.0	0.0
DEX0451 032.nt.1	19332.0	10.0	14.3	7.7	13.3	15.0	23.1	0.0	0.0
DEX0451 032.nt.1	19333.0	10.0	14.3	11.5	18.8	20.0	28.6	0.0	0.0
DEX0451 032.nt.1	19387.0	10.0	10.0	23.1	23.1	35.0	35.0	0.0	0.0
DEX0451 032.nt.2	19248.0	10.0	10.0	23.1	23.1	30.0	30.0	6.2	6.2
DEX0451 032.nt.2	19250.0	10.0	10.0	19.2	19.2	30.0	30.0	0.0	0.0
DEX0451 032.nt.2	19260.0	10.0	10.0	19.2	19.2	30.0	30.0	0.0	0.0
DEX0451 032.nt.2	19265.0	10.0	10.0	23.1	23.1	30.0	30.0	6.2	6.2
DEX0451 032.nt.3	19246.0	10.0	12.5	11.5	14.3	20.0	26.7	0.0	0.0
DEX0451 032.nt.3	19247.0	10.0	33.3	3.8	14.3	10.0	28.6	0.0	0.0
DEX0451 032.nt.3	19262.0	10.0	50.0	3.8	16.7	10.0	28.6	0.0	0.0
DEX0451 032.nt.3	19332.0	10.0	14.3	7.7	13.3	15.0	23.1	0.0	0.0
DEX0451 032.nt.3	19333.0	10.0	14.3	11.5	18.8	20.0	28.6	0.0	0.0
DEX0451 032.nt.4	19246.0	10.0	12.5	11.5	14.3	20.0	26.7	0.0	0.0
DEX0451 032.nt.4	19247.0	10.0	33.3	3.8	14.3	10.0	28.6	0.0	0.0
DEX0451 032.nt.4	19262.0	10.0	50.0	3.8	16.7	10.0	28.6	0.0	0.0
DEX0451 032.nt.4	19332.0	10.0	14.3	7.7	13.3	15.0	23.1	0.0	0.0
DEX0451 032.nt.4	19333.0	10.0	14.3	11.5	18.8	20.0	28.6	0.0	0.0
DEX0451 032.nt.5	19191.0	10.0	10.0	23.1	23.1	35.0	35.0	0.0	0.0
DEX0451 032.nt.5	19194.0	10.0	10.0	7.7	7.7	15.0	15.0	0.0	0.0
DEX0451 032.nt.5	19248.0	10.0	10.0	23.1	23.1	30.0	30.0	6.2	6.2
DEX0451 032.nt.5	19250.0	10.0	10.0	19.2	19.2	30.0	30.0	0.0	0.0
DEX0451 032.nt.5	19260.0	10.0	10.0	19.2	19.2	30.0	30.0	0.0	0.0
DEX0451 032.nt.5	19265.0	10.0	10.0	23.1	23.1	30.0	30.0	6.2	6.2
DEX0451 032.nt.6	19190.0	10.0	10.0	23.1	23.1	35.0	35.0	0.0	0.0
DEX0451 032.nt.6	19191.0	10.0	10.0	23.1	23.1	35.0	35.0	0.0	0.0
DEX0451 032.nt.6	19194.0	10.0	10.0	7.7	7.7	15.0	15.0	0.0	0.0
DEX0451 032.nt.6	19246.0	10.0	12.5	11.5	14.3	20.0	26.7	0.0	0.0
DEX0451 032.nt.6	19247.0	10.0	33.3	3.8	14.3	10.0	28.6	0.0	0.0
DEX0451 032.nt.6	19262.0	10.0	50.0	3.8	16.7	10.0	28.6	0.0	0.0
DEX0451 032.nt.6	19332.0	10.0	14.3	7.7	13.3	15.0	23.1	0.0	0.0
DEX0451 032.nt.6	19333.0	10.0	14.3	11.5	18.8	20.0	28.6	0.0	0.0
DEX0451 032.nt.6	19387.0	10.0	10.0	23.1	23.1	35.0	35.0	0.0	0.0
DEX0451 033.nt.1	12500.0	40.0	57.1	11.5	17.6	5.0	6.7	37.5	66.7
DEX0451 033.nt.1	12505.0	30.0	30.0	15.4	15.4	5.0	5.0	37.5	37.5

DEX0451_033.nt.1	12506.0	30.0	30.0	15.4	15.4	10.0	10.0	31.2	31.2
DEX0451_033.nt.1	33560.0	50.0	62.5	15.4	17.4	10.0	11.1	43.8	53.8
DEX0451_033.nt.1	33561.0	20.0	50.0	11.5	33.3	5.0	12.5	25.0	80.0
DEX0451_033.nt.2	12500.0	40.0	57.1	11.5	17.6	5.0	6.7	37.5	66.7
DEX0451_033.nt.2	33560.0	50.0	62.5	15.4	17.4	10.0	11.1	43.8	53.8
DEX0451_033.nt.2	33561.0	20.0	50.0	11.5	33.3	5.0	12.5	25.0	80.0
DEX0451_034.nt.1	14003.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_034.nt.1	14004.0	20.0	20.0	26.9	26.9	35.0	35.0	12.5	12.5
DEX0451_034.nt.1	27151.0	20.0	20.0	23.1	23.1	30.0	30.0	12.5	12.5
DEX0451_034.nt.1	27152.0	10.0	10.0	26.9	26.9	40.0	40.0	0.0	0.0
DEX0451_036.nt.1	23858.0	60.0	60.0	61.5	61.5	75.0	75.0	43.8	43.8
DEX0451_036.nt.1	23859.0	60.0	60.0	61.5	61.5	75.0	75.0	43.8	43.8
DEX0451_036.nt.1	37858.0	40.0	40.0	65.4	65.4	70.0	70.0	43.8	43.8
DEX0451_036.nt.2	23858.0	60.0	60.0	61.5	61.5	75.0	75.0	43.8	43.8
DEX0451_036.nt.2	23859.0	60.0	60.0	61.5	61.5	75.0	75.0	43.8	43.8
DEX0451_036.nt.2	37858.0	40.0	40.0	65.4	65.4	70.0	70.0	43.8	43.8
DEX0451_036.nt.3	23858.0	60.0	60.0	61.5	61.5	75.0	75.0	43.8	43.8
DEX0451_036.nt.3	23859.0	60.0	60.0	61.5	61.5	75.0	75.0	43.8	43.8
DEX0451_036.nt.3	37858.0	40.0	40.0	65.4	65.4	70.0	70.0	43.8	43.8
DEX0451_037.nt.1	15045.0	30.0	30.0	30.8	30.8	45.0	45.0	12.5	12.5
DEX0451_037.nt.1	15066.0	50.0	50.0	26.9	26.9	50.0	50.0	12.5	12.5
DEX0451_037.nt.2	15044.0	20.0	20.0	26.9	26.9	40.0	40.0	6.2	6.2
DEX0451_037.nt.2	15045.0	30.0	30.0	30.8	30.8	45.0	45.0	12.5	12.5
DEX0451_037.nt.2	15062.0	50.0	50.0	26.9	26.9	50.0	50.0	12.5	12.5
DEX0451_037.nt.2	15063.0	40.0	50.0	23.1	24.0	45.0	45.0	6.2	7.7
DEX0451_037.nt.2	15066.0	50.0	50.0	26.9	26.9	50.0	50.0	12.5	12.5
DEX0451_037.nt.2	33432.0	40.0	40.0	23.1	23.1	45.0	45.0	6.2	6.2
DEX0451_037.nt.3	15044.0	20.0	20.0	26.9	26.9	40.0	40.0	6.2	6.2
DEX0451_037.nt.3	15045.0	30.0	30.0	30.8	30.8	45.0	45.0	12.5	12.5
DEX0451_037.nt.3	15062.0	50.0	50.0	26.9	26.9	50.0	50.0	12.5	12.5
DEX0451_037.nt.3	15063.0	40.0	50.0	23.1	24.0	45.0	45.0	6.2	7.7
DEX0451_037.nt.3	15066.0	50.0	50.0	26.9	26.9	50.0	50.0	12.5	12.5
DEX0451_037.nt.3	33432.0	40.0	40.0	23.1	23.1	45.0	45.0	6.2	6.2
DEX0451_037.nt.4	15044.0	20.0	20.0	26.9	26.9	40.0	40.0	6.2	6.2
DEX0451_037.nt.4	15045.0	30.0	30.0	30.8	30.8	45.0	45.0	12.5	12.5
DEX0451_037.nt.4	15066.0	50.0	50.0	26.9	26.9	50.0	50.0	12.5	12.5
DEX0451_037.nt.4	15071.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_037.nt.4	33432.0	40.0	40.0	23.1	23.1	45.0	45.0	6.2	6.2
DEX0451_037.nt.5	15062.0	50.0	50.0	26.9	26.9	50.0	50.0	12.5	12.5
DEX0451_037.nt.5	15063.0	40.0	50.0	23.1	24.0	45.0	45.0	6.2	7.7

COLON CANCER CHIPS

For colon cancer two different chip designs were evaluated with overlapping sets of a total of 38 samples, comparing the expression patterns of colon cancer derived polyA+ RNA to polyA+ RNA isolated from a pool of 7 normal colon tissues. For the Colon Array Chip all 38 samples (23 Ascending colon carcinomas and 15 Rectosigmoidal carcinomas including: 5 stage I cancers, 15 stage II cancers, 15 stage III and 2 stage IV cancers, as well as 28 Grade1/2 and 10 Grade 3 cancers) were analyzed. The histopathologic grades for cancer are classified as follows: GX, cannot be assessed; G1, well differentiated; G2, Moderately differentiated; G3, poorly differentiated; and G4,

undifferentiated. AJCC Cancer Staging Handbook, 5th Edition, 1998, page 9. For the Colon Array Chip analysis, samples were further divided into groups based on the expression pattern of the known colon cancer associated gene Thymidilate Synthase (TS) (13 TS up 25 TS not up). The association of TS with advanced colorectal cancer is well documented. Paradiso *et al.*, *Br J Cancer* 82(3):560-7 (2000); Etienne *et al.*, *J Clin Oncol.* 20(12):2832-43 (2002); Aschele *et al.* *Clin Cancer Res.* 6(12):4797-802 (2000). For the Multi-Cancer Array Chip a subset of 27 of these samples (14 Ascending colon carcinomas and 13 Rectosigmoidal carcinomas including: 3 stage I cancers, 9 stage II cancers, 13 stage III and 2 stage IV cancers) were assessed.

The results for the statistically significant up-regulated genes on the Colon Array Chip are shown in Tables 3 and 4. No results for the statistically significant up-regulated genes on the Multi-Cancer Array Chip are shown.

The first two columns of each table contain information about the sequence itself (Seq ID, Oligo Name), the next columns show the results obtained for all ("ALL") the colon samples, ascending colon carcinomas ("ASC"), Rectosigmoidal carcinomas ("RS"), cancers corresponding to stages I and II ("ST1,2"), stages III and IV ("ST3,4"), grades 1 and 2 ("GR1,2"), grade 3 ("GR3"), cancers exhibiting up-regulation of the TS gene ("TSup") or those not exhibiting up-regulation of the TS gene ("NOT TSup"). '%up' indicates the percentage of all experiments in which up-regulation of at least 2-fold was observed n=38 for the Colon Array Chip (n=27 for the Multi-Cancer Array Chip), '%valid up' indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

Table 3.

DEX ID	Oligo Name	Cln ALL %up n=38	Cln ALL % valid up n=38	Cln ASC %up n=23	Cln ASC % valid up n=23	Cln RS %up n=15	Cln RS % valid up n=15	Cln ST1, 2 %up n=20	Cln ST1, 2 % valid up n=20	Cln ST3, 4 %up n=18	Cln ST3, 4 % valid up n=18
DEX0451_010.nt.1	36158.0	15.8	15.8	13.0	13.0	20.0	20.0	15.0	15.0	16.7	16.7
DEX0451_026.nt.1	9521.0	7.9	7.9	13.0	13.0	0.0	0.0	5.0	5.0	11.1	11.1
DEX0451_028.nt.1	32686.0	5.3	5.7	4.3	4.8	6.7	7.1	5.0	5.6	5.6	5.9
DEX0451_028.nt.1	32687.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_028.nt.1	35234.0	13.2	13.2	13.0	13.0	13.3	13.3	10.0	10.0	16.7	16.7
DEX0451_028.nt.1	35235.0	13.2	13.2	13.0	13.0	13.3	13.3	10.0	10.0	16.7	16.7

DEX0451_028.nt.2	35234.0	13.2	13.2	13.0	13.0	13.3	13.3	10.0	10.0	16.7	16.7
DEX0451_028.nt.2	35235.0	13.2	13.2	13.0	13.0	13.3	13.3	10.0	10.0	16.7	16.7
DEX0451_030.nt.1	34752.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1
DEX0451_030.nt.1	34753.0	7.9	7.9	8.7	8.7	6.7	6.7	5.0	5.0	11.1	11.1
DEX0451_030.nt.2	34752.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1
DEX0451_030.nt.2	34753.0	7.9	7.9	8.7	8.7	6.7	6.7	5.0	5.0	11.1	11.1
DEX0451_033.nt.1	36947.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.1	36948.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.1	38489.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	36947.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	36948.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	38489.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_036.nt.1	35114.0	5.3	5.3	8.7	8.7	0.0	0.0	5.0	5.0	5.6	5.6
DEX0451_036.nt.1	35115.0	5.3	5.3	8.7	8.7	0.0	0.0	5.0	5.0	5.6	5.6
DEX0451_036.nt.2	35114.0	5.3	5.3	8.7	8.7	0.0	0.0	5.0	5.0	5.6	5.6
DEX0451_036.nt.2	35115.0	5.3	5.3	8.7	8.7	0.0	0.0	5.0	5.0	5.6	5.6
DEX0451_036.nt.3	35114.0	5.3	5.3	8.7	8.7	0.0	0.0	5.0	5.0	5.6	5.6
DEX0451_036.nt.3	35115.0	5.3	5.3	8.7	8.7	0.0	0.0	5.0	5.0	5.6	5.6
DEX0451_037.nt.2	19356.0	2.6	2.6	0.0	0.0	6.7	6.7	0.0	0.0	5.6	5.6

Table 4.

DEX ID	Oligo Name	Cln GR1,2 %up n=28	Cln GR1,2 %valid up n=28	Cln GR3 %up n=10	Cln GR3 %valid up n=10	Cln TS %up n=13	Cln TS %valid up n=13	Cln NOT TS %up n=25	Cln NOT TS %valid up n=25
DEX0451_010.nt.1	36158.0	17.9	17.9	10.0	10.0	0.0	0.0	24.0	24.0
DEX0451_026.nt.1	9521.0	7.1	7.1	10.0	10.0	15.4	15.4	4.0	4.0
DEX0451_028.nt.1	32686.0	3.6	3.8	10.0	11.1	7.7	7.7	4.0	4.5
DEX0451_028.nt.1	32687.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_028.nt.1	35234.0	10.7	10.7	20.0	20.0	7.7	7.7	16.0	16.0
DEX0451_028.nt.1	35235.0	14.3	14.3	10.0	10.0	15.4	15.4	12.0	12.0
DEX0451_028.nt.2	35234.0	10.7	10.7	20.0	20.0	7.7	7.7	16.0	16.0
DEX0451_028.nt.2	35235.0	14.3	14.3	10.0	10.0	15.4	15.4	12.0	12.0
DEX0451_030.nt.1	34752.0	7.1	7.1	0.0	0.0	7.7	7.7	4.0	4.0
DEX0451_030.nt.1	34753.0	7.1	7.1	10.0	10.0	7.7	7.7	8.0	8.0
DEX0451_030.nt.2	34752.0	7.1	7.1	0.0	0.0	7.7	7.7	4.0	4.0
DEX0451_030.nt.2	34753.0	7.1	7.1	10.0	10.0	7.7	7.7	8.0	8.0

DEX0451_033.nt.1	36947.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.1	36948.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.1	38489.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	36947.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	36948.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	38489.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_036.nt.1	35114.0	3.6	3.6	10.0	10.0	7.7	7.7	4.0	4.0	
DEX0451_036.nt.1	35115.0	3.6	3.6	10.0	10.0	7.7	7.7	4.0	4.0	
DEX0451_036.nt.2	35114.0	3.6	3.6	10.0	10.0	7.7	7.7	4.0	4.0	
DEX0451_036.nt.2	35115.0	3.6	3.6	10.0	10.0	7.7	7.7	4.0	4.0	
DEX0451_036.nt.3	35114.0	3.6	3.6	10.0	10.0	7.7	7.7	4.0	4.0	
DEX0451_036.nt.3	35115.0	3.6	3.6	10.0	10.0	7.7	7.7	4.0	4.0	
DEX0451_037.nt.2	19356.0	0.0	0.0	10.0	10.0	7.7	7.7	0.0	0.0	

LUNG CANCER CHIPS

For lung cancer two different chip designs were evaluated with overlapping sets of a total of 29 samples, comparing the expression patterns of lung cancer derived polyA+ RNA to polyA+ RNA isolated from a pool of 12 normal lung tissues. For the Lung Array Chip all 29 samples (15 squamous cell carcinomas and 14 adenocarcinomas including 14 stage I and 15 stage II/III cancers) were analyzed and for the Multi-Cancer Array Chip a subset of 22 of these samples (10 squamous cell carcinomas, 12 adenocarcinomas) were assessed.

The results for the statistically significant up-regulated genes on the Lung Array Chip are shown in Table 5. No results for the statistically significant up-regulated genes on the Multi-Cancer Array Chip are shown. The first two columns of each table contain information about the sequence itself (DEX ID, Oligo Name), the next columns show the results obtained for all ("ALL") lung cancer samples, squamous cell carcinomas ("SQ"), adenocarcinomas ("AD"), or cancers corresponding to stage I ("ST1"), or stages II and III ("ST2,3"). '%up' indicates the percentage of all experiments in which up-regulation of at least 2-fold was observed (n=29 for Lung Array Chip, n=22 for Multi-Cancer Array Chip), '%valid up' indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

Table 5.

DEX ID	Oligo Name	Lng ALL %up n=29	Lng ALL % valid up n=29	Lng SQ %up n=15	Lng SQ % valid up n=15	Lng AD %up n=14	Lng AD % valid up n=14	Lng ST1 %up n=14	Lng ST1 % valid up n=14	Lng ST2,3 %up n=15	Lng ST2,3 % valid up n=15
DEX0451_024.nt.1	5882.0	20.7	20.7	26.7	26.7	14.3	14.3	14.3	14.3	26.7	26.7
DEX0451_029.nt.1	3470.0	6.9	6.9	0.0	0.0	14.3	14.3	14.3	14.3	0.0	0.0

DEX0451_029.nt.1	3471.0	3.4	3.4	0.0	0.0	7.1	7.1	7.1	7.1	0.0	0.0
DEX0451_033.nt.1	5781.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.1	5782.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	5503.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	5504.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	5781.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	5782.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

OVARIAN CANCER CHIPS

For ovarian cancer two different chip designs were evaluated with overlapping sets of a total of 19 samples, comparing the expression patterns of ovarian cancer derived total RNA to total RNA isolated from a pool of 9 normal ovarian tissues. For the Multi-Cancer Array Chip, all 19 samples (14 invasive carcinomas, 5 low malignant potential samples) were analyzed and for the Ovarian Array Chip, a subset of 17 of these samples (13 invasive carcinomas, 4 low malignant potential samples) were assessed.

The results for the statistically significant up-regulated genes on the Ovarian Array Chip are shown in Table 6. No results for the statistically significant up-regulated genes on the Multi-Cancer Array Chip are shown. The first two columns of each table contain information about the sequence itself (DEX ID, Oligo Name), the next columns show the results obtained for all ("ALL") ovarian cancer samples, invasive carcinomas ("INV") and low malignant potential ("LMP") samples. '%up' indicates the percentage of all experiments in which up-regulation of at least 2-fold was observed (n=19 for the Multi-Cancer Array Chip, n=17 for the Ovarian Array Chip), '%valid up' indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

Table 6.

DEX ID	Oligo Name	Ovr ALL %up n=17	Ovr ALL %valid up n=17	Ovr INV %up n=13	Ovr INV %valid up n=13	Ovr LMP %up n=4	Ovr LMP %valid up n=4
DEX0451_007.nt.4	20797.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_007.nt.4	20797.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.1	9846.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0451_033.nt.1	9846.02	0.0	0.0	0.0	0.0	0.0	0.0

PROSTATE CANCER

For prostate cancer three different chip designs were evaluated with overlapping sets of a total of 29 samples, comparing the expression patterns of prostate cancer or benign disease derived total RNA to total RNA isolated from a pool of 35 normal prostate tissues. For the Prostate1 Array and Prostate2 Array Chips all 29 samples (17 prostate cancer samples, 12 non-malignant disease samples) were analyzed. For the Multi-Cancer Array Chip a subset of 28 of these samples (16 prostate cancer samples, 12 non-malignant disease samples) was analyzed.

The results for the statistically significant up-regulated genes on the Prostate1 Array Chip and the Prostate2 Array Chip are shown in Table 7. No results for the statistically significant up-regulated genes on the Multi-Cancer Array Chip are shown. The first two columns of each table contain information about the sequence itself (DEX ID, Oligo Name), the next columns show the results obtained for prostate cancer samples ("CAN") or non-malignant disease samples ("DIS"). '%up' indicates the percentage of all experiments in which up-regulation of at least 2-fold was observed (n=29 for the Prostate2 Array Chip and the Multi-Cancer Array Chip), '%valid up' indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

Table 7.

DEX ID	Oligo Name	Pro CAN %up n=17	Pro CAN %valid up n=17	Pro DIS %up n=12	Pro DIS %valid up n=12
DEX0451_006.nt.1	27839.01	0.0	0.0	8.3	8.3
DEX0451_006.nt.1	27839.02	0.0	0.0	8.3	8.3
DEX0451_006.nt.1	38183.01	5.9	5.9	8.3	8.3
DEX0451_006.nt.1	38183.02	0.0	0.0	0.0	0.0
DEX0451_006.nt.2	27839.01	0.0	0.0	8.3	8.3
DEX0451_006.nt.2	27839.02	0.0	0.0	8.3	8.3
DEX0451_006.nt.2	38183.01	5.9	5.9	8.3	8.3
DEX0451_006.nt.2	38183.02	0.0	0.0	0.0	0.0
DEX0451_006.nt.3	27839.01	0.0	0.0	8.3	8.3
DEX0451_006.nt.3	27839.02	0.0	0.0	8.3	8.3
DEX0451_006.nt.3	38183.01	5.9	5.9	8.3	8.3
DEX0451_006.nt.3	38183.02	0.0	0.0	0.0	0.0
DEX0451_006.nt.4	27839.01	0.0	0.0	8.3	8.3
DEX0451_006.nt.4	27839.02	0.0	0.0	8.3	8.3
DEX0451_006.nt.4	38183.01	5.9	5.9	8.3	8.3
DEX0451_006.nt.4	38183.02	0.0	0.0	0.0	0.0
DEX0451_006.nt.5	27839.01	0.0	0.0	8.3	8.3
DEX0451_006.nt.5	27839.02	0.0	0.0	8.3	8.3
DEX0451_006.nt.5	38183.01	5.9	5.9	8.3	8.3
DEX0451_006.nt.5	38183.02	0.0	0.0	0.0	0.0
DEX0451_006.nt.6	27839.01	0.0	0.0	8.3	8.3
DEX0451_006.nt.6	27839.02	0.0	0.0	8.3	8.3
DEX0451_006.nt.6	38183.01	5.9	5.9	8.3	8.3

DEX0451_006.nt.6	38183.02	0.0	0.0	0.0	0.0
DEX0451_006.nt.7	27839.01	0.0	0.0	8.3	8.3
DEX0451_006.nt.7	27839.02	0.0	0.0	8.3	8.3
DEX0451_006.nt.7	38183.01	5.9	5.9	8.3	8.3
DEX0451_006.nt.7	38183.02	0.0	0.0	0.0	0.0
DEX0451_006.nt.8	27839.01	0.0	0.0	8.3	8.3
DEX0451_006.nt.8	27839.02	0.0	0.0	8.3	8.3
DEX0451_006.nt.8	38183.01	5.9	5.9	8.3	8.3
DEX0451_006.nt.8	38183.02	0.0	0.0	0.0	0.0
DEX0451_009.nt.1	30679.01	0.0	0.0	0.0	0.0
DEX0451_009.nt.1	30679.02	0.0	0.0	0.0	0.0
DEX0451_009.nt.1	30679.03	0.0	0.0	0.0	0.0
DEX0451_033.nt.1	29721.01	0.0	0.0	0.0	0.0
DEX0451_033.nt.1	29721.02	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	29721.01	0.0	0.0	0.0	0.0
DEX0451_033.nt.2	29721.02	0.0	0.0	0.0	0.0

SEQ ID NO: 1-72 was up-regulated on various tissue microarrays. Accordingly, nucleotide SEQ ID NO: 1-72 or the encoded protein SEQ ID NO: 73-179 may be used as a cancer therapeutic and/or diagnostic target for the tissues in which expression is shown.

5

The following table lists the location (Oligo Location) where the microarray oligos (Oligo ID) map on the transcripts (DEX ID) of the present invention. Each Oligo ID may have been printed multiple times on a single chip as replicates. The Oligo Name is an exemplary replicate (e.g. 1000.01) for the Oligo ID (e.g. 1000), and data from other replicates (e.g. 1000.02, 1000.03) may be reported. Additionally, the Array (Chip Name) that each oligo and oligo replicates were printed on is included.

10

DEX NT ID	Oligo ID	Oligo Name	Chip Name	Oligo Location
DEX0451_001.nt.1	22403	22403.0	Breast array	371-430
DEX0451_002.nt.1	19368	19368.0	Breast array	890-949
DEX0451_002.nt.1	19369	19369.0	Breast array	816-875
DEX0451_003.nt.1	20532	20532.0	Breast array	675-734
DEX0451_003.nt.1	20531	20531.0	Breast array	772-831
DEX0451_004.nt.1	40416	40416.0	Breast array	6-65
DEX0451_005.nt.1	10310	10310.0	Breast array	2608-2667
DEX0451_006.nt.1	12495	12495.0	Breast array	279-338
DEX0451_006.nt.1	27839	27839.02	Prostate1 array	279-338
DEX0451_006.nt.1	38183	38183.02	Prostate1 array	279-338
DEX0451_006.nt.2	12495	12495.0	Breast array	291-350
DEX0451_006.nt.2	27839	27839.02	Prostate1 array	291-350
DEX0451_006.nt.2	38183	38183.02	Prostate1 array	291-350
DEX0451_006.nt.3	27839	27839.02	Prostate1 array	307-366
DEX0451_006.nt.3	38183	38183.02	Prostate1 array	307-366

DEX0451_006.nt.3	12495	12495.0	Breast array	307-366
DEX0451_006.nt.4	27839	27839.02	Prostate1 array	273-332
DEX0451_006.nt.4	12495	12495.0	Breast array	273-332
DEX0451_006.nt.4	38183	38183.02	Prostate1 array	273-332
DEX0451_006.nt.5	12495	12495.0	Breast array	248-307
DEX0451_006.nt.5	27839	27839.02	Prostate1 array	248-307
DEX0451_006.nt.5	38183	38183.02	Prostate1 array	248-307
DEX0451_006.nt.6	12495	12495.0	Breast array	249-308
DEX0451_006.nt.6	27839	27839.02	Prostate1 array	249-308
DEX0451_006.nt.7	12495	12495.0	Breast array	268-327
DEX0451_006.nt.7	27839	27839.02	Prostate1 array	268-327
DEX0451_006.nt.7	38183	38183.02	Prostate1 array	268-327
DEX0451_006.nt.8	27839	27839.02	Prostate1 array	336-395
DEX0451_006.nt.8	12495	12495.0	Breast array	336-395
DEX0451_006.nt.8	38183	38183.02	Prostate1 array	336-395
DEX0451_007.nt.1	33254	33254.0	Breast array	1192-1251
DEX0451_007.nt.1	16882	16882.0	Breast array	425-484
DEX0451_007.nt.1	33255	33255.0	Breast array	1152-1211
DEX0451_007.nt.2	16882	16882.0	Breast array	929-988
DEX0451_007.nt.2	33254	33254.0	Breast array	1696-1755
DEX0451_007.nt.3	16882	16882.0	Breast array	254-313
DEX0451_007.nt.3	33255	33255.0	Breast array	981-1040
DEX0451_007.nt.3	16883	16883.0	Breast array	234-293
DEX0451_007.nt.4	16882	16882.0	Breast array	785-844
DEX0451_007.nt.4	20797	20797.01	Ovarian array	1202-1261
DEX0451_007.nt.5	33254	33254.0	Breast array	363-422
DEX0451_007.nt.5	33255	33255.0	Breast array	323-382
DEX0451_008.nt.1	19444	19444.0	Breast array	618-677
DEX0451_008.nt.1	19445	19445.0	Breast array	586-645
DEX0451_008.nt.1	31908	31908.0	Breast array	298-357
DEX0451_008.nt.1	18463	18463.0	Breast array	401-460
DEX0451_008.nt.1	19448	19448.0	Breast array	129-188
DEX0451_009.nt.1	12220	12220.0	Breast array	4012-4071
DEX0451_009.nt.1	13615	13615.0	Breast array	2029-2088
DEX0451_009.nt.1	12219	12219.0	Breast array	4059-4118
DEX0451_009.nt.1	30679	30679.03	Prostate2 array	3406-3465
DEX0451_010.nt.1	36158	36158.0	Colon array	840-899
DEX0451_011.nt.1	28011	28011.0	Breast array	1046-1105
DEX0451_012.nt.1	22451	22451.0	Breast array	712-771
DEX0451_012.nt.1	22452	22452.0	Breast array	557-616
DEX0451_013.nt.1	28395	28395.0	Breast array	2949-3008
DEX0451_013.nt.1	28396	28396.0	Breast array	2710-2769
DEX0451_013.nt.2	28395	28395.0	Breast array	2318-2377
DEX0451_013.nt.2	28396	28396.0	Breast array	2079-2138
DEX0451_014.nt.1	16523	16523.0	Breast array	1061-1120
DEX0451_015.nt.1	15187	15187.0	Breast array	1314-1373
DEX0451_015.nt.1	27235	27235.0	Breast array	1848-1907
DEX0451_015.nt.1	27236	27236.0	Breast array	1705-1764

DEX0451_015.nt.2	15187	15187.0	Breast array	816-875
DEX0451_015.nt.2	27236	27236.0	Breast array	1207-1266
DEX0451_015.nt.2	27235	27235.0	Breast array	1350-1409
DEX0451_016.nt.1	40554	40554.0	Breast array	802-861
DEX0451_017.nt.1	20532	20532.0	Breast array	677-736
DEX0451_017.nt.1	20531	20531.0	Breast array	774-833
DEX0451_018.nt.1	16056	16056.0	Breast array	2484-2543
DEX0451_018.nt.1	16050	16050.0	Breast array	1245-1304
DEX0451_018.nt.1	15234	15234.0	Breast array	1901-1960
DEX0451_018.nt.1	15980	15980.0	Breast array	1159-1218
DEX0451_018.nt.1	16055	16055.0	Breast array	2543-2602
DEX0451_018.nt.1	33563	33563.0	Breast array	2523-2582
DEX0451_018.nt.1	15987	15987.0	Breast array	2523-2582
DEX0451_018.nt.2	33563	33563.0	Breast array	2690-2749
DEX0451_018.nt.2	16055	16055.0	Breast array	2710-2769
DEX0451_018.nt.2	15980	15980.0	Breast array	1419-1478
DEX0451_018.nt.2	15987	15987.0	Breast array	2690-2749
DEX0451_018.nt.2	16056	16056.0	Breast array	2651-2710
DEX0451_018.nt.2	15234	15234.0	Breast array	2068-2127
DEX0451_018.nt.2	16050	16050.0	Breast array	1505-1564
DEX0451_020.nt.1	32801	32801.0	Breast array	2692-2751
DEX0451_021.nt.1	19437	19437.0	Breast array	630-689
DEX0451_021.nt.1	19436	19436.0	Breast array	686-745
DEX0451_021.nt.2	19437	19437.0	Breast array	630-689
DEX0451_021.nt.2	19436	19436.0	Breast array	686-745
DEX0451_021.nt.3	19437	19437.0	Breast array	540-599
DEX0451_021.nt.3	19436	19436.0	Breast array	596-655
DEX0451_022.nt.1	20618	20618.0	Breast array	1284-1343
DEX0451_022.nt.1	20617	20617.0	Breast array	1399-1458
DEX0451_023.nt.1	18017	18017.0	Breast array	1792-1851
DEX0451_023.nt.1	18016	18016.0	Breast array	1859-1918
DEX0451_023.nt.1	28313	28313.0	Breast array	4052-4111
DEX0451_023.nt.1	18012	18012.0	Breast array	1958-2017
DEX0451_023.nt.1	18013	18013.0	Breast array	1918-1977
DEX0451_023.nt.1	18019	18019.0	Breast array	1555-1614
DEX0451_023.nt.1	28314	28314.0	Breast array	3867-3926
DEX0451_023.nt.1	18018	18018.0	Breast array	1595-1654
DEX0451_024.nt.1	5882	5882.0	Lung array	630-689
DEX0451_024.nt.1	36510	36510.0	Breast array	663-722
DEX0451_025.nt.1	21189	21189.0	Breast array	668-727
DEX0451_026.nt.1	30172	30172.0	Breast array	214-273
DEX0451_026.nt.1	9521	9521.0	Colon array	52-111
DEX0451_026.nt.1	30171	30171.0	Breast array	307-366
DEX0451_026.nt.2	30172	30172.0	Breast array	1314-1373
DEX0451_026.nt.2	9521	9521.0	Colon array	1152-1211
DEX0451_027.nt.1	14001	14001.0	Breast array	2240-2299
DEX0451_027.nt.1	31768	31768.0	Breast array	2420-2479
DEX0451_027.nt.1	20396	20396.0	Breast array	3155-3214
DEX0451_027.nt.1	31769	31769.0	Breast array	2380-2439
DEX0451_027.nt.1	13999	13999.0	Breast array	3175-3234
DEX0451_028.nt.1	32687	32687.0	Colon array	1165-1224
DEX0451_028.nt.1	32686	32686.0	Colon array	1327-1386
DEX0451_028.nt.1	35235	35235.0	Colon array	2085-2144
DEX0451_028.nt.1	35234	35234.0	Colon array	2131-2190
DEX0451_028.nt.1	9670	9670.0	Breast array	2141-2200
DEX0451_028.nt.2	35235	35235.0	Colon array	787-846
DEX0451_028.nt.2	35234	35234.0	Colon array	833-892

DEX0451_028.nt.2	9670	9670.0	Breast array	843-902
DEX0451_029.nt.1	3471	3471.0	Lung array	1239-1298
DEX0451_029.nt.1	3470	3470.0	Lung array	1279-1338
DEX0451_029.nt.1	37563	37563.0	Breast array	1706-1765
DEX0451_030.nt.1	34753	34753.0	Colon array	1085-1144
DEX0451_030.nt.1	34949	34949.0	Breast array	1090-1149
DEX0451_030.nt.1	34752	34752.0	Colon array	1125-1184
DEX0451_030.nt.2	34753	34753.0	Colon array	1353-1412
DEX0451_030.nt.2	34752	34752.0	Colon array	1393-1452
DEX0451_030.nt.2	34949	34949.0	Breast array	1358-1417
DEX0451_032.nt.1	19246	19246.0	Breast array	645-704
DEX0451_032.nt.1	19262	19262.0	Breast array	605-664
DEX0451_032.nt.1	19190	19190.0	Breast array	165-224
DEX0451_032.nt.1	19247	19247.0	Breast array	605-664
DEX0451_032.nt.1	19333	19333.0	Breast array	524-583
DEX0451_032.nt.1	19387	19387.0	Breast array	304-363
DEX0451_032.nt.1	19332	19332.0	Breast array	544-603
DEX0451_032.nt.1	19191	19191.0	Breast array	135-194
DEX0451_032.nt.2	19250	19250.0	Breast array	631-690
DEX0451_032.nt.2	19265	19265.0	Breast array	631-690
DEX0451_032.nt.2	19260	19260.0	Breast array	475-534
DEX0451_032.nt.2	19248	19248.0	Breast array	631-690
DEX0451_032.nt.3	19246	19246.0	Breast array	211-270
DEX0451_032.nt.3	19332	19332.0	Breast array	110-169
DEX0451_032.nt.3	19333	19333.0	Breast array	90-149
DEX0451_032.nt.3	19247	19247.0	Breast array	171-230
DEX0451_032.nt.3	19262	19262.0	Breast array	171-230
DEX0451_032.nt.4	19246	19246.0	Breast array	225-284
DEX0451_032.nt.4	19247	19247.0	Breast array	185-244
DEX0451_032.nt.4	19332	19332.0	Breast array	124-183
DEX0451_032.nt.4	19333	19333.0	Breast array	104-163
DEX0451_032.nt.4	19262	19262.0	Breast array	185-244
DEX0451_032.nt.5	19191	19191.0	Breast array	836-895
DEX0451_032.nt.5	19260	19260.0	Breast array	406-465
DEX0451_032.nt.5	19248	19248.0	Breast array	562-621
DEX0451_032.nt.5	19250	19250.0	Breast array	562-621
DEX0451_032.nt.5	19265	19265.0	Breast array	562-621
DEX0451_032.nt.5	19194	19194.0	Breast array	712-771
DEX0451_032.nt.6	19333	19333.0	Breast array	1199-1258
DEX0451_032.nt.6	19191	19191.0	Breast array	810-869
DEX0451_032.nt.6	19262	19262.0	Breast array	1280-1339
DEX0451_032.nt.6	19190	19190.0	Breast array	840-899
DEX0451_032.nt.6	19246	19246.0	Breast array	1320-1379
DEX0451_032.nt.6	19387	19387.0	Breast array	979-1038
DEX0451_032.nt.6	19194	19194.0	Breast array	686-745
DEX0451_032.nt.6	19247	19247.0	Breast array	1280-1339
DEX0451_032.nt.6	19332	19332.0	Breast array	1219-1278
DEX0451_033.nt.1	36948	36948.0	Colon array	734-793
DEX0451_033.nt.1	12505	12505.0	Breast array	336-395
DEX0451_033.nt.1	5782	5782.0	Lung array	736-795
DEX0451_033.nt.1	12506	12506.0	Breast array	316-375
DEX0451_033.nt.1	36947	36947.0	Colon array	777-836
DEX0451_033.nt.1	9846	9846.01	Ovarian array	317-376
DEX0451_033.nt.1	29721	29721.02	Prostate1 array	777-836
DEX0451_033.nt.1	38489	38489.0	Colon array	457-516
DEX0451_033.nt.1	33561	33561.0	Breast array	737-796

DEX0451_033.nt.1	12500	12500.0	Breast array	790-849
DEX0451_033.nt.1	5781	5781.0	Lung array	777-836
DEX0451_033.nt.1	33560	33560.0	Breast array	777-836
DEX0451_033.nt.2	5782	5782.0	Lung array	412-471
DEX0451_033.nt.2	33561	33561.0	Breast array	413-472
DEX0451_033.nt.2	36947	36947.0	Colon array	453-512
DEX0451_033.nt.2	5781	5781.0	Lung array	453-512
DEX0451_033.nt.2	5504	5504.0	Lung array	59-118
DEX0451_033.nt.2	36948	36948.0	Colon array	410-469
DEX0451_033.nt.2	5503	5503.0	Lung array	83-142
DEX0451_033.nt.2	12500	12500.0	Breast array	466-525
DEX0451_033.nt.2	29721	29721.02	Prostate1 array	453-512
DEX0451_033.nt.2	33560	33560.0	Breast array	453-512
DEX0451_033.nt.2	38489	38489.0	Colon array	133-192
DEX0451_034.nt.1	27151	27151.0	Breast array	1116-1175
DEX0451_034.nt.1	14003	14003.0	Breast array	786-845
DEX0451_034.nt.1	27152	27152.0	Breast array	876-935
DEX0451_034.nt.1	14004	14004.0	Breast array	680-739
DEX0451_036.nt.1	35114	35114.0	Colon array	1258-1317
DEX0451_036.nt.1	23859	23859.0	Breast array	1952-2011
DEX0451_036.nt.1	35115	35115.0	Colon array	1103-1162
DEX0451_036.nt.1	37858	37858.0	Breast array	864-923
DEX0451_036.nt.1	23858	23858.0	Breast array	2009-2068
DEX0451_036.nt.2	35115	35115.0	Colon array	3666-3725
DEX0451_036.nt.2	23859	23859.0	Breast array	4515-4574
DEX0451_036.nt.2	23858	23858.0	Breast array	4572-4631
DEX0451_036.nt.2	37858	37858.0	Breast array	3427-3486
DEX0451_036.nt.2	35114	35114.0	Colon array	3821-3880
DEX0451_036.nt.3	37858	37858.0	Breast array	865-924
DEX0451_036.nt.3	23859	23859.0	Breast array	1953-2012
DEX0451_036.nt.3	35115	35115.0	Colon array	1104-1163
DEX0451_036.nt.3	23858	23858.0	Breast array	2010-2069
DEX0451_036.nt.3	35114	35114.0	Colon array	1259-1318
DEX0451_037.nt.1	15066	15066.0	Breast array	216-275
DEX0451_037.nt.1	15045	15045.0	Breast array	443-502
DEX0451_037.nt.2	15063	15063.0	Breast array	896-955
DEX0451_037.nt.2	33432	33432.0	Breast array	714-773
DEX0451_037.nt.2	15045	15045.0	Breast array	581-640
DEX0451_037.nt.2	19356	19356.0	Colon array	719-778
DEX0451_037.nt.2	15044	15044.0	Breast array	624-683
DEX0451_037.nt.2	15062	15062.0	Breast array	928-987
DEX0451_037.nt.2	15066	15066.0	Breast array	354-413
DEX0451_037.nt.3	33432	33432.0	Breast array	644-703
DEX0451_037.nt.3	15045	15045.0	Breast array	511-570
DEX0451_037.nt.3	15066	15066.0	Breast array	284-343
DEX0451_037.nt.3	15044	15044.0	Breast array	554-613
DEX0451_037.nt.3	15063	15063.0	Breast array	826-885
DEX0451_037.nt.3	19356	19356.0	Colon array	649-708
DEX0451_037.nt.3	15062	15062.0	Breast array	858-917
DEX0451_037.nt.4	19356	19356.0	Colon array	1338-1397
DEX0451_037.nt.4	15045	15045.0	Breast array	1200-1259
DEX0451_037.nt.4	15066	15066.0	Breast array	973-1032
DEX0451_037.nt.4	15044	15044.0	Breast array	1243-1302
DEX0451_037.nt.4	33432	33432.0	Breast array	1333-1392
DEX0451_037.nt.4	15071	15071.0	Breast array	1843-1902
DEX0451_037.nt.5	15062	15062.0	Breast array	331-390

DEX0451_037.nt.5	15063	15063.0	Breast array	299-358
------------------	-------	---------	--------------	---------

Example 2b: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman[®] probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman[®]) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene are evaluated for every sample in normal and cancer tissues. Total RNA is extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA is prepared with reverse transcriptase and the polymerase chain reaction is done using primers and Taqman[®] probes specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

One of ordinary skill can design appropriate primers. The relative levels of expression of the BSNA versus normal tissues and other cancer tissues can then be determined. All the values are compared to the calibrator. Normal RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

The relative levels of expression of the BSNA in pairs of matched samples may also be determined. A matched pair is formed by mRNA from the cancer sample for a

particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. All the values are compared to the calibrator.

In the analysis of matching samples, the BSNAs show a high degree of tissue specificity for the tissue of interest. These results confirm the tissue specificity results obtained with normal pooled samples. Further, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual are compared. This comparison provides an indication of specificity for the cancer state (*e.g.* higher levels of mRNA expression in the cancer sample compared to the normal adjacent).

Information on the samples tested in the QPCR experiments below include the Sample ID (Smpl ID), Tissue, Tissue Type (Tiss Type), Diagnosis (DIAG), Disease Detail, and Stage or Grade (STG or GRD) in following table.

Sample ID	Tissue	Tiss Type	Diagnosis	Disease Detail	Stage or Grade
355	Mammary	CAN	Invasive lobular carcinoma	Invasive lobular carcinoma	Stage IIB
355	Mammary	NAT	NAT		
B011X	Mammary	CAN		Cancer	
B011X	Mammary	NAT		NAT	
S621	Mammary	CAN	Infiltrating ductal carcinoma	Infiltrating Duct Adenocarcinoma	G3; T1NxMx
S621	Mammary	NAT		NAT	
S516	Mammary	CAN	Infiltrating ductal carcinoma	Infiltrating Ductal Carcinoma with Lymphatic Invasion	Stage I G2; T1N0M0
S516	Mammary	NAT		NAT	
522	Mammary	CAN	Infiltrating ductal carcinoma	Infiltrating ductal carcinoma	G III
522	Mammary	NAT		NAT	
76DN	Mammary	CAN		Invasive ductal carcinoma	G3, poorly diff.
76DN	Mammary	NAT		NAT	
19DN	Mammary	CAN	Invasive ductal carcinoma	Invasive ductal carcinoma	G3, Stage IIA; T2N0M0
19DN	Mammary	NAT		NAT	
42DN	Mammary	CAN	Invasive ductal carcinoma	Invasive Ductal Carcinoma	T3aN1M0 IIIA, G3
42DN	Mammary	NAT		NAT	
517	Mammary	CAN	Infiltrating ductal carcinoma	Infiltrating ductal carcinoma	St. IIA, G3
517	Mammary	NAT		NAT	

781M	Mammary	CAN	Invasive ductal carcinoma		Architectural grade-3/3, Nuclear grade-3/3
781M	Mammary	NAT		NAT	
869M	Mammary	CAN	Invasive carcinoma	Invasive Carcinoma	Stage IIA G1;T2NoMo
869M	Mammary	NAT		NAT	
976M	Mammary	CAN	Invasive ductal carcinoma	Invasive Ductal Carcinoma	T2N1M0 (Stage 2B Grade 2-3)
976M	Mammary	NAT		NAT	
S570	Mammary	CAN	Carcinoma	Carcinoma	Stage IIA;T1N1Mo
S570	Mammary	NAT		NAT	
S699	Mammary	CAN	Invasive lobular carcinoma	Invasive Lobular Carcinoma	Stage IIB G1;T2N1Mo
S699	Mammary	NAT		NAT	
S997	Mammary	CAN	Invasive ductal carcinoma	Invasive Ductal Carcinoma	Stage IIB G3; T2N1Mo
S997	Mammary	NAT		NAT	
030B	Urinary Bladder	CAN	Carcinoma	invasive Carcinoma, poorly differentiated	Stage III, Grade 3
030B	Urinary Bladder	NAT		NAT	
520B	Urinary Bladder	CAN	Sarcomatoid transitional cell carcinoma	Sarcomatoid transitional cell carcinoma	
520B	Urinary Bladder	NAT		NAT	
TR17	Urinary Bladder	CAN	Carcinoma	transitional cell carcinoma	StageII/GradeI II
TR17	Urinary Bladder	NAT		NAT	
401C	Colon	CAN	Adenocarcinoma	Adenocarcinoma of ascending colon and cecum	Stage III
401C	Colon	NAT		NAT	
AS43	Colon	CAN	Adenocarcinoma	malignant	
AS43	Colon	NAT	Adenocarcinoma	NAT	
AS98	Colon	CAN	Adenocarcinoma	Moderately to poorly differentiated adenocarcinoma	Duke's C
AS98	Colon	NAT		NAT	
CM12	Colon	CAN		T	Stage D
CM12	Colon	NAT	Adenocarcinoma	Nat	
DC19	Colon	CAN		T	Stage B
DC19	Colon	NAT		NL	
RC01	Colon	CAN	Cancer		Stage IV
RC01	Colon	NAT		NAT	

RS53	Colon	CAN	Adenocarcinoma	moderately differentiated adenocarcinoma	
RS53	Colon	NAT	Adenocarcinoma	NAT	
SG27	Colon	CAN		malig	Stage B
SG27	Colon	NAT		NAT	
TX01	Colon	CAN	Adenocarcinoma	Moderately differentiated adenocarcinoma of cecum	Stage II; T3NoMo
TX01	Colon	NAT		NAT	
KS52	Cervix	CAN	Squamous cell carcinoma	Keratinizing Squamous Cell Carcinoma	IIIB, well diff. G1; T3bNxM0
KS52	Cervix	NAT		NAT	
NK23	Cervix	CAN		Nonkeratinizing Large Cell	FIGO IIIB, undiff. G4; T3bNxM0
NK23	Cervix	NAT		NAT	
NKS54	Cervix	CAN	Squamous cell carcinoma	Nonkeratinizing Squamous Cell Carcinoma	IIB, mod diff. G2; T2bNxM0
NKS54	Cervix	NAT		NAT	
NKS55	Cervix	CAN	Squamous cell carcinoma	Nonkeratinizing Squamous Cell Carcinoma	IIIB, Mod diff. G2; T3bNxM0
NKS55	Cervix	NAT		NAT	
NKS81	Cervix	CAN	Squamous cell carcinoma	large cell nonkeratinizing sq carc, IIB, moderately diff	IIB
NKS81	Cervix	NAT		NAT	
10479	Endometrium	CAN		malignant mixed mullerian tumor	T?, Nx, M1
10479	Endometrium	NAT		NAT	
28XA	Endometrium	CAN	Endometrial adenocarcinoma	malignant	II/III
28XA	Endometrium	NAT		NAT	II/III
8XA	Endometrium	CAN	mod. diff, invasive, squamous differentiation, FIGO-II		
8XA	Endometrium	NAT		NAT	
106XD	Kidney	CAN	Renal cell carcinoma	renal cell carcinoma, clear cell, localized	3
106XD	Kidney	NAT		NL	

107XD	Kidney	CAN	Renal cell carcinoma	renal cell carcinoma, clear cell, with metastatic	G III
107XD	Kidney	NAT		NL	
109XD	Kidney	CAN		Malignant	G III
109XD	Kidney	NAT		NL	
10XD	Kidney	CAN	Renal cell carcinoma	renal cell carcinoma, clear cell, localized, grade 2-3	3
10XD	Kidney	NAT		NL	
22K	Kidney	CAN	Renal cell carcinoma	Renal cell carcinoma	G2, Mod. Diff.
22K	Kidney	NAT		NAT	
15XA	Liver	CAN		Sarcoma, Retroperitoneal Tumor	Grade-2
15XA	Liver	NAT		CA	St. I, G4
174L	Liver	CAN	Hepatocellular carcinoma	Moderate to well differentiated hepatocellular carcinoma	
174L	Liver	NAT	Hepatocellular carcinoma	NAT	
187L	Liver	CAN	Adenocarcinoma	Metastatic Adenocarcinoma	Liver (Gallbladder)
187L	Liver	NAT		NAT	
205L	Lung	CAN	Adenocarcinoma	poorly differentiated adenocarcinoma	T2, N1, Mx
205L	Lung	NAT		NAT	
315L	Lung	CAN	Squamous cell carcinoma		
315L	Lung	NAT	Adenocarcinoma	NAT	
507L	Lung	CAN	Bronchioalveolar carcinoma	bronchioalveolar carcinoma	Stage IB, G1, well diff.
507L	Lung	NAT		NAT	
528L	Lung	CAN	Adenocarcinoma	Adenocarcinoma	St. IV, T2N0M1, infiltrating poorly diff.
528L	Lung	NAT		NAT	
8837L	Lung	CAN	Squamous cell carcinoma	Squamous cell carcinoma	T2, N0, M0
8837L	Lung	NAT		NAT	
AC11	Lung	CAN	Adenocarcinoma	poorly differentiated adenocarcinoma	T2, N2, M1
AC11	Lung	NAT		NAT	
AC39	Lung	CAN	Adenocarcinoma	intermediate grade adenocarcinoma	T2, N2, Mx
AC39	Lung	NAT		NAT	

SQ80	Lung	CAN	Squamous cell carcinoma	poorly differentiated squamous cell carcinoma	T1, N1, M0
SQ80	Lung	NAT		NAT	
SQ81	Lung	CAN	Squamous cell carcinoma	poorly differentiated squamous carcinoma	T3, N1, Mx
SQ81	Lung	NAT		NAT	
G021	Ovary	CAN	Carcinoma	St. IIIC, poorly diff.	Stage- IIIC, poorly diff.
G021	Ovary	NAT		NAT	
206I	Ovary	NRM		NL	
5150	Ovary	NRM		Normal	
18GA	Ovary	NRM		NL	
3370	Ovary	NRM		Normal	
1230	Ovary	NRM		Normal	
C177	Ovary	NRM		several fluid filled cysts	
40G	Ovary	NRM		NL	
10050	Ovary	CAN		papillary serous and endometrioid ovarian carcinoma, concurrent metastatic breast cancer	3
10400	Ovary	CAN		papillary serous adeno, metastatic	
1050	Ovary	CAN		Papillary Serous Carcinoma with Focal Mucinous Differentiation	Stage IC G0; T1cNOM0
130X	Ovary	CAN		Ovarian cancer	
C004	Ovary	NRM		NL	
7180	Ovary	CAN	Adenocarcinoma	malignant tumor	IIIC
A1B	Ovary	CAN	Adenocarcinoma	CA	
71XL	Pancreas	CAN		villous adenoma with paneth cell metaplasia	localized
71XL	Pancreas	NAT		NL	
82XP	Pancreas	CAN		serious cystadenoma	
82XP	Pancreas	NAT		NL	
92X	Pancreas	CAN	Ductal adenocarcinoma	ductal adenocarcinoma	mod to focally poorly diff.
92X	Pancreas	NAT		NL	
23B	Prostate	CAN		Prostate tumor	Gleason's 3+4
23B	Prostate	NAT		NAT	
675P	Prostate	CAN	Adenocarcinoma	adenocarcinoma	
675P	Prostate	NAT		Normal	
958P	Prostate	CAN	Adenocarcinoma	Adenocarcinoma	T2C, NO, MX

958P	Prostate	NAT		NAT	
65XB	Prostate	CAN	Adenocarcinoma	adenocarcinom	3+4=7
65XB	Prostate	NAT		NL	
84XB	Prostate	CAN	Adenocarcinoma	adenocarcinom	2+3
84XB	Prostate	NAT		NL	
855P	Prostate	BPH		BPH	
276P	Prostate	BPH		BPH	
767B	Prostate	BPH		prostate BPH	
263C	Prostate	BPH		BPH	
10R	Prostate	PROS T		active chronic prostatitis	T0, N0, M0
20R	Prostate	PROS T		PROSTATITIS	
39A	Skin	CAN		CA	St. II
39A	Skin	NAT		CA	St. II
287S	Skin	CAN	Squamous cell carcinoma	Invasive Keratinizing Squamous Cell Carcinoma	Moderately Differentiated
287S	Skin	NAT		NAT	
669S	Skin	CAN	Melanoma	Nodular malignant melanoma	
669S	Skin	NAT		NAT	
171S	Small Intestine	CAN	Adenocarcinoma	Moderately differentiated Adenocarcinoma , invasive	
171S	Small Intestine	NAT		NAT	
H89	Small Intestine	CAN	Adenocarcinoma	Adenocarcinoma	80% tumor, 50% necrosis, moderately differentiated , G2-3; T3N1MX
H89	Small Intestine	NAT	Adenocarcinoma	NAT	
20SM	Small Intestine	CAN	Adenocarcinoma	Adenocarcinoma , metastatic to lung & liver	St. IV, poorly diff.
20SM	Small Intestine	NAT		NAT	
88S	Stomach	CAN	Adenocarcinoma	Mucinous adenocarcinoma	T3N1M0, St. IIIA
88S	Stomach	NAT		NAT	
261S	Stomach	CAN	Signet-ring cell carcinoma	Signet-ring cell carcinoma	Stage IIIA, T3N1M0
261S	Stomach	NAT		NAT	
288S	Stomach	CAN	Adenocarcinoma	Infiltrating Adenocarcinoma	Moderately Differentiated
288S	Stomach	NAT		NAT	
AC93 or 509L	Stomach	CAN	Adenocarcinoma	Adenocarcinoma	St. IV, G4, T4N3M0, poorly diff.

AC93 or 509L	Stomach	NAT		NAT	
39X	Testes	CAN		CA	
39X	Testes	NAT		NAT	
647T	Testes	CAN	Teratocarcinom a	Teratocarcinom a	Stage IA
647T	Testes	NAT	Teratocarcinom a	NAT	
663T	Testes	CAN	Teratocarcinom a	Teratocarcinom a	
663T	Testes	NAT		NAT	
56T	Thyroid Gland	CAN	Papillary carcinoma	Papillary Carcinoma	St. III; T4N1M0
56T	Thyroid Gland	NAT		NAT	
143N	Thyroid Gland	CAN	Follicular carcinoma	Follicular Carcinoma	
143N	Thyroid Gland	NAT		NAT	
270T	Thyroid Gland	CAN		CA	
270T	Thyroid Gland	NAT		NAT	
135XO	Uterus	CAN		Uterus normal	
135XO	Uterus	NAT		Uterus tumor	
85XU	Uterus	CAN		endometrial carcinoma	I
85XU	Uterus	NAT		NL	
B1	Blood	NRM		Normal	
B3	Blood	NRM		Normal	
B5	Blood	NRM		Normal	
B6	Blood	NRM		Normal	
B11	Blood	NRM		Normal	
982B	Blood	NRM		Normal	
48AD	Adrenal Gland	NRM		Normal	
10BR	Brain	NRM		Normal	
01CL	Colon	NRM		Normal	
06CV	Cervix	NRM		Normal	
01ES	Esophagu s	NRM		Normal	
46HR	Heart	NRM		Normal	
00HR	Human Referenc e	CAN	CAN	Cancer pool	
55KD	Kidney	NRM		Normal	
89LV	Liver	NRM		Normal	
90LN	Lung	NRM		Normal	
01MA	Mammary	NRM		Normal	
84MU	Skeletal Muscle	NRM		Normal	
3APV	Ovary	NRM		Normal	
04PA	Pancreas	NRM		Normal	
59PL	Placenta	NRM		Normal	
09PR	Prostate	NRM		Normal	
21RC	Rectum	NRM		Normal	

59SM	Small Intestine	NRM		Normal	
7GSP	Spleen	NRM		Normal	
09ST	Stomach	NRM		Normal	
4GTS	Testes	NRM		Normal	
99TM	Thymus Gland	NRM		Normal	
16TR	Trachea	NRM		Normal	
57UT	Uterus	NRM		Normal	

DEX0451 015.nt.1 (Mam126)

The relative expression level of Mam126 in various tissue samples is included below. Tissue samples include 76 pairs of matching samples, 7 non matched cancer samples, and 34 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 5 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis (PROST), and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to breast cancer sample MAM522 (calibrator).

The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Tissue Abbreviation and Sample ID (Tiss Abrev, Sample ID), and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Tiss Abrev, Sample ID	CAN	NAT	NRM	BPH	PROST
MAM355	3.81	0.02			
MAMB011X	0.08	0.47			
MAMS621	1.11	0.51			
MAMS516	0.00	2.92			
MAM522	1.00	0.07			
MAM76DN	0.43	0.40			
MAM976M	0.34	0.00			
MAM781M	1.17	0.00			
MAM19DN	0.29	0.50			
MAM517	1.43	0.00			
MAMS997	2.58	0.33			
MAM869M	0.01				
MAMS699	0.00	0.00			

MAMS570	0.00	0.69			
BLD030B	0.00	0.29			
BLD520B	1.27	0.43			
BLDTR17	0.67	0.17			
CLN401C	0.05	0.02			
CLNAS43	0.10	0.00			
CLNAS98	0.10	0.00			
CLNCM12	0.16	0.03			
CLNDC19	0.00	0.00			
CLNRC01	0.06	0.01			
CLNRS53	0.52	0.25			
CLNSG27	0.19	0.00			
CLNTX01	0.11	0.00			
CVXKS52	0.00	0.04			
CVXNK23	0.02	0.00			
CVXNKS54	0.64	0.28			
CVXNKS55	0.00	0.07			
CVXNKS81	0.11	0.00			
ENDO10479	0.20	0.00			
ENDO28XA	0.11	0.10			
ENDO8XA	0.88	0.06			
KID106XD	0.00	0.04			
KID107XD	0.00	0.05			
KID109XD	0.03	0.00			
KID10XD	0.00	0.03			
KID22K	0.02	0.05			
LNG205L	0.18	0.00			
LNG315L	0.04	0.00			
LNG507L	0.37	0.00			
LNG528L	0.08	0.12			
LNG8837L	0.08	0.40			
LNGAC11	0.71	0.18			
LNGAC39	0.18	0.33			
LNGSQ80	0.13	0.30			
LNGSQ81	0.78	0.28			
LVR15XA	0.03	0.06			
LVR174L	0.17	0.07			
LVR187L	0.00	0.00			
OVRG021	0.14	0.28			
OVR10050	0.73				
OVR10400	2.20				
OVR1050	0.09				
OVR130X	0.00				
OVR1B	0.42				
OVR123O			0.58		
OVR18GA			2.21		
OVR206I			1.70		

OVR337O			0.00		
OVR40G			1.00		
OVR515O			0.26		
OVR004			0.00		
OVR0177			0.75		
PAN71XL	0.03	0.07			
PAN82XP	0.02	0.00			
PAN92X	0.18	0.00			
PRO23B	0.10	0.05			
PRO65XB	0.61	1.73			
PRO675P	0.26	0.41			
PRO84XB	2.44	0.14			
PRO958P	0.14	0.05			
PRO263C				0.00	
PRO276P				0.02	
PRO767B				0.07	
PRO855P				0.02	
PRO10R					0.00
PRO20R					0.00
SKN287S	0.15	0.21			
SKN39A	0.58	0.69			
SKN669S	2.47	0.18			
SMINT171S	0.00	0.00			
SMINT20SM	0.23	0.08			
SMINTH89	0.35	0.09			
STO261S	0.00	0.00			
STO288S	0.17	0.03			
STO88S	0.00	0.03			
THRD143N	0.41	0.17			
THRD270T	0.03	0.00			
THRD56T	0.25	0.00			
TST39X	0.97	0.37			
TST647T	3.18	0.23			
TST663T	6.63	0.20			
UTR135XO	0.16	0.20			
UTR85XU	0.56	1.22			
BLOB1			0.00		
BLOB3			0.00		
BLOB6			0.00		
BLOB11			0.00		
BLO982B			0.00		
ADR48AD			0.19		
CLN01CL			0.00		
ESO01ES			0.00		
HRT46HR			0.03		
HUMREF00HR	1.50				
KID55KD			0.05		

LVR89LV			0.07		
LNG90LN			1.14		
MAM01MA			2.19		
MSL84MU			0.00		
OVR3APV			2.36		
PAN04PA			0.00		
PLA59PL			1.02		
PRO09PR			0.17		
REC21RC			0.08		
SMINT59SM			0.01		
SPL7GSP			0.29		
STO09ST			0.00		
THYM99TM			0.00		
TRA16TR			0.56		
TST4GTS			0.01		
UTR57UT			0.07		

0.00= Negative or no expression

The sensitivity for Mam126 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Mam126 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of breast tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Mam126 being useful as a breast cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	89%	56%	50%	0%	40%
Sensitivity, Down vs. NAT	0%	22%	21%	0%	20%
Sensitivity, Up vs. NRM	89%	0%	0%	17%	40%
Sensitivity, Down vs. NRM	0%	78%	60%	50%	0%
Specificity	27.32%	31.15%	39.53%	37.1%	34.59%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Mam126 a good marker for diagnosing, monitoring, staging, imaging and/or treating breast cancer.

Additionally, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Mam126 a good marker for diagnosing, monitoring, staging, imaging and/or treating colon cancer.

Primers used for QPCR Expression Analysis of Mam126 are as follows:

- 5 (Mam126_forward): CTTGTGACAGCCACGACTTTG (SEQ ID NO:180)
(Mam126_reverse): GCATCCAGCCAGGCTTCTC (SEQ ID NO:181)
(Mam126_probe): TTTGTTGTTAATGTAATTAGAGACACCAG (SEQ ID NO:182)

Conclusions

- 10 Altogether, the high level of tissue specificity, plus the mRNA overexpression in matched samples tested are indicative of SEQ ID NO: 1-72 being a diagnostic marker and/or a therapeutic target for cancer.

Example 3: Protein Expression

- 15 The BSNA is amplified by polymerase chain reaction (PCR) and the amplified DNA fragment encoding the BSNA is subcloned in pET-21d for expression in *E. coli*. In addition to the BSNA coding sequence, codons for two amino acids, Met-Ala, flanking the NH₂-terminus of the coding sequence of BSNA, and six histidines, flanking the COOH-terminus of the coding sequence of BSNA, are incorporated to serve as initiating Met/restriction site and purification tag, respectively.

- 20 An over-expressed protein band of the appropriate molecular weight may be observed on a Coomassie blue stained polyacrylamide gel. This protein band is confirmed by Western blot analysis using monoclonal antibody against 6X Histidine tag.

- 25 Large-scale purification of BSP is achieved using cell paste generated from 6-liter bacterial cultures, and purified using immobilized metal affinity chromatography (IMAC). Soluble fractions that are separated from total cell lysate were incubated with a nickel chelating resin. The column is packed and washed with five column volumes of wash buffer. BSP is eluted stepwise with various concentration imidazole buffers.

Example 4: Fusion Proteins

- 30 The human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. For example, if pC4 (Accession No.

209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 2, is ligated into this
5 BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced. If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. *See, e.g.*, WO 96/34891.

10 **Example 5: Production of an Antibody from a Polypeptide**

In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine
15 serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100, µg/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from
20 the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.*, *Gastroenterology* 80: 225-232 (1981).

The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide. Alternatively,
25 additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such
30 an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic

antibodies to the protein specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

Example 6: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

5 RNA is isolated from individual patients or from a family of individuals that have a phenotype of interest. cDNA is then generated from these RNA samples using protocols known in the art. *See*, Sambrook (2001), *supra*. The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO: 1-72. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C;
10 and 60-120 seconds at 70°C, using buffer solutions described in Sidransky *et al.*, *Science* 252(5006): 706-9 (1991). *See also* Sidransky *et al.*, *Science* 278(5340): 1054-9 (1997).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons are also determined and genomic PCR products
15 analyzed to confirm the results. PCR products harboring suspected mutations are then cloned and sequenced to validate the results of the direct sequencing. PCR products is cloned into T-tailed vectors as described in Holton *et al.*, *Nucleic Acids Res.*, 19: 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

20 Genomic rearrangements may also be determined. Genomic clones are nick-translated with digoxigenin deoxyuridine 5' triphosphate (Boehringer Mannheim), and FISH is performed as described in Johnson *et al.*, *Methods Cell Biol.* 35: 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

25 Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C-and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. Johnson (1991). Image collection, analysis and
30 chromosomal fractional-length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the

genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 7: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

5 Antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described above. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced. The coated wells are then
10 incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide. Next, 50 µl of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three
15 times with deionized or distilled water to remove unbound conjugate. 75 µl of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution are added to each well and incubated 1 hour at room temperature.

The reaction is measured by a microtiter plate reader. A standard curve is prepared, using serial dilutions of a control sample, and polypeptide concentrations are
20 plotted on the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear scale). The concentration of the polypeptide in the sample is calculated using the standard curve.

Example 8: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion
25 consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

30 As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1, µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to

therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 μ g/kg/hour to about 50 mg/kg/hour, either by 1-4 injections per day or by continuous
5 subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are
10 administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which
15 include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semipermeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-
20 release matrices include polylactides (U. S. Pat. No.3,773,919, EP 58,481, the contents of which are hereby incorporated by reference herein in their entirety), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22: 547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981), and R. Langer, Chem. Tech. 12: 98-105 (1982)), ethylene vinyl acetate
25 (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE Epstein et al., Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese
30 Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324, the contents of which are hereby incorporated by reference herein in their entirety. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the

lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage
5 injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides. Generally, the
10 formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably, the carrier is a parenteral carrier, more preferably, a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-
15 aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate,
20 succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates
25 including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will
30 be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron

membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1 % (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 9: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided above.

Example 10: Method of Treating Increased Levels of the Polypeptide

Antisense or RNAi technology are used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided
5 above.

Example 11: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and
10 separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e. g., Ham's F12 media, with 10% FBS, penicillin and
15 streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks. pMV-7 (Kirschmeier, P. T. et al., DNA, 7: 219-25 (1988)), flanked by the long terminal repeats of the Moloney murine
20 sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in
25 Example 3. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB 101, which are
30 then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now
5 produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached
10 producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.

If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector
15 that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 12: Method of Treatment Using Gene Therapy-In Vivo

20 Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide.

The polynucleotide of the present invention may be operatively linked to a
25 promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, Tabata H. *et al. Cardiovasc. Res.* 35 (3): 470-479 (1997); Chao J *et al. Pharmacol. Res.* 35 (6): 517-522 (1997); Wolff J. A. *Neuromuscul. Disord.* 7 (5): 314-318 (1997), Schwartz B. *et al. Gene Ther.* 3 (5): 405-411 (1996); and Tsurumi Y. *et al. Circulation* 94 (12): 3281-3290 (1996); W0 90/11092, W0 98/11779; U. S. Patent No.
30 5,693,622; 5,705,151; 5,580,859, the contents of which are hereby incorporated by reference herein in their entirety.

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, breast, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

5 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P. L. *et al. Ann. NY*
10 *Acad. Sci.* 772: 126-139 (1995) and Abdallah B. *et al. Biol. Cell* 85 (1): 1-7 (1995)) which can be prepared by methods well known to those skilled in the art.

 The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art
15 can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

20 The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, breast, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide
25 matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They
30 may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin

fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 $\mu\text{g/kg}$ body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to breasts or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle in vivo is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 μm cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection

may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

5 **Example 13: Transgenic Animals**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e. g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific
10 embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (I. e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection
15 (Paterson et al., *Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver et al., *Biotechnology* 11: 1263-1270 (1993); Wright et al., *Biotechnology* 9: 830-834 (1991); and U. S. Pat. No. 4,873,191, the contents of which is hereby incorporated by reference herein in its entirety); retrovirus mediated gene transfer into germ lines (Van der Putten et al., *Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)), blastocysts or embryos; gene targeting
20 in embryonic stem cells (Thompson et al., *Cell* 56: 313-321 (1989)); electroporation of cells or embryos (Lo, 1983, *Mol Cell. Biol.* 3: 1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e. g., Ulmer et al., *Science* 259: 1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm mediated gene transfer
25 (Lavitrano et al., *Cell* 57: 717-723 (1989). For a review of such techniques, see Gordon, "Transgenic Animals," *Intl. Rev. Cytol.* 115: 171-229 (1989).

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence
30 (Campell et al., *Nature* 380: 64-66 (1996); Wilmut et al., *Nature* 385: 810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells,

I. e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al.,
5 *Proc. Natl. Acad. Sci. USA* 89: 6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some
10 nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., *Science* 265: 103-106 (1994)). The regulatory sequences required for such a
15 cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished
20 by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR).
25 Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding
30 strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous

transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 14: Knock-Out Animals

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E. g., see Smithies et al., *Nature* 317: 230-234 (1985); Thomas & Capecchi, *Cell* 51: 503-512 (1987); Thompson et al., *Cell* 5: 313-321 (1989)) Alternatively, RNAi technology may be used. For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e. g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However, this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e. g., knockouts) are administered to a

patient in vivo. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e. g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e. g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e. g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U. S. Patent No. 5,399,349; and Mulligan & Wilson, U. S. Patent No. 5,460,959, the contents of which are hereby incorporated by reference herein in their entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

210

While preferred illustrative embodiments of the present invention are described, one skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments, which are presented for purposes of illustration only and not by way of limitation. The present invention is limited only by the claims that follow.

We claim:

1. An isolated nucleic acid molecule comprising:
 - (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 73-179;
 - 5 (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-72;
 - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
 - (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b).
- 10 2. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a cDNA.
- 15 3. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is genomic DNA.
4. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is an RNA.
- 20 5. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a mammalian nucleic acid molecule.
6. The nucleic acid molecule according to claim 5, wherein the nucleic acid molecule is a human nucleic acid molecule.
- 25 7. A method for determining the presence of a breast specific nucleic acid (BSNA) in a sample, comprising the steps of:
 - (a) contacting the sample with the nucleic acid molecule of SEQ ID NO: 1-72
 - 30 under conditions in which the nucleic acid molecule will selectively hybridize to a breast specific nucleic acid; and

(b) detecting hybridization of the nucleic acid molecule to a BSNA in the sample, wherein the detection of the hybridization indicates the presence of a BSNA in the sample.

5 8. A vector comprising the nucleic acid molecule of claim 1.

9. A host cell comprising the vector according to claim 8.

10. A method for producing a polypeptide encoded by the nucleic acid molecule
10 according to claim 1, comprising the steps of:

- (a) providing a host cell comprising the nucleic acid molecule operably linked to one or more expression control sequences, and
- (b) incubating the host cell under conditions in which the polypeptide is produced.

15

11. A polypeptide encoded by the nucleic acid molecule according to claim 1.

12. An isolated polypeptide selected from the group consisting of:

- (a) a polypeptide comprising an amino acid sequence with at least 95%
20 sequence identity to of SEQ ID NO: 73-179 ; or
- (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-72.

25 13. An antibody or fragment thereof that specifically binds to:

- (a) a polypeptide comprising an amino acid sequence with at least 95%
sequence identity to of SEQ ID NO: 73-179 ; or
- (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule
30 comprising a nucleic acid sequence of SEQ ID NO: 1-72.

14. A method for determining the presence of a breast specific protein in a sample, comprising the steps of:

- (a) contacting the sample with a suitable reagent under conditions in which the reagent will selectively interact with the breast specific protein comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 73-179; and
- 5 (b) detecting the interaction of the reagent with a breast specific protein in the sample, wherein the detection of binding indicates the presence of a breast specific protein in the sample.
15. A method for diagnosing or monitoring the presence and metastases of breast
- 10 cancer in a patient, comprising the steps of:
- (a) determining an amount of:
- (i) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 73-179;
- (ii) a nucleic acid molecule comprising a nucleic acid sequence of SEQ
- 15 ID NO: 1-72;
- (iii) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (i) or (ii);
- (iv) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (i) or (ii);
- 20 (v) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 73-179 ; or
- (vi) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-72
- 25 and;
- (b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the breast specific marker in a normal control; wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the
- 30 presence of breast cancer.

16. A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence of:

- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 73-179;
- 5 (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-72;
- (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
- (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b); or
- 10 (e) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 73-179 ; or
- (f) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule
- 15 comprising a nucleic acid sequence of SEQ ID NO: 1-72.

17. A method of treating a patient with breast cancer, comprising the step of administering a composition consisting of:

- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 73-179;
- 20 (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-72;
- (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b);
- 25 (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b);
- (e) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 73-179 ; or
- (f) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule
- 30 comprising a nucleic acid sequence of SEQ ID NO: 1-72;

to a patient in need thereof, wherein said administration induces an immune response against the breast cancer cell expressing the nucleic acid molecule or polypeptide.

18. A vaccine comprising the polypeptide or the nucleic acid encoding the polypeptide of claim 12.

1

SEQUENCE LISTING

<110> diaDexus, Inc.
Macina, Roberto
Turner, Leah
Sun, Yongming

<120> Compositions, Splice Variants and Methods Relating to Breast Specific Genes and Proteins

<130> DEX-0451

<150> US 60/431,097
<151> 2002-12-05

<150> US 60/431,122
<151> 2002-12-05

<160> 182

<170> PatentIn version 3.1

<210> 1
<211> 609
<212> DNA
<213> Homo sapien

<400> 1
cagccaaggg caggaataga agcagggcacc agctcgagct gtgcgaattc agaggaagga 60
gaccgaatcc agcctgggca caggagggaa agcgtcctgg aggcagctgg tccccaggtg 120
gcccttaagg ataaagaaaa gttagcttgg tgaagggctg aggaaggcag tgagccttct 180
aggaagaggg gagaaatcaa gcacaggcgt ggccctgaca cggagggctg cacagaaggt 240
ggctctcact gggaacatgg ccaagagtgg acaacacctg gggacccctg ccgaatctgc 300
cggtgcctgg agggtcacat ccagtgccgc cagcgagaat gtgccagcct gtgtccattt 360
ctgagaaggc aatgtatcct gattactttg ccaagagaga acagtggaag aaactgcgga 420
gggaaagctg ggaacgagag gttaagcagc tgcaggagga aacgccacct ggtggctcctt 480
taactgaagc tttgccccct gcccgaaagg aaggtgattt gccccactc gtggtggtat 540
attgtgacca gaccccgga gggccatgt agaaagagag agactcatct ttcattgctt 600
caagtgaaa 609

<210> 2
<211> 913
<212> DNA
<213> Homo sapien

<400> 2
cagccaaggg caggaataga agcagggcacc agctcgagct gtgcgaattc agaggaagga 60
gaccgaatcc agcctgggca caggagggaa agcgtcctgg aggcagctgg tccccaggtg 120

2

```

gcccttaagg ataaagaaaa gttagcttgg tgaagggtcg aggaaggcag tgagccttct 180
aggaagaggg gagaaatcaa gcacaggcgt ggccctgaca cggaggggtga gtgtgcaatg 240
ttggctggga aggtgtgaga ggtgacgagg ggccagagat aggtggggca catgggtgtg 300
gctatgctct gtccacggaa gaccagaaag ggcggtctaa ggaactgagg cctcaccttg 360
cctggggcac tgggagccac tggggaatct aggcagagat ctgaccccat ctagtcttgg 420
ctcgggagag agccctcaga gggcatgtgg acaaggaagg cgggcaggct gaggctgggg 480
tccaggccag ctcccaccag gcctccctct tctcaacccc tcaaccctag gctgcacaga 540
aggtggctct cactgggaac atggccaaga gtggacaaca cctggggacc cctgccgaat 600
ctgccggtgc ctggagggtc acatccagtg ccgccagcga gaatgtgcca gcctgtgtcc 660
atttctgaga aggcaatgta tcctgattac ttgccaaga gagaacagtg gaagaaactg 720
cggagggaaa gctgggaacg agaggttaag cagctgcagg aggaaacgcc acctggtggt 780
cctttaactg aagctttgcc ccctgccga aaggaagggtg atttgcccc actcgtggtg 840
gtatatgtg accagacccc gggagcggcc atgtagaaag agagagactc atctttcatg 900
cttgaagtg aaa 913

```

```

<210> 3
<211> 970
<212> DNA
<213> Homo sapien

```

```

<400> 3
gcaagggtctg acttgtgggg ccacgtgttt caggagtcg agggttttaa taagatccca 60
ggaaaagggg gtgtgtgttc tcagacttcc cactcctac gtctgctggt ctgggggctg 120
gagtctaagc caggctcgga ggatatgcaa gccacatgg gggccccagg cacagagtcc 180
ctctctctgc ccctcaatcg gatctgggtg gggttgggag tcccagacga ggttcccggc 240
gcgatggggc cgggatgggg gtccctgggca cagtcagagt cccaccccc tccccggga 300
actgcatcgg ccagacgttc gccatggctg agatgaaggt ggtcctggcg ctacgctgc 360
tgcgcttccg cgtcctgccg gaccacgcgg agccccgcag gaagttggag ctgatcgtgc 420
gcgcggagga tggacttttg ctacgggttg agccctgag cgcggatctg cagtgaacca 480
ccactgtcag gtctcagagc caccgcgcc ctctcaggc acctttgcag attccgggga 540
atcaatctgt gcctgagtc cacagacagc cagcaggggg cgtcggagaa ctgcagggat 600
ccagggcctg gcgaggggaa ggcgaggat ttctgagcca agaccctgac agcctctctg 660
gttgatcaca gtggccccgt gctgagggcg ggttgcccc gagcgcagg ggggacagta 720
tcctgtgggc gatagggagc catggcgggt gtttgagcag gagagggacc agggttgagg 780

```


3

aggcacctat ggggcaggtt tgaggctctg agtcaactgag gaaaaccaga gcggcactac 840
 atccccgccc ctcgatctca attctcatct cctaatacat ccagttgttt tttttcctct 900
 cacctcaggg ttcttcaccg ttttcattgt tottaaacga ctgcacttat taaacaataa 960
 taagcctgat 970

<210> 4
 <211> 848
 <212> DNA
 <213> Homo sapien

<400> 4
 tggaagtccc aggtggccga ktaaagggga caggagactg cgkgcaggac ctcggtctgg 60
 atcagagccg ggtkgtgaaa ggggaggaga actggcaggg cagataagtg ggtggggcct 120
 ctggaggtgc gggggcaagg ttggagcccc gggacgaaga agggacgcgg gtcagcgagg 180
 cctgaagagt gggaggagat gggacccggc tgtagagtgc ccagaggtct aggccagggg 240
 ccgcgctgcc gcaggaagat gcgagagttt ggctttgggtg atctggtcca cccggggcca 300
 gtcttgcccc ctctgccacc gcagcgtagg gcctcctgca ttccgtttct ctggccggaa 360
 gggctctagtg ttcatccctc tcaggctttg gcctcctccc actctcccgc cctggggccc 420
 attcgtttag gaagaatggg agagccggtc gtggcccctg ggcggggtaa aggagggagg 480
 cttggtaaac ctctgctggg gaggaccag tacagtggca gctccttgct ggggaaagaa 540
 cggatctggg gaaagaacgg atctgcgtca cacgctctta caggggaacc ctaaggggcc 600
 tgaggggtag ggcttgggtc ccaccagag ggaaggagaa atttttcgag tcgtaaagaa 660
 atgtatcaga agccatggaa catttacagc cgcacacgct gggctctcca acaaacagat 720
 cccaaaata ttttccagtg ctgtactcgt ggcataagacc cagaccaca gaccaggagg 780
 aagcgctaga gatgtcaaca gccaacaaaa acagtgcctt acacacttgt aaaattgtga 840
 cctacagg 848

<210> 5
 <211> 616
 <212> DNA
 <213> Homo sapien

<400> 5
 atcacatttc aggagcacct gaatggtccc ctgcctgtgc ccttcaccaa tggggagata 60
 cagaaggaga acagtcgtga agycctggca gaggcagcct tggagagccc caggccagac 120
 ctgggtgagaa tccgcactcc atggctgata ccaaacgaag gagctgaatt tccacaatga 180
 catgtctccc ctccaagaat cgaggctact cacagcgacc cgtcgatcgt accatccgtc 240
 ctccgacccc atcctagact tcaacatctc cctggctcatg tgcctaagtg agagggcctc 300

accatgaaac g	cagtcagca a	acggggcccc	gcagatggac	tggagcaaga	aaaacgaaact	360
cttcagcgaa	cctctgagcg	ccctgctgcc	actccagtga	catggctagg	gcctgagcca	420
gcgattcaca	tgcacacct	ttttccttct	cccccaattac	tcccctgaga	tcgatgtaca	480
aatcagtaac	cagatgctcc	tttcttgaca	taatgatgtc	gtctagagaa	ctatgttctt	540
cccgtgactt	tagggaaggt	gaatgtgtcc	cgtcctcccc	cagtcacgaa	aggagactct	600
ggctccctcc	tcctca					616

<210> 6

<211> 2768

<212> DNA

<213> Homo sapien

<400> 6

gtgctgcctg	gcggcggggc	gcggggcacg	ctgggacgtc	tcgctggcgg	gaggccacgg	60
gctttccaca	gcgcggggga	acgggaggct	gcaggatggt	caagctgacg	gcggagctga	120
tcgagcaggc	ggcgcagtac	accaacgcgg	tgcgcgaccg	ggagctggac	ctccgggggt	180
ataaaattcc	cgtcattgaa	aatctagggt	ctacgttaga	ccagtttgat	gctattgatt	240
tttctgacaa	tgagatcagg	aaactggatg	gttttccttt	gttgagaaga	ctgaaaacat	300
tgttagtgaa	caacaacaga	atatgccgta	taggtgaggg	acttgatcag	gctctgccct	360
gtctgacaga	actcattctc	accaataata	gtctcgtgga	actgggtgat	ctggaccctc	420
tggcatctct	caaatcgctg	acttacctaa	gtatcctaag	aaatccggta	accaataaga	480
agcattacag	attgtatgtg	atttataaag	ttccgcaagt	cagagtactg	gattttccaga	540
aagtgaaact	aaaagtaagt	agtaatctgt	tgcttgtgag	ccattataga	gttggtgtgt	600
tttctttata	tttttggttac	tgattattaa	aattgtctaa	atgagtaa	atgagtaa	660
gtttgtaata	aaagtgggag	ggaaaatgtt	acatcacatt	tttttcta	atgagtaa	720
atgatagaac	ttttaagttg	gagctctctt	atgtaatgct	ggctattccg	aagttcgcaa	780
agtgcctgag	ccacgggtgag	cagtcctaac	agtggattgt	ctgcctagat	acgttcccag	840
cggagaactt	aatgtaacct	actttcgtgc	agctccgtgt	gttaggatga	tttttcctt	900
tattaggaat	tcattatttt	attattcatt	taattgcctt	cttagttccc	tgggatcccc	960
tccttggagc	taggagaatg	aactttcttc	agggagctct	accaaagaaa	gaagaccact	1020
gtgtcttctc	ttaatgtgaa	attgcttttt	ggtattttca	ccagcccggg	gtactgtagg	1080
agagttcgct	tcattgtctt	ctgaggaatg	catctaaatg	catgtggtat	tcctatttcc	1140
attaactctg	tgtgtggtgt	cgctgtagga	gcgtcaggaa	gcagagaaaa	tgttcaaggg	1200
caaacggggg	gcacagcttg	caaaggatat	tgccaggaga	agcaaaacgt	aagacacgga	1260

tatccaactt aactctactt caccttcaga aacatgatct gatctgtctg gcagttcgtc	1320
tcctacaaaa ttaaccaaaa actctgacat attaatgtgg tattaaattt gagtgccttat	1380
agtcacatgta catcaatggg ccacacatca caagaaattt ctaccagctt agcagagcaa	1440
atatttccagt agtcagtctt catgtgatac catgtacatc ctattttcta tataggaaga	1500
tgaactggat ggtgtttctg aaggagagag ttcttgtatc agtttgtaa caaagataag	1560
atactacact ggttgaatta ctttcaaaag cttttgaaag taaaagagaa gcaacttctg	1620
ttgggtctagg tctaacagtt atgttcttcc ccctcttaag ttttaatcca ggtgctgggt	1680
tgccaactga caaaaagaaa ggtggggccat ctccagggga tgtagaagca atcaaggtaa	1740
tcatgtgtta ggattcttgg actggaatga gctaagatgg gttcagaaca caaagctgga	1800
taataaacat gttccgaaca ttgcagattt cattttccca cagttattag catacagcaa	1860
tatttctgtt taaggaaaaa ctagcataaa gttattattt gatcagactt gaaattacac	1920
aagctaatta atgtggaggc agctttgtct ttctcatttt ccaagggtgca tttatcactt	1980
cgaacagtta cttaccttgg tatgctgtct cagtgtttgc ctttaattttt actttcgaag	2040
atlttgctgtc tggcaaattcc ttttgactga tcagtaggga ccctcgtttt ataattattgc	2100
ctccttaaat tattcagtaa cataattgca aatagttact tcacttagct acgatttttag	2160
aacatgtgga gtgattattt ataagaaggc ctgcatctct tcaccaattt tagaaatttg	2220
tggtttggct tctagtttta tttttgtggg ccaataacat tcttccccct acaccaaagt	2280
atttaattgtt cctgatggag aagttgctgt gaatttctgt aggtgattga cacttagttt	2340
tctgggtagc tgatacttgg ttgaagttaa tcatccatct ccattgccct ctgtcctcca	2400
gaatgccata gcaaattgctt caactctggc tgaagtggag aggctgaagg ggttgctgca	2460
gtctggtcag atccctggca gagaacgcag atcagggccc actgatgatg gtgaagaaga	2520
gatggaagaa gacacagtca caaacgggtc ctgagcagtg aggcagatgt ataataatag	2580
gccctcttgg aacaagtctt gcttttctga catggtataa tagccttgtt tgtgttagca	2640
aagtggaatc tatcagcatt gttgaaatgc ttaagactgc tgctgataat tttgtaatat	2700
aagttttgaa atctaaatgt caattttcta caaattataa aaataaactc cactcactat	2760
gctaccaa	2768

<210> 7

<211> 390

<212> DNA

<213> Homo sapien

<400> 7

tcgagcggcg ccagtgtgat ggatgtcgcg gccgaggtcg aagttttgcc aaaacctcgg	60
---	----

```

atgcgtggcc ttctggccag gcgtctgcca aatcatatgg ctgtagcatt cgtgctatcc 120
ctggggggttg cagctttgta taagtttcgt gtggctgata aaagaaagaa ggcatatgca 180
gatttctaca gaaactacga tgtcatgaaa gattttgagg agatgaggaa ggctgggtatc 240
tttcagagtg taaagtaatc ttggaatata aagaatttct tcagggttgaa ttacctagaa 300
gtttgtcact gacttgtgtt cctgaactat gacacatgaa tatgtgggct aagaaatagt 360
tcctcttgat aaataaacia ttaacaaata 390

```

```

<210> 8
<211> 402
<212> DNA
<213> Homo sapien

```

```

<400> 8
atcatgctcg agcggcgcca gtgtgatgga tgcgtggctcg cggccgaggt cgaagttttg 60
ccaaaacctc ggatgcgtgg ccttctggcc aggcgtctgc gaaatcatat ggctgtagca 120
ttcgtgctat ccctgggggt tgcagctttg tataagtttc gtgtggctga tcaagaaag 180
aaggcatatc cagatttcta cagaaactac gatgtcatga aagattttga ggagatgagg 240
aaggctggta tctttcagag tgtaaagtaa tcttggaata taaagaattt cttcagggtg 300
aattacctag aagtttgtca ctgacttggt ttctgaact atgacacatg aatatgtggg 360
ctaagaaata gttcctcttg ataaataaac aattaacaaa ta 402

```

```

<210> 9
<211> 418
<212> DNA
<213> Homo sapien

```

```

<400> 9
aatcatgctc gagcggcgca gtgtgatgga tgcgtggctcg cgggcaggtg taactaccat 60
ggctcccga gttttgcaa aacctcgat gcgtggcctt ctggccaggc gtctgcgaaa 120
tcatatggct gtagcattcg tgctatccct ggggggttgca gctttgtata agtttcgtgt 180
ggctgatcaa agaaagaagg catatgcaga tttctacaga aactacgatg tcatgaaaga 240
ttttgaggag atgaggaagg ctggtatctt tcagagtgtg aagtaatctt ggaatataaa 300
gaatttcttc aggttgaatt acctagaagt ttgtcactga cttgtgttcc tgaactatga 360
cacatgaata tgtgggctaa gaaatagttc ctcttgataa ataaacaatt aacaaata 418

```

```

<210> 10
<211> 384
<212> DNA
<213> Homo sapien

```

<400> 10
 gccagtgtga tggatcgtgg tcgcgggcgag gtcgaagttt tgccaaaacc tcggatgcgt 60
 ggccttcttg ccaggcgtct gcgaaatcat atggctgtag cattcgtgct atccctgggg 120
 gttgcagctt tgtataagtt tcgtgtggct gatcaaagaa agaaggcata cgcagatttc 180
 tacagaaaact acgatgtcat gaaagatfff gaggagatga ggaaggctgg tatctttcag 240
 agtgtaaagt aatcttggaa tataaagaat ttcttcaggt tgaattacct agaagtttgt 300
 cactgacttg tgttcctgaa ctatgacaca tgaatatgtg ggctaagaaa tagttcctct 360
 tgataaataa acaattaaca aata 384

<210> 11
 <211> 359
 <212> DNA
 <213> Homo sapien

<400> 11
 gagcggcgcc agtgtgatgg atgtggtcgc ggccgagggt tctggccagg cgtctgcgaa 60
 atcatatggc tgtagcattc gtgctatccc tgggggttgc agctttgtat aagtttctgtg 120
 tggctgatca aagaaagaag gcatacgcag atttctacag aaactacgat gtcatgaaag 180
 attttgagga gatgaggaag gctggatatct ttcagagtgt aaagtaatct tggaatataa 240
 agaatttctt caggttgaat tacctagaag tttgtcactg acttgtgttc ctgaactatg 300
 acacatgaat atgtgggcta agaaatagtt cctcttgata aataaacaat taacaaata 359

<210> 12
 <211> 360
 <212> DNA
 <213> Homo sapien

<400> 12
 tcgagcggcc gccagtgtga tggatgcgcg ccgggcaggt ttctggccag gcgtctgcga 60
 aatcatatgg ctgtagcatt cgtgctatcc ctgggggttg cagctttgta taagtttctgt 120
 gtggctgatc aaagaaagaa ggcatacgca gatttctaca gaaactacga tgtcatgaaa 180
 gattttgagg agatgaggaa ggctggatc tttcagagtg taaagtaatc ttggaatata 240
 aagaatttct tcaggttgaa ttacctagaa gtttgtcact gacttgtgtt cctgaactat 300
 gacacatgaa tatgtgggct aagaaatagt tcctcttgat aaataaaca ttaacaaata 360

<210> 13
 <211> 379
 <212> DNA
 <213> Homo sapien

<400> 13
 agatgcatgc tcgagcggcg caktgtgatg gatcgggcgc ccgggcaggt caaatgtgca 60

```

gctctccctc aggtcgtggg atctgggtcc aacagtcttg cctttcagcc ttcaggctgt 120
tttaggcttg aagtttcgtg tggctgatca aagaaagaag gcatacgag atttctacag 180
aaactacgat gtcatgaaag attttgagga gatgaggaag gctgggtatct ttcagagtgt 240
aaagtaatct tggaatataa agaatttctt cagggttgaat tacctagaag tttgtcactg 300
acttgtgttc ctgaactatg acacatgaat atgtgggcta agaaatagtt cctcttgata 360
aataaacaat taacaaata 379

```

```

<210> 14
<211> 964
<212> DNA
<213> Homo sapien

```

```

<400> 14
gccagtgtga tggatcgtgg tcgcggcgag gtgtcaggaa ggacgttggt gttgaggtta 60
gcatacgat caaggacagt aactaccatg gctcccgaag ttttgccaaa acctcggatg 120
cgtggccttc tggccaggcg tctgcgaaat catatggctg tagcattcgt gctatccctg 180
gggggttcag ctttgtataa gtttcgtgtg gctgatcaaa gaaagaaggc atacgcagat 240
ttctacagaa actacgatgt catgaaagat tttgaggaga tgaggaaggc tggatatctt 300
cagagtgtaa agtaatcttg gaatataaag aatttcttca ggttgaatta cctagaagtt 360
tgtcactgac ttgtgttcct gaactatgac acatgaatat gtgggctaag aaatagttcc 420
tcttgataaa taaacaatta acaaataaaa aaaaaaaaaa aaaaaaaaaa aaaaaaawa 480
raaaaaaaaa acacaaaaaaaa acacaaaaaaaa aaaggggggg ggcgccccac aaaataccct 540
ccgggggggg acgccccaac gagcaacccc ctttttggga aaaggggggc ccacaaagag 600
ggggcacaaa aaacggcggc gggcggtaac aaacggcgag cggacaaacc gagcgcgcg 660
ggacaacggg agcgacagac cccccaccgc cgtggggggc accgacccgg ggccccaac 720
ccaccgacgg agcagacccg ccgcagggcg aagacaacaa cagcgcgaga tgcggggcaa 780
cccaccgcac gaagcgcggc gacagctgcc ctcacgctat ctggaacgat tcagggcgcg 840
gcgataaacc gagccacac acccgcaagc cagacaacac gccgcccgc acacgcagac 900
gccaccacac cccgccccac caactacggc agctcagcg agaacctcg aaccccgccg 960
caca 964

```

```

<210> 15
<211> 1433
<212> DNA
<213> Homo sapien

```

```

<400> 15

```

```

acatgccctt cttccggtgc ggaagactat accactccca taccctataa ctttgtttgt      60
tctatttcac acatataatt ttccgagaca agatgttctc atttaagcaa caagaagatt      120
cgtctctcgc tattactgta actgctgttt atatcgtcac gtcccggaaa ggtccctgtc      180
ttccctgaat ggtctctacc aacttcacct ccggttctag gtgtcatggc tgccccaaga      240
gtctagagac gacaacttct ccgcttcctc ggcgatggcg gcgtccggga gcggtatggc      300
ccagaaaacc tgggaactgg ccaacaacat gcaggaagct cagagtatcg atgaaatcta      360
caaatacgac aagaaacagc agcaagaaat cctggcggcg aagccctgga ctaaggatca      420
ccattacttt aagtactgca aaatctcagc attggctctg ctgaagatgg tgatgcatgc      480
cagatcggga ggcaacttgg aagtgatggg tctgatgcta ggaaagggtg atggtgaaac      540
catgatcatt atggacagtt ttgctttgcc tgtggagggc actgaaaccc gagtaaatgc      600
tcaggctgct gcatatgaat acatggctgc atacatagaa aatgcaaaac aggttggccg      660
ccttgaaaat gcaatcgggt ggtatcatag ccaccctggc tatggctgct ggctttctgg      720
gattgatgtt agtactcaga tgctcaatca gcagttccag gaaccatttg tagcagtggg      780
gattgatcca acaagaacaa tatccgcagg gaaagtgaat cttggcgcct ttaggacata      840
cccaaagggc tacaacctc ctgatgaagg accttctgag taccagacta ttccacttaa      900
taaaatagaa gattttgggtg tacttgcaa acaatattat gccttagaag tctcatattt      960
caaatcctct ttggatcgca aattgcttga gctgttgtgg aataaatact ggggtgaatac     1020
gttgagttct tctagcttgc ttactaatgc agactatacc actggtcagg tctttgattt     1080
gtctgaaaag ttagagcagt cagaagccca gctgggacga gggagtttca tgttgggttt     1140
agaaacgcat gaccgaaaat cagaagacaa acttgccaaa gctacaagag acagctgtaa     1200
aactaccata gaagctatcc atggattgat gtctcagggt attaaggata aactgtttta     1260
tcaaattaac atctcttaaa cagtctctga gaagtacttt acctgaaaga cagtatgaga     1320
aaaatattca agtaacactt taaaaccagt taccctaaat ctgattagaa gtataaggtg     1380
ctctgaagtg tcctaaatat taatatcctg taataaagct ctttaaaatg aaa             1433

```

<210> 16

<211> 1937

<212> DNA

<213> Homo sapien

<400> 16

```

agcggactac ctgcccaccc aggaacaagc aatttacaaa tttaaaaaa gtagagttaa      60
tgctacagag aagacaaaaa cgggagctgg tcatgccaga aaaaccaacc atgtgatttg      120
agggttgggc ctttgcgcca tgtgacatca gccaggccta aggggaatga atacagcagg      180

```

10

gctggagatc aagccaagga gcaacaattc aaccaatcat tctacataa ggaaaatcca	240
gtaaaaactc tggacactca ggcttagcca aagaacacca ggaaaactac cacagttaag	300
ttggatgtac tactcattgc attaaggaat gcacggagaa cacacaccat ggggaaccct	360
gtggtatcgt gatgttctca ttttaagcaac aagaagattc gtctctcgtc attactgtaa	420
ctgctgttta tatcgtcatg tcccggaaag gtccctgtct tccctgaatg gtctctacca	480
acttcacctc cggttctagg tgtcatggct gcccgaagag tctagagacg acaacttctc	540
cgttctctcg gcgatggcgg cgtccgggag cggtatggcc cagaaaacct ggggaactggc	600
caacaacatg caggaagctc agagtatcga tgaaatctac aaatacgaca agaaacagca	660
gcaagaaatc ctggcggcga agccctggac taaggataaa gggagaagcc aagatttcga	720
ttcatgtctt gacttccaac atgaggtcta cacatttttc agcttttggt tgaaatctgg	780
caaagcttag gaattaaatt tggattcttt ctgtgggcag acatctaaaa aggctttgta	840
gagacgttga ctgactgctc tgtaaggctg cttaagttgc ttggttatct gcttgcttct	900
gtaacaggct gtgcatttta gtcaccatta ctttaagtac tgcaaaatct cagcattggc	960
tctgctgaag atggtgatgc atgccagatc gggaggcaac ttggaagtga tgggtctgat	1020
gctaggaaaag gtggatggtg aaaccatgat cattatggac agttttgctt tgcctgtgga	1080
gggcactgaa acccgagtaa atgctcaggc tgctgcatat gaatacatgg ctgcatacat	1140
agaaaatgca aaacagggtg gccgccttga aaatgcaatc ggggtggtatc atagccaccc	1200
tggctatggc tgctggcttt ctgggattga tgtagtact cagatgctca atcagcagtt	1260
ccaggaacca tttgtagcag tggtgattga tccaacaaga acaatatccg cagggaaagt	1320
gaatcttggc gccttttaga catacccaaa gggctacaaa cctcctgatg aaggaccttc	1380
tgagtaccag actattccac ttaataaaat agaagatttt ggtgtacact gcaacaata	1440
ttatgcctta gaagtctcat atttcaaatc ctctttggat cgcaaatgct ttgagctgtt	1500
gtggaataaa tactgggtga atacgttgag ttcttctagc ttgcttacta atgcagacta	1560
taccactggc caggtctttg atttgtctga aaagttagag cagtcagaag cccagctggg	1620
acgagggagt ttcattgttg gtttagaaac gcatgaocga aaatcagaag acaaacttgc	1680
caaagctaca agagacagct gtaaaactac catagaagct atccatggat tgatgtctca	1740
ggttattaag gataaactgt ttaatcaaata taacatctct taaacagtct ctgagaagta	1800
ctttacctga aagacagtat gagaaaaata ttcaagtaac actttaaaac cagttacca	1860
aaatctgatt agaagtataa ggtgctctga agtgccttaa atattaatat cctgtaataa	1920
agctctttta aatgaaa	1937

11

<210> 17
 <211> 1262
 <212> DNA
 <213> Homo sapien

<400> 17
 acatgccctt cttccggtgc ggaagactat accactccca taccctataa ctttgtttgt 60
 tctatttcac acatataatt ttccgagaca agatgttctc atttaagcaa caagaagatt 120
 cgtctctcgc tattactgta actgctgttt atatcgtcac gtcccggaaa ggtccctgtc 180
 ttccctgaat ggtctctacc aacttcacct ccggttctag gtgtcatggc tgccccaaga 240
 gtctagtcac cattacttta agtactgcaa aatctcagca ttggctctgc tgaagatggc 300
 gatgcatgcc agatcgggag gcaacttgga agtgatgggt ctgatgctag gaaaggtgga 360
 tggtgaaacc atgatcatta tggacagttt tgctttgcct gtggagggca ctgaaacccg 420
 agtaaagtct caggctgctg catatgaata catggctgca tacatagaaa atgcaaaaca 480
 ggttggccgc cttgaaaatg caatcgggtg gtatcatagc caccctggct atggctgctg 540
 gctttctggg attgatgtta gtactcagat gctcaatcag cagttccagg aaccatttgt 600
 agcagtgggtg attgatccaa caagaacaat atccgcaggg aaagtgaatc ttggcgcctt 660
 taggacatac ccaaagggtc acaaacctcc tgatgaagga ccttctgagt accagactat 720
 tccacttaat aaaatagaag attttgggtg acactgcaaa caatattatg ccttagaagt 780
 ctcatatttc aaatcctctt tggatcgcaa attgcttgag ctgttggtga ataaatactg 840
 ggtgaatacg ttgagttctt ctagcttgct tactaatgca gactatacca ctggtcaggt 900
 ctttgatttg tctgaaaagt tagagcagtc agaagcccag ctgggacgag ggagtttcat 960
 gttgggttta gaaacgcatg accgaaaatc agaagacaaa cttgccaaag ctacaagaga 1020
 cagctgtaaa actaccatag aagctatcca tggattgatg tctcaggtta ttaaggataa 1080
 actgtttaat caaatataca tctcttaaac agtctctgag aagtacttta cctgaaagac 1140
 agtatgagaa aaatattcaa gtaacacttt aaaaccagtt acccaaatc tgattagaag 1200
 tataaggtgc tctgaagtgt cctaaatatt aatatcctgt aataaagctc tttaaaatga 1260
 aa 1262

<210> 18
 <211> 1314
 <212> DNA
 <213> Homo sapien

<400> 18
 agcggactac ctgcccattc aggaacaagc aatttacaaa ttacaaaaa gtagagttta 60
 tgctacagag aagacaaaaa cgggagctgg tcatgccaga aaaaccaacc atgtgatttg 120

12

```

agggttgggc ctttgcgcca tgtgacatca gccaggccta aggggaatga atacagcagg 180
gctggagatc aagccaagga gcaacaattc aaccaatcat tcctacataa ggaaaatcca 240
gtaaaaactc tggacactca ggcttagcca aagaacacca ggaaaactac cacagttaag 300
ttggatgtac tactcattgc attaaggaat gcacggagaa cacacaccat ggggaaccct 360
gtggtatcgt gatgttctca ttttaagcaac aagaagattc gtctctcgct attactgtaa 420
ctgctgttta tatcgtcatg tcccggaaag gtccctgtct tccctgaatg gtctctacca 480
acttcacctc cggttctagg tgtcatggct gcccgaagag tctaggtaag agtttgttcc 540
cgtggtgcgg aggggtcaagg cccacacccg gaaacctagc gaggtaaagt tgcgtcttgg 600
ttgtagagac gacaacttct ccgettctc ggcatggcg gcgtccggga gcggtatggc 660
ccagaaaacc tgggaactgg ccaacaacat gcaggaagct cagagtatcg atgaaatcta 720
caaatacgac aagaaacagc agcaagaaat cctggcgggc aagccctgga ctaaggatca 780
ccattacttt aagtactgca aaatctcagc attggctctg ctgaagatgg tgatgcatgc 840
cagatcggga ggcaacttgg aagtgatggg tctgatgcta ggaaagggtg atggtgaaac 900
catgatcatt atggacagtt ttgctttgcc tgtggagggc actgaaacc gagtaaagtc 960
tcaggctgct gcatatgaat acatggctgc atacatagaa aatgcaaac aggttggccg 1020
ccttgaaaat gcaatcgggt ggtatcatag ccaccctggc tatggctgct ggctttctgg 1080
gattgatgtt agtactcaga tgctcaatca gcagttccag gaaccatttg tagcagtggc 1140
ggttactatg ggcaaggcgg catgagtggg ggtggatggc gtgggatgta ctgaaagcaa 1200
aaacaccaac atacaagtct tgacaacagc atctggctca ctagactttc ttacagattt 1260
aatttctttt gtatttaaag aactttataa tgactgaagt gtcgggaccg agct 1314

```

```

<210> 19
<211> 604
<212> DNA
<213> Homo sapien

```

```

<400> 19
ctcagaaggt ccttcatcag gaggtttgta gccctttggg tatgtcctaa aggcgccaat 60
attccactta ataaaataga agattttggg gtacactgca aacaatatta tgccttagaa 120
gtctcatatt tcaaatcctc tttggatcgc aaattgcttg agctgttgtg gaataaatac 180
tgggtgaata cgttgagttc ttctagcttg ctactaatg cagactatac cactggtcag 240
gtctttgatt tgtctgaaaa gtttagagcag tcagaagccc agctgggacg agggagtttc 300
atgttggggt tagaaacgca tgaccgaaaa tcagaagaca aacttgcaa agctacaaga 360
gacagctgta aaactacat agaagctatc catggattga tgtctcagggt tattaaggat 420

```

13

aaactgttta atcaaattaa catctcttaa acagtctctg agaagtactt tacctgaaag	480
acagtatgag aaaaatattc aagtaacact ttaaaaccag ttacccaaaa tctgattaga	540
agtataaggt gctctgaagt gtcctaaata ttaatatcct gtaataaagc tctttaaaat	600
gaaa	604

<210> 20
 <211> 940
 <212> DNA
 <213> Homo sapien

<400> 20	
aggttgacgt aagccaacac cgtgccactg cactacagcc tgggcgacag gctgatagga	60
agatgtcttc aggaaatgct aaaattgggc accctgcccc caacttcaaa gccacagctg	120
ttatgccaga tggtcagttt aaagatatca gcctgtctga ctacaaagga aaatatgttg	180
tgttcttctt ttaccctctt gacttcacct ttgtgtgccc cacggagatc attgctttca	240
gtgatagggc agaagaattt aagaaactca actgccaagt gattggtgct tctgtggatt	300
ctcacttctg tcatctagca tgggtcaata cacctaagaa acaaggagga ctgggaccca	360
tgaacattcc tttggtatca gacccgaagc gcaccattgc tcaggattat ggggtcttaa	420
aggctgatga aggcacctcg ttcaggggccc tttttatcat tgatgataag ggtattcttc	480
ggcagatcac tgtaaatagac ctccctgttg gccgctctgt ggatgagact ttgagactag	540
ttcaggcctt ccagttcact gacaaacatg gggaagtgtg cccagctggc tggaaacctg	600
gcagtgatac catcaagcct gatgtccaaa agagcaaaga atatttctcc aagcagaagt	660
gagcgctggg ctgttttagt gccaggctgc ggtgggcagc catgagaaca aaacctcttc	720
tgtatttttt ttttccatta gtaaaacaca agacttcaga ttcagccgaa ttgtggtgtc	780
ttacaaggca ggcctttcct acaggggggtg gagagaccag cctttcttcc tttggtagga	840
atggcctgag ttggcgttgt gggcaggcta ctggtttgta tgatgtatta gtagagcaac	900
ccattaatct tttgtagttt gtattaaact tgaactgaga	940

<210> 21
 <211> 4171
 <212> DNA
 <213> Homo sapien

<400> 21	
gtcccccca tgtgcagcct cctgattggg gcacaggaac tcaacctgaa tcagcctctt	60
gtgtattaca ggcagggggc gagatctcga ctgtgaacct tgagcagtac tccaaacgct	120
tcaacgagtt tatgtccaac atcctgacgt agttctcttc taccttcagc cagagccaga	180
gagctggata tggggtcggg gatcgggagt tagggagaag ggtgtatttg ggctagatgg	240

gaggggtggga gcagagtcgg gtttgggagg gcttttagcaa tgagactgca gcctgtgaca	300
ccgaaagaga ctttagctga agaggagggg gatgtgctgt gtgtgcacct gctcacagga	360
tgtaacccca ccttctgctt acccttgatt ttttctcccc atttgacacc cagggttaaaa	420
aggggttccc tttttggtac cttgtaacct tttaagatac cttggggcta gagatgactt	480
cgtgggttta tttgggtttt gtttctgaaa ttctattgct ccagggttgc tatttataat	540
catatttcat cagcctaccc accctcccca tctttgctga gctctcagtt cccttcaatt	600
aaagagatac ccggtagacc cagcacaagg gtccctccag aaccaagtgc tatggatgcc	660
agattggaga ggtcagacac ctgcacctgc tgcatttgc cttgtctgga ttaactttgt	720
aatttatgga gtattgtgca caacttcctc cacctttccc ttggattcaa gtgaaaactg	780
ttgcattatt cctccatcct gtctggaata caccaggta acaccagaga tctcagatca	840
gaatcagaga tctcagaggg gaataagttc atcctcatgg gatggtgagg ggcaggaaaag	900
cggctgggct cttggacacc tggttctcag agaaccctgt gatgatcacc caagccccag	960
gctgtcttag cccctggagt tcagaagtcc tctctgtaaa gcctgcctcc cactaggta	1020
agaggaacta gagtaccttt ggatttatca ggacctcat gtttaaattg ttatttccct	1080
ttgggaaaac ttcagaaact gatgtatcaa atgaggccct gtgccctcga tctatttct	1140
tcttcttctt gacctcctcc caggcaactct tacttctagc cgaactctta gctctgggca	1200
gatctccaag cgctggagt gctttttagc agagacacct cgtaagctc cgggatgacc	1260
ttgtaggaga tctgtctccc tgtgcctgga gagttacagc cagcaagggtg ccccatctt	1320
agagtgtggt gtccaaacgt gaggtggctt cctagttaca tgaggatgtg atccaggaaa	1380
tccagtttgg aggcttgatg tgggttttga cctggcctca gccttggggc tgtttttcct	1440
tgttgccccg ctctagactt ttagcagatc tgcagccac aggctttttt ggaaggagtg	1500
gcttctgca ggtgttccac ctgccttcgg agcctgccac ccaggccctc agaactgagc	1560
cacaggctgc tctggccagg agagaaacag ctctgttgtt ctgcattggg ggaggtacat	1620
tctgcatct tctaccccc tcaaccagga actggggatt tgggatgaga tatggtcaga	1680
ctttagata accccaaaga tgtgaagatc gcttgtgaaa ccattttgaa tgaatagatt	1740
ggtttctgt ggctccctcc aaacctggcc aagcccagct tccgaagcag gaaccagcac	1800
tgtctctgtg cctgactcac agcatatagg tcaggaaaga atggagacgg cattcttggga	1860
cttctactggg gctgctggat tggatgggaa accttctgga agaggcagat ggggggtcaaa	1920
ccactgcctt ggccccagga agggggcata ggtaggtctg aacaactgcc gcaagaccac	1980
tacatgactt agggaaactg aaaccaactg gctcatggag aaaacaaatt tgacttggga	2040

15

aagggattat	gtaggaataa	tgtttgact	tgatttcccc	acgtcataat	gaagaatgga	2100
agtttgatc	tgctcctcgt	caggcgcagc	atctctgaag	cttggaagc	tgtcttccag	2160
cagcctcgt	ggcctcgggt	tcctaccggc	ttctctgcat	ttggtctgct	gatcatgttg	2220
ccataatgtg	tatggaaagt	gtaacacatt	cttactgggt	aaagacgact	accaggtatc	2280
taacttgttt	aacattgagt	ttgtgtgtgt	gtgtgtatgt	ttgtgtgttt	tgtatattgt	2340
ttacattttg	agaggtagca	ttctgtttca	aatgcttttt	gtttttctga	cagtattgtt	2400
gactgggtca	taacattttg	agctgtgggt	tggtggattt	tcaatttttt	tttttaaagg	2460
tcattcgctg	tgctatcttc	aaaaccttga	gtttggcccc	caatttttgg	cattcaaagt	2520
tttaaaagct	atttatcttg	gtttatacaa	gtttcctttc	tcttcttttt	gtcatggtat	2580
tctatttggt	ctgcagtttg	aatgtagaga	aagtggactg	atccccaag	cgttgtctgc	2640
ccccactctt	tcctccttgg	gtcccgccat	tcttttactg	ggcagtcgag	ggcattggag	2700
gggaagtgac	tgccctcagc	ctcactccct	ggggccatga	agaaaagcta	aacagtctca	2760
tggcatctca	gaataatgtt	gggtctccca	agaagaaagg	tgtaagaata	acgacatggc	2820
tgattaggcg	aggccaggat	agggctaagg	ccaggattcc	tggctggcat	ccagtcaccc	2880
cttctcccat	ccttccccct	cttcttccac	aagtccgcag	ccgagacact	gtagtctccc	2940
agccacagtg	atgagtgcc	tggagactcc	actgacctct	agatgaaggc	ccctggccct	3000
ggttcctggt	aattaacctc	tgggtctttg	agtccccag	cacaaacttc	tttctgttac	3060
cctgcccgtt	ggggtcacag	ggcatgccgg	gaagccacag	ctgaggggcg	cagactgaag	3120
cagtgtcca	cctctccttc	tttagctcag	gggttgctgg	tctgtggcag	gcgccacgag	3180
tggcccctgt	ggctgttctc	agtggcagtc	tcttaagtct	ccaccacagg	cagctcttta	3240
tccccctctc	ctacttgact	ctttctcttg	cctgtgcttt	tggcctcaaa	caggcctgct	3300
ggtagcgctc	agggcgtgag	gtacactcc	tgccctgcct	ttcctgtctt	catggctctgc	3360
cagggcatac	cttggggagg	tggaccaaag	accaggact	ttttgcagta	gccagtccca	3420
ccccccagtt	gtctttttac	caattcaggg	tgggagagaa	aactgcagca	ccccagcatg	3480
tgagttactc	aggtgttggg	ggctagaagg	gacagtgcgt	ttaaacaaca	ctcagagctc	3540
tggccttaaa	cctgtggccc	cccaagtcta	ggagcctcat	ctcttcttgg	cagtcatgcg	3600
ggcaggaggt	cctgaaaggg	aaaaccatt	cagacaactg	ttccccaatc	taccagccat	3660
ctgcaggggt	cagtgaccgt	ggccctctcc	ctcctctaga	atgtgccact	tatgaagagt	3720
gccccatggg	gaaaaggaga	ctcagctgtc	ccttggcagc	ttgtgccagt	atcccagggc	3780
agaagtctcc	acaggagcct	cttgcccttg	cgcagagcca	ctgtgagagg	cgggtgggagc	3840
caacaccctt	gggggagggg	gcagtactgc	tcggcacatc	ccagcatcag	gtcagatcac	3900

16

```

tgaaattaaa aaatgtgaat taagttcata tccacctttt ggggaagcag gacaaaccac 3960
caccaccacca agtgtgtgac ttctccatat cccactgcag tttccatttt ttaaattggga 4020
attttcaatc ccctgtgctt gtctaacgtc tgctttaaaa agtttgagac cctgttactg 4080
tttgaaaatg catgcatggt acgatgaatc tccaacctga ggaaaaaaat aaaactcaaa 4140
aagctttgtg taaaaaaaaa aagtgtgagt c 4171

```

```

<210> 22
<211> 926
<212> DNA
<213> Homo sapien

```

```

<400> 22
agggcatgagg tcccgcaatt ttgccggagg ccagcggggc tggcgctgtg acaactgccg 60
cagacctggg ggtgaaccca gtcccgaagg cactactggc cagtcctaca accagtattc 120
tcagagatac catcagagaa caaacactaa tgtaattgc ccaattgagt gcttcatgcc 180
tttagatgta caggctgaca gagaagattc ccgagagtaa atcatctttc caatccagag 240
gaacaagcat gtctctctgc caagatccat ctaaaactgga gtgatgttag cagaccagc 300
ttagagttct tctttctttc ttaagccctt tgctctggag gaagttctcc agcttcagct 360
caactcacag cttctccaag catcacctg ggagtttctt gagggttttc tcataaatga 420
gggctgcaca ttgcctgttc tgcttcgaag tattcaatac cgctcagtat tttaaatgaa 480
gtgattctaa gatttggttt gggatcaata ggaaagcata tgcagccaac caagatgcaa 540
atgttttgaa atgatatgac caaaatttta agtaggaaag tcacccaaac acttctgctt 600
tcacttaagt gtctggcccg caatactgta ggaacaagca tgatcttggt actgtgatat 660
tttaaataatc cacagtactc actttttcca aatgaccta gtaattgcct agaaatatct 720
ttctcttacc tgttatatat caatttttcc cagtattttt atacggaaaa aattgtattg 780
aaaacactta gtatgcagtt gataagagga atttgtata attatggtgg gtgattatct 840
tttatactgt atgtgccaaa gctttactac tgtggaaaga caactgtttt aataaaagat 900
ttacattcca aaaaaaaaaa tcatct 926

```

```

<210> 23
<211> 1152
<212> DNA
<213> Homo sapien

```

```

<400> 23
tgcctcaaca gcgagggaag gcctttatgt tggggcctat ggtggaaact ctagccccgt 60
gcttcacact cggccgcgac cacgtcgagc gctcgcccg gcaggtaaac tctgccaccc 120

```

17

tgagtgggaag agtgggagact actggattga cccaaccaa ggctgcacct tggacgccat	180
gaaggttttc tgcaacatgg agactggcga gacttgcgtc taccccaatc cagcaaacgt	240
tccaagaag aactggtgga gcagcaagag caaggagaag aaacacatct gggttggaga	300
aaccatcaat ggtggcttcc atttcagcta tggagatgac aatctggctc ccaacactgc	360
caacgtccag atgaccttcc taogcctgct gtccacggaa ggctcccaga acatcaccta	420
ccactgcaag aacagcattg cctatctgga cgaagcagct ggcaacctca agaaggccct	480
gctcatccag ggctccaatg acgtggagat cggggcagag ggcaatagca gggttcacgta	540
cactgccctg aaggatggct gcacgaaaca taccggtaag tggggcaaga ctgttatcga	600
gtaccggtca cagaagacct caccgctccc catcattgac attgcacca tggacatagg	660
agggccccgag caggaattcg gtgtggacat agggccggctc tgcttcttgt aaaaacctga	720
accagaaac aacacaatcc gttgcaaacc caaaggacct aagtactttc caatctcagt	780
cactctagga ctctgcactg aatggctgac ctgacctgat gtccattcat cccacctct	840
cacagttcgg acttttctcc cctctctttc taagagacct gaactgggca gactgcaaaa	900
taaaatctcg gtgttctatt tatttattgt ctccctgtaa gaccttcggg tcaaggcaga	960
ggcaggaaac taactggtgt gagtcaaagc cccctgagt gactgcccc agcccaggcc	1020
agaagacctc ccttcagggtg ccgggcgcag gaactgtgtg tgcctacac aatgggtgcta	1080
ttctgtgtca aacacctctg tattttttta aacatcaatt gatattaaaa atgaaaagat	1140
tattggaaag ta	1152

<210> 24
 <211> 801
 <212> DNA
 <213> Homo sapien

<400> 24	
ggtactctca ggcattgttt ctgattgaat ccagagggtg caagcatgcc ttctgtatt	60
acctgttgga gcaggtttaa ttttataaat tttaaacaca aactctatga gtttctagtt	120
cataattggt ctttttgggg atccactcag atgaacagta ttgcatctgt aagagatacc	180
cacttcccag gaccagattt gattggaata tcagtggcaa cagactccat ctgtagctca	240
tccagtacat caccgctac atcgccagtc tgaagcagcg ttatacgcag agcaatgggc	300
gcaggccgtt tggcatctct gccctcatcg tgggtttcga ctttgatggc actcctaggc	360
tctatcagac tgacctctcg ggcacatacc atgcctggaa ggccaatgcc ataggccggg	420
gtgccaaagtc agtgctgag ttcttgagga agaactatac tgacgaagcc attgaaacag	480
atgatctgac cattaagctg gtgatcaagg cactcctgga agtggttcag tcagggtggca	540

18

aaaacattga acttgctgtc atgaggcgag atcaatccct caagatttta aatcctgaag 600
 aaattgagaa gtatgttgct gaaattgaaa aagaaaaaga agaaaacgaa aagaagaaac 660
 aaaagaaagc atcatgatga ataaaatgtc tttgcttgta attttttaaat tcatatcaat 720
 catggatgag tctcgatgtg taggcctttc cattccattt attcacactg agtgtcctac 780
 aataaacttc cgtattttta a 801

<210> 25
 <211> 3111
 <212> DNA
 <213> Homo sapien

<400> 25
 ggagaaacaa agtccacctc cctcatatac acacctcccc cttcttcttt cacttagttc 60
 aactccaga taggaccagg aataagttgt ctgggctttt atttcccccc accccaactt 120
 tagttccttc attttcacat cctgagtata acagcattag atatagaaaa acagtcttag 180
 aaataactcc tatgaaccac aactcaactt aattcatcat tggcttagga tatgatttcg 240
 aatgagatcc atttcaatga aacactatth aagttattta atttctcctg gagagggagg 300
 agtgactggg aactcagacc aggtggattc cttggagctc ttggaatgat caggttgtgt 360
 ggaaagctcc tcctaatacag ccagctgcat ttccagcgaa ggcagaagtt ggtttttaat 420
 cagagggagc agcacagcaa atactatgaa gttttatttg ttgtgatttg tacctctgga 480
 agagttagaa aaaagtagtt aaaaacaccc agaggagcaa acaccatatg taagactcct 540
 acaattttta ttaaggcatt tagaatctcc ctccatacac actgttcctg tacccttgcc 600
 ttttgctgc tttgcactcc ccaaaaagcg gctaaaatgt tatagttaag tgggtgattc 660
 ctttcccatt ttctcccaa gcctgggggt tgaaattgct gaaatcatgt ggccctctga 720
 gtcaacttgg ggtctaaagt ttcagatcct tgcttccctt gtcccgga gagcgtacaa 780
 aagccgggct tctccatttg tcaattgtat ttttttctt cctctctgta ctctctgtct 840
 ctctctgct ctatctctct ttctctgtct ccttctctgg ctctcttccc ctctctctct 900
 ccgctcccag gaccggcacg atggtgtccc gagccacagc tcgcggtct cccagctggg 960
 ctcggtgtcc caaggaccct actcgagcgc cccgcccgtg tcccacaccc cgtcgtcgga 1020
 cttccagccg cctacttcc ccccccccta ccagccgctc ccctaccacc agagccagga 1080
 cccctactcc cacgtcaacg acccctactc cctgaacca ctgcaccagc cccagcaaca 1140
 tccctggggg caacggcagc ggcaagaagt ggggttcggaa gccggctctc tcctgcccc 1200
 gcctcgggccc gccttgcccc agctctcggg ccttgacccc cggagggact accactcgg 1260
 ccgcccggccg gacgtgctgc tgcattcggc gcaccacggc ctggacgcgg gcatgggtga 1320

19

cagcctctcg	ctgcacggcc	tcggccatcc	cggaatggaa	gacgtccagt	cagttgaaga	1380
tgccaataac	agcggcatga	atctattgga	ccagtctgtc	attaaaaaag	ttccagttcc	1440
tcccaaatcg	gtgacttctc	taatgatgaa	taaagacggc	ttcctgggag	gcatgtctgt	1500
caacacccggc	gaggtgtttt	gctccgtccc	aggcggtttg	tctctgctca	gttcaacttc	1560
gaagtacaaa	gtaactgtgg	gagaagttca	gagacggctg	tcgccccctg	aatgcctcaa	1620
tgcatctctc	ctcggcggag	tcctcagaag	agccaaatcg	aaaaatgggg	ggagatcttt	1680
gcgagaaagg	ctagaaaaaa	tcggtttgaa	tttaccgcgc	ggcaggcgca	aagcagcaaa	1740
tgtcacgtta	ctcacctccc	tggtggaagg	agaagctggt	cacttagcta	gggattttgg	1800
gtacatttgc	gaaacggagt	ttcccgccaa	agccgtctct	gagtatttga	accggcagca	1860
cacagacccg	agtgacctgc	actcccgaaa	gaatatgctg	ttggccacca	agcaactttg	1920
taaagaatth	acggatctac	tggcgcagga	cgggacaccg	atagggaaca	gccgaccag	1980
ccccatcctg	gagccgggga	tccagagctg	cctcaacgac	ttcagcctca	tcacgcacgg	2040
cttcggcgcc	cgggccatth	gcgcgcgcgt	cacggccctg	cagaactatc	tcaccgaggc	2100
gctcaaaggc	atggacaaga	tgthcttgaa	caacaccacc	actaacaggc	acacgtctgg	2160
ggaaggccca	ggtagtaaaa	ctggcgacaa	ggaggagaaa	cacaggaaat	gaaaaattht	2220
taaaaaaaga	aggaaaaatg	ttttaaatat	aaaaggaaaa	acagacaaaa	atttaattht	2280
agctthaaaa	tattggattg	gctthggaag	aattatatta	ggtagaatat	acatacaatc	2340
aaaatthtaa	aaaaaaaagc	taaataactt	aaaaaaaaac	tgaggcgtag	aacggagcaa	2400
caatatcggt	tctcagtgtc	tatttcaaga	tacatttgga	gacaaccgtc	cggattthtc	2460
acttcggthc	tttcgagtht	agtaatactg	ataataaaaag	aaaaccatga	tttccccttc	2520
cctthtgaaa	ataaacataa	gactaaacat	gagaaaaacg	ctaacttatt	ggaagaaaat	2580
cggagaaaacg	ttggtgtcaa	tgctthgaga	gctgggtgac	tgagacgcac	gaactthtta	2640
attthtaata	tattthtagg	aaactctcgc	agtccccgcc	ctccatctca	cctcaccctg	2700
ctcccaacca	ccctthtcca	tgthaccctc	ccttcctcac	attgttacgg	gaatcttctg	2760
ggatgaaaat	gagtgtggtt	ggccctthtg	cgttgthtca	gtcctctcgg	tacctccccg	2820
cccagccctg	cgatcttaac	tcaccggggc	cggctccccg	gccgcttgca	taattaggga	2880
gggcgagggc	ggggcgggag	gcctgtggag	accaggcgga	ggctgcaatt	tttggtgccg	2940
gccggcagag	caggttctgg	cggctgagga	aaatccggac	caataagttg	attcaaacat...	3000
catcagthtc	tttcagaaat	gttactagct	cccagccttg	ccagcatctg	catagagaga	3060
atctcacatt	tattatattt	gtgtcatcta	ctaattthtat	gaactatagt	a	3111

20

<210> 26
 <211> 2480
 <212> DNA
 <213> Homo sapien

<400> 26
 gtttttttctc tttgctgagg cttacttgtc cagcctattg tttgagacaa cagatataag 60
 ttgcgatggg agaggagcgt cggatttggt gtgtatcccc catttccaat tatagatgga 120
 tcattacaga cagcggagtc ctgagaagcc agacatctgc tcctcacatg aatgcactca 180
 cctcctagag accaggtgct catcatgctc tggagcctt tggagaatgt caagtacgaa 240
 gatatctatg agatgttagt ccacacctat tcatccatgg accggcacga tgggtgtcccg 300
 agccacagct cgcggctctc ccagctgggc tcgggtgtccc aaggacccta ctcgagcgcc 360
 ccgcccgtgt cccacacccc gtctgtggac ttccagccgc cctacttccc acccccctac 420
 cagccgctcc cctaccacca gagccaggac ccctactccc acgtcaacga cccctactcc 480
 ctgaaccacac tgcaccagcc ccagcaacat ccctgggggc aacggcagcg gcaagaagtg 540
 ggttcggaag ccggtctctc cctgccccag cctcgggccg ccttgcccca gctctcgggc 600
 cttgaccccc ggagggacta ccactcggtc cgccggccgg acgtgctgct gcattcggcg 660
 caccacggcc tggacgcggg catgggtgac agcctctcgc tgcacggcct cggccatccc 720
 ggaatggaag acgtccagtc agttgaagat gccaaataaca gcggcatgaa tctattggac 780
 cagtctgtca ttaaaaaagt tccagttcct cccaaatcgg tgacttctct aatgatgaat 840
 aaagacggct tcctgggagg catgtctgtc aacaccggcg aggtgttttg ctccgtccca 900
 ggcggtttgt ctctgctcag ttcaacttcg aagtacaaag taactgtggg agaagttcag 960
 agacggctgt cgtccctga atgcctcaat gcatctctcc tcggcgaggc ctcagaaga 1020
 gccaaatcga aaaatggggg gagatctttg cgagaaaggc tagaaaaaat cggtttgaat 1080
 ttaccgcggg gcaggcgcaa agcagcaa atgtcacgttac tcacctccct ggtggaagga 1140
 gaagctgttc acttagctag ggattttggg tacatttgcg aaacggagtt tcccgccaaa 1200
 gccgtctctg agtatgtgaa ccggcagcac acagaccga gtgacctgca ctcccgaaag 1260
 aatatgctgt tggccaccaa gcaactttgt aaagaattta cggatctact ggcgcaggac 1320
 cggacaccga tagggaacag ccgaccagc cccatcctgg agccggggat ccagagctgc 1380
 ctcacgcact tcagcctcat cagcacggc ttccggcgccc cggccatttg cgcgcgctc 1440
 acggccctgc agaactatct caccgaggcg ctcaaaggca tggacaagat gttcttgaac 1500
 aacaccacca ctaacaggca cagctctggg gaaggcccag gtagtaaaac tggcgacaag 1560
 gaggagaaac acaggaaatg aaaaatTTTT aaaaaaagaa ggaaaaatgt tttaaataca 1620
 aaaggaaaaa cagacaaaaa tttaatttta gctttaaatt attggattgg ctttggaaga 1680

```

attatattag gtagaataca catacaatca aaatttttaa aaaaaaagct aaataactta 1740
aaaaaaaact gaggcgtaca acggagcaac aatatcggtt ctcagtgtct atttcaagat 1800
acatttggag acaaccgtcc ggattttcca cttcggttct ttcgagttta gtaatactga 1860
taataaaaaga aaaccatgat ttcccccttc ctttggaaaa taaacataag actaaacatg 1920
agaaaaacgc taacttattg gaagaaaatc ggagaaacgt tgggtgtcaat gctttgagag 1980
ctgggtgact gagacgcacg aactttttta ttttaaatat atttttagga aactctcgca 2040
gtccccgccc tccatctcac ctcacccgtc tcccaaccac ctttttccat gttaccctcc 2100
cttcctcaca ttgttacggg aatcttcttg gatgaaaatg agtgtggttg gcccttttgc 2160
gttgtttcag tcctctcggt acctccccgc ccagccctgc gatcttaact caccgggccc 2220
ggctccccgg ccgcttgc attagggag ggcgagggcg ggcgggagg cctgtggaga 2280
ccaggcggag gctgcaattt ttggtgccgg ccggcagagc aggttctggc ggctgaggaa 2340
aatccggacc aataagttga ttcaaacatc atcagttcct ttcagaaatg ttactagctc 2400
ccagccttgc cagcatctgc atagagagaa tctcacattt attatatttg tgtcatctac 2460
taattttatg aactatagta 2480

```

```

<210> 27
<211> 1437
<212> DNA
<213> Homo sapien

```

```

<400> 27
tgagaagggc aaatgctatc attggaaaaa ctgacaaaag tcccaatagg aaaaataagg 60
aagtggagag ttactatggt tctaattttt catgtgcttc tatttttttc ctacttcaga 120
gccattgact aatagttgag tataacacag gttgtgtttc cgggctgctg aaacatgaca 180
ctaataattt caaagaactg tggaagccta aaaggaagcc aatgagaaat aactaaatga 240
gagtttagga ctgcagcctt ctttttcatt caaagattta aaagtttcca taaagtaaaa 300
tgttcttctc cggccacctg ttttcatagt tctgtgtttt ccttcaggcc tttctggctt 360
cctatatggc agtaagaaaa tgatgtgctt aatgattaca aatttcatat ggaatacgaa 420
ctttcagttt gtacatatga tgcacagaga tgcttttgtg gttttatttg ttttcatatt 480
acaaacaaag aaactagaaa atgaaaccat tccaaaagtg gaagtaattt ctcaactgcc 540
ctgtgataaa ctgtggtcac tggctgtggc agcaactatt ataagatgct ctgaaaactc 600
ttcagacact gaggggcacc agaggagcag actacaagaa tggcacacgc tatggaaaac 660
tcctggacaa tcagtaaaga gtaccatatt gatgaagaag tgggctttgc tctgccaaat 720
ccacaggaaa atctacctga tttttataat gactggatgt tcattgctaa acatctgctt 780

```

```

gatctcatag agtctggcca gcttcgagaa agagttgaga agttaaacat gctcagcatt      840
gatcatctca cagaccacaa gtcacagcgc cttgcacgtc tagttctggg atgcatcacc      900
atggcatatg tgtggggcaa aggtcatgga gatgtccgta aggtcttgcc aagaaatatt      960
gctgttcctt actgccaaact ctccaagaaa ctggaactgc ctctattttt ggtttatgca    1020
gactgtgtct tggcaaactg gaagaaaaag gatcctaata agcccctgac ttatgagaac    1080
atggacgttt tgttctcatt tcgtgatgga gactgcagta aaggattctt cctgggtctct    1140
ctattgggtg aaatagcagc tgcttctgca atcaaagtac gtctatcctc acttcaaaat    1200
ttatatgtca atttacgtaa gcagagcaat cacttcggag cctaaactat actaagcatg    1260
agttaacttt atccttaaca agtacaacat gggatcattt aattgggggt aaaggatcaa    1320
ttattttatt ttgtgtatta cctaaaatat aaaatctcag agccatatac ttaaaatcca    1380
acttgaaacc tctgtaggag ataaaaattt tcaataaaat ctggctttgg aactata      1437

```

<210> 28

<211> 1911

<212> DNA

<213> Homo sapien

<400> 28

```

cggagagacc tgggctggcg cgggcgggag ctgcggcgga tacccttgcg tgctgtggag      60
accctactct cttcgctgag aacggccgct agcggggact gaaggccggg agcccactcc    120
cgacccgggg ctagcgtgcg tccctagagt cgagcggggc aaggagacca gtggccgccc      180
acgggggacc gggaaacttt tctgggctcc tgggcgcgcc ctgtagccgc gctccatgct    240
ccggcagcgg ccgaaacccc agcccccgcc ctgacggcgc ccgcccgtcc gggcagggcc    300
catgcccctg cgcctccggg ggtcgtaggc tgccgcgag ccggggctcc ggaagccggc    360
gggggcgcgc cggccgtgcg gggcgtcaat ggatcgccac tccagctaca tcttcatctg    420
gctgcagctg gagctctgcg ccatggccgt gctgctcacc aaaggtgaaa ttcgatgcta    480
ctgtgatgct gccactgtg tagccactgg ttatatgtgt aaatctgagc tcagcgctg      540
cttctctaga cttcttgatc ctcagaactc aaattcccca ctcaacctg gctgcctgga    600
ctctcttgca agcacgacag acatctgcca agccaaacag gcccgaaacc actctggcac    660
caccataccc acattggaat gctgtcatga agacatgtgc aattacagag ggctgcacga    720
tgttctctct cctcccaggg gtgaggcctc aggtaggtgg aagcogtttc taaccagaat    780
gcctgcctga tctatagact tgtgacagcc acgactttgt atgtctgcta ttgattttgt    840
tgttaatgta attagagaca ccagagggag aagcctggct ggatgcaaag atgcatcttg    900
attgagtggc ttttatgtct gagcattaga tgtctgtcta cataataggt ttgacctgtt    960

```

```

ttttcaacat tttgaagaca ttaaaaggcc attacatctc agtaatgaca gtctgtaaac 1020
aaatgcgttt gtaagcttct tcagatagtt ttgcaatggt ttctaaatat cgttgattta 1080
attgtaagct tctttttaat ggaattcttg gttaaaatga attgatgatt atgaatatcc 1140
ctaggaggag ttagcatgga gtttgatcat tttctttgta ctcttttagg acaaggaaac 1200
aggatcagc atgatggtag cagaaacctt atcaccaagg tgcaggagct gacttcttcc 1260
aaagagttgt ggttccgggc agcggtcatt gccgtgccca ttgctggagg gctgatttta 1320
gtgttgctta ttatgttggc cctgaggatg cttcgaagtg aaaataagag gctgcaggat 1380
cagcggcaac agatgctctc ccgtttgcac tacagctttc acggacacca ttccaaaaag 1440
gggcaggttg caaagttaga cttggaatgc atgggtgccg tcagtgggca cgagaactgc 1500
tgtctgacct gtgataaaat gagacaagca gacctcagca acgataagat cctctcgctt 1560
gttctactgg gcatgtacag tgggcacggg aagctggaat tcgtatgacg gagtcttata 1620
tgaactacac ttactgaaca gcttgaaggc cttttgagtt ctgctggaca ggagcacttt 1680
atctgaagac aaactcattt aatcatcttt gagagacaaa atgacctctg caaacagaat 1740
cttgatatt tcttctgaag gattatttgc acagacttaa atacagttaa atgtgttatt 1800
tgctttaaaa ttataaaaag caaagagaag actttgtaca cactgtcacc agggttattt 1860
gcatccaagg gagctggaat tgagtaccta aataaacaaa aatgtgccct a 1911

```

```

<210> 29
<211> 1413
<212> DNA
<213> Homo sapien

```

```

<400> 29
cggagagacc tgggctggcg cgggcgggag ctgcggcgga tacccttgcg tgctgtggag 60
accctactct cttcgctgag aacggccgct agcggggact gaaggccggg agccactcc 120
cgaccggggg ctacgctgcg tccctagagt cgagcggggc aaggggagcca gtggccgccc 180
acgggggacc gggaaacttt tctgggctcc tgggcgcgac ctgtagccgc gctccatgct 240
ccggcagcgg cccgaaacct agccccgccc ctgacggcgc ccgcccgtcc gggcagggcc 300
catgcctgca gcgctccggg ggtcgtaggc tgccgcgcgag ccggggctcc ggaagccggc 360
gggggcgcgc cggccgtgcg gggcgtcaat ggatcgccac tccagctaca tcttcatctg 420
gctgcagctg gagctctgcg ccatggccgt gctgctcacc aaaggtgaaa ttcgatgcta 480
ctgtgatgct gccactgtg tagccactgg ttatatgtgt aaatctgagc tcagcgctg 540
cttctctaga cttcttgatc ctcaaaactc aaattcccca ctacccatg gctgcctgga 600
ctctcttgca agcacgacag acatctgcc aagcaaacag gcccgaaacc actctggcac 660

```

24

```

caccataccc acattggaat gctgtcatga agacaaggaa acaggatatca gcatgatggg 720
agcagaaacc ttatcaccaa ggtgcaggag ctgacttctt ccaaagagtt gtgggtccgg 780
gcagcgggtca ttgccgtgcc cattgctgga gggctgattt tagtggtgct tattatgttg 840
gccctgagga tgcttcgaag tgaaaataag aggctgcagg atcagcggca acagatgctc 900
tcccgtttgc actacagctt tcacggacac cattccaaaa aggggcagggt tgcaaagtta 960
gacttggaat gcatgggtgcc ggtcagtggt cagcagaact gctgtctgac ctgtgataaa 1020
atgagacaag cagacctcag caacgataag atcctctcgc ttgttctactg gggcatgtac 1080
agtgggcacg ggaagctgga attcgtatga cggagtctta tctgaactac acttactgaa 1140
cagcttgaag gccttttgag ttctgctgga caggagcact ttatctgaag acaaaactcat 1200
ttaatcatct ttgagagaca aaatgacctc tgcaaacaga atcttgata tttcttctga 1260
aggattatct gcacagactt aaatacagtt aaatgtgtta tttgctttaa aattataaaa 1320
agcaaagaga agactttgta cacactgtca ccagggttat ttgcatcaa gggagctgga 1380
attgagtacc taaataaaca aaaatgtgcc cta 1413

```

<210> 30

<211> 2533

<212> DNA

<213> Homo sapien

<400> 30

```

atccacttcc gggctcggca gctagactag cgggggcagc ctcagagcgg gtgagcttgg 60
ggacgcacgg agaggtgcag ctgggtgagt gggcggcgcc gtgcgccgag ggcatggagg 120
agggagcgct gaggcggcg cgtgcgccgt ggccggggcg cggcccgcc gccatcgaga 180
ctgagggcag gaccctcggc ccttcgatga ttgtacgctg ggtgctcgat gggaggaggg 240
tttgctgggt gagctggttc agactccttg aaaaatcatc gtcactcttt ctctctcgcg 300
gacgtcctgc ccatcgctct gagccggcgc cccaagtaga gccagagtag ttcgtacca 360
gccttttcac gtaactcggc cgaggtggtt cttctccgaa tttttccgt caggcccaga 420
ttagcagatt ttggggtcag ctgggagagg cgtaaacttt tcttcgcaca ctcttgcttt 480
gtgcgctcaa ccacagtctg aattctcgca gaggcgttcc ttgagtagcc cttggccaca 540
ctgctcacct ccctgcagaa gtcaaagccc cagccctcct ctgcgaatcc cgaggccagc 600
ctgggttggtt accttctccc cttcgccctt tactccaggc cgtccagcat caaacactag 660
cctccacacg tggaaaagac cctgactccc acagtagact agtcttatgg gagtcctggc 720
tcttgggcca ggctgcatta ggaaaatgga aaccagactg tcttcaaatt cttctgccta 780
gccttagcca ttagagagag gtcctgctaa agatggactg caaatgcgct tgatggaagg 840

```

```

agatgtcaat tccactgaag tcctcatttc tgctaggagc tacctgtgca ccctgcctcc 900
ggctctcctg agcagagaga tcctgatggc tgactcagaa gcactcccct cccttgctgg 960
ggacccagtg gctgtggaag ccttgctccg ggccgtgttt ggggttggtg tggatgagggc 1020
cattcagaaa ggaaccagtg tctcccagaa ggtctgtgag tggaaaggagc ctgaggagct 1080
gaagcagctg ctggatttgg agctgctggag ccagggcgag tcacagaagc agatcctgga 1140
gcggtgtcgg gctgtgattc gctacagtgt caagactggt caccctcggt tcttcaacca 1200
gctcttctct gggttggatc cccatgctct ggccggggcg attatcactg agagcctcaa 1260
caccagccag tgagcatccc aaggccctc taccatccca caaaggattt aggtttgcta 1320
gagagggtgc tgaggggtag gggaggagaa tggttctgcc ctctctctac tgcttctggg 1380
aatccctgtc ggagagagt ttttctcat atcctttgga ccactttct ccaaactttc 1440
tcaggcctcc tgaccctgt tttctcttcc ttgcttccct ggttctgtca ccaactcggt 1500
cttctccttg gactgttgct ttgctcactc ttactgcct cctttttgtg actcctgtgc 1560
agtttaaggg cctgtctggg cagtccctcc ccatctctcc tttctcgtcg ttctctctcc 1620
tggcaggtac acatatgaaa tcgccccgt gtttgtgctc atggaaggagg aggtgctgag 1680
gaaactgcgg gccctggtgg gctggagctc tggggacgga atcttctgcc ctggtggctc 1740
catctccaac atgtatgctg taaatctggc ccgctatcag cgctaccgg attgcaagca 1800
gaggggcctc cgcacactgc cggccctggc cctattcaca tcgaaggagg tggggaagag 1860
gcacaggccc aaccctgggc tcctgattct aatctccagc cagctaagta gagaccttcc 1920
aggctctctc cctgccctcc ctacatctc caaggccagc ctgccccag gcggatgtgc 1980
ttccttccaa tcaaggaggt caagtaactg ctctgttca cattgccttc tgtttggggg 2040
cagaggaggg gccgtgagtg cagtggacac agtcatact ctctctactc aagagtgtgg 2100
tctgtggacc agcagcattg gtatgacctg gggcttggtt gaaatgcaga atctggccgg 2160
gcacggtgac tcacgcctgt aatcccagca ctttgagagg ctgaggtggg tggattgcct 2220
gagctcagga gtttgatacc accctgggaa acatagtga ataaataggg aaaagcaata 2280
tcaggaaaag tattaaggag ggatatttaa tctattccat tcaaaataac ctttaaagtc 2340
tttactgtta tgatccttaa caaatacaac atacattcct aaagattttt ccaagtcatt 2400
ctgtaactaa ggagacaata tgatctttca actagtttct catctaatta tgcttttact 2460
tcagcatgga cgtactctga cctcaacctt cccagcagg ttattttttg ttaccctgc 2520
gtgacacctc agt 2533

```

26

<211> 1961
 <212> DNA
 <213> Homo sapien

<400> 31

```

atccacttcc gggctcggca gctagactag cgggggcagc ctcagagcgg gtgagcttgg      60
ggacgcacgg agaggtgcag ctgggtgagt gggcggcgcc gtgcgccgag ggcattggagg      120
agggagcgct gagggcggcg cgtgcgccgt ggccggggcg cggcccggcc gccatcgaga      180
ctgagggcag gaccctcggc ctttcgatga ttgtacgctg ggtgctcgat gggaggaggg      240
tttgctgggt gagctgggtc agactccttg aaaaatcatc gtcactcttt cttcctcgcg      300
gacgtcctgc ccatcgctct gagccggcgc cccaagtaga gccagagtag ttcgtaccca      360
gccttttcac gtaactcggc cgaggtgggt cttctccgaa ttttttccgt caggcccaga      420
ttagcagatt ttggggtcag ctgggagagg cgtaaacttt tcttcgcaca ctcttgcttt      480
gtgcgctcaa ccacagtctg aattctcgca gaggcgttcc ttgagtagcc cttggccaca      540
ctgctcacct ccctgcagaa gtcaaagccc cagccctcct ctgcgaatcc cgaggccagc      600
ctggttggtt accttctccc cttgcgccct tactccaggc cgtccagcat caaacactag      660
cctccacacg tggaaaagac cctgactccc acagtagact agtcttatgg gagtccctggc      720
tcttgggcca ggctgcatta ggaaaatgga aaccagactg tcttcaaatt cttctgccta      780
gccttagcca ttagagagag gtccctgctaa agatggactg caaatgcgct tgatggaagg      840
agatgtcaat tccactgaag tcctcatctt tgctaggagc tacctgtgca ccctgcctcc      900
ggctctcctg agcagagaga tcctgatggc tgactcagaa gcactcccct cccttgctgg      960
ggaccagtg gctgtggaag ccttgctccg ggccgtgttt ggggttggtt tggtatgaggc     1020
cattcagaaa ggaaccagtg tctcccagaa ggtctgtgag tggaaggagc ctgaggagct     1080
gaagcagctg ctggatttgg agctgcggag ccagggcgag tcacagaagc agatcctgga     1140
gcggtgtcgg gctgtgattc gctacagtgt caagactggt caccctcggt tcttcaacca     1200
gctcttctct gggttggatc cccatgctct ggccgggcgc attatcactg agagcctcaa     1260
caccagccag tgagcatccc aaggccctc taccatccca caaaggattt aggtttgcta     1320
gagaggtgcc tgaggggtag gggaggagaa tggttctgcc ctctctctac tgcttctggg     1380
aatccctgtc ggcagagagt ttttcctcat atcctttgga ccactttct ccaaactttc     1440
tcaggcctcc tgaccctgt tttctcttct ttgcttccct ggttctgtca ccaactcgtt     1500
cttctccttg gactgttgct ttgctcactc ttactgcct cctttttgtg actcctgtgc     1560
agtttaaggg cctgtctggg cagtcctcc ccatctctcc tttctcgtcg ttctctctcc     1620
tggcaggtag acatatgaaa tcgcccccg gtttgtgtc atggaagagg aggtgctgag     1680

```


27

gaaactgcgg gccctggtgg gctggagctc tggggacgga atcttctgcc ctggtttgtg 1740
 agaaggagga ggacctttct ttgccctttt tatgagttcc tcctcccca ccgttctctt 1800
 gctctagtgt ctggcaggga gggatgattc ctctttgatt cctctccagc tggacccagg 1860
 ccaggccagg gaggcggctg cctggtccct tcatgctcat gtttgtcacc attccctggg 1920
 gtcagtggtc tagttcctgc tatctccgga cgggggctgt c 1961

<210> 32
 <211> 1228
 <212> DNA
 <213> Homo sapien

<400> 32
 cgcagcttct gagaccaggg ttgctccgag taaaggggga caggagacgt gcggggcagg 60
 acctcggggc tggatgcaga ggccggggtg gtggaaaggg gaggagaact gggcagggca 120
 gataagtggg tggggcctct ggaggtggcg ggggcaagggt tggagccccg ggacgaagaa 180
 gggacgcggg tcagcgaggc ctgaagagtg ggaggagatg ggaccggct gtagagtgcc 240
 cagaggtcta ggccaggggc cgcgctgccg caggaagatg cgagagtttg gctttggtga 300
 tctggtccac ccggggccag tcttgcccc tctgccaccg cagcgtaggg cctcctgcat 360
 tccgtttctc tggccggaag ggtctagtgt tcatccctct caggctttgg cctcctcca 420
 ctctcccgcc ctggggccca ttcgtttagg aagaatggga gagccggtcg tggcccctgg 480
 gcggggtaaa ggagggaggc ttggtaaacc tctgctgggg aggaccaggt acagtggcag 540
 ctctttgtcg gggaaagaac ggatctgcgt cacacgctct tacaggggaa ccctaagggg 600
 cctgaggggt agggcttggg ctccaccag aggggaaggag aaatttttcg agtcgtaaag 660
 aaatgtatca gaagccatgg aacatttaca gccgcacacg ctgggtctcc caacaaacag 720
 atccccaaaa tattttccag tgctgtactc gtggcataga ccagaccca cagaccagga 780
 ggaagcgcta gagatgtcaa cagccaacaa aaacagtgtt ttacacactt gtaaaattgt 840
 gacctacagg ggctgggcac tgtggctcac gcctgtaacc ccagcacttt ggggtggcaa 900
 ggtgggagga ttgcttgagc cccaggagtt tgagatcagc ctggcaaaca tggtaaaatc 960
 ctgtctctac taaaaatata aaaattagct gggcgtgggt gtgcatgcct gtaatcccag 1020
 ctacctggga ggctgaggca ggagaattgc tggaaaccaa gaggcggagg ctgcagttag 1080
 ccgagattgc gccattgcac ttcagtctcg gccacagagc gagagtccgt ctcaaaaaaa 1140
 aaaaaaaaaa aaaaaaaaaa ggaattagct tggcatgggt gcgtgtgcct tgcagcgagc 1200
 tgtacgtgat cagtgcact gcactcca 1228

<210> 33

28

<211> 2620
 <212> DNA
 <213> Homo sapien

<400> 33

```

acagtggcat aaacatgggc tttggcgta gacagccctg agcggggccc cattgcccga      60
cccccgagga aggcgagggg ggggtggcagg gggctgcgga aaggggctgg gctgggttgg      120
gctgtctgca gctctagtcc aggaggctga gacttcgaga gggacttaga gaaggcagac      180
gcatcccgaa ctcgctggag gacaaggctc agctcttgcc aggcctaaatt gagacatgtc      240
tgacacaagc gagagtgggt caggtctaac tcgcttccag gctgaagctt cagaaaagga      300
cagtagctcg atgatgcaga ctctgttgac agtgaccacag aatgtggagg tcccagagac      360
accgaaggcc tcaaaggcac tggaggtctc agaggatgtg aaggtctcaa aagcctctgg      420
gggtctcaag gccacagagg tctcaaagac ccagagggtc cgggaggcac ctgccaccca      480
ggcctcatct actactcagc tgactgatac ccagggttctg gcagctgaaa acaagagtct      540
agcagctgac accaagaaac agaattgctga ccgcagggtc gtgacaatgc ctgccactga      600
gacaaaaaag gtcagccatg tggctgatac aaaggtcaat acaaaggctc aggagactga      660
ggctgcaccc tctcaggccc cagcagatga acctgagcct gagagtgcag ctgcccagtc      720
tcaggagaat caggatactc ggccaaggt caaagccaag aaagcccgaa aggtgaagca      780
tctggatggg gaagaggatg gcagcagtga tcagagtcag gcttctggaa ccacaggtgg      840
ccgaagggtc tcaaaggccc taatggcctc aatggcccg cagggttcaa ggggtcccat      900
agccttttgg gcccgaggg catcaaggac tcggttggct gcttggggcc ggagagcctt      960
gctctccctg agatcaccta aagcccgtag gggcaaggct cgccgtagag ctgccaagct     1020
ccagtcaccc caagagcctg aagcaccacc acctcgggat gtggcccttt tgcaaggagag     1080
ggcaaattgat ttggtgaagt accttttggc taaagaccag acgaagattc ccatcaagcg     1140
ctcggacatg ctgaaggaca tcatcaaaga atacactgat gtgtaccccg aaatcattga     1200
acgagcaggc tattccttgg agaaggtatt tgggattcaa ttgaaggaaa ttgataagaa     1260
tgaccacttg tacattcttc tcagcacctt agagcccact gatgcaggca tactgggaac     1320
gactaaggac tcaccaagc tgggtctgct catggtgctt cttagcatca tcttcatgaa     1380
tggaatcgg tccagtgagg gtgagtggct gggcttgag ctgaatgggt ggctgtggtc     1440
tagattccat gtgttcaatt tctgtccctg tctcctcttg cctcccctcg cagctgtcat     1500
ctgggagggtg ctgcgcaagt tggggctgag ccctgggtat gattgggctc tctcagcgct     1560
tgctgtccgt gttgtccttt ggcaagagag gacggtccta ggattgcac agtctgggtg     1620
tctggtggag cgggtggggt gctggactgg gtagagggcc cagggttctg acctgggtgg     1680

```

29

atgatgggtg	aatggctcctg	aactctctgc	tccctctctc	agtgtctctt	gggtctctat	1740
ggagcttccc	tcttgctgctg	gaaacctctt	ttccatcttg	gaaatgcctc	tgccacatc	1800
tgggaagtgc	catagccttg	agtgaattta	tttgtttatt	tatctttctt	tttcttctct	1860
caggatacat	cattcactct	ttggggacgt	gaagaagctc	atcactgatg	agtttggtgaa	1920
gcagaagtac	ctggactatg	ccagagtccc	caatagcaat	ccccctgaat	atgagttctt	1980
ctggggcctg	cgctcttact	atgagaccag	caagatgaaa	gtcctcaagt	ttgcctgcaa	2040
ggtacaaaag	aaggatccca	aggaatgggc	agctcagtac	cgagaggcga	tggaagcgga	2100
tttgaaggct	gcagctgagg	ctgcagctga	agccaaggct	agggccgaga	ttagagctcg	2160
aatgggcatt	gggctcggct	cggagaatgc	tgccgggccc	tgcaactggg	acgaagctga	2220
tatcggaccc	tgggccaaag	cccggatcca	ggcgggagca	gaagctaaag	ccaaagccca	2280
agagagtggc	agtgccagca	ctggtgccag	taccagtacc	aataacagtg	ccagtgccag	2340
tgccagcacc	agtgggtggct	tcagtgtctg	tgccagcctg	accgccactc	tcacatttgg	2400
gctcttcgct	ggccttggtg	gagctgggtg	cagcaccagt	ggcagctctg	gtgcctgtgg	2460
tttctcctac	aagtgagatt	ttagatattg	ttaatcctgc	cagtctttct	cttcaagcca	2520
gggtgcatcc	tcagaaacct	actcaacaca	gcactctagg	cagccactat	caatcaattg	2580
aagttgacac	tctgcattaa	atctatctgc	catttcaaaa			2620

<210> 34
 <211> 2787
 <212> DNA
 <213> Homo sapien

<400> 34	
acagtggcat	aaacatgggc tttggcgtca gacagccctg agcggggccc cattgccccca 60
cccccgagga	aggcgagggg ggggtggcagg gggctgcgga aaggggctgg gctgggttgg 120
gctgtctgca	gctctagtcc aggaggctga gaactcgaga gggacttaga gaaggcagac 180
gcatcccgaa	ctcgtctggag gacaaggctc agctcttgcc aggccaaatt gagacatgtc 240
tgacacaagc	gagagtgggtg caggtctaac tcgcttccag gctgaagctt cagaaaagga 300
cagtagctcg	atgatgcaga ctctgttgac agtgaccagc aatgtggagg tcccagagac 360
accgaaggcc	tcaaaggcac tggaggctctc agaggatgtg aaggtctcaa aagcctctgg 420
ggtctcaaag	gccacagagg tctcaaagac ccagagggtc cgggaggcac ctgccaccca 480
ggcctcatct	actactcagc tgactgatac ccaggttctg gcagctgaaa acaagagtct 540
agcagctgac	accaagaaac agaattgctga ccgcagggtc gtgacaatgc ctgccactga 600
gacaaaaaag	gtcagccatg tggctgatac aaaggtcaat acaaaggctc aggagactga 660

ggctgcaccc tctcaggccc cagcagatga acctgagcct gagagtgcag ctgcccagtc	720
tcaggagaat caggatactc ggcccaaggt caaagccaag aaagcccgaa aggtgaagca	780
tctggatggg gaagaggatg gcagcagtga tcagagtcag gcttctggaa ccacagggtg	840
ccgaagggtc tcaaaggccc taatggcctc aatggcccg c agggcttcaa ggggtcccat	900
agccttttgg gcccgagggt catcaaggac tcggttggct gcttgggccc ggagagcctt	960
gctctccctg agatcaccta aagcccgtag gggcaaggct cgcgtagag ctgccaagct	1020
ccagtcattc caagagcctg aagcaccacc acctcgggat gtggcccttt tgcaaggag	1080
ggcaaagtat ttggtgaagt acccttttggc taaagaccag acgaagattc ccatcaagcg	1140
ctcgggtaaa gtcctaccaa tctcctctc gccctgagct ctgccctcca ttgcccttac	1200
accattgtgc tggggatata cctgctctt atgcttatgt ctctgtctc ccaaagttct	1260
gatttggcag tgctagcatc tctgttgata agcacagaac cgggttatgc cacccttgg	1320
gtggttggca aagagtctat agcttgggca tcagggccac ctggcatctc ttcagtcagg	1380
tgctcacaac actctccctc tgcagacatg ctgaaggaca tcatcaaaga atacactgat	1440
gtgtaccccg aaatcattga acgagcaggc tattccttgg agaaggtatt tgggattcaa	1500
ttgaaggaaa ttgataagaa tgaccacttg tacattcttc tcagcacctt agagcccact	1560
gatgcaggca tactgggaac gactaaggac tcaccaagc tgggtctgct catggtgctt	1620
cttagcatca tcttcattga tggaaatcgg tcagtgagg ctgtcatctg ggaggtgctg	1680
cgaagttgg ggctgcgcc tgggtatgat tgggtctctc cagcgcttgc tgtccgtgtt	1740
gtccttttggc aagagaggac ggtcctagga ttgcatcagt ctggtggtct ggtggagcgg	1800
gtgggtgct ggactgggta gagggcccag ggtcttgacc tgggtggatg atgggtgaat	1860
ggtcctgaac tctctgctcc ctctctcagt gtctcttggg cttctatgga gcttccctct	1920
tgtgctggaa acctcttttc catcttgga atgcctctgc ccacatctgg gaagtccat	1980
agccttgagt gaatttattt gtttatttat ttttcttttt cttctctcag gatacatcat	2040
tcactctttg gggacgtgaa gaagctcatc actgatgagt ttgtgaagca gaagtacctg	2100
gactatgcca gagtcccaa tagcaatccc cctgaatatg agttcttctg gggcctgcgc	2160
tcttactatg agaccagcaa gatgaaagtc ctcaagtttg cctgcaagggt acaaaagaag	2220
gatcccaagg aatgggcagc tcagtaccga gaggcgatgg aagcggattt gaaggctgca	2280
gctgaggctg cagctgaagc caaggctagg gccgagatta gagctcgaat gggcattggg	2340
ctcggctcgg agaattgctgc cgggccctgc aactgggacg aagctgatat cggaccctgg	2400
gccaaagccc ggatccaggc gggagcagaa gctaaagcca aagcccaaga gagtggcagt	2460
gccagcactg gtgccagtac cagtaccaat aacagtgcc gtgccagtgc cagcaccagt	2520

31

```

gggtggcttca gtgctgggtgc cagcctgacc gccactctca catttgggct cttcgttggc 2580
cttgggtggag ctgggtgccag caccagtggc agctctgggtg cctgtgggtt ctcctacaag 2640
tgagatttta gatattgtta atcctgccag tctttctctt caagccaggg tgcctcctca 2700
gaaacctact caacacagca ctctaggcag ccactatcaa tcaattgaag ttgacactct 2760
gcattaaatc tatttgccat ttcaaaa 2787

```

```

<210> 35
<211> 912
<212> DNA
<213> Homo sapien

```

```

<400> 35
gccctgacgg cgctcccggg agcagccggg gcgcggcggc ggcacgaccc cctgcgcctc 60
cgaggcagac gagcccatcg ggagaaggcg aggcagggaa gtgcctaaac caacgggata 120
ggattcaaaa ctaggtgaca aactcatgag aaatccaacc tggctgaatg tctgagaggc 180
tgctactgta tcaacatcac aagataaagc actctgggtat cacctgcccata tctctcctt 240
agtgtcaccc aagacatttg actctgatgt ggttaattga taacttttct tgctccactt 300
tacaatgttt tgtttcctac atcttattac cttgggacac aaaagtggca gagttgttga 360
gagctgatga caataaaaag gagaacacta gaggaaatga gacaggaaag aaagccaaag 420
ctgattttcc aactctatgc tgactccaac ctgcagaaaa agctgaatat agaaatcttc 480
ttccatatat gatgaagtca ctccacttac gacataacac acaaaggaat cacctggctt 540
ttttttttta acccagaaga gttgtgctgg ggaccatgcc ccatcccgtc gatacagatc 600
ctgaatggaa taatcaggaa tggcacagtg caggtgtcaa tatcaaagta aggccgcaga 660
atTTTTgaga ggaccctcca aatactgaga acttctgttg cactcgaaac agtctcctgg 720
atttctatat ttttatgtga agggctctta ttgatgtccc ccagaatcca gactcagacc 780
tatttctcca aaaaggtcca attgggttgc tacatagtag caagggttta tcttcatgct 840
cacctagcat tccaggcccc cattacttca aaagtgaagt tgaaattgtt ttaagtgaac 900
tatggctgcg ga 912

```

```

<210> 36
<211> 893
<212> DNA
<213> Homo sapien

```

```

<400> 36
gccctgacgg cgctcccggg agcagccggg gcgcggcggc ggcacgaccc cctgcgcctc 60
cgaggcagac gagcccatcg ggagaagaaa ccaacgggat aggattcaaa actaggtgac 120

```

32

aaactcatga gaaatccaac ctggctgaat gtctgagagg ctgctactgt atcaacatca	180
caagataaag cactctggta tcacctgccc atatcctcct tagtgtcacc caagacattt	240
gactctgatg tggttaattg ataacttttc ttgctccact ttacaatggt ttgtttccta	300
catcttatta ccttgggaca caaaagtggc agagttgttg agagctgatg acaataaaaa	360
ggagaacact agaggaaatg agacaggaaa gaaagccaaa gctgattttc caactctatg	420
ctgactccaa cctgcagaaa aagctgaata tagaaatctt cttccatata tgatgaagtc	480
actccactta cgacataaca cacaaaggaa tcacctggct tttttttttt aaccagaag	540
agttgtgctg gggaccatgc cccatccgc tgatacagat cctgaatgga ataatacagga	600
atggcacagt gcagggtgtca atatcaaagt aaggccgcag aatttttgag aggaccctcc	660
aaatactgag aacttctggt gcactcgaaa cagtctcctg gatctctata tttttatgtg	720
aagggtctct attgatgtcc cccagaatcc agactcagac ctatttctcc aaaaagggtcc	780
aattgggttg ctacatagta gcaagggtt atcttcatgc tcacctagca ttccaggccc	840
ccattacttc aaaagtgagc ttgaaattgt tttaagtga ctatggctgc gga	893

<210> 37

<211> 3828

<212> DNA

<213> Homo sapien

<400> 37

ggccggcggc amgtgaccca ccgcgccggg gccggcggcc cagaaatagc agcggcggcg	60
gttccgcccc cggcgccgc gagcgagggg cagaggcgag agacgccggc gggcgccggg	120
cgcgccggcc ccggaggatg ctgctgagcc ccggcactgc ctggctgcga gcacatgatg	180
gcgatacggg agctcaaagt gtgccttctc ggggacactg gggttgggaa atcaagcatc	240
gtgtgtcgat ttgtccagga tcactttgac cacaacatca gccctactat tggggcatct	300
tttatgacca aaactgtgcc ttgtggaaat gaacttcaca agttcctcat ctgggacact	360
gctggtcagg aacggggagg ttcccctgaa ggatgctaag gaatacgctg aatccatagg	420
tgccatcgtg gttgagacaa gtgcaaaaaa tgctattaat atcgaagagc tctttcaagg	480
aatcagccgc cagatccac ccttggaccc ccatgaaaat ggaaacaatg gaacaatcaa	540
agttgagaag ccaaccatgc aagccagccg ccggtgctgt tgaccaagg gccgtgggtcc	600
acggtacttg aagaagccag agcccacatc ctgtgcactg ctgaaggacc ctacgctcgg	660
tgccctggca cctcactttg agaagagtga gcacactggc ttgcatcct ggaagacctg	720
cagggggcgg ggcaggaaat gtacctgaaa aggattttag aaaaccctgg gaaaaccac	780
cacaccacca caaaatggcc tttagtgtat gaaatgcaca tggaggggat gtagttgcat	840

ttttgctaaa aaaaaaaaaa aacctttaaa aattgttggg tgtgtacaaa agtcttactg	900
ccttattatg tgtatgggat tctaaagtgg cattccactt ggatttcctg tgctacctat	960
ccaaattcca gtaactactt cagtgtcatt gcctttgtta cctaaccaac ctccactgaa	1020
aggcaaattt agttcaggag gtttagttttt agctagcttt ggaagtaagc ctttattttat	1080
tacttttttg aggaaatcag agaagtgtca atggaccgtc actcagactg agacttgagt	1140
tattacagaa gccaggaaaa gtgtattaga aactgttgtc tacaccactt ttaattggtg	1200
aacaattttt ctaagttatg gtcatatata cccaaacaaa ccaaatcaaa cttaaattact	1260
gcatataatt ttgggattgg gtggcctagt ttgaaagagt gatttaagta atcactatgt	1320
aagtggtag agatgcagga catacacatt attcaagaga ccacctgaca tgcactcct	1380
ccgcaggaat acattcgtcc tctcttagag aagtttaacg cacatagtat tattttacta	1440
agagaatatc tcttgggtgtc atatctaggg gaagagaatt aactagaatt aaatttaatg	1500
tttgaatcta aatcattggg caaacttcta ataataacaa ttaataatag gttacaggaa	1560
agccagccag aggaagtgtc agcactttaa aattctagac ccaaaaaaac tacaaaatca	1620
gaaaaagtat ttttatgttt ctagcttgag gagaagggtt ttagggctaa ccagaggtct	1680
gacctagaa tgccaaggaa ctgagaatgg gctccgatga aaaccttcct tttcagattc	1740
cctgtctgct caattaaaga tgtttgaatc caaaggaagt caaggaagaa aaagcatgga	1800
aaggaagaga actgattcct actgaaaatt caaattctat taccattcta actttcataa	1860
aaagtggga tcaagaagca gctgatttcc tgccagggtt tatattaggg gggtgattct	1920
taaaggacat taggattggg gctcagaaat ggttaatcat gctgtgtgct agccaggggc	1980
agctggtacc ttctttgcca tgagcattca agggacagct aacctttatt gacaatctat	2040
attgcaaaag tcaggaaaga ggttgtgagc tgattggatt aaagacctgg cacttcagta	2100
actcagcacg cttccacttc actcaactta agagagttca ttgacagtgt taggatgtga	2160
aggctgggaa acacttattt tgcttcaaga gttccacttg gctctcccaa ataggtaacct	2220
caaaaactgt tagcaagcgg catttggatg tottgacagg ggctttgcag ggatttttag	2280
ggttttttcc acattgtcca cattaatggg tggcatgatt gtgcttgag gccaaagaaat	2340
gatcatacc cttgccaaag gtataaaaaa aaaaaaaaaa atgagttgaa aattgaagtg	2400
acctctttcc agctgacttg caggcttatt ttgtaacctt tcctcatcca gttttccctg	2460
agaacctggg tttatctcta gatagctgtt cagggttttt agctgagggg taagtatcct	2520
agctgagagt tttgcatctt tgggctgggt ttgcagtggg tgtgttttgc ataaaaatgc	2580
tagtctttgc cacagatagt gagctaccca ctaatgagcc catggtttta tttcagaagc	2640
acatgagggt gtgaaaccac tctgttacct ttctgtattg tcttagctat tcaagccagt	2700

```

cagaggataa tatatatatt ctcatcagca ctacagagtag tcagtgaaga gagtagatca 2760
cacttgggca caccaggatt cacataaaca ttgtatcttc tctgtggatg ctacggcctt 2820
gtctacaatg aggctttaca accttccttt gttttggctc gggattactt cctggctgtc 2880
taataattga accataacca tgtaatatta tgtaaaggcc tggaaattac tgttgctaaa 2940
aaaagtcatg tagtttcatg tagtgtagca tccttggcat cgttttccaa aatttggtcc 3000
ttctcccttt tttttttctt tcgtgtgtgg catgagtgtg tatctgtgta aatatgattg 3060
tatatgtgtt actccgatat gtaatccatt tcactggctg agtttggccc ctagccatgt 3120
gttaatataa agtaggcatg gcttcccaat ggaaatctct gagaatgaca gtggagtgtg 3180
gcaagcattt tacattgcca cataattgac ttgccatttt atggttaaaa acggcacatt 3240
aggcagttga atatgacgtt accttgca gaataaagggt gaaggccga aactaacttt 3300
tagctaaca taagggtgt gcccgaatgg aaactgagtt cattttctga gaaagggttg 3360
gatgactgaa atatttcttc tacagtcaag gactttggca tgcggtggct gaaactgagc 3420
ttttttgtgt gggctccagt tctcactgtt ctgcaatgct catggcaagt tgaatggtga 3480
gctagcttat aaattaaaga gctctgaact gtattcagac cgactgggta tctagcttac 3540
tgttttaaca tcattgttga aaccagaccc tgtagtccag tgggtgctgcc ctgttggtga 3600
aactgctcct ttttctgtg tttttgtaaa gagcttccat ctgggctgga ccagttctt 3660
gcacatacaa gacaccgtg cagtcagcta ggacctttcc gccatgtatt ctattctgta 3720
gtaaagcatt tccatcaaca atgcctaatt gtatctgtta tttttggttt aacacacact 3780
gattcatact aataaatatt ttcagtttta ccgtttgtct ttttctta 3828

```

<210> 38

<211> 3410

<212> DNA

<213> Homo sapien

<400> 38

```

gtcgacgatc ggtgtctggt gactcttggg aatcgggtgct gcgcggcgaa ggagtggact 60
gtgagaggcc gccagatccc acccttggac ccccatgaaa atggaaacaa tggaacaatc 120
aaagttgaga agccaacccat gcaagccagc cgccggtgct gttgacccaa gggccgtggt 180
ccacggtact tgaagaagcc agagcccaca tcctgtgcac tgctgaagga ccctacgctc 240
gggtggcctgg cacctcactt tgagaagagt gagcacactg gctttgcac cttggaagacc 300
tgcagggggc ggggcaggaa atgtacctga aaaggatttt agaaaaccct gggaaaaccc 360
accacaccac caaaaaatgg cctttagtgt atgaaatgca catggagggg atgtagttgc 420
atttttgcta aaaaaaaaaa aaaaccttta aaaattgttg gatgtgtaca aaagtcttac 480

```


tgcccttatta tgtgtatggg attctaaagt ggcattccac ttggatttcc tgtgctacct	540
atccaaattc cagtaactac ttcagtgtca ttgcctttgt tacctaacca accttcactg	600
aaaggcaaat ttagttcagg aggttagttt ttagctagct ttggaagtaa gcctttatct	660
attacttttt ggaggaaatc agagaagtgt caatggaccg tcactcagac tgagacttga	720
gttattacag aagccaggaa aagtgtatta gaaactgttg tctacaccac ttttaattgg	780
tgaacaatct tcttaagtta tgggtcatata taccctaaaca aaccaaatac aactaaatta	840
ctgcatataa ttttgggatt ggggtggccta gtttgaaaga gtgatttaag taatcactat	900
gtaagtgggtg agagatgcag gacatacaca ttattcaaga gaccacctga catgcatctc	960
ctccgcagga atacattcgt cctctcttag agaagtttaa cgcacatagt attatcttac	1020
taagagaata tctcttgggtg tcatatctag gggaagagaa ttaactagaa ttaaatttaa	1080
tgtttgaatc taaatcattg ggcaaaactc taataataac aattaataat aggttacagg	1140
aaagccagcc agaggaagtg tcagcacttt aaaattctag acccaaaaaa actacaaaat	1200
cagaaaaagt atttttatgt ttctagcttg aggagaaggg ctttagggct aaccagaggt	1260
ctgacctag aatgccagg aactgagaat gggctccgat gaaaaccttc cttttcagat	1320
tccctgtctg ctcaattaaa gatgtttgaa tccaaaggaa gtcaaggaag aaaaagcatg	1380
gaaaggaaga gaactgattc ctactgaaaa ttcaaatctc attaccattc taactttcat	1440
aaaaagttgg gatcaagaag cagctgattt cctgccaggg cttatattag gggggtgatt	1500
cttaaaggac attaggattg gtgctcagaa atggttaatc atgctgtgtg ctagccaggg	1560
ccagctggta ccttctttgc catgagcatt caagggacag ctaaccttta ttgacaatct	1620
atattgcaaa agtcaggaaa gaggttgtga gctgattgga ttaaagacct ggcacttcag	1680
taactcagca cgcttccact tcaactcaact taagagagtt cattgacagt gttaggatgt	1740
gaaggctggg aaacacttat tttgcttcaa gagttccact tggctctccc aaataggtac	1800
ctcaaaaact gttagcaagc ggcatttgga tgtcttgaca ggggctttgc agggattttt	1860
agggtttttt ccacattgtc cacattaatg gttggcatga ttgtgcttgc aggccaaaga	1920
atgatcatc cccttgccaa aggtaaaaaa aaaaaaaaaa aaatgagttg aaaattgaag	1980
tgacctcttt ccagctgact tgcaggctta ttttgtaacc tttcctcatc cagttttccc	2040
tgagaacctg ggtttatctc tagatagctg ttcaggtttt ttagctgagg ggtaagtatc	2100
ctagctgaga gttttgcatc tttgggctgg gtttgacagt gttgtgtttt gcataaaatg	2160
tctagtcttt gccacagata gtgagctacc cactaatgag cccatgggtt tatttcagaa	2220
gcacatgagg gtgtgaaacc actctgttac ctttctgtat tgtcttagct attcaagcca	2280

36

gtcagaggat aatatatata ttctcatcag cactcagagt agtcagtga gagagtagat 2340
 cacacttggg cacaccagga ttacataaaa cattgtatct tctctgtgga tgctcaggcc 2400
 ttgtctacaa tgaggcttta caaccttcct ttgttttggc tcgggattac ttccctggctg 2460
 tctaataatt gaaccataac catgtaatat tatgtaaagg cctggaaatt actgttgcta 2520
 aaaaaagtca tgtagtttca tgtagtgtag catccttggc atcgttttcc aaaatttggt 2580
 ccttctccct ttttttttct tttcgtgtgt ggcatgagtg tgtatctgtg taaatatgat 2640
 tgtatatgtg ttactccgat atgtaatcca tttcactggc tgagtttggc ccctagccat 2700
 gtgttaatat aaagtaggca tggcttccca atggaaatct ctgagaatga cagtggagtt 2760
 gtgcaagcat ttacattgc cacataattg acttgccatt ttatgggtta aaacggcaca 2820
 ttaggcagtt gaatatgacg ttaccttgca gactaaaagg ttgaaggccc gaaactaact 2880
 tttagctaac aataagggct gtgccccaat ggaaactgag ttcattttct gagaaagggt 2940
 tggatgactg aaatatattcc tctacagtca aggactttgg catgcggtgg ctgaaactga 3000
 gcttttttgt gtgggctcca gttctcactg ttctgcaatg ctcatggcaa gttgaatggt 3060
 gagctagctt ataaattaaa gagctctgaa ctgtattcag accgactggg tatctagctt 3120
 actgttttaa catcattgtt gaaaccagac cctgtagtcc agtggtgctg ccctgttgtg 3180
 caaactgctc ctttttctcg tgtttttgta aagagcttcc atctgggctg gaccagttc 3240
 ttgcacatac aagacaccgc tgcagtcagc taggacctt ccgccatgta ttctattctg 3300
 tagtaaagca tttccatcaa caatgcctaa ttgtatctgt tatttttggg ttaacacaca 3360
 ctgattcata ctaataaata ttttcagttt taccgtttgt ctttttctta 3410

<210> 39

<211> 1726

<212> DNA

<213> Homo sapien

<400> 39

gcggaagaaa aaagcaagat gggaccgcaa gctggacgtg actgtaaggg gtcattggctg 60
 cggaatccag caggggcatt ggggttgacg tgcaactcag gccagacttc ttctagttc 120
 ctcaacctct tggctactat gggctggtcc ggaagggtcag gcaaggggaa gctgcgcagg 180
 cgcagtgtga gcggcaacat ggcgtccagg tctaagcggc gtgccgtgga aagtggggtt 240
 ccgcagccgc cggatcccc agtccagcgc gacgaggaag aggaaaaaga agtcgaaaat 300
 gaggatgaag acgatgatga cagtgaacaag gaaaaggatg aagaggacga ggtcattgac 360
 gaggaagtga atattgaatt tgaagcttat tccctatcag ataattgatta tgacggaatt 420
 aagaaattac tgcagcagct ttttctaaag gctcctgtga aactgcaga actaacagat 480

37

ctcttaattc aacagaacca tattgggagt gtgattaagc aaacggatgt ttcagaagac 540
 agcaatgatg atatggatga agatgagggtt tttgggtttca taagcctttt aaattttaact 600
 gaaagaaagg gtacccagtg tgttgaacaa attcaagagt tggttctacg cttctgtgag 660
 aagaactgtg aaaagagcat ggttgaacag ctggacaagt ttttaaataa caccaccaag 720
 cctgtggggc ttctcctaag tgaaagattc attaatgtcc ctccacagat cgctctgccc 780
 atgtaccagc agcttcagaa agaactggcg ggggcacaca gaaccaataa gccatgtggg 840
 aagtgtact tttaccttct gattagtaag acatttgtgg aagcaggaaa aaacaattcc 900
 aaaaagaaac ctagcaacaa aaagaaagct gcgttaatgt ttgcaaatgc agaggaagaa 960
 tttttctatg aggtgggttca cgggggcaag tgacagccct ggtttctctg aaggctggac 1020
 taattcaatc aagatcaact ctaagtgatt tccagggaaac cttcatgact gttggaattg 1080
 ctctgtcata ataagtcagg gatatttagg aggtcatag tctcctggag ggataaaaca 1140
 tctcggcacc tagtaatggc aaattagtca atatttgtta gtttcgtttg agatctcaaa 1200
 tgttaggatt ttctgaagtc tcagtgtctt tcagagtttg agataccttg ttttcatttt 1260
 ttctaatttt taatttaaaa gtaataaaga atattttgta atgattagga tgaaaatttt 1320
 atcgtcaatt ataagccaaa atttgctaaa attaaagtca gtatacttga aacaagtttc 1380
 tagtaagttc tctggggtaa gataactaatt actctgataa aggggctatc aaaaaatcc 1440
 agtaaattgt tcataagaag agatcagttt aagagtcaaa caatttgctt tgctagtacc 1500
 ttagctaaag aaaaaatact attaaagatg actatcacct ttatgctcta gtagttgagt 1560
 cttccctcaa aactttctcc tttggcagct caatcaattt aattcatttc caaacctcca 1620
 acatgctaatt ggaatcaaga cttttgttac tggctgcaat aattcttctt tgcactcatg 1680
 accaaattca acgaatcccc aggtcacata gttcatcctc acttcc 1726

<210> 40

<211> 1032

<212> DNA

<213> Homo sapien

<400> 40

gcggaagaaa aaagcaagat gggaccgcaa gctggacgtg actgtaaggg gtcattggctg 60
 cggaatccag caggggcatt ggggttgacg tgcactcagc gccgagcttc ttcgtagtcc 120
 ctcacccctt tggctactat gggctggtcc ggaaggctcag gcaaggggaa gctgcgcagg 180
 cgcaagtgtga gcggcaacat ggcgtccagg tctaagcggc gtgcccgtgga aagtgggggtt 240
 ccgcagccgc cggatcccc agtcacgcgc gacgaggaag aggaaaaaga agtcgaaaat 300
 gaggatgaag acgatgatga cagtgacaag gaaaaggatg aagaggacga ggtcattgac 360

38

gaggaagtga atattgaatt tgaagcttat tccctatcag ataatgatta tgacggaatt 420
 aagaaattac tgcagcagct ttttctaaag gtcctgtga aactgcaga actaacagat 480
 ctcttaattc aacagaacca tattgggagt gtgattaagc aaacggatgt ttcagaagac 540
 agcaatgatg atatggatga agatgaggtt tttggtttca taagcctttt aaatttaact 600
 gaaagaaagg gtaccagtg tgttgaacaa attcaagagt tggttctacg cttctgtgag 660
 aagaactgtg aaaagagcat ggttgaacag ctggacaagt ttttaaataga caccaccaag 720
 cctgtgggcc ttctcctaag tgaaagattc attaatgtcc ctccacagat cgctctgccc 780
 atgtaccagc agcttcagta agagattctg ggaaaatatc tttgaacagt aatttttttt 840
 tcaaatagat tcctaaatgt catttaagta gaatatgtag atatagaaag agttctgtcc 900
 ttggtttaag tgggttttagt gtgaggggag tggaagaaac atcctgtgaa gtacatacat 960
 tattaacaac tggctttttg aagagtttgt gacaataatc atgaaatttt aacttaagat 1020
 ttaagtgata ta 1032

<210> 41
 <211> 942
 <212> DNA
 <213> Homo sapien

<400> 41
 gcggaagaaa aaagcaagat gggaccgcaa gctggacgtg actgtaaggg gtcattggctg 60
 cggaatccag caggggcatt ggggttgacg tgcaactcagc gccagagcttc ttcgtagttc 120
 ctacccccct tggctactat gggctggtcc ggaagggtcag gcaaggggaa gctgcgcagg 180
 cgcagtgtga gcggaacat ggcgtccagg tctaagcggc gtgccgtgga aagtgggggtt 240
 ccgcagccgc cggatcccc agtccagcgc gacgaggaag aggaaaaaga agtcgaaaat 300
 gaggatgaag acgatgatga cagtgaacag gaaaaggatg aagaggacga ggtcattgac 360
 gaggaagtga atattgaatt tgaagcttat tccctatcag ataatgatta tgacggaatt 420
 aagaaattac tgcagcagct ttttctaaag gtcctgtga aactgcaga actaacagat 480
 ctcttaattc aacagaacca tattgggagt gtgattaagg gtaccagtg tgttgaacaa 540
 attcaagagt tggttctacg cttctgtgag aagaactgtg aaaagagcat ggttgaacag 600
 ctggacaagt ttttaaataga caccaccaag cctgtgggcc ttctcctaag tgaaagattc 660
 attaatgtcc ctccacagat cgctctgccc atgtaccagc agcttcagta agagattctg 720
 ggaaaatatc tttgaacagt aatttttttt tcaaatagat tcctaaatgt catttaagta 780
 gaatatgtag atatagaaag agttctgtcc ttggtttaag tgggttttagt gtgaggggag 840
 tggaagaaac atcctgtgaa gtacatacat tattaacaac tggctttttg aagagtttgt 900

gacaataatc atgaaatttt aacttaagat ttaagtgata ta 942

<210> 42

<211> 1520

<212> DNA

<213> Homo sapien

<400> 42

cttcggccttg tggcggttcg cggttgtttg gccatccagt gccttccgca gcgccgctaa	60
agcgcagttc tcgttggtgt aactttttct ttttttttcc agccacttcc ggctcctgcg	120
tcgctccgga agcctgcgag ttccggaagc cttggtaatc cagattcggc taggaaaaga	180
caagctttcc agagaatgtt tcagagaaag ttacgtggag cgtgggcgtt tcgcagactc	240
ctaagagacc ttcagagaag acatggcttc cagaaaagag aatgcgaaga gtgcaaacag	300
agtgctaaga ataagccagt tggatgcact tgaactaaac aaggccctgg agcagctagt	360
ttgggtcccag ttactcagt gctttcatgg atttaaacct gggctgttag ctgcgtttga	420
gccagagggtg aaagcgtgct tatgggtttt cttgtggaga ttaccatct actccaaaaa	480
tgccacagtg ggacagtcag ttttgaatat taagtacaaa aatgattttt cccctaacct	540
gagatatcag ccaccagta aaaatcaaaa aatctggtat gctgtttgta caattggtgg	600
cagggtggtta gaagaacgat gctatgattt gtttcgaaac catcatttag catcatttgg	660
gaaagtcaag cagtgtgtga attttgtgat tggacttttg aaattagggtg ggctgattaa	720
ttttttgatt ttccttcaga ggggaaagtt tgcaactttg acagaacgtc tcctaggtat	780
tcattctgta ttttgcaagc ctcaaaacat acgtgaagtt ggctttgaat acatgaatag	840
ggaacttctc tggcatgggt ttgctgaatt tctgattttt ctcttaccac ttatcaatgt	900
ccagaagttg aaagccaagc tgtcttcatg gtgtattcct cttactgggtg cacctaatag	960
tgacaataca ttagccacca gtggcaaaga atgcgctcta tgtggagagt ggcccacat	1020
gcctcacacc ataggatgtg agcatatttt ctgttatttc tgtgctaaga gtagtttctt	1080
atltgacgtg tactttactt gtcctaagtg tggcacagaa gtacacagtc tgcagccact	1140
gaaatcagga atcgagatgt cagaagtaaa tgctcttttag aaactaaaat tgcttccttt	1200
gaggaaaaaa atgcaccgtg tttaaattct taatattagt catcctaagt ataccattta	1260
tgtatccttt ataaggaatg tgctcctagc cactgtcttc tcctttccag gcatgactga	1320
aatctaata ca ctggaaacca tgtgattcta aatatattat gtaaattgta atgtattatg	1380
tttttttaaat cattgcattc aatttttaat gtcaagaata atggacagct tttgtcaggt	1440
gactactaac aatgctcctt cattttacta cttcttaaaa caagggtgga ttctaaagat	1500
aaagattttg gagactctgg	1520

<210> 43
 <211> 4353
 <212> DNA
 <213> Homo sapien

<400> 43
 tacgcgcgcg cggcgtggat cgcggcccaa gccgccattg ttccgccgag ggaggacagc 60
 ggggcctggc gctggcgccg agacgccgct tagcggccgc cactggagac actccctccc 120
 gcctcccggg tctcctggcg gcggcggagt gaggtgaca gcggggaacc tgggagaccc 180
 ctccgccctc cccgcggtgg cagcggccga tccccggctc cggcgcgagg gacggccgcg 240
 atgcgctcgg cctgaggtta cccggcccgg cccttctctg cttccctcga ctattccact 300
 gcgtctccgc gccccggcgt catcctgcga gtccctctga cgggagggaa gatggctgca 360
 cggagctggc aggacgagct ggcccagcag gccgaggagg gctcggcccc gctgcgggaa 420
 atgctctcgg tcggcctagg ctttctgcgc accgagctgg gcctcgacct ggggctggag 480
 ccgaaacggg accccggctg ggtgatcctg gtgggcaactg gcgcgctcgg gctgctgctg 540
 ctgtttctgc tgggctacgg ctgggcccgc gcttgcgccg gcgcccgcaa aaagcggagg 600
 agcccgcgcc gcaagcggga ggaggcggcg gccgtgccgg ccgcgggccc cgacgacctg 660
 gccttgctga agaattctccg gagcgaggaa cagaagaaga agaaccggaa gaaactgtcc 720
 gagaagccca aaccaaattg gcggactgtt gaagtggctg aggggtgaagc tggtcgaaca 780
 cctcaaagtg taacagcaaa gcagccacca gagattgaca agaaaaatga aaagtcaaag 840
 aaaaataaga agaaatcaaa gtcagatgct aaagcagtgc aaaacagttc acgccatgat 900
 ggaaaggaag ttgatgaagg agcctgggaa actaaaatta gtcacagaga gaaacgacag 960
 cagcgtaaac gtgataaggt gctgactgat tctggttcat tggattcaac tatccctggg 1020
 atagaaaata ccatcacagt taccaccgag caacttacia ccgcatcatt tcctgttggg 1080
 tccaagaaga ataaaggtga ttctcatcta aatgttcaag ttagcaactt taaatctgga 1140
 aaaggagatt ctacacttca ggtttcttca ggattgaatg aaaacctcac tgtcaatgga 1200
 ggaggctgga atgaaaagtc tgtaaaactc tctcacaga tcagtgcagg tgaggagaag 1260
 tggaactccg tttcacctgc ttctgcagga aagaggaaaa ctgagccatc tgctgggagt 1320
 caagacactg gagatgctaa taaaaatgga aaagactggg gaaggagttg gagtgaccgt 1380
 tcaatatattt ctggcattgg gtctactgct gagccagttt ctcagtctac cacttctgat 1440
 tatcagtggg atgttagccg taatcaaccc tatatcgatg atgaatgggtc tgggttaaatt 1500
 ggtctgtctt ctgctgatcc caactctgat tggaatgcac cagcagaaga gtggggcaat 1560
 tgggtagacg aagaaagagc ttcacttcta aagtcccagg aaccaattcc tgatgatcaa 1620

aaggtctcag	atgatgataa	agaaaagggga	gagggagctc	ttccaactgg	gaaatccaaa	1680
aagaaaaaaa	agaaaaagaa	gaagcaaggt	gaagataact	ctactgcaca	ggacacagaa	1740
gaattagaaa	aagagattag	agaagacctt	ccagtgaata	cctctaaaac	ccgtccaaaa	1800
caggaaaaag	ctttttcctt	gaagaccata	agcactagt	atccagccga	agtactcgtc	1860
aaaaatagcc	agcctatcaa	gactcttcca	cctgctactt	ctaccgagcc	atctgtaatc	1920
ttatcaaaaa	gtgattctga	caagagctct	tcccaagtgc	cgccaatact	acaagagaca	1980
gataaatcca	agtcaaatac	caagcaaaat	agtggtgcctc	cttcacagac	caagtctgaa	2040
actagctggg	aatctcccaa	acaaataaaa	aagaagaaaa	aagccagacg	agaaacgtga	2100
aatttttttt	cctgaattgg	acatgtgttt	gcaaacactt	gtcttgaaga	ttatgctggt	2160
tatgcaataa	tttgtgaaca	tgtacagagt	tttatataaa	tttaaaccac	tttttaaaac	2220
aaaactgctg	acaccaccat	aaaaatggaa	tcaaaagaaa	gttaatttat	gaaattaaga	2280
ggtcagcaga	atatactcag	tgatggaaga	cacttgggaa	agtcttttta	atagaacaag	2340
aacgatctta	atttaagaat	attatcctgg	tttaacaaca	gtgccctgtt	tacaacagat	2400
tgtgccctat	ctcatctgca	gccgaggaat	aaaggattct	gattagaaag	agggttgcct	2460
acagattagt	aagcaattcc	ttggatctta	tgcacagAAC	ttgtaccatt	tgaatctggt	2520
ttatgcttaa	atcaaagtgc	tttgatcaaa	tgcataacct	gccatatctt	tacatatgtg	2580
ttggtagcaa	tttgtattaa	agaaatcaca	agtgcaaaata	aaaagtcatt	tatcatttgt	2640
ttacttaaac	tgtcatgggt	tagtttaca	tttttaaaaa	gttcttaaaa	tactgaaaat	2700
gcagttgaca	cttgtgtatg	gcttatgaag	ttatttttga	tagtcttaca	ttacttgaat	2760
tgttcaaagt	acagtatatt	ttaaattaag	aaaagtgaac	tatatgtatt	tgttttatac	2820
atttaaggct	tagactcata	aataatgcta	ttgtttatga	tttgaaaact	ttcaggcaaa	2880
atccaattta	cattttttccc	ttccctagca	attacttttt	tccagcttca	actcttctta	2940
gttactaata	ctttgttgac	tttaaaaaatg	aaatcattca	caaacttttg	gtatatgatg	3000
gagaatgaaa	aactagagtc	agacagcttt	aattgacatt	gtcaaacact	ccagttatca	3060
ggaatacatt	tttttactgc	cttaacctgt	agtgcgtaga	atatgcatca	atttcttgaa	3120
ggagattcat	gtttttataa	gaattttcat	gtaattattg	caattgtggg	caaataagga	3180
acgtttcctg	cttgaaatta	tattgattta	aatgatgtgt	gagatgtttc	accattttca	3240
ggcactgtgt	aattctattg	taataaaactg	gcaggatatc	ttgtaactat	aaatagtgcA	3300
tgctcagcca	tgtacactgt	aaatagcctt	taccaaacgt	gtttgacaag	gaccataatt	3360
aacatcactt	agtgaattgt	gataaagaaa	aaaaagccat	gatttattcg	atgtgattgg	3420
cttggtttta	tgtggcgcca	agaacgaacc	tgtttaacag	ctgtaaccaa	tggtactgat	3480

```

ctatccatcc aatgttgcca ttatatattga ctgtgggtcca acagtattgc gttgtcagac 3540
taggaaagct aaacgaacaa aatgggtttta gttttgctga agactggcct tattaatgga 3600
cagctttcct aacaagagat tattaacttt tatcaggtgt taacatctgt ttcaggaaca 3660
tggcagtatg tttacatgtc agaagttttg ttttaattcta tggatatttct aaattgactt 3720
gtttaaataa attcagcaaa tggatagcat tgttttttat ttgcttcaat atgggggtag 3780
ataatagcta aagagccaag gatgaatttc ttcaaatac tttattctgt tagctttaca 3840
taggtgttgg aggattccta aggtgtcagc attttgtaaa ggtaccacaa aggagaagtt 3900
gatagggaat ctaatttttag aatgtgcca atggtctgtg ctcaacaata taattgaact 3960
ctctcaactc tacctcacca tttctttatc tcaaaattct gttggctttg tcaaactgtg 4020
gattttatatt ctgcagccta gtatctcccc attctaccac ctatgccaga tgttaaagac 4080
agcagatggt ttgaggagaa tggcattgtg gagatgcaga gatgcgttgc taagttgagg 4140
tggatccagt atagagatac ctctatttct tctttatggc tcaagagcta ggacttggat 4200
tttgttttta gagatggcag ctggccgggt gcagtggctc acgtctgtaa tccaagctct 4260
ttgggaggcc aacgcgggag gattgtttga gccaggagt ttgaaacat cctgagcaat 4320
agagagaccc ccatctcgac aaaaaaaaaa aaa 4353

```

```

<210> 44
<211> 1616
<212> DNA
<213> Homo sapien

```

```

<400> 44
gtgatggatg cgtgggtcgcg gccgaggtac tccttagagc cagttgctgt agaactcaaa 60
tctctgctgg gcaaaagtaa gtgccaggct ctggtgctgg tagacttgctg gcgggggaag 120
ttgtcaagca cgttgttact ggtttttaac tttcatactg ctcaagtgtc ttcattctctt 180
cctcttctca gggatgttct gttcttgaag gactgtgtag gccagaagt ggagaaagcc 240
tgtgccaacc cagctgctgg gtctgtcatc ctgctggaga acctccgctt tcatgtggag 300
gaagaaggga agggaaaaga tgcttctggg aacaagggtta aagccgagcc agccaaaata 360
gaagctttcc gagcttcact ttccaagcta ggggatgtct atgtcaatga tgcttttggc 420
actgtcaca gagccacag ctccatggta ggagtcaatc tgccacagaa ggctgggtggg 480
tttttgatga agaaggagct gaactacttt gcaaaggcct tggagagccc agagcgaccc 540
ttcctggcca tcctgggcgg agctaaagtt gcagacaaga tccagctcat caataatatg 600
ctggacaaag tcaatgagat gattattggg ggtggaatgg cttttacctt ccttaagggtg 660
ctcaacaaca tggagattgg cacttctctg tttgatgaag agggagccaa gattgtcaaa 720

```



```

gacctaattgt ccaaagctga gaagaatggt gtgaagatta ccttgccctgt tgactttgtc 780
actgctgaca agtttgatga gaatgccaaag actggccaag ccactgtggc ttctggcata 840
cctgctggct ggatgggctt ggactgtggg cctgaaagca gcaagaagta tgctgaggct 900
gtcactcggg ctaagcagat tgtgtggaat ggtcctgtgg gggatatttga atgggaagct 960
tttgcccggg gaaccaaagc tctcatggat gaggtgggtga aagccacttc taggggctgc 1020
atcaccatca taggtgggtg agacactgcc acttgctgtg ccaaattggaa cacggaggat 1080
aaagtcagcc atgtgagcac tgggggtggt gccagtttgg agctcctgga aggtaaagtc 1140
cttcctgggg tggatgctct cagcaatatt tagtactttc ctgcctttta gttcctgtgc 1200
acagccccta agtcaactta gcattttctg catctccact tggcattagc taaaaccttc 1260
catgtcaaga ttcagctagt ggccaagaga tgcagtgcc a ggaaccctta aacagttgca 1320
cagcatctca gctcatcttc actgcaccct ggatttgc at acattcttca agatcccatt 1380
tgaatttttt agtgactaaa ccattgtgca ttctagagtg catatattta tattttgcct 1440
gttaaaaaga aagtgagcag tgtagctta gttctctttt gatgtagggt attatgatta 1500
gctttgtcac tgtttcacta ctcagcatgg aaacaagatg aaattccatt tgtaggtagt 1560
gagacaaaat tgatgatcca ttaagtaa ac aataaaagtg tccattgaaa ccgtga 1616

```

```

<210> 45
<211> 1217
<212> DNA
<213> Homo sapien

```

```

<400> 45
ctctcggcca atgcggagcc ccgcgcggag gtcacgtgcc tctgtttggc gcttttgtgc 60
gogcccgggt ctgttggtgc tcagagtgtg gtcaggcggc tggactgag caggactttc 120
cttatcccag ttgattgtgc agaatacact gcctgtcgt tgtcttctat tcaccatggc 180
ttcttctgat atccaggtga aagaactgga gaagcgtgcc tcaggccagg cttttgagct 240
gattctcagc cctcggc aaagaatctgt tccagaattc cccctttccc ctcaaagaa 300
gaaggatctt tccctggagg aaattcagaa gaaattagaa gctgcagaag aaagacgcaa 360
gtcccatgaa gctgaggtct tgaagcagct ggctgagaaa cgagagcacg agaaagaagt 420
gcttcagaag gcaatagaag agaacaacaa cttcagtaaa atggcagaag agaaactgac 480
ccacaaaatg gaagctaaag tgttttactc tttttctaaa gtgttggtct ttctaattga 540
gctatttttc ttgttgcatc ttttctactt cagtacactt ggtgtactgg gttaatggct 600
agtactgtat tggctctgtg aaaacatatt tgtgaaaaga gtatgtagtg gcttcttttg 660
aactgttaga tgctgaatat ctgttcactt ttcaatccca attctgtccc aatcttacca 720

```

44

```

gatgctactg gacttgaatg gttaataaaa ctgcacagtg ctggttggtgg cagtgacttc      780
ttttgagtta ggtaataaaa tcaagccata gagccctcc tggttgatac ttgttccaga      840
tggggccttt ggggctggta gaaataccca acgcacaaat gaccgcacgt totctgcccc      900
gtttcttgcc ccagtgtggt ttgcattgtc tccttccaca atgactgctt tgtttggatg      960
cctcagccca ggtcagctgt tactttcttt cagatgttta tttgcaaaca accatttttt    1020
gttctgtgtc ccttttaaaa ggcagattaa aagcacaagc gtgtttctag agaacagttg    1080
agagagaatc tcaagattct acttggtggt ttgcttgctc tacgttacag gtggggcatg    1140
tcctcatcct ttctgcat aaaagctatg acacgagaat cagaatatta ataaaacttt    1200
atgtactgct gtagcaa                                           1217

```

```

<210> 46
<211> 376
<212> DNA
<213> Homo sapien

```

```

<400> 46
gtcagggagg ctaatggttg ctctgctgaa tgtttctggg gtgtgaagag cttggagtca      60
gccttgaagg acctcaagat caaatgacct gtgaggaata tgttgccctc atcctagctg    120
ctggggaagc ggggagaggg gtcagggagg ctaatggttg ctttctgtaa tgtttctggg    180
gtaccaatac gagttcccat aggggctgct ccctcaaaaa gggagggggac agatggggag    240
cttttcttac ctattcaagg aatacgtgcc tttttcttaa atgctttcat ttattgaaaa    300
aaaaaaaaat gccccaaaag cactatgctg gtcatgaact gcttcaaaat gtggaggtaa    360
taaaatgcaa ctgtgt                                           376

```

```

<210> 47
<211> 1476
<212> DNA
<213> Homo sapien

```

```

<400> 47
ggcaggcccc gcccccgcc cagcaggaag tggctgctgc tccggcgcgagg agcccagagc      60
cggttcggcg cgtcgactgc ccagagtcgg cgcccggggc gcgggaggag ccaagccgcc    120
atggcctacc acagcttcct ggtggagccc atcagctgcc acgcctggaa caaggaccgc    180
accagattg ccatctgccc caacaacat gaggtgcata totatgaaaa gagcgggtgcc    240
aaatggacca aggtgcacga gctcaaggag cacaacgggc aggtgacagg catcgactgg    300
gccccgaga gtaaccgtat tgtgacctgc ggcacagacc gcaacgccta cgtgtggacg    360
ctgaaggggc gcacatggaa gccacgctg gtcacctgc ggatcaaccg ggctgcccgc    420

```

45

tgcgtgcgct	gggcccccaa	cgagaacaag	tttgcgtgtgg	gcagcggctc	tgcgtgtgatc	480
tccatctgtt	atttcgagca	ggagaatgac	tggtggggttt	gcaagcacat	caagaagccc	540
atccgctcca	cgcctcctcag	cctggactgg	caccccaaca	atgtgctgct	ggctgccggc	600
tcctgtgact	tcaagtgtcg	gatcttttca	gcctacatca	aggaggtgga	ggaacggccg	660
gcacccaccc	cgtggggctc	caagatgccc	tttggggaac	tgatgttcga	atccagcagt	720
agctgcgggt	gggtacatgg	cgtctgtttc	tcagccagcg	ggagccgcgt	ggcctcgtcg	780
cgactctggc	ctctgaaaca	ctaccactgc	tggcgctgac	cttcatcaca	gacaacagcc	840
tggtggcagc	gggccacgac	tgcttcccgg	tgctgttcac	ctatgacgcc	gccgcgggga	900
tgctgagctt	cggcggggcg	ctggacgttc	ctaagcagag	ctcgcagcgt	ggcttgacgg	960
cccgcgagcg	cttcagaac	ctggacaaga	aggcgagctc	cgaggggtggc	acggctgcgg	1020
gcgcggggct	agactcgctg	cacaagaaca	gcgtcagcca	gatctcgggtg	ctcagcggcg	1080
gcaaggccaa	gtgctcgag	ttctgcacca	ctggcatgga	tggcggcatg	agtatctggg	1140
atgtgaagag	cttgaggtca	gccttgaagg	acctcaagat	caaatgacct	gtgaggaata	1200
tgttgccttc	atcctagctg	ctggggaagc	ggggagaggg	gtcagggagg	ctaattggtt	1260
ctttgctgaa	tgtttctggg	gtaccaatac	gagttcccat	aggggctgct	ccctcaaaaa	1320
gggaggggac	agatggggag	cttttcttac	ctattcaagg	aatacgtgcc	tttttcttaa	1380
atgctttcat	ttattgaaaa	aaaaaaaaat	gcccccaaag	cactatgctg	gtcatgaact	1440
gcttcaaaat	gtggaggtaa	taaaatgcaa	ctgtgt			1476

<210> 48

<211> 3431

<212> DNA

<213> Homo sapien

<400> 48

cctccttttt	tataccttcc	cgaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aactctcaaa	60
ttgaagggga	ctgtaagaag	ataggggtcag	ctcagctgca	gtaagatata	agtctcagga	120
agaagcatgc	tctggagtca	aggcagagaa	ggacattcta	ggccaaagaa	atggctgtgc	180
aaaggtagga	ggcataggga	caagggttat	tattacaact	gtacctctta	aatttacaca	240
ataattgttg	agaatatggc	ttttccaggc	taggaagttg	tgctgcatcc	aaaaatgcta	300
aagtctattt	cagccgggag	aacactgaca	gctgggaaag	gaccacacgt	ggcgtgcccc	360
taacctaaagt	tgttcagatt	taggaagtga	ccccagtaag	tcctttcggga	gtttcgtgta	420
agattgactt	cttcagctgg	gagccactgc	gcccggcctc	atctcacatc	tttcttcttc	480
tgcagcacac	gacacgccct	agttggaaac	aaagtcggag	tttgtggatt	gggggaaggg	540

cggggtctaa	cctcaggtca	ggcgccgtgc	aaggtacatc	ttggcaccgc	gaagaggccc	600
agtacagttg	cccccgaggt	gacccgacct	cccctaccaa	ttgaggcgcc	cttgttgcca	660
ggcttgcggc	gggggagcgg	cgggggagcg	acggggatgc	gctcattggt	caaggaaggg	720
gcgcctgtta	ctagaggcga	gaaccggagc	ccattggtcg	gaacacctca	caatggaccc	780
cagcggcgcg	caaaatcctt	atgattgggt	tgctggctgc	ctcgggagac	cctgttgcca	840
ggatacttgg	cgttcccgac	ccgacccccg	ttccccattg	gctgtcaggg	caaaagccgc	900
catctaata	ggagcgaggt	gcggtgcccc	gaagcgctcg	cttcccgcg	tgcatctag	960
tcctgcagta	ggcgccccgg	ggccacaccg	cgcccgccca	agccagtgc	aggcccaggg	1020
gcctgacatc	gctcccagcg	ctcgaggacc	gaggcctgct	gtggaggaca	ccgtgctccc	1080
tcgggacctg	ctctggattc	cgccccggac	gtccccttgg	agctctgcat	ctccaacctg	1140
gaacccaacc	cagaagtctc	aagtttgacg	catcacgtgg	cgtgcggatc	cactgagggg	1200
ccacagagag	gggcgccccat	ctcctgcgtc	tcagttatcc	tggtgttggg	aattctgtgc	1260
cctaaagaat	tccgactcag	atccgaacgg	ggatctgggtg	gaatcgaggg	tgaaagacca	1320
gagggacaat	gttctactat	cccaacgtgc	ttcagcgcca	caccggctgc	tttgccacca	1380
tctggctggc	ggcgactcgc	ggcagccggt	tggtgaagcg	cgaataacctg	aggggtgaatg	1440
tggtgaaaac	ctgcgaggaa	atcctcaatt	acgtgctggg	acgagtgc	ccccgcagc	1500
ccggcctgcc	gcgccccgc	ttctccctct	atctctcagc	ccaacttcag	atcgggtgtga	1560
tcgcgtcta	ttctcaacaa	tgccagtacc	tcgtggagga	catccagcac	atcttgagc	1620
gcctccaccg	tgcccagctg	cagatccgaa	tagatatgga	gactgagcta	cccagcctgc	1680
tgcttcctaa	ccacctggcc	atgatggaga	ccotagaaga	tgctccagat	cccttttttg	1740
ggatgatgtc	tgtggatccc	agacttccta	gtcctttcga	tatccctcag	attcgacacc	1800
tcttagaggc	tgcaatccca	gagagagttg	aagagatccc	tcctgaagtt	cctacagagc	1860
ccagggagcc	agagaggatt	ccggtcactg	tgctgccacc	tgaggccatc	acgatcctgg	1920
aggcagagcc	catacggatg	ctggagattg	aggggtgaacg	ggagctccca	gaggtcagcc	1980
gccgagaact	ggacctgctg	atcgagaggg	aagaagaagc	tatcttggtta	gaaatccgc	2040
ggctcccacc	tccagctcct	gcagaggtgg	aagggaatagg	agaggcactg	ggctcctgagg	2100
agctgaggct	gacaggctgg	gaacctgggg	ccctactcat	ggagggtgacc	cccccgagg	2160
agctgcgtct	gccagcccca	cccagcccag	agaggaggcc	cccagtcccc	ccacctctc	2220
gccgcgcgcg	tcgtcgccgg	ttactgttct	gggacaagga	gactcagatc	ttcccggaga	2280
aattccagga	acaactgcaa	accagagccc	actgctggga	atgtcctatg	gtgcagccgc	2340
ccgagaggac	catcagaggc	cctgcggagt	tggtcagaac	occaaactctc	tgtaagaatg	2400

gtggggggttg ggcacgaagt atcctcaaaa ccaattcctc attcctgggtg ctccctcacgc 2460
 ctcaaaccct gtgcctacta ccctcttgct cacagctggc tggctacccc ctgaactact 2520
 gggctctctgg acccattgtg cccagccacc cccaaaagcc ctcaggcgag agctgcctga 2580
 ggaggcgagcc gctgaggagg aaaggagaaa gattgaagtt ccaagtgaga ttgagggtccc 2640
 gagggaggcc ctggagccca gtgttccct tatgggtgtct ttagagatct ccctagaggc 2700
 agctgaagag gagaagtccc gcatcagcct catcccacca gaagaacggg gggcctggcc 2760
 tgagggtggag gcgccagaag ctccctgcatt gcccggtgtg cctgaactcc ctgagggtgcc 2820
 catggagatg cctttgggtg tgccccaga gctcgagctg ctctcactgg aagcagtgc 2880
 cagggcagtg gcactggagc tgcaggctaa caggggagccc gacttcagca gcctgggtgtc 2940
 acctctcagc ccccgagga tggctgccc ggtcttctac ctgctcctgg tgctctcagc 3000
 gcaacagatt cttcacgtga aacaagaaaa gccatatggc cgctcctga tccagccggg 3060
 gccagattc cactgagggt agagtccatt tacaaaagctg ccaggaaacc ggccacttct 3120
 agtaaaccac gtcgtgcctc actgggtcct gcttacctca tttctgaatg tgcatttcca 3180
 gccttcttgc tctcagagct attgttcaag cagaaaacaa gctgctttta ttacagtaaa 3240
 aaaaaaaga aaaagccccg gggaacacac actatacggg gtggcgga aaagagggtc 3300
 atgaactggg cccctgggca catcacggg tccccggacc cacgttttgt ggaccaaggg 3360
 ggaactctcc gcggaacccc aaaaggagc gaataaccga ataaccagg accctgatat 3420
 gaactcgga a 3431

<210> 49
 <211> 2283
 <212> DNA
 <213> Homo sapien

<400> 49
 tttttttttt ttttgagaca gagtctcatt ctattgcctg ggctggagca cagtggcgag 60
 atctcggtc accacaacct ccacctcca ggttcaagt attctcctgc ctcagcctcc 120
 tgagtacctg ggactacagg cgtgagccac catgcccggc taatttttgt attttttagta 180
 gagacggggt ttactatgt tggccaggct ggtcttgaac tctgacctc gtgatccgc 240
 tgcttggcc tcccaaagt cgggattac aggcgtgagc cactgtgcc agccggcagg 300
 cttttattaa gcgttagatg ggaggataga ggagtgaagt ggtactggca ggaagtacca 360
 aggttccagc tggcgtaatc aggaaggct catggaggaa gcagcctttg agctgcctgt 420
 ggagtgggtg gcagggtgtt gtgaagtggc aatcactgga ttttgcttct ggtacgaggt 480
 gtggccagat gcaagaaaga gcagggtgga ctttgggtgca attgggtggg gtctgggtctg 540

taggggttccc	gtgggggagcc	gtggaggggag	gcagcaaagg	agggagggggc	acagaggatg	600
ctggactgtg	tttaagaggc	agcaggggagc	catggcaggt	gcttgaggag	aagcgagtga	660
tgtgttttaa	gcagcccttt	caggaggctc	aggctcacag	caggatgtgc	acagtagccc	720
tgtcttgagc	taaagcagat	gaagggtttg	ccctctgcac	ttccccacgt	gagaaacgaa	780
gatgcacccg	cagattcctt	gaggcagctc	ccccacttct	cagttgccag	aaatcagccc	840
agagaaacaa	acccgtaatc	agcccagggt	gctttccctt	ccctttctcg	agggggctgc	900
tggttcgcac	ataaggagtg	gtcactccc	gcttgggaga	aagcagcaga	attccttcac	960
agccaggtaa	gatgtgccag	tggtcgatgg	atgaaatcta	gccggggagt	tggaatctgt	1020
gttgccagca	gtgacctgtg	agcagtgaca	aagccaaagg	tacaagaaga	acttgaaggc	1080
cctctacgtg	gtgcaccca	ccagcttcat	caaggctcctg	tggaacatct	tgaagccct	1140
catcagtcac	aagtttgga	agaaagtcac	ctatttcaac	tacctgagtg	agctccacga	1200
acaccttaaa	tacgaccagc	tggtcatccc	tcccgaagtt	ttgcggtacg	atgagaagct	1260
ccagagcctg	cacgagggcc	ggacgccgcc	ttccaccaag	acaccaccgc	cgcgggcccc	1320
gctgcccaca	cagcagtttg	gcgtcagtct	gcaatacctc	aaagacaaaa	atcaaggcga	1380
actcatcccc	cctgtgctga	ggttcacagt	gacgtacctg	agagagaaaag	gcctgcgcac	1440
cgagggcctg	ttccggagat	ccgccagcgt	gcagaccgtc	cgcgagatcc	agaggctcta	1500
caaccaaggg	aagcccgtga	actttgacga	ctacggggac	attcacatcc	ctgccgtgat	1560
cctgaagacc	ttcctgcgag	agctgcccc	gcogetctctg	accttccagg	cctacgagca	1620
gattctcggg	atcacctgtg	tggagagcag	cctgogtgtc	actggctgcc	gccagatctt	1680
acggagcctc	ccagagcaca	actacgtcgt	cctccgctac	ctcatgggct	tcctgcatgc	1740
gggtgtcccg	gagagcatct	tcaacaaaat	gaacagctct	aacctggcct	gtgtcttcgg	1800
gctgaatttg	atctggccat	cccaggggggt	ctcctccctg	agtgcccttg	tgccccgtgaa	1860
catgttcact	gaactgctga	tcgagtacta	tgaaaagatc	ttcagcacc	cggaggcacc	1920
tggggagcac	ggcctggcac	catgggaaca	ggggagcagg	gcagcccctt	tgaggaggc	1980
tgtgccacgg	acacaagcca	cgggcctcac	caagcctacc	ctacctccga	gtcccctgat	2040
ggcagccaga	agacgtctct	agtgttgcca	acactctgta	tatttcgagc	tacctccac	2100
acctgtctgt	gcacttgat	gttttgtaaa	cttggcatct	gtaaaaataa	ccagccatta	2160
gatgaattca	gaaccttcta	atgaaaactc	catgcctctg	gtccttggac	tcttgtccat	2220
ggttcctgag	ctgtggaccg	ggatagaata	atgcatttgt	taggatggat	gttttgatcc	2280
caa						2283

<210> 50
 <211> 985
 <212> DNA
 <213> Homo sapien

<400> 50
 atttgaggaa caaataaatg tgtggaggcc agccacaggt gggatgatgcc atgggcaggg 60
 gagtgtcata taatgtcctg gaagcccttt gggctgggac ctgtgagatg cctggaagct 120
 cctctcctgc aggcctgcgc accgagggcc tgttcggag atccgccagc gtgcagaccg 180
 tccgcgagat ccagaggctc tacaaccaag ggaagccgt gaactttgac gactacgggg 240
 acattcacat ccctgccgtg atcctgaaga ccttcctgcg agagctgccc cagccgcttc 300
 tgaccttcca ggcctacgag cagattctcg ggatcacctg tgtggagagc agcctgcgtg 360
 tcaactggctg ccgccagatc ttacggagcc tcccagagca caactacgtc gtccctccgt 420
 acctcatggg cttcctgcat gcggtgtccc gggagagcat cttcaacaaa atgaacagct 480
 ctaacctggc ctgtgtcttc gggctgaatt tgatctggcc atcccagggg gtctcctccc 540
 tgagtgccct tgtgcccctg aacatgttca ctgaactgct gatcgagtac tatgaaaaga 600
 tottcagcac ccggaggca cctggggagc acggcctggc accatgggaa caggggagca 660
 gggcagcccc tttgcaggag gctgtgccac ggacacaagc cacgggcctc accaagccta 720
 ccctacctcc gagtcccctg atggcagcca gaagacgtct ctagtgttgc gaacactctg 780
 tatatttcga gctacctccc acacctgtct gtgcacttgt atgttttgta aacttggcat 840
 ctgtaaaaaat aaccagccat tagatgaatt cagaaccttc taatgaaaac tccatgcctc 900
 tggtccttgg actcttgtcc atggttcctg agctgtggac cgggatagaa taatgcattt 960
 gttaggatgg atgttttgat cccaa 985

<210> 51
 <211> 1815
 <212> DNA
 <213> Homo sapien

<400> 51
 ggggggagag cggctgggac gggatgggat tcttctcacg ggcacgctc tgtgggaggga 60
 gtggggaggag ctgccggggt cagttggtcc aagtgtcccg gcctgagggtg tcggccggat 120
 ccctccttct cccggcgct caagcggaag accattcctc aagaattttg tatccaaggc 180
 ccaaaagtgtt gttaccaag atgatgaatg ctgacatgga tgatctctct gcaagagtag 240
 atgcagttaa ggaagaaaat ctgaagctaa aatcagaaaa ccaagttctt ggacaatata 300
 tagaaaatct catgtcagct tctagtgttt ttcaaacaac tgacacaaaa agcaaaagaa 360
 agtaagggat tgacaccctt ctgttttatg gaattgctgc tgatcatttt ttcttttaaaa 420

```

cttggataga ttccaaaagt tacagtacct ttgtggcttc attgaatatt tatgaagata      480
atgtcagatg tagacaaaaa taacacaata acaggagact tccataagtt tgtgtattat      540
gttagtctat gaaaacgtgc aaatgtattg tagagacttt atgattagaa ttgcatatat      600
ttatgaaact taaagatgaa tgttttattg aatttgtagg tttagcactg tcttttatta      660
taggattagt aagatataca agaaaataac caccgtgttg tgaaaaagtg accaaaatca      720
tgtactaaat gcacagcttt atgtaccctg tccaccatct tgtgcctctt ctccatttgc      780
ctcttccttc ctatttccct tccgctaagg aaaaaaattg gtgtcacatt tgtaaaagta      840
attttaatag ttaatcatct ctgagagtaa cctgtatttt aattgttgaa acttaaccaa      900
aataagatac tgtctcagct agggcttgtc atttgtgtat ttagtgtaa gataggaatg      960
ctagtgtctc ttttaattaat tggaaataga tggaggctaa aaatgaagggt ttttctttga    1020
aactgaatta acttgggaat atttgttgtt aaaaacttct ttttgcccaa aataactcat    1080
tttgtattat ctgaaaatat ataatttctg gtcatgtgta tgttaaaata gaaaattttg    1140
aggaaaaatg gaaataggggt ggaaaagtac tcggtaaaca gtagtaacca aatattttca    1200
ctccagattt gtgttttctc tggcacagag tagatctttt gggaaatata tatgaaagtg    1260
gattaagttt gactaccctt atgttagcca catctggatg agaacagtta caaagagttt    1320
ggctctotaag ttgatttgta ccagtggggt caacttctgc aaaattccgt aatgggtgat    1380
tagtattaga atagtgaata aaatgggaaa gttatacatg tatacttatt atcttgctca    1440
gtattttatc tcacttggtc tagaattttc tgtaaaccct gctactgggt ttgaagagtt    1500
ttagtcatcc ttaacaatt ttaaaaaatt tagcttctag attccatttg gtaaggaaat    1560
caatattgga agtattgcta aaatcttata atatgaaaag agatccacta atgtagctta    1620
aggttattag atttgggctt ttaatcatgg aataatctta tgtattgggtg taagagttga    1680
tgaatgactt tagctgtgtg aatatataat agtcaaaactg caaacatttt gcaccccttt    1740
tgtgacctaa ttacagaca tttaaattgt gttgcagttc tgctttgccg ttttaataaaa    1800
agctatttca gaggt                                     1815

```

```

<210> 52
<211> 1298
<212> DNA
<213> Homo sapien

```

```

<400> 52
aatagcgacc actataggga atttagccct gagcagtaat tcggcacgag gggacgaagg      60
ggtagttctt tcacctcggc tgggcgccta gaaaagccta gaaacagctc cttttttctt    120
ccgcctccga gtcttcgcgt cagcgtcctg cgcagggccc ttggggcgaa tcgcggtgcg    180

```



```

cgtcggggcg accgccctcc ctccctggga ggggcgaggg ggctagcggc gacggctggg 240
gcgagcgcg ctcgcgcgtg ggtgattttt tcacgtgtcg ccagggccgg actgcgagtc 300
tctttgcggc gctacactag agcagagtac gagtctgagg cggagggagt aatgggtgag 360
tcccgcgtag ccccgaggcc tgcaggcccg ggctgtctg aggcgtacgg ggatccctga 420
cgccctctt ttgttgggct gggcgggagg gattggtggc cactcagtga ccagcgccc 480
atggcacctt ggagcggcaa ggcccggccg acccttttct ccccagggc tctttgcacg 540
cgcggtgtgt gccggtgtgt aaggcagggg ggcgagaacc cgggcgcacg cgcagcgtct 600
cacctgcttc tgcagggcct ttgtggatgt gtaatatctt gggtaaaaat catggtgcca 660
ggcagggagc ttgaccagc gtttcctgaa aatttctgga aaaacctgaa gaaggaaaac 720
atttgacctt ggaataaact aagggtgacc ttaaagctgg tctgggtgct caccggagga 780
gcgacaacga cccctaacag acgcaggaca agcgtttaga aagtttcttc cactctttga 840
ccgagtattg gttgaaagga gtgctgctga aactgtaacc aaaggaggca ttatgcttcc 900
agaaaaatct caaggaaaag tattgcaagc aacagtagtc gctgttggat cgggttctaa 960
aggaaagggg ggagagattc aaccagttag cgtgaaagtt ggagataaag ttcttctccc 1020
agaatatgga ggcaccaaag tagttctaga tgacaaggat tatttcctat ttagagatgg 1080
tgacattctt ggaaagtacg tagactgaaa taagtacta ttgaaatggc atcaacatga 1140
tgctgcccac tccactgaag ttctgaaatc ttctgtcatg taaataattt ccatatttct 1200
cttttataat aaactaatga taactaatga catccagtgt ctccaaaatt gtttccttgt 1260
actgatataa acacttccaa ataaaaatat gtaaatga 1298

```

```

<210> 53
<211> 1566
<212> DNA
<213> Homo sapien

```

```

<400> 53
aatagcgacc actataggga atttagccct gagcagtaat tcggcacgag gggacgaagg 60
ggtagttctt tcacctcggc tgggcgccta gaaaagccta gaaacagctc cttttttctt 120
ccgcctccga gtcttcgctg cagcgtcctg cgcagggccc ttggggcgaa tcgcggtgcg 180
cgtcggggcg accgccctcc ctccctggga ggggcgaggg ggctagcggc gacggctggg 240
gcgagcgcg ctcgcgcgtg ggtgattttt tcacgtgtcg ccagggccgg actgcgagtc 300
tctttgcggc gctacactag agcagagtac gagtctgagg cggagggagt aatgggtgag 360
tcccgcgtag ccccgaggcc tgcaggcccg ggctgtctg aggcgtacgg ggatccctga 420
cgccctctt ttgttgggct gggcgggagg gattggtggc cactcagtga ccagcgccc 480

```

```

atggcacctt ggagcggcaa ggcccggccg acccttttct ccccagggc tctttgcaag 540
cgcgtgtgct gccggtgtgt aaggcagggg ggcgagaacc cgggcgcacg cgcagcgtct 600
cacctgcttc tgcagggcct ttgtggatgt gtaatatctt gggtaaaaat catggtgcca 660
ggcagggagc ttgacccagc gtttctgaa aatttctgga aaaacctgaa gaaggaaaac 720
at ttgacctt ggaataaact aaggttgacc ttaaagctgg tctggttgct caccggagga 780
gcgacaacga ccctaacag acgtaaggaa tcgggaatta aacttggaaat attgggttag 840
tacattcaaa tgcgcttcct taacgaataa gctgaggttt ggtgttaact ttcaaagcca 900
aaacgtgttg agatgtatag cacgggtggcg ttgcctgttg ataatgtgat tacatttagt 960
ttttgtttca aaacatttct ctctctacag gcaggacaag cgttttagaaa gtttcttcca 1020
ctctttgacc gagtattggt tgaaaggagt gctgctgaaa ctgtaaccaa aggaggcatt 1080
atgcttccag aaaaatctca aggaaaagta ttgcaagcaa cagtagtcgc tggtggatcg 1140
ggttctaaag gaaaggttg agagattcaa ccagttagcg tgaaagttgg agataaagtt 1200
cttctcccag aatatggagg caccaaagta gttctagatg acaaggtgtg taaacttaat 1260
aattctaaaa agaagtcaga tatttgcaat tagttgtctt aactaatggg ttttttcaact 1320
tgcaggatta tttctatatt agagatggtg acattcttgg aaagtacgta gactgaaata 1380
agtcactatt gaaatggcat caacatgatg ctgccattc cactgaagtt ctgaaatctt 1440
tcgtcatgta aataatttcc atatttctct ttataataa actaatgata actaatgaca 1500
tccagtgtct ccaaaattgt ttcttgtac tgatataaac acttccaaat aaaaatatgt 1560
aatga 1566

```

<210> 54

<211> 630

<212> DNA

<213> Homo sapien

<400> 54

```

aggactgatg ttgtaagtac tctagagaga tctcttctga ctgcacccgc tggacagcca 60
ggccagcaac aatgcccacg atggggatgg tggactggga agatggctcc catctcaggg 120
tgaggggctt cggcagcccc tcatgctgta catggcatgt gtatctctgc tcttctccag 180
aaggcaccac cacagctgcc caattctgga aggttctatc tctgctggt ctggtctcca 240
caagctcagt gtctgagtt tggctctcgc catcccgctg ccaggtcagt gtgatctccg 300
cagggtagaa gcccagggcc cagcacctca gggcggcctc atggtcagag acgggggtgg 360
gggtcacgtg tgtctttggg gggcggcgc gctgcagcgt ctcttcccg ttctccaggt 420
atctgcggag ccactccacg cacgtgccct ccaggtaggc tctcacctgc tccgccacac 480

```

53

gggcgcctc ccacttgccg tgggtgatct gagccgcggt gtccgcccgc gtccaggagc 540
gcaggtcctc gttcagggcg atgtaatcct tgccgtcgta ggcgactgg ttatgcccgc 600
ggaggaggcg cccgtccggc cccacgtcgc 630

<210> 55
<211> 714
<212> DNA
<213> Homo sapien

<400> 55
tgcattgctc agcggcgctg tgtgatggat gcgtggctgc ggccgaaatc agtacgctga 60
ggggccaagt gggaggccag gtcagtgtgg aggtggattc cgctccgggc accgatctcg 120
ccaagatcct gagtgcacat cgaagccaat atgaggtcat ggccgagcag aaccggaagg 180
atgctgaagc ctggttcacc agccggactg aagaattgaa ccgggaggtc gctggccaca 240
cggagcagct ccagatgagc aggtccgagg ttactgacct gggcgccacc cttcagggtc 300
ttgagattga gctgcagtca cagctgagca tgaaagctgc cttggaagac aactggcag 360
aaacggaggc gcgctttgga gccagctgg cgcatatcca ggcgctgac agcggattg 420
aagcccagct gggcgatgtg cgagctgata gtgagcggca gaatcaggag taccagcggc 480
tcatggacat caagtcgagg ctggagcagg agattgccac ctaccgcagc ctgctcgagg 540
gacaggaaga tcactacaac aatttgtctg cctccaaggc cctctgaggc agcaggctct 600
ggggcttctg ctgtcctttg gaggtgtct tctgggtaga gggatgggaa ggaagggacc 660
cttaccoccg gctcttctcc tgacctgcca ataaaaattt atggtccaag ggag 714

<210> 56
<211> 950
<212> DNA
<213> Homo sapien

<400> 56
agatatccgc ccctgacacc attcctccct tccccctcc accggccgcg ggcataaaag 60
gcgccagggt agggcctcgc cgctcctccc gcgaatcgca gcttctgaga ccacttctga 120
gaccagggtt gctccgtccg tgctccgcct cgccatgact tcctacagct atcgccagtc 180
gtcggccacg tcgtccttcg gaggcctggg cggcggtcc gtgcgttttg ggccgggggt 240
cgcttttcgc gcgccagca ttcacggggg ctccggcggc cggcggtat ccgtgtcctc 300
cgcccgcttt gtgtcctcgt cctcctcggg gggctacggc ggcggtacg gcggcgtcct 360
gaccgcgtcc gacgggctgc tggcgggcaa cgagaagcta accatgcaga acctcaacga 420
ccgcctggcc tcctacctgg acaagggtgc cgccctggag gggccaacg gcgagctaga 480

54

```

ggatgaagatc cgcgactggt accagaagca ggggcctggg ccctcccgcg actacagcca 540
ctactacacg accatccagg acctgcggga caagattctt ggtgccacca ttgagaactc 600
caggattgtc ctgcagatcg acaacgcccc tctggctgca gatgacttcc gaaccaagtt 660
tgagacggaa caggctctgc gcatgagcgt ggaggccgac atcaacggcc tgcgcagggt 720
gctggatgag ctgaccctgg ccaggaccga cctggagatg cagatcgaag gcctgaagga 780
agagctggcc tacctgaaga agaaccatga ggaggaaatc agtacgctga ggtggggggcc 840
acaaaggggtg ggggggaacg gggggccaag ggttccaagg tgttgagcgg tggatccgct 900
cgggcacgat ctgcgagatc tgagtgcacat gcgagcatat gagtcatgcg 950

```

```

<210> 57
<211> 280
<212> DNA
<213> Homo sapien

```

```

<400> 57
tgtcgagcgg cgcagtggtga tggatcggcc gcccgggcag ggcggtcat ggacatcaag 60
tcgcggctgg agcaggagat tgccacctac cgcagcctgc tcgagggaca ggaagatcac 120
tacaacaatt tgtctgcctc caaggtcctc tgaggcagca ggctctgggg cttctgctgt 180
cctttggagg gtgtcttctg ggtagaggga tgggaaggaa gggaccctta ccccggtc 240
ttctcctgac ctgccaataa aaatttatgg tccaaggagg 280

```

```

<210> 58
<211> 294
<212> DNA
<213> Homo sapien

```

```

<400> 58
gcggccgcct actactacta ctgctcgaat tcaagcttct aacgatgtac ggggagcggc 60
tcatggacat caagtcgcgg ctggagcagg agattgccac ctaccgcagc ctgctcgagg 120
gacaggaaga tcactacaac aatttgtctg cctccaaggc cctctgaggc agcaggctct 180
ggggcttctg ctgtcctttg gaggtgtct tctgggtaga gggatgggaa ggaagggacc 240
cttaccocccg gctcttctcc tgacctgcca ataaaaattt atggtccaag ggag 294

```

```

<210> 59
<211> 1028
<212> DNA
<213> Homo sapien

```

```

<400> 59
aaacctaggg taggtmgagg ckgggtgtgaa tcggcmgagg gcagcttctg agaccagggt 60
tgctccgtcc gtgctccgcc tcgcatgac ttctacagc tatcgccagt cgtcgccac 120

```

55

```

gtcgtccttc ggaggcctgg gcggcggtc cgtgcgtttt gggcggggg tcgcttttcg 180
cgcgccagc attcacggg gctccggcg ccgcggcgta tccgtgtcct ccgcccgctt 240
tgtgtcctcg tcctcctcgg ggggctacgg cggcggtac ggcggcgctc tgaccgcgtc 300
cgacgggctg ctggcgggca acgagaagct aaccatgcag aacctcaacg accgcctggc 360
ctcctacctg gacaaggtgc gcgccctgga ggcggccaac ggcgagctag aggtgaagat 420
ccgcgactgg taccagaagc aggggcctgg gccctccgc gactacagcc actactacac 480
gaccatccag gacctgcggg acaagattct tgggtgccacc attgagaact ccaggattgt 540
cctgcagatc gacaacgcc gtctgggtgc agatgacttc cgaaccaagt ttgagacgga 600
acaggctctg cgcattgagc tggaggccga catcaacggc ctgcgcaggg tgctggatga 660
gctgacctg gccaggaccg acctggagat gcagatcgaa ggcctgaagg aagagctggc 720
ctacctgaag aagaacattg aggaggaaat cagtacgctg aggggccaag tgggaggcca 780
ggtcagtgtg gaggtggatt ccgctccggg caccgatctc gccaatatcc tgagtacat 840
gcgaagccaa tatgaggtca tggccgagca gaaccggaag gatgctgaag cctggttcac 900
cagccggctg aaaattgacg ggrgcstgc ccacgrgrag ccraamacg scmggwatgr 960
crgggcccc aggttaagag gggcacatag agctgtaaca ccaaagggg ttgccagcat 1020
acgccgga 1028

```

```

<210> 60
<211> 1389
<212> DNA
<213> Homo sapien

```

```

<400> 60
agtttcatg cacacaggtc tcagagattt cctccccagg cttgccttcc tgccctcccc 60
caccgaagtc cccctggctc cagttttctt cctgccccag cttctgggca tggactgttt 120
gcaaggcctc ccagagagcg ggccaatggg cggcagatgc tggctagggc tttggtctct 180
aggggtgccg ggtatattca tttgctcccc tctctcttct ggggaagaaag tgagtgggca 240
gtgccttgtg gttgaactgg taccaacctc tgctctgcc ttccagatat tcttggtgcc 300
accattgaga actccaggat tgtcctgcag atcgacaacg ccgctctggc tgcagatgac 360
ttccgaacca agtgagtgtc tctgtcctgg ggcctgcaga agccaggact ggggtagggg 420
ttgggggggt tagaatctgc cctcacctag cctagatggc ctgaagctaa cccccctatg 480
gactcctgaa ctctggggag gtagggaagt cttcagagat gctgaggaag ctctgcctgg 540
ctgcaactat ttcctttgaa aggtttgaga cggaacaggc tctgcgcatg agcgtggagg 600
ccgacatcaa cggcctgcgc aggggtgctg atgagctgac cctggccagg accgacctgg 660

```

56

```

agatgcagat cgaaggcctg aaggaagagc tggcctacct gaagaagaac catgaggagg 720
aatcagtag gctgaggggc caagtgggag gccaggctcag tgtggagggtg gattccgctc 780
cgggcaccga tctcgccaag atcctgagtg acatgcgaag ccaatatgag gtcattggccg 840
agcagaaccg gaaggatgct gaagcctggt tcaccagccg gactgaagaa ttgaaccggg 900
aggctcgtgg ccacacggag cagctccaga tgagcagggtc cgaggttact gacctgcggc 960
gcacccttca ggggtcttgag attgagctgc agtcacagct gagcatgaaa gctgccttgg 1020
aagacacact ggcagaaacg gaggcgcgct ttggagccca gctggcgcag atccaggcgc 1080
tgatcagcgg tattgaagcc cagctgggag atgtgcgagc tgatagttag cggcagaatc 1140
aggagtacca gcggctcatg gacatcaagt cgcggctgga gcaggagatt gccacctacc 1200
gcagcctgct cgagggacag gaagatcact acaacaattt gtctgcctcc aaggctcctc 1260
gaggcagcag gctctggggc ttctgctgtc ctttggagggt tgtcttcttg gtagagggat 1320
gggaaggaag ggacccttac ccccggtctc tctcctgacc tgccaataaa aatttatggt 1380
ccaagggag 1389

```

```

<210> 61
<211> 1042
<212> DNA
<213> Homo sapien

```

```

<400> 61
gaaaacggga aagtcctctc ctctaacctg gcactgcgtc gctggcttgg agacaggatga 60
cggctccctgc gggccttgtc ctgattggct gggcacgcgt ttaatataag tggaggygtc 120
gcgctggcgg gcattcctga agctgacagc attcgggccc agatgtctcg ctccgtggcc 180
ttagctgtgc tcgcgtact ctctctttct ggctggagg ctatccagcg tactccaaag 240
attcaggttt actcacgtca tccagcagag aatggaaagt caaatttcct gaattgctat 300
gtgtctgggt ttcatccatc cgacattgaa gttgacttac tgaagaatgg agagagaatt 360
gaaaaagtgg agcattcaga cttgtctttc agcaaggact ggtctttcta tctctgtac 420
tacactgaat tcacccccac tgaaaaagat gaatcgagac atgtaagcag catcatggag 480
gtttgaagat gccgcatttg gattggatga attccaaatt ctgcttgctt gctttttaat 540
attgatatgc ttatacactt acactttatg cacaaaatgt agggttataa taatgttaac 600
atggacatga tcttctttat aattctactt tgagtgtgtc ctccatgtt gatgtatctg 660
agcagggttg tccaaggtg gctctaggag ggctggcaac ttagagggtg ggagcagaga 720
attctcttat ccaacatcaa catcttggtc agatttgaac tcttcaatct cttgcactca 780
aagcttggtt agatagttaa gcgtgcataa gttaacttcc aatttacata ctctgcttag 840

```

57

aatttgggggg aaaattttaga aatataattg acaggattat tggaaatttg ttataatgaa 900
 tgaaacattt tgtcatataa gattcatatt tactttcttat acatttgata aagtaaggca 960
 tggttgtggt taatctggtt tatttttggt ccacaagtta aataaatcat aaaacttgaa 1020
 aaaaaaatc ttaaaaaaca ct 1042

<210> 62
 <211> 718
 <212> DNA
 <213> Homo sapien

<400> 62
 gagcgccgc agtgtgatgg atggccgccc gggcaggtag tacactgaat tccccccac 60
 tgaaaaagat gagtatgcct gccgtgtgaa ccatgtgact ttgtcacagc ccaagatagt 120
 taagtgggat cgagacatgt aagcagcatc atggagggtt gaagatgccg catttggatt 180
 ggatgaattc caaattctgc ttgcttgctt tttaatatg atatgcttat acacttacac 240
 tttatgcaca aaatgtaggg ttataataat gttaacatgg acatgatctt ctttataatt 300
 ctactttgag tgctgtctcc atgtttgatg tatctgagca ggttgctcca caggtagctc 360
 taggagggct ggcaacttag aggtggggag cagagaattc tcttatccaa catcaacatc 420
 ttggtcagat ttgaactctt caatctcttg cactcaaagc ttgttaagat agttaagcgt 480
 gcataagtta acttccaatt tacatactct gcttagaatt tgggggaaaa tttagaaata 540
 taattgacag gattattgga aatttggtat aatgaatgaa acattttgtc atataagatt 600
 catatttact tcttatacat ttgataaagt aaggcatggt tgtgggtaat ctggtttatt 660
 tttgttccac aagttaaata aatcataaaa cttgaaaaaa aaaatcttaa aaaacact 718

<210> 63
 <211> 1308
 <212> DNA
 <213> Homo sapien

<400> 63
 gtaggtggtc ccttccgcac atttcaactct gtacagcaaa tggtttcttc ccatttgcta 60
 gacagagggc tagattttcc ccgcccactc tcgactcttc aggtagttag cccctccccg 120
 tgaccggtgg gtggtttctc cctcctcccc gcctcgggag ctggatggtc tcgcctctcc 180
 ctccccccac cccgtgccgg gtgcgcggcc tgggagtcag cggcccagac ggggaagcgcc 240
 gggcgagccc actgtgcggc cgtcgtgggg gaagcgaagg ttcttgattc cacctacctc 300
 ctaagtgaag gcttccgtcc ctggagagga ggcggcgccc tgtatcggcc ttggtcctcc 360
 gcgggtgtgc tagcgttggg acggtccttt gttgccgcga ggggtaggag tgggcgtggc 420
 ggagccagct ccgttcggaa cactccccgg cgcacccgac tcgctcatcc tgcaggagct 480

gcggcgccaa gatgagtgga gaggagaacc cagccagcaa gccacgccc gtgcaggacg 540
 tacagggcga cggcgctgg atgtccctgc accatcggtt cgtggctgac agcaaagata 600
 aggaaccgga agtcgtcttc atcggggaact ccttgggtcca gctcatgcac cagtgcgaga 660
 tctggcgaga gctcttctct cctctgcatg cacttaactt tggcattggg ggtgacggca 720
 cacagcatgt actgtggcgg ctggagaatg gggagctgga acacatccgg cccaaggatga 780
 ggggggcttg ggtggggctc taaaacatct tttggctgcc ccctcaccgc tgcttcatgt 840
 ctctttttcc acagattgtg gtggtctggg tgggcaccaa caaccacgga cacacagcag 900
 agcagggtgac tgggtggcatc aaggccattg tgcaactggg gaatgagcga cagccccagg 960
 cccgggttgt ggtgctgggc ctgcttccgc gaggccaaca tcccaaccca cttcgggaga 1020
 agaaccgaca ggtgaacgag ctggtacggg cggcactggc tggccaccct cgggccact 1080
 tcttagatgc cgaccctggc tttgtgcaact cagatggcac catcagccat catgacatgt 1140
 atgattacct gcatctgagc cgcctgggct acacacctgt ttgccgggct ctgactccc 1200
 tgcttctgcg tctgctggcc caagaccagg gccaaagtgc tcccctgctg gagcccgcac 1260
 cctaagcatc ctgctgcctt cccacaacat taaactctcc ttcctcag 1308

<210> 64
 <211> 933
 <212> DNA
 <213> Homo sapien

<400> 64
 atataaccgc gtggcccgcg cgcgcgcttc cctcccggcg cagtcaccgg cgcggtctat 60
 ggctgcgact tctctaattg ctgctttggc tgcccggctg ctgcagcccg cgcacagctg 120
 ctcccttcgc cttcgccctt tccacctcgc ggcagttcga aatgaagctg ttgtcatttc 180
 tggaaggaaa ctggcccagc agatcaagca ggaagtgcgg caggaggtag aagagtgggt 240
 ggctcaggc aacaaacggc cacacctgag tgtgatcctg gttggcgaga atcctgcaag 300
 tcactcctat gtcctcaaca aaaccagggc agctgcagtt gtgggaatca acagtgcagc 360
 aattatgaaa ccagcttcaa tttcagagga agaattgttg aatttaata ataaactgaa 420
 taatgatgat aatgtagatg gcctccttgt tcagttgcct cttccagagc atattgatga 480
 gagaaggatc tgcaatgctg tttctccaga caaggatgtt gatggctttc atgtaattaa 540
 tgtaggacga atgtgtttgg atcagtattc catgttaccg gctactccat ggggtgtgtg 600
 ggaaataatc aagcgaactg gcattccaac cctaggggaag aatgtgggtg tggctggaag 660
 gtcaaaaaac gttggaatgc ccattgcaat gttactgcac acagatgggg cgcagtaacg 720
 tcccggagggt gatgccactg ttacaatatc tcatcgatat actcccaaag agcagttgaa 780

gaaacataca attcttgacag atattgtaat atctgctgca ggtatgtctc ttcaactgct 840
 cttccagagc atattgatga gagaaggatc tgcaatgctg tttctccaga caaggatggt 900
 gatggctttc atgttattac tgtaggacga atg 933

<210> 65
 <211> 2352
 <212> DNA
 <213> Homo sapien

<400> 65
 aggtggttgg gtgacgcccc aggaaagcgc tccaggccga gggcggggcg cgccgcccgc 60
 cccgacgcct ctgggggttg ggacttcgcg ggagtcgccg gcggaggcga ggaggagctc 120
 tgcgcgggcg gcggggcgat ccgagccggg acgggctgca ggcgggggtg ctgcagagga 180
 cacgaggcgg cgggctggag acatggaccg cggcgagcaa ggtctgctga gaacagaccc 240
 agtccctgag gaaggagaag atgttgctgc cacgatcagt gccacagaga ccctctcgga 300
 agaggagcag gaagagctaa gaagagaact tgcaaaggta gaagaagaaa tccagactct 360
 gtctcaagtg ttagcagcaa aagagaagca tctagcagag atcaagcggg aacttggaa 420
 caattctcta caggaactaa aacagaacat tgccaaaggg tggcaagacg tgacagcaac 480
 atctgcttac aagaagacat ctgaaacctt atcccaggct ggacagaagg cctcagctgc 540
 tttttcgtct gttggctcag tcatcaccaa aaagctggaa gatgtaaaat tgcaagcctt 600
 ttcacattcc tttagtatac gttccattca gcattcaatt agcatgcctg ctatgagaaa 660
 ctccccaaact tttaaatcat ttgaagaaaa ggtcgaaaaac ttaaagtcta aagtaggggg 720
 aaccaagcct gctgggtgtg attttgaga agtcttgaat tcggctgcaa atgctagtgc 780
 caccaccacg gagcctcttc cagaaaagac acaggagagc ctgtgagatt cctacctttg 840
 ttctgctacc cactgccaga tgctgcaagc gaggtccaag cacatcttgt caacatgcat 900
 tgccatgaat ttctaccaga tgtgctttta tttagcttta catattcctt tgaccaaata 960
 gtttgtgggt taaacaaaat gaaaatatct tcacctctat tcttgggaaa caccctttag 1020
 tgtacattta tgttccttta tttaggaaac accattataa aaacacttat agtaaatggg 1080
 gacattcact ataatgatct aagaagctac agattgtcat agttgttttc ctgctttaca 1140
 aaattgctcc agatctggaa tgccagtttg acctttgtct tctataatat ttcctttttt 1200
 tccccctctt gaatctctgt atatttgatt cttaactaaa attgttctct taaatattct 1260
 gaatcctggg aattaaaagt ttgggtgtat tttctttacc tccaaggaaa gaactactag 1320
 ctacaaaaaa tattttggaa taagcattgt tttggtataa ggtacatatt ttgggtgaag 1380
 acaccagact gaagtaaaca gctgtgcatc caatttatta tagttttgta agtaacaata 1440

60

```

tgtaatcaaa cttctaggtg acttgagagt ggaacctcct atatcattat ttagcaccgt 1500
ttgtgacagt aaccatttca gtgtattggt tattatacca cttatatcaa cttatttttc 1560
accagggttaa aattttaatt tctacaaaat aacatttctga atcaagcaca ctgtatgttc 1620
agtaggttga actatgaaca ctgtcatcaa tgttcagttc aaaagcctga aagtttagat 1680
ctagaagctg gtaaaaatga caatatcaat cacattaggg gaaccattgt tgtcttcact 1740
taatccattt agcactattt aaaataagca caccaagtta tatgactaat ataacttgaa 1800
aattttttat actgaggggt tggtgataac tcttgaggat gtaatgcatt aataaaaaatc 1860
aactcatcat tttctacttg ttttcaatgt gttggaaact gtaaaatgat actgtagaac 1920
ctgtctccta ctttgaaaac tgaatgtcag ggctgagtga atcaaagtgt ctagacatat 1980
ttgcatagag gccaaggtat tctattctaa taactgctta ctcaacacta ccaccttttc 2040
cttatactgt atatgattat ggcctacaat gttgtatttg ttatttatta aattgtgatt 2100
gttttattat tgtttatgcc aaatgttaac tgccaagctt ggagtgcct aaagcatttt 2160
ttaaaagcat ggctagattt acttcagtat aaattatctt atgaaaacca aattttaaaa 2220
gccacaggtg ttgattgtta taaaataaca tgctgccatt cttgattgct agagtttttg 2280
ttagtacttt ggatgcaatt aaaactatgt gctatcacat gtgaaaagct taataaatc 2340
catctatcag ta 2352

```

```

<210> 66
<211> 4915
<212> DNA
<213> Homo sapien

```

```

<400> 66
gagcctcctg ggccggcgcc gcaagttgca tctcccgat ccggatctgg catcctgggg 60
ccctggaagg agcggctctg gcgggggcag atgggactgc atgtgtgagt gtgagtgtgc 120
gtgtgtgggg gagagggaga gaaggttctg ggaggtggcg aaggggctag cgtcaggggc 180
tggcggccgt gatgcgcttt ggggtgaaag ccgcgtgaag ggagcacggc gcagccagct 240
cctgtaagtg actggaacca ggaacagagg acagtgagtc gctctcgtcc ctccaggtct 300
gctgagaaca gaccagtcct ctgaggaagg agaagatgtt gctgccacga tcagtgccac 360
agagaccctc tcggaagagg agcaggaaga gctaagaaga gaacttgcaa aggtagaaga 420
agaaatccag actctgtctc aagtgttagc agcaaaagag aagcatctag cagagatcaa 480
gcggaaactt ggaatcaatt ctctacagga actaaaacag aacattgcca aagggtggca 540
agacgtgaca gcaacatctg cttacaagaa gacatctgaa accttatccc aggctggaca 600
gaaggcctca gctgcttttt cgtctgttgg ctcagtcatc accaaaaagc tggaagatgt 660

```

aaaaaactcc ccaactttta aatcatttga agaaaagggtc gaaaacttaa aggcaagtag	720
agagatgaac aggggtctttt gatacattgc ctgggtgtctt aattaacttt gctgtgcgaa	780
aatcattgac attaatattt ctttctaaaa atatctaaag aatgtaaata actttactcc	840
ttatgttact agtggacatt taagggtgtta tgtacttaat atcttttttag tgtatgctgt	900
agtgtggcag catgccacat gctgaaagga aatgtacaat ttacaaagaa atggcacttt	960
agaaatttgt gctgcttttt gctttattca tttcaagtac ctttgtaggt ggacaaaatt	1020
taatataact ttcttgtcaa caattaacaa gaatatagga agcacaagaa agaaaacaaa	1080
aaattggtcc taccactcag acagtgatag atgtatgtgc tattatgctg ttacgcttta	1140
aaaaagaagt agccatacat cataatcatt ttcctgtatc agtaagtatt ctctttcaat	1200
attatgtgca atggctgctt gtatattact tttttttttt ttgagatgga gtctcactct	1260
ccagcctggg tgacagagcc agaccctgtc tcaaaaaaaaa aaaaaaaaaa aaaaaaaaaag	1320
gatagcgtat taaacagata cccaagtat cctaaggaag ctgtaaaatt acatgctggg	1380
gatataattt tgttaaatta catttatatt taattaaaca tgagggtccat ttagattttg	1440
ggttgattca ttcactctgtg attactgagc atttgccatg tgccagtcaa tcagtattag	1500
gcaccagagt taccacagtg agcaagagag acatggaccc cttctgcaag atgcctagac	1560
aattaaatgg ccaatgaaac taaagtgagg taagggttct gatgtgaaaa gctgaggggtg	1620
tgatgaggac aagtggcaga aagttcacct ggcttggtgg aaggaaggt cagagaagac	1680
ctcttagagg actcagtaat gtccattgag gattttaggt tgaagggaat gtttgaagtt	1740
tgagggccct tttgaggacc accaagaact tcaactgtgt gtaggatatt gagcaggagg	1800
tgaagctaga gagatgtgta ggccacattg cagagtttga acttggggca atgggaagcc	1860
attgaagggg tttaaacaac ccaagtgggt cattcttctg taaatgttag agagatcagt	1920
ggctgccctg cacatcaaag gggagaacga ttggagacag gcagattaga tgggaaggacg	1980
gagttgtact ccaagccaaa gatgatggag agtgaattaa gttagtgcaa tgggaccaag	2040
tctagagcta tttagaagtg agaagtgaca oggaaaaaaaa aaaagattga ttggatgtag	2100
aacaagttgg ataagaatcc aggacaaccc cagggtgtcag gctggggcag ctaggttaggt	2160
gctattgcca tataaagtgt taaaaaagaa tagagaaggg gctagttgtc gggggaagga	2220
gttcagtttt agacatgttg aactgcaagg agatttgata ctataattaa ggaatgtgtt	2280
tttaataaatt taataaacia tgaacacaca ttattcgcat ttcccaaaca atttggtggt	2340
tagatcaaaa agaattgagag tgaaaataag ggggtctgtga ccaactcaatt aagattgagc	2400
taagagcaag gtcaagttca aaccactat aagcttcttg catccatggt cactgactgt	2460

tttcttactg ttagctgtcc tgttggacag tgtaacagtg agagagcata tacagattag	2520
cattgaaaag gataaagtga catgtgtaag ggttttgaaa aagtattata caaatgcaag	2580
gcagatatat tgaaataaat gcttattggc aaaatttcag gccagatagg ttggagtagt	2640
gcttcacaaa ctataatgtg cacatgaaca actcagggat tttgttcaag tgttgatttc	2700
aattctgtag ctggagttgg gtggggtaga aaggatatct gagatcctgc atttctaata	2760
agctcccagg taatgttgag tctgtaggtc cttgaaccac actttaagta ttaaagggtt	2820
agaaagctta tactgtaact gagaaaaaaa catatatttc tttcccatgt tgtattcaat	2880
atttcttgaa tgagtgtagc taaatgagca attcgatgca atacaaaatg ttatgcaagt	2940
gtagagacag acagttcact aggtacttta aaataataga ccttacaaag ttttctagac	3000
agacttcctg tgaagaacaa ggagcagggg gaaaggggaa ggggtagaat ttaccaatct	3060
gaatatttca gcaagggaga atgcatgagt ttactataa aaccacactg aacattgcaa	3120
caatactaaa ttccatacat atataataat cactgagcta taagggttgct gatgtatttg	3180
ttcttgaaag tgaattagag ttactttatg cagaatcagc tagttttatg tttcataatg	3240
tctttccctt ttttgaactt ttttttaagt ctaaagtagg ggggaaccaag cctgctggtg	3300
gtgatttttg agaagtcttg aattcggctg caaatgctag tgccaccacc acggagcctc	3360
ttccagaaaa gacacaggag agcctgtgag attcctacct ttgttctgct acccactgcc	3420
agatgctgca agcgagggtcc aagcacatct tgtcaacatg cattgccatg aatttctacc	3480
agatgtgctt ttatttagct ttacatatct ctttgaccaa atagtttgtg ggtaaacaa	3540
aatgaaaata tcttcacctc tattcttggg aaacaccctt tagtgtacat ttatgttcct	3600
ttatttagga aacaccatta taaaaacact tatagtaaat ggggacattc actataatga	3660
tctaagaagc tacagattgt catagttgtt ttctgctttt acaaaattgc tccagatctg	3720
gaatgccagt ttgaccttg tcttctataa tatttccttt ttttccctc tttgaatctc	3780
tgtatatttg attcttaact aaaattgttc tcttaaatat tctgaatcct ggtaattaaa	3840
agtttgggtg tattttcttt acctccaagg aaagaactac tagctacaaa aaatattttg	3900
gaataagcat tgttttggta taaggtagat attttgggtg aagacaccag actgaagtaa	3960
acagctgtgc atccaattta ttatagtttt gtaagtaaca atatgtaatc aaacttctag	4020
gtgacttgag agtggaacct cctatatcat tatttagcac cgtttgtgac agtaaccatt	4080
tcagtgtatt gtttattata ccacttatat caacttattt ttaccagggt taaaatttta	4140
atttctacaa aataacattc tgaatcaagc acactgtatg ttcagtaggt tgaactatga	4200
acactgtcat caatgttcag ttcaaaagcc tgaaagttaa gatctagaag ctggtaaaaa	4260
tgacaatatc aatcacatta ggggaacctt tgttgtcttc acttaatcca tttagcacta	4320

tttaaaataa gcacaccaag ttatatgact aatataactt gaaaattttt tatactgagg 4380
 ggttggtgat aactcttgag gatgtaatgc attaataaaa atcaactcat cattttctac 4440
 ttgtttttcaa tgtgttgga actgtaaaat gatactgtag aacctgtctc ctactttgaa 4500
 aactgaatgt cagggctgag tgaatcaaag tgtctagaca tatttgcata gaggccaagg 4560
 tattctattc taataactgc ttactcaaca ctaccacctt ttccttatac tgtatatgat 4620
 tatggcctac aatgttgtat ttgttattta ttaaattgtg attgttttat tattgtttat 4680
 gccaaatgtt aactgccaag cttggagtga cctaaagcat tttttaaaag catggctaga 4740
 ttactttcag tataaattat cttatgaaaa ccaaatttta aaagccacag gtgttgattg 4800
 ttataaaaata acatgctgcc attcttgatt gctagagttt ttgttagtac tttggatgca 4860
 attaaaacta tgtgctatca catgtgaaaa gcttaataaa ttccatctat cagta 4915

<210> 67

<211> 2353

<212> DNA

<213> Homo sapien

<400> 67

aggtggttgg gtgacgcccc aggaaagcgc tccaggccga gggcgggcgg cgccgccgcg 60
 cccgacgcct ctgggggtgg ggacttcgcg ggagtcgcgc gcggaggcga ggaggagctc 120
 tgcgcggcgc ggcgggcgat ccgagccggg acgggctgca ggcgggggtg ctgcagagga 180
 cagcaggcgg cgggctggag acatggaccg cggcgagcaa ggtctgctga gaacagaccc 240
 agtccctgag gaaggagaag atgttgctgc cagcatcagt gccacagaga ccctctcgga 300
 agaggagcag gaagagctaa gaagagaact tgcaaaggta gaagaagaaa tccagactct 360
 gtctcaagtg ttagcagcaa aagagaagca tctagcagag atcaagcggg aacttggaat 420
 caattctcta caggaactaa aacagaacat tgccaaaggg tggcaagacg tgacagcaac 480
 atctgcgagg agcaagcttc tagcagcaga aaccgaactg ctctgtcttc tgtattgaga 540
 gccatctgca gagctgttac aagaagacat ctgaaacctt atcccaggct ggacagaagg 600
 cctcagctgc tttttcgtct gttggctcag tcatcaccaa aaagctggaa gatgtaaaaa 660
 actccccaac ttttaaatca tttgaagaaa aggtcgaaaa cttaaagtct aaagtagggg 720
 gaaccaagcc tgctggtggt gatatttgag aagtcttgaa ttcggctgca aatgctagtg 780
 ccaccaccac ggagcctctt ccagaaaaga cacaggagag cctgtgagat tcctaccttt 840
 gttctgctac ccactgccag atgctgcaag cgagggtccaa gcacatcttg tcaacatgca 900
 ttgccatgaa tttctaccag atgtgctttt atttagcttt acatattcct ttgaccaaatt 960
 agtttgtggg ttaaacaaaa tgaaaatatc ttcacctcta ttcttgggaa acacccttta 1020

64

```

gtgtacat ttt atgttccttt attttaggaaa caccattata aaaacactta tagtaaatgg 1080
ggacattcac tataatgatc taagaagcta cagattgtca tagttgtttt cctgctttac 1140
aaaattgctc cagatctgga atgccagttt gacctttgtc ttctataata tttccttttt 1200
ttcccctctt tgaatctctg tatatttgat tcttaactaa aattgttctc ttaaataatc 1260
tgaatcctgg taattaaaag tttgggtgta ttttctttac ctccaaggaa agaactacta 1320
gctacaaaaa atattttgga ataagcattg ttttggtata aggtacatat tttggttgaa 1380
gacaccagac tgaagtaaag agctgtgcat ccaatttatt atagttttgt aagtaacaat 1440
atgtaatcaa acttctaggt gacttgagag tggaaacctc tatatcatta tttagcaccg 1500
tttgtgacag taaccatttc agtgtattgt ttattatacc acttatatca acttattttt 1560
caccagggtta aaattttaat ttctacaaaa taacattctg aatcaagcac actgtatggt 1620
cagtaggttg aactatgaac actgtcatca atgttcagtt caaaagcctg aaagtttaga 1680
tctagaagct ggtaaaaatg acaatatcaa tcacattagg ggaaccattg ttgtcttcac 1740
ttaatccatt tagcactatt taaaataagc acaccaagtt atatgactaa tataacttga 1800
aaatttttta tactgagggg ttggtgataa ctcttgagga tgtaatgcat taataaaaat 1860
caactcatca ttttctactt gttttcaatg tgttggaac tgtaaaatga tactgtagaa 1920
cctgtctcct actttgaaaa ctgaatgtca gggctgagtg aatcaaagtg tctagacata 1980
tttgcataga ggccaaggta ttctattcta ataactgctt actcaacact accacctttt 2040
ccttatactg tatatgatta tggcctacaa tgttgtattt gttatttatt aaattgtgat 2100
tgttttatta ttgtttatgc caaatgttaa ctgccagct tggagtgacc taaagcattt 2160
tttaaaagca tggctagatt tacttcagta taaattatct tatgaaaacc aaattttaaa 2220
agccacaggt gttgattgtt ataaaataac atgctgccat tcttgattgc tagagttttt 2280
gttagtactt tggatgcaat taaaactatg tgctatcaca tgtgaaaagc ttaataaatt 2340
ccatctatca gta 2353

```

```

<210> 68
<211> 564
<212> DNA
<213> Homo sapien

```

```

<400> 68
ctatatacaa tcatgctcgg tacctcatag gtctgcakgt cccaggaagg tggcgtcagc 60
atctgcagcc gcgtcgacgt tgtcggagcc tccgaggagg acccaggaga gccggactag 120
gaccagggcc ctgggcctcc ccacactccc catggagaag ctggcggcct ctacagagcc 180
ccaagggcct cggccggtcc tgggcccgtga gagtgtccag gtgcccgatg accaagactt 240

```

tcgcagcttc	cggtcagagt	gtgaggctga	ggtagggctgg	aacctgacct	atagcagggc	300
tgggggtgtct	gtctgggtgc	aggctgtgga	gatggatcgg	acgctgcaca	agatcaagtg	360
ccggatggag	tgctgtgatg	tgccagccga	gacactctac	gacgtcctac	acgacattga	420
gtaccgcaag	aaatgggaca	gcaacgtcat	tgagactttt	gacatcgccc	gcttgacagt	480
caacgctgac	gtgggctatt	actcctggag	tgtcccaagc	ycctgcgaac	ctatgaggta	540
ccgagctcga	ttcgatcatg	tcaa				564

<210> 69

<211> 1333

<212> DNA

<213> Homo sapien

<400> 69

gcagcctgga	aaatcccgag	ccgcggccgc	cgagcccccg	agcccccgag	cccccagcct	60
agccgggagg	ggcgcgcggg	gctggggccc	ggggcggggc	cgggcggcgg	gacccactgc	120
tcctcccacc	agagcccccg	cgcggccccg	ggctctcccg	gcagctgcgg	cggcggcgct	180
ggcaccgccg	ccccggcggg	ccccggcgga	gcggcgggca	aaggctccag	gaagggtggcg	240
tcagcatctg	cagccgcgtc	gacgttgtcg	gagcctcccc	acactcccca	tggagaagct	300
ggcggcctct	acagagcccc	aagggcctcg	gccggtcctg	ggccgtgaga	gtgtccaggt	360
gcccgatgac	caagactttc	gcagcttccg	gtcagagtgt	gaggctgagg	tgggctggaa	420
cctgacctat	agcagggctg	gggtgtctgt	ctgggtgcag	gctgtggaga	tggatcggac	480
gctgcacaag	atcaagtgcc	ggatggagtg	ctgtgatgtg	ccagccgaga	cactctacga	540
cgtcctacac	gacattgagt	accgcaagaa	atgggacagc	aacgtcattg	agacttttga	600
catcgcccg	ttgacagtca	acgctgacgt	gggctattac	tcctggagggt	gtcccaagcc	660
cctgaagaac	cgtgatgtca	tcacctccg	ctcctggctc	cccatgggcg	ctgattacat	720
cattatgaac	tactcagtca	aacatcccaa	ataccacct	cggaaagact	tgggtccgagc	780
tgtgtccatc	cagacgggct	acctcatcca	gagcacaggg	ccaagagct	gcgtcatcac	840
ctacctggcc	caggtggacc	ccaaaggctc	cttacccaag	tgggtggtga	ataaatcttc	900
tcagttcctg	gctcccaagg	ccatgaagaa	gatgtacaag	gcgtgcctca	agtaccccg	960
gtggaaacag	aagcacctgc	ctcacttcaa	gccgtggctg	caccgcggagc	agagcccgtt	1020
gccgagcctg	gcgctgtcgg	agctgtcggg	gcagcatgcg	gactcactgg	agaacatcga	1080
cgagagcgcg	gtggccgaga	gcagagagga	gcggatgggc	ggcgcggggc	gcgagggcag	1140
cgacgacgac	acctcgctca	cctgagcgcc	gcaccgcttc	agggacggag	acaggaccgg	1200
gcgagccctg	gggcggcggc	cgtcctgca	ctttctcccc	ccccccacc	ggcacctgggt	1260

66

ggcaccgggc caggcccagg cgggtgctgc agcctggctg gacagagccc caataaacga 1320
 tcccacagcc tca 1333

<210> 70
 <211> 1263
 <212> DNA
 <213> Homo sapien

<400> 70
 gccttgttgc cttgcacaac ctgtgaattt gctccatcaa aactggcagg cagggttacc 60
 cctgaggagg ggggtggggga gaaggggtag ggggtgggacc ctatcatctc ccagagggga 120
 gatcaaggca gccatcatct gtcgaactag atgggtcccag gaaggtggcg tcagcatctg 180
 cagccgcgtc gacgttgctg gagcctcccc acactcccca tggagaagct ggcggcctct 240
 acagagcccc aagggcctcg gccggctcctg ggccgtgaga gtgtccagggt gcccgatgac 300
 caagactttc gcagcttccg gtcagagtgt gaggtgagg tgggttgaa cctgacctat 360
 agcagggctg ggggtgtctgt ctgggtgcag gctgtggaga tggatcggac gctgcacaag 420
 atcaagtgcc ggatggagtg ctgtgatgtg ccagccgaga cactctacga cgtcctacac 480
 gacattgagt accgcaagaa atgggacagc aacgtcattg agacttttga catcgcccgc 540
 ttgacagtca acgctgacgt gggctattac tcctggagggt gtcccaagcc cctgaagaac 600
 cgtgatgtca tcaccctccg ctccctggctc cccatgggag ctgattacat cattatgaac 660
 tactcagtca aacatcccaa ataccacact cggaaagact tgggtccgagc tgtgtccatc 720
 cagacgggct acctcatcca gagcacaggc cccaagagct gcgtcatcac ctacctggcc 780
 caggtggacc ccaaaggctc cttacccaag tgggtgggtga ataaatcttc tcagtctctg 840
 gctcccaagg ccatgaagaa gatgtacaag gcgtgcctca agtaccgccg gtggaaacag 900
 aagcacctgc ctcaactcaa gccgtggctg caccggagc agagcccgtt gccgagcctg 960
 gcgctgtcgg agctgtcggg gcagcatgcg gactcactgg agaacatcga cgagagcgcg 1020
 gtggccgaga gcagagagga gcggatgggc ggcgcgggag gcgagggcag cgacgacgac 1080
 acctcgctca cctgagcgcc gcaccgcttc agggacggag acaggaccgg gcgagccctg 1140
 gggcgggcgg cgctcctgca ctttctcccc tccccaccc ggacacctggg ggcaccgggc 1200
 caggcccagg cgggtgctgc agcctggctg gacagagccc caataaacga tcccacagcc 1260
 tca 1263

<210> 71
 <211> 1932
 <212> DNA
 <213> Homo sapien

<400> 71
 ctgagcgaag ataaccgtaa taaatagtaa cctaacgggc cagtcacgt tctgtggtcc 60
 tttcttttat gattcacaag gaatgacct cttcatcgcc tctcctaatt cagtcctcac 120
 aacagtcctt ttacaaatgg gacaacaggt tagaggaagt caggcagatt tccagcatca 180
 tagagagtaa aggaccaggg aaggatcagg attcaaggac tgcacccagg ctctgcttcc 240
 agcttgctgt gtgacttttg gtaattttgt tcccttaggg aactgagctt tctcatttgt 300
 aaatgcaaac aggctgttgg gaggatcaaa tgagatccag gggtgaaaac agcttagttt 360
 actttcagga atttaccac gcggtatata aaggcaaaat attattatag tcagggtgatt 420
 gtagattgag gaacccattt cctcattctg caaattgcaa acctgagggc ccaaagaggg 480
 acaggggctt gcccaggtc tcagcaggct gtgagcaaga gctaaagcct aatcctcctg 540
 cctttggggc tggagccctt ccttgtacct caggggtcag tgtctttgtt ggatacaggc 600
 ttagattgac tgactgtacc ctgagaacct aggggagtc ctgttccaa ttcttctcct 660
 accccacct tggcctgatg gaggaagacc ctgctgtgtt gagatgagca ccagagccaa 720
 gaagctgagg aggatctgga gaattctgga ggaagaggag agtggtgctg gagctgtaca 780
 gaccctgctt ctgaggtccc aggaagggtg cgtcagcatc tgcagccgcg tcgacgttgt 840
 cggagcctcc gcggaggacc caggagagcc ggactaggac cagggccctg ggccctccca 900
 cactcccat ggagaagctg gcggcctcta cagagccca agggcctcgg ccggtcctgg 960
 gccgtgagag tgtccagggt cccgatgacc aagactttcg cagcttccgg tcagagtgtg 1020
 aggctgaggt gggctggaac ctgacctata gcagggtggt ggtgtctgtc tgggtgcagg 1080
 ctgtggagat ggatcggacg ctgcacaaga tcaagtgccg gatggagtgc tgtgatgtgc 1140
 cagccgagac actctacgac gtcctacacg acattgagta ccgcaagaaa tgggacagca 1200
 acgtcattga gacttttgac atgccccgt tgacagtcaa cgctgacgtg ggctattact 1260
 cctggagggtg tccaagccc ctgaagaacc gtgatgtcat caccctccgc tcctggctcc 1320
 ccatgggcgc tgattacatc attatgaact actcagtcaa acatcccaaa taccacctc 1380
 ggaaagactt ggtccgagct gtgtccatcc agacgggcta cctcatccag agcacagggc 1440
 ccaagagctg cgtcatcacc tacctggccc aggtggacct caaagctcct taccgaagtg 1500
 ggtggtgct ctgctccac ggtgtccagc gccagaatg cggcttctgg tcctgctatg 1560
 ggggtgcctg ctgctcccag gttatgaagc cctggagggc ccagaggaaa tcagcgggtt 1620
 cgaaggggac actgtgtccc tgcagtgcac ctacaggga gagctgagg accaccgga 1680
 gtactggtgc aggaagggtg ggatcctctt ctctcgctgc tctggacca tctatgccga 1740
 agaagaaggc caggagacaa tgaagggcag ggtgtccatc cgtgacagcc gccaggagct 1800

68

ctcgctcatt gtgaccctgt ggaacctcac cctgcaagac gctggggagt actggtgtgg 1860
 ggtcgaaaaa cggggccccc atgagtcctt actgatctct ctgctcgtct ctccaccttc 1920
 tcctgggctc ta 1932

<210> 72
 <211> 736
 <212> DNA
 <213> Homo sapien

<400> 72
 tccagccttg ggcaataatg agctactccc agcctgggca ataatgagct actcctagct 60
 cggggcaatg aatgagctac taccagctct gggccgataa gagctactcc tagcctgggc 120
 aataagagct actccagcct gggcaataag agctactcca gcctgggcaa taagagctac 180
 tccagcctgg gcaataagag ctactccagc ctgggcaata aggcccaaga gctgcgtcat 240
 cacctacctg gccaggtgg accccaaagg ctccctaccc aagtgggtgg tgaataaaatc 300
 ttctcagttc ctggctccca aggccatgaa gaagatgtac aaggcgtgcc tcaagtaccc 360
 cgagtggaaa cagaagcacc tgcctcactt caagccgtgg ctgcaccgg agcagagccc 420
 gttgccgagc ctggcgctgt cggagctgtc ggtgcagcat gcggactcac tggagaacat 480
 cgacgagagc gcggtggccg agagcagaga ggagcggatg ggcggcgcgg gcggcgaggg 540
 cagcgacgac gacacctcgc tcacctgagc gccgcaccgc ttcagggacg gagacaggac 600
 cgggcgagcc ctggggcggc ggccgctcct gcactttctc ccctcccca cccggcacct 660
 ggtggcaccg ggccaggccc aggcgggtgc tgcagcctgg ctggacagag cccaataaaa 720
 cgatcccaca gcctca 736

<210> 73
 <211> 91
 <212> PRT
 <213> Homo sapien

<400> 73
 Met Cys Gln Pro Val Ser Ile Ser Glu Lys Ala Met Tyr Pro Asp Tyr
 1 5 10 15
 Phe Ala Lys Arg Glu Gln Trp Lys Lys Leu Arg Arg Glu Ser Trp Glu
 20 25 30
 Arg Glu Val Lys Gln Leu Gln Glu Thr Pro Pro Gly Gly Pro Leu
 35 40 45
 Thr Glu Ala Leu Pro Pro Ala Arg Lys Glu Gly Asp Leu Pro Pro Leu

69

50

55

60

Val Val Val Tyr Cys Asp Gln Thr Pro Gly Ser Gly Pro Cys Arg Lys
 65 70 75 80

Arg Glu Thr His Leu Ser Cys Leu Gln Val Lys
 85 90

<210> 74
 <211> 117
 <212> PRT
 <213> Homo sapien

<400> 74

His Gly Gly Leu His Arg Arg Trp Leu Ser Leu Gly Thr Trp Pro Arg
 1 5 10 15

Val Asp Asn Thr Trp Gly Pro Leu Pro Asn Leu Pro Val Pro Gly Gly
 20 25 30

Ser His Pro Val Pro Pro Ala Arg Met Cys Gln Pro Val Ser Ile Ser
 35 40 45

Glu Lys Ala Met Tyr Pro Asp Tyr Phe Ala Lys Arg Glu Gln Trp Lys
 50 55 60

Lys Leu Arg Arg Glu Ser Trp Glu Arg Glu Val Lys Gln Leu Gln Glu
 65 70 75 80

Glu Thr Pro Pro Gly Gly Pro Leu Thr Glu Ala Leu Pro Pro Ala Arg
 85 90 95

Lys Glu Gly Asp Leu Pro Pro Leu Val Val Val Tyr Cys Asp Gln Thr
 100 105 110

Pro Gly Ala Ala Met
 115

<210> 75
 <211> 157
 <212> PRT
 <213> Homo sapien

<400> 75

Met Trp Thr Arg Lys Ala Gly Arg Leu Arg Leu Gly Ser Arg Pro Ala
 1 5 10 15

70

Pro Thr Arg Pro Pro Ser Ser Gln Pro Leu Asn Pro Arg Leu His Arg
20 25 30

Arg Trp Leu Ser Leu Gly Thr Trp Pro Arg Val Asp Asn Thr Trp Gly
35 40 45

Pro Leu Pro Asn Leu Pro Val Pro Gly Gly Ser His Pro Val Pro Pro
50 55 60

Ala Arg Met Cys Gln Pro Val Ser Ile Ser Glu Lys Ala Met Tyr Pro
65 70 75 80

Asp Tyr Phe Ala Lys Arg Glu Gln Trp Lys Lys Leu Arg Arg Glu Ser
85 90 95

Trp Glu Arg Glu Val Lys Gln Leu Gln Glu Glu Thr Pro Pro Gly Gly
100 105 110

Pro Leu Thr Glu Ala Leu Pro Pro Ala Arg Lys Glu Gly Asp Leu Pro
115 120 125

Pro Leu Val Val Val Tyr Cys Asp Gln Thr Pro Gly Ser Gly Pro Cys
130 135 140

Arg Lys Arg Glu Thr His Leu Ser Cys Leu Gln Val Lys
145 150 155

<210> 76

<211> 153

<212> PRT

<213> Homo sapien

<400> 76

Ser Trp Leu Gly Arg Glu Pro Ser Glu Gly Met Trp Thr Arg Lys Ala
1 5 10 15

Gly Arg Leu Arg Leu Gly Ser Arg Pro Ala Pro Thr Arg Pro Pro Ser
20 25 30

Ser Gln Pro Leu Asn Pro Arg Leu His Arg Arg Trp Leu Ser Leu Gly
35 40 45

Thr Trp Pro Arg Val Asp Asn Thr Trp Gly Pro Leu Pro Asn Leu Pro
50 55 60

Val Pro Gly Gly Ser His Pro Val Pro Pro Ala Arg Met Cys Gln Pro
65 70 75 80

71

Val Ser Ile Ser Glu Lys Ala Met Tyr Pro Asp Tyr Phe Ala Lys Arg
 85 90 95

Glu Gln Trp Lys Lys Leu Arg Arg Glu Ser Trp Glu Arg Glu Val Lys
 100 105 110

Gln Leu Gln Glu Glu Thr Pro Pro Gly Gly Pro Leu Thr Glu Ala Leu
 115 120 125

Pro Pro Ala Arg Lys Glu Gly Asp Leu Pro Pro Leu Val Val Val Tyr
 130 135 140

Cys Asp Gln Thr Pro Gly Ala Ala Met
 145 150

<210> 77
 <211> 73
 <212> PRT
 <213> Homo sapien

<400> 77

Met Gly Val Leu Gly Thr Val Arg Val Pro Thr Pro Ser Pro Gly Asn
 1 5 10 15

Cys Ile Gly Gln Thr Phe Ala Met Ala Glu Met Lys Val Val Leu Ala
 20 25 30

Leu Thr Leu Leu Arg Phe Arg Val Leu Pro Asp His Ala Glu Pro Arg
 35 40 45

Arg Lys Leu Glu Leu Ile Val Arg Ala Glu Asp Gly Leu Trp Leu Arg
 50 55 60

Val Glu Pro Leu Ser Ala Asp Leu Gln
 65 70

<210> 78
 <211> 199
 <212> PRT
 <213> Homo sapien

<400> 78

Glu Val Pro Gly Gly Arg Leu Lys Gly Asp Arg Arg Arg Ala Val Gln
 1 5 10 15

Asp Leu Gly Ala Gly Cys Arg Gly Arg Gly Gly Gly Lys Gly Arg Arg

72

20 25 30
 Thr Gly Arg Ala Asp Lys Trp Val Gly Pro Leu Glu Val Arg Gly Gln
 35 40 45
 Gly Trp Ser Pro Gly Thr Lys Lys Gly Arg Gly Ser Ala Arg Pro Glu
 50 55 60
 Glu Trp Glu Glu Met Gly Pro Gly Cys Arg Val Pro Arg Gly Leu Gly
 65 70 75 80
 Gln Gly Pro Arg Cys Arg Arg Lys Met Arg Glu Phe Gly Phe Gly Asp
 85 90 95
 Leu Val His Pro Gly Pro Val Leu Pro Pro Leu Pro Pro Gln Arg Arg
 100 105 110
 Ala Ser Cys Ile Pro Phe Leu Trp Pro Glu Gly Ser Ser Val His Pro
 115 120 125
 Ser Gln Ala Leu Ala Ser Ser His Ser Pro Ala Leu Gly Pro Ile Arg
 130 135 140
 Leu Gly Arg Met Gly Glu Pro Val Val Ala Pro Gly Arg Gly Lys Gly
 145 150 155 160
 Gly Arg Leu Gly Lys Pro Leu Leu Gly Arg Thr Gln Tyr Ser Gly Ser
 165 170 175
 Ser Leu Ser Gly Lys Glu Arg Ile Trp Gly Lys Asn Gly Ser Ala Ser
 180 185 190
 His Ala Leu Thr Gly Glu Pro
 195

<210> 79

<211> 132

<212> PRT

<213> Homo sapien

<400> 79

Ile Thr Phe Gln Glu His Leu Asn Gly Pro Leu Pro Val Pro Phe Thr
 1 5 10 15

Asn Gly Glu Ile Gln Lys Glu Asn Ser Arg Glu Ala Leu Ala Glu Ala
 20 25 30

73

Ala Leu Glu Ser Pro Arg Pro Asp Leu Val Arg Ile Arg Thr Pro Trp
 35 40 45

Leu Ile Pro Lys Lys Glu Leu Asn Phe His Asn Asp Met Ser Pro Leu
 50 55 60

Glu Glu Ser Arg Tyr Ser Thr Ala Thr Arg Arg Ser Tyr His Pro Ser
 65 70 75 80

Ser Asp Pro Ile Leu Asp Phe Asn Ile Ser Leu Val Met Cys Leu Ser
 85 90 95

Glu Arg Ala Ser Pro Gly Asn Ala Val Ser Lys Arg Ala Pro Gln Met
 100 105 110

Asp Trp Ser Lys Lys Asn Glu Leu Phe Ser Glu Pro Leu Ser Ala Leu
 115 120 125

Leu Pro Leu Gln
 130

<210> 80
 <211> 66
 <212> PRT
 <213> Homo sapien

<400> 80

Ala Ser Asp Ser His Arg Thr Pro Phe Ser Phe Ser Pro Ile Thr Pro
 1 5 10 15

Leu Arg Ser Met Tyr Lys Ser Val Thr Arg Cys Ser Phe Leu Asp Ile
 20 25 30

Met Met Ser Ser Arg Glu Leu Cys Ser Ser Arg Asp Phe Arg Glu Gly
 35 40 45

Glu Cys Val Pro Ser Ser Arg Ser His Glu Arg Arg Leu Trp Leu Pro
 50 55 60

Pro Pro
 65

<210> 81
 <211> 175
 <212> PRT
 <213> Homo sapien

74

<400> 81

Met Val Lys Leu Thr Ala Glu Leu Ile Glu Gln Ala Ala Gln Tyr Thr
 1 5 10 15

Asn Ala Val Arg Asp Arg Glu Leu Asp Leu Arg Gly Tyr Lys Ile Pro
 20 25 30

Val Ile Glu Asn Leu Gly Ala Thr Leu Asp Gln Phe Asp Ala Ile Asp
 35 40 45

Phe Ser Asp Asn Glu Ile Arg Lys Leu Asp Gly Phe Pro Leu Leu Arg
 50 55 60

Arg Leu Lys Thr Leu Leu Val Asn Asn Asn Arg Ile Cys Arg Ile Gly
 65 70 75 80

Glu Gly Leu Asp Gln Ala Leu Pro Cys Leu Thr Glu Leu Ile Leu Thr
 85 90 95

Asn Asn Ser Leu Val Glu Leu Gly Asp Leu Asp Pro Leu Ala Ser Leu
 100 105 110

Lys Ser Leu Thr Tyr Leu Ser Ile Leu Arg Asn Pro Val Thr Asn Lys
 115 120 125

Lys His Tyr Arg Leu Tyr Val Ile Tyr Lys Val Pro Gln Val Arg Val
 130 135 140

Leu Asp Phe Gln Lys Val Lys Leu Lys Val Ser Ser Asn Leu Leu Leu
 145 150 155 160

Val Ser His Tyr Arg Val Val Cys Phe Ser Leu Tyr Phe Cys Tyr
 165 170 175

<210> 82

<211> 79

<212> PRT

<213> Homo sapien

<400> 82

Met Asp Val Ala Ala Glu Val Glu Val Leu Pro Lys Pro Arg Met Arg
 1 5 10 15

Gly Leu Leu Ala Arg Arg Leu Arg Asn His Met Ala Val Ala Phe Val
 20 25 30

75

Leu Ser Leu Gly Val Ala Ala Leu Tyr Lys Phe Arg Val Ala Asp Gln
 35 40 45

Arg Lys Lys Ala Tyr Ala Asp Phe Tyr Arg Asn Tyr Asp Val Met Lys
 50 55 60

Asp Phe Glu Glu Met Arg Lys Ala Gly Ile Phe Gln Ser Val Lys
 65 70 75

<210> 83
 <211> 88
 <212> PRT
 <213> Homo sapien

<400> 83

Met Leu Glu Arg Arg Gln Cys Asp Gly Cys Val Val Ala Ala Glu Val
 1 5 10 15

Glu Val Leu Pro Lys Pro Arg Met Arg Gly Leu Leu Ala Arg Arg Leu
 20 25 30

Arg Asn His Met Ala Val Ala Phe Val Leu Ser Leu Gly Val Ala Ala
 35 40 45

Leu Tyr Lys Phe Arg Val Ala Asp Gln Arg Lys Lys Ala Tyr Ala Asp
 50 55 60

Phe Tyr Arg Asn Tyr Asp Val Met Lys Asp Phe Glu Glu Met Arg Lys
 65 70 75 80

Ala Gly Ile Phe Gln Ser Val Lys
 85

<210> 84
 <211> 93
 <212> PRT
 <213> Homo sapien

<400> 84

Met Leu Glu Arg Arg Ser Val Met Asp Ala Trp Ser Arg Ala Gly Val
 1 5 10 15

Thr Thr Met Ala Pro Glu Val Leu Pro Lys Pro Arg Met Arg Gly Leu
 20 25 30

Leu Ala Arg Arg Leu Arg Asn His Met Ala Val Ala Phe Val Leu Ser
 35 40 45

76

Leu Gly Val Ala Ala Leu Tyr Lys Phe Arg Val Ala Asp Gln Arg Lys
 50 55 60

Lys Ala Tyr Ala Asp Phe Tyr Arg Asn Tyr Asp Val Met Lys Asp Phe
 65 70 75 80

Glu Glu Met Arg Lys Ala Gly Ile Phe Gln Ser Val Lys
 85 90

<210> 85
 <211> 80
 <212> PRT
 <213> Homo sapien

<400> 85

Met Asp Arg Gly Arg Gly Glu Val Glu Val Leu Pro Lys Pro Arg Met
 1 5 10 15

Arg Gly Leu Leu Ala Arg Arg Leu Arg Asn His Met Ala Val Ala Phe
 20 25 30

Val Leu Ser Leu Gly Val Ala Ala Leu Tyr Lys Phe Arg Val Ala Asp
 35 40 45

Gln Arg Lys Lys Ala Tyr Ala Asp Phe Tyr Arg Asn Tyr Asp Val Met
 50 55 60

Lys Asp Phe Glu Glu Met Arg Lys Ala Gly Ile Phe Gln Ser Val Lys
 65 70 75 80

<210> 86
 <211> 68
 <212> PRT
 <213> Homo sapien

<400> 86

Met Trp Ser Arg Pro Arg Phe Leu Ala Arg Arg Leu Arg Asn His Met
 1 5 10 15

Ala Val Ala Phe Val Leu Ser Leu Gly Val Ala Ala Leu Tyr Lys Phe
 20 25 30

Arg Val Ala Asp Gln Arg Lys Lys Ala Tyr Ala Asp Phe Tyr Arg Asn
 35 40 45

Tyr Asp Val Met Lys Asp Phe Glu Glu Met Arg Lys Ala Gly Ile Phe
 50 55 60

77

Gln Ser Val Lys
65

<210> 87
<211> 53
<212> PRT
<213> Homo sapien

<400> 87

Met Ala Val Ala Phe Val Leu Ser Leu Gly Val Ala Ala Leu Tyr Lys
1 5 10 15

Phe Arg Val Ala Asp Gln Arg Lys Lys Ala Tyr Ala Asp Phe Tyr Arg
20 25 30

Asn Tyr Asp Val Met Lys Asp Phe Glu Glu Met Arg Lys Ala Gly Ile
35 40 45

Phe Gln Ser Val Lys
50

<210> 88
<211> 72
<212> PRT
<213> Homo sapien

<400> 88

Trp Ile Gly Arg Pro Gly Arg Ser Asn Val Gln Leu Ser Leu Arg Ser
1 5 10 15

Trp Asp Leu Gly Pro Thr Val Trp Pro Phe Ser Leu Gln Ala Val Leu
20 25 30

Gly Leu Lys Phe Arg Val Ala Asp Gln Arg Lys Lys Ala Tyr Ala Asp
35 40 45

Phe Tyr Arg Asn Tyr Asp Val Met Lys Asp Phe Glu Glu Met Arg Lys
50 55 60

Ala Gly Ile Phe Gln Ser Val Lys
65 70

<210> 89
<211> 80
<212> PRT
<213> Homo sapien

78

<400> 89

Met Leu Glu Ala Ala Gln Cys Asp Gly Ser Ala Ala Arg Ala Gly Gln
 1 5 10 15

Met Cys Ser Ser Pro Ser Gly Ser Trp Asp Leu Gly Pro Thr Val Trp
 20 25 30

Pro Phe Ser Leu Gln Ala Val Leu Gly Leu Lys Phe Arg Val Ala Asp
 35 40 45

Gln Arg Lys Lys Ala Tyr Ala Asp Phe Tyr Arg Asn Tyr Asp Val Met
 50 55 60

Lys Asp Phe Glu Glu Met Arg Lys Ala Gly Ile Phe Gln Ser Val Lys
 65 70 75 80

<210> 90

<211> 174

<212> PRT

<213> Homo sapien

<220>

<221> MISC_FEATURE

<222> (13)..(14)

<223> X=any amino acid

<400> 90

Gln Ile Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Xaa Xaa Lys Lys
 1 5 10 15

Asn Thr Lys Lys His Lys Lys Lys Arg Gly Gly Arg Pro Thr Lys Tyr
 20 25 30

Pro Pro Gly Gly Asp Ala Gln Thr Ser Asn Pro Pro Phe Gly Lys Arg
 35 40 45

Gly Pro Pro Gln Glu Gly Ala Gln Lys Thr Ala Ala Gly Gly Asn Lys
 50 55 60

Arg Arg Ala Asp Lys Pro Ser Ala Arg Gly Gln Arg Glu Arg Gln Thr
 65 70 75 80

Pro His Arg Arg Gly Gly Asp Arg Pro Gly Ala Pro Thr Pro Pro Thr
 85 90 95

Glu Gln Thr Arg Arg Arg Ala Lys Thr Thr Thr Ala Arg Asp Val Gly
 100 105 110

79

Gln Pro Thr Ala Arg Ser Ala Ala Thr Ala Ala Leu Thr Leu Ser Gly
 115 120 125

Thr Ile Gln Gly Ala Ala Ile Asn Arg Ala His Thr Pro Ala Ser Gln
 130 135 140

Thr Thr Arg Arg Pro Pro His Ala Asp Ala Thr Thr Pro Arg Pro Thr
 145 150 155 160

Asn Tyr Gly Ser Ser Ala Gln Asn Leu Ala Thr Pro Pro His
 165 170

<210> 91
 <211> 101
 <212> PRT
 <213> Homo sapien

<400> 91

Met Asp Arg Gly Arg Gly Glu Val Ser Gly Arg Thr Leu Val Leu Arg
 1 5 10 15

Leu Ala Tyr Val Ser Arg Thr Val Thr Thr Met Ala Pro Glu Val Leu
 20 25 30

Pro Lys Pro Arg Met Arg Gly Leu Leu Ala Arg Arg Leu Arg Asn His
 35 40 45

Met Ala Val Ala Phe Val Leu Ser Leu Gly Val Ala Ala Leu Tyr Lys
 50 55 60

Phe Arg Val Ala Asp Gln Arg Lys Lys Ala Tyr Ala Asp Phe Tyr Arg
 65 70 75 80

Asn Tyr Asp Val Met Lys Asp Phe Glu Glu Met Arg Lys Ala Gly Ile
 85 90 95

Phe Gln Ser Val Lys
 100

<210> 92
 <211> 216
 <212> PRT
 <213> Homo sapien

<400> 92

Met Val Ser Thr Asn Phe Thr Ser Gly Ser Arg Cys His Gly Cys Pro

1 5 80 10 15
 Lys Ser Leu Glu Thr Thr Thr Ser Pro Leu Pro Arg Arg Trp Arg Arg
 20 25 30
 Pro Gly Ala Val Trp Pro Arg Lys Pro Gly Asn Trp Pro Thr Thr Cys
 35 40 45
 Arg Lys Leu Arg Val Ser Met Lys Ser Thr Asn Thr Thr Arg Asn Ser
 50 55 60
 Ser Lys Lys Ser Trp Arg Arg Ser Pro Gly Leu Arg Arg Ser His His
 65 70 75 80
 Tyr Phe Lys Tyr Cys Lys Ile Ser Ala Leu Ala Leu Leu Lys Met Val
 85 90 95
 Met His Ala Arg Ser Gly Gly Asn Leu Glu Val Met Gly Leu Met Leu
 100 105 110
 Gly Lys Val Asp Gly Glu Thr Met Ile Ile Met Asp Ser Phe Ala Leu
 115 120 125
 Pro Val Glu Gly Thr Glu Thr Arg Val Asn Ala Gln Ala Ala Ala Tyr
 130 135 140
 Glu Tyr Met Ala Ala Tyr Ile Glu Asn Ala Lys Gln Val Gly Arg Leu
 145 150 155 160
 Glu Asn Ala Ile Gly Trp Tyr His Ser His Pro Gly Tyr Gly Cys Trp
 165 170 175
 Leu Ser Gly Ile Asp Val Ser Thr Gln Met Leu Asn Gln Gln Phe Gln
 180 185 190
 Glu Pro Phe Val Ala Val Val Ile Asp Pro Thr Arg Thr Ile Ser Ala
 195 200 205
 Gly Lys Ser Glu Ser Trp Arg Leu
 210 215

<210> 93
 <211> 352
 <212> PRT
 <213> Homo sapien
 <400> 93

Val 1	Ser	Trp	Leu	Pro 5	Gln	Glu	Ser	Arg	Asp 10	Asp	Asn	Phe	Ser	Ala 15	Ser
Ser	Ala	Met	Ala 20	Ala	Ser	Gly	Ser	Gly 25	Met	Ala	Gln	Lys	Thr 30	Trp	Glu
Leu	Ala 35	Asn	Asn	Met	Gln	Glu	Ala 40	Gln	Ser	Ile	Asp	Glu 45	Ile	Tyr	Lys
Tyr	Asp 50	Lys	Lys	Gln	Gln	Gln 55	Glu	Ile	Leu	Ala	Ala 60	Lys	Pro	Trp	Thr
Lys 65	Asp	His	His	Tyr	Phe 70	Lys	Tyr	Cys	Lys	Ile 75	Ser	Ala	Leu	Ala	Leu 80
Leu	Lys	Met	Val	Met 85	His	Ala	Arg	Ser	Gly 90	Gly	Asn	Leu	Glu	Val 95	Met
Gly	Leu	Met	Leu 100	Gly	Lys	Val	Asp	Gly 105	Glu	Thr	Met	Ile	Ile 110	Met	Asp
Ser	Phe	Ala 115	Leu	Pro	Val	Glu	Gly 120	Thr	Glu	Thr	Arg	Val 125	Asn	Ala	Gln
Ala	Ala 130	Ala	Tyr	Glu	Tyr	Met 135	Ala	Ala	Tyr	Ile	Glu	Asn	Ala	Lys	Gln
Val 145	Gly	Arg	Leu	Glu	Asn 150	Ala	Ile	Gly	Trp	Tyr 155	His	Ser	His	Pro	Gly 160
Tyr	Gly	Cys	Trp	Leu 165	Ser	Gly	Ile	Asp	Val 170	Ser	Thr	Gln	Met	Leu 175	Asn
Gln	Gln	Phe	Gln 180	Glu	Pro	Phe	Val	Ala 185	Val	Val	Ile	Asp	Pro 190	Thr	Arg
Thr	Ile	Ser 195	Ala	Gly	Lys	Val	Asn 200	Leu	Gly	Ala	Phe	Arg 205	Thr	Tyr	Pro
Lys	Gly 210	Tyr	Lys	Pro	Pro	Asp 215	Glu	Gly	Pro	Ser	Glu	Tyr	Gln	Thr	Ile
Pro 225	Leu	Asn	Lys	Ile	Glu 230	Asp	Phe	Gly	Val	His 235	Cys	Lys	Gln	Tyr	Tyr 240

Ala Leu Glu Val Ser Tyr Phe Lys Ser Ser Leu Asp Arg Lys Leu Leu
245 250 255

Leu Leu Thr Asn Ala Asp Tyr Thr Thr Gly Gln Val Phe Asp Leu Ser
275 280 285

Leu Gly Leu Glu Thr His Asp Arg Lys Ser Glu Asp Lys Leu Ala Lys
305 310 315 320

Met Ser Gln Val Ile Lys Asp Lys Leu Phe Asn Gln Ile Asn Ile Ser
340 345 350

<400> 94

Ser Ile Asp Glu Ile Tyr Lys Tyr Asp Lys Lys Gln Gln Gln Glu Ile
20 25 30

Phe Asp Ser Cys Leu Asp Phe Gln His Glu Val Tyr Thr Phe Phe Ser
50 55 60

<400> 95

83

Gln	Ala	Val	His	Phe	Ser	His	His	Tyr	Phe	Lys	Tyr	Cys	Lys	Ile	Ser	1	5	10	15
Ala	Leu	Ala	Leu	Leu	Lys	Met	Val	Met	His	Ala	Arg	Ser	Gly	Gly	Asn	20	25	30	
Leu	Glu	Val	Met	Gly	Leu	Met	Leu	Gly	Lys	Val	Asp	Gly	Glu	Thr	Met	35	40	45	
Ile	Ile	Met	Asp	Ser	Phe	Ala	Leu	Pro	Val	Glu	Gly	Thr	Glu	Thr	Arg	50	55	60	
Val	Asn	Ala	Gln	Ala	Ala	Ala	Tyr	Glu	Tyr	Met	Ala	Ala	Tyr	Ile	Glu	65	70	75	80
Asn	Ala	Lys	Gln	Val	Gly	Arg	Leu	Glu	Asn	Ala	Ile	Gly	Trp	Tyr	His	85	90	95	
Ser	His	Pro	Gly	Tyr	Gly	Cys	Trp	Leu	Ser	Gly	Ile	Asp	Val	Ser	Thr	100	105	110	
Gln	Met	Leu	Asn	Gln	Gln	Phe	Gln	Glu	Pro	Phe	Val	Ala	Val	Val	Ile	115	120	125	
Asp	Pro	Thr	Arg	Thr	Ile	Ser	Ala	Gly	Lys	Val	Asn	Leu	Gly	Ala	Phe	130	135	140	
Arg	Thr	Tyr	Pro	Lys	Gly	Tyr	Lys	Pro	Pro	Asp	Glu	Gly	Pro	Ser	Glu	145	150	155	160
Tyr	Gln	Thr	Ile	Pro	Leu	Asn	Lys	Ile	Glu	Asp	Phe	Gly	Val	His	Cys	165	170	175	
Lys	Gln	Tyr	Tyr	Ala	Leu	Glu	Val	Ser	Tyr	Phe	Lys	Ser	Ser	Leu	Asp	180	185	190	
Arg	Lys	Leu	Leu	Glu	Leu	Leu	Trp	Asn	Lys	Tyr	Trp	Val	Asn	Thr	Leu	195	200	205	
Ser	Ser	Ser	Ser	Leu	Leu	Thr	Asn	Ala	Asp	Tyr	Thr	Thr	Gly	Gln	Val	210	215	220	
Phe	Asp	Leu	Ser	Glu	Lys	Leu	Glu	Gln	Ser	Glu	Ala	Gln	Leu	Gly	Arg	225	230	235	240

84

Gly Ser Phe Met Leu Gly Leu Glu Thr His Asp Arg Lys Ser Glu Asp
 245 250 255

Lys Leu Ala Lys Ala Thr Arg Asp Ser Cys Lys Thr Thr Ile Glu Ala
 260 265 270

Ile His Gly Leu Met Ser Gln Val Ile Lys Asp Lys Leu Phe Asn Gln
 275 280 285

Ile Asn Ile Ser
 290

<210> 96
 <211> 158
 <212> PRT
 <213> Homo sapien

<400> 96

Met Val Ser Thr Asn Phe Thr Ser Gly Ser Arg Cys His Gly Cys Pro
 1 5 10 15

Lys Ser Leu Gly His His Tyr Phe Lys Tyr Cys Lys Ile Ser Ala Leu
 20 25 30

Ala Leu Leu Lys Met Val Met His Ala Arg Ser Gly Gly Asn Leu Glu
 35 40 45

Val Met Gly Leu Met Leu Gly Lys Val Asp Gly Glu Thr Met Ile Ile
 50 55 60

Met Asp Ser Phe Ala Leu Pro Val Glu Gly Thr Glu Thr Arg Val Asn
 65 70 75 80

Ala Gln Ala Ala Ala Tyr Glu Tyr Met Ala Ala Tyr Ile Glu Asn Ala
 85 90 95

Lys Gln Val Gly Arg Leu Glu Asn Ala Ile Gly Trp Tyr His Ser His
 100 105 110

Pro Gly Tyr Gly Cys Trp Leu Ser Gly Ile Asp Val Ser Thr Gln Met
 115 120 125

Leu Asn Gln Gln Phe Gln Glu Pro Phe Val Ala Val Val Ile Asp Pro
 130 135 140

Thr Arg Thr Ile Ser Ala Gly Lys Ser Glu Ser Trp Arg Leu
 145 150 155

85

<210> 97
 <211> 295
 <212> PRT
 <213> Homo sapien

<400> 97

Val Ser Trp Leu Pro Gln Glu Ser Ser His His Tyr Phe Lys Tyr Cys
 1 5 10 15

Lys Ile Ser Ala Leu Ala Leu Leu Lys Met Val Met His Ala Arg Ser
 20 25 30

Gly Gly Asn Leu Glu Val Met Gly Leu Met Leu Gly Lys Val Asp Gly
 35 40 45

Glu Thr Met Ile Ile Met Asp Ser Phe Ala Leu Pro Val Glu Gly Thr
 50 55 60

Glu Thr Arg Val Asn Ala Gln Ala Ala Ala Tyr Glu Tyr Met Ala Ala
 65 70 75 80

Tyr Ile Glu Asn Ala Lys Gln Val Gly Arg Leu Glu Asn Ala Ile Gly
 85 90 95

Trp Tyr His Ser His Pro Gly Tyr Gly Cys Trp Leu Ser Gly Ile Asp
 100 105 110

Val Ser Thr Gln Met Leu Asn Gln Gln Phe Gln Glu Pro Phe Val Ala
 115 120 125

Val Val Ile Asp Pro Thr Arg Thr Ile Ser Ala Gly Lys Val Asn Leu
 130 135 140

Gly Ala Phe Arg Thr Tyr Pro Lys Gly Tyr Lys Pro Pro Asp Glu Gly
 145 150 155 160

Pro Ser Glu Tyr Gln Thr Ile Pro Leu Asn Lys Ile Glu Asp Phe Gly
 165 170 175

Val His Cys Lys Gln Tyr Tyr Ala Leu Glu Val Ser Tyr Phe Lys Ser
 180 185 190

Ser Leu Asp Arg Lys Leu Leu Glu Leu Leu Trp Asn Lys Tyr Trp Val
 195 200 205

86

Asn Thr Leu Ser Ser Ser Ser Leu Leu Thr Asn Ala Asp Tyr Thr Thr
 210 215 220

Gly Gln Val Phe Asp Leu Ser Glu Lys Leu Glu Gln Ser Glu Ala Gln
 225 230 235 240

Leu Gly Arg Gly Ser Phe Met Leu Gly Leu Glu Thr His Asp Arg Lys
 245 250 255

Ser Glu Asp Lys Leu Ala Lys Ala Thr Arg Asp Ser Cys Lys Thr Thr
 260 265 270

Ile Glu Ala Ile His Gly Leu Met Ser Gln Val Ile Lys Asp Lys Leu
 275 280 285

Phe Asn Gln Ile Asn Ile Ser
 290 295

<210> 98
 <211> 152
 <212> PRT
 <213> Homo sapien

<400> 98

Met Lys Ser Thr Asn Thr Thr Arg Asn Ser Ser Lys Lys Ser Trp Arg
 1 5 10 15

Arg Ser Pro Gly Leu Arg Arg Ser His His Tyr Phe Lys Tyr Cys Lys
 20 25 30

Ile Ser Ala Leu Ala Leu Leu Lys Met Val Met His Ala Arg Ser Gly
 35 40 45

Gly Asn Leu Glu Val Met Gly Leu Met Leu Gly Lys Val Asp Gly Glu
 50 55 60

Thr Met Ile Ile Met Asp Ser Phe Ala Leu Pro Val Glu Gly Thr Glu
 65 70 75 80

Thr Arg Val Asn Ala Gln Ala Ala Ala Tyr Glu Tyr Met Ala Ala Tyr
 85 90 95

Ile Glu Asn Ala Lys Gln Val Gly Arg Leu Glu Asn Ala Ile Gly Trp
 100 105 110

Tyr His Ser His Pro Gly Tyr Gly Cys Trp Leu Ser Gly Ile Asp Val
 115 120 125

87

Ser Thr Gln Met Leu Asn Gln Gln Phe Gln Glu Pro Phe Val Ala Val
 130 135 140

Val Val Thr Met Gly Lys Ala Ala
 145 150

<210> 99
 <211> 211
 <212> PRT
 <213> Homo sapien

<400> 99

Glu Phe Val Pro Val Val Arg Arg Val Lys Ala His Thr Arg Lys Pro
 1 5 10 15

Ser Glu Val Lys Leu Arg Leu Gly Cys Arg Asp Asp Asn Phe Ser Ala
 20 25 30

Ser Ser Ala Met Ala Ala Ser Gly Ser Gly Met Ala Gln Lys Thr Trp
 35 40 45

Glu Leu Ala Asn Asn Met Gln Glu Ala Gln Ser Ile Asp Glu Ile Tyr
 50 55 60

Lys Tyr Asp Lys Lys Gln Gln Gln Glu Ile Leu Ala Ala Lys Pro Trp
 65 70 75 80

Thr Lys Asp His His Tyr Phe Lys Tyr Cys Lys Ile Ser Ala Leu Ala
 85 90 95

Leu Leu Lys Met Val Met His Ala Arg Ser Gly Gly Asn Leu Glu Val
 100 105 110

Met Gly Leu Met Leu Gly Lys Val Asp Gly Glu Thr Met Ile Ile Met
 115 120 125

Asp Ser Phe Ala Leu Pro Val Glu Gly Thr Glu Thr Arg Val Asn Ala
 130 135 140

Gln Ala Ala Ala Tyr Glu Tyr Met Ala Ala Tyr Ile Glu Asn Ala Lys
 145 150 155 160

Gln Val Gly Arg Leu Glu Asn Ala Ile Gly Trp Tyr His Ser His Pro
 165 170 175

88

Gly Tyr Gly Cys Trp Leu Ser Gly Ile Asp Val Ser Thr Gln Met Leu
 180 185 190

Asn Gln Gln Phe Gln Glu Pro Phe Val Ala Val Val Val Thr Met Gly
 195 200 205

Lys Ala Ala
 210

<210> 100
 <211> 149
 <212> PRT
 <213> Homo sapien

<400> 100

Leu Arg Arg Ser Phe Ile Arg Arg Phe Val Ala Leu Trp Val Cys Pro
 1 5 10 15

Lys Gly Ala Asn Ile Pro Leu Asn Lys Ile Glu Asp Phe Gly Val His
 20 25 30

Cys Lys Gln Tyr Tyr Ala Leu Glu Val Ser Tyr Phe Lys Ser Ser Leu
 35 40 45

Asp Arg Lys Leu Leu Glu Leu Leu Trp Asn Lys Tyr Trp Val Asn Thr
 50 55 60

Leu Ser Ser Ser Ser Leu Leu Thr Asn Ala Asp Tyr Thr Thr Gly Gln
 65 70 75 80

Val Phe Asp Leu Ser Glu Lys Leu Glu Gln Ser Glu Ala Gln Leu Gly
 85 90 95

Arg Gly Ser Phe Met Leu Gly Leu Glu Thr His Asp Arg Lys Ser Glu
 100 105 110

Asp Lys Leu Ala Lys Ala Thr Arg Asp Ser Cys Lys Thr Thr Ile Glu
 115 120 125

Ala Ile His Gly Leu Met Ser Gln Val Ile Lys Asp Lys Leu Phe Asn
 130 135 140

Gln Ile Asn Ile Ser
 145

<210> 101
 <211> 199

89

<212> PRT

<213> Homo sapien

<400> 101

Met Ser Ser Gly Asn Ala Lys Ile Gly His Pro Ala Pro Asn Phe Lys
 1 5 10 15

Ala Thr Ala Val Met Pro Asp Gly Gln Phe Lys Asp Ile Ser Leu Ser
 20 25 30

Asp Tyr Lys Gly Lys Tyr Val Val Phe Phe Phe Tyr Pro Leu Asp Phe
 35 40 45

Thr Phe Val Cys Pro Thr Glu Ile Ile Ala Phe Ser Asp Arg Ala Glu
 50 55 60

Glu Phe Lys Lys Leu Asn Cys Gln Val Ile Gly Ala Ser Val Asp Ser
 65 70 75 80

His Phe Cys His Leu Ala Trp Val Asn Thr Pro Lys Lys Gln Gly Gly
 85 90 95

Leu Gly Pro Met Asn Ile Pro Leu Val Ser Asp Pro Lys Arg Thr Ile
 100 105 110

Ala Gln Asp Tyr Gly Val Leu Lys Ala Asp Glu Gly Ile Ser Phe Arg
 115 120 125

Gly Leu Phe Ile Ile Asp Asp Lys Gly Ile Leu Arg Gln Ile Thr Val
 130 135 140

Asn Asp Leu Pro Val Gly Arg Ser Val Asp Glu Thr Leu Arg Leu Val
 145 150 155 160

Gln Ala Phe Gln Phe Thr Asp Lys His Gly Glu Val Cys Pro Ala Gly
 165 170 175

Trp Lys Pro Gly Ser Asp Thr Ile Lys Pro Asp Val Gln Lys Ser Lys
 180 185 190

Glu Tyr Phe Ser Lys Gln Lys
 195

<210> 102

<211> 49

<212> PRT

<213> Homo sapien

90

<400> 102

Ser Pro His Val Gln Pro Pro Asp Trp Gly Thr Gly Thr Gln Pro Glu
 1 5 10 15

Ser Ala Ser Cys Val Leu Gln Ala Gly Ala Glu Ile Ser Thr Val Asn
 20 25 30

Pro Glu Gln Tyr Ser Lys Arg Phe Asn Glu Phe Met Ser Asn Ile Leu
 35 40 45

Thr

<210> 103

<211> 132

<212> PRT

<213> Homo sapien

<400> 103

Thr Thr Leu Arg Ala Leu Ala Leu Asn Leu Trp Pro Pro Lys Ser Arg
 1 5 10 15

Ser Leu Ile Ser Ser Trp Gln Ser Cys Gly Gln Glu Val Leu Lys Gly
 20 25 30

Lys Thr His Ser Asp Asn Cys Ser Pro Ile Tyr Gln Pro Ser Ala Gly
 35 40 45

Val Ser Asp Arg Gly Pro Leu Pro Pro Leu Glu Cys Ala Thr Tyr Glu
 50 55 60

Glu Cys Pro Met Gly Lys Arg Arg Leu Ser Cys Pro Leu Ala Ala Cys
 65 70 75 80

Ala Ser Ile Pro Gly Gln Lys Phe Pro Gln Glu Pro Leu Ala Leu Ala
 85 90 95

Gln Ser His Cys Glu Arg Arg Trp Glu Pro Thr Pro Leu Gly Glu Gly
 100 105 110

Ala Val Leu Leu Gly Thr Ser Gln His Gln Val Arg Ser Leu Lys Leu
 115 120 125

Lys Asn Val Asn
 130

91

<210> 104
 <211> 71
 <212> PRT
 <213> Homo sapien

<400> 104

Met Arg Ser Arg Asn Phe Ala Gly Gly Gln Arg Gly Trp Arg Cys Asp
 1 5 10 15

Asn Cys Arg Arg Pro Gly Gly Glu Pro Ser Pro Glu Gly Thr Thr Gly
 20 25 30

Gln Ser Tyr Asn Gln Tyr Ser Gln Arg Tyr His Gln Arg Thr Asn Thr
 35 40 45

Asn Val Asn Cys Pro Ile Glu Cys Phe Met Pro Leu Asp Val Gln Ala
 50 55 60

Asp Arg Glu Asp Ser Arg Glu
 65 70

<210> 105
 <211> 177
 <212> PRT
 <213> Homo sapien

<400> 105

Met Lys Val Phe Cys Asn Met Glu Thr Gly Glu Thr Cys Val Tyr Pro
 1 5 10 15

Asn Pro Ala Asn Val Pro Lys Lys Asn Trp Trp Ser Ser Lys Ser Lys
 20 25 30

Glu Lys Lys His Ile Trp Phe Gly Glu Thr Ile Asn Gly Gly Phe His
 35 40 45

Phe Ser Tyr Gly Asp Asp Asn Leu Ala Pro Asn Thr Ala Asn Val Gln
 50 55 60

Met Thr Phe Leu Arg Leu Leu Ser Thr Glu Gly Ser Gln Asn Ile Thr
 65 70 75 80

Tyr His Cys Lys Asn Ser Ile Ala Tyr Leu Asp Glu Ala Ala Gly Asn
 85 90 95

Leu Lys Lys Ala Leu Leu Ile Gln Gly Ser Asn Asp Val Glu Ile Arg
 100 105 110

92

Ala Glu Gly Asn Ser Arg Phe Thr Tyr Thr Ala Leu Lys Asp Gly Cys
 115 120 125

Thr Lys His Thr Gly Lys Trp Gly Lys Thr Val Ile Glu Tyr Arg Ser
 130 135 140

Gln Lys Thr Ser Arg Leu Pro Ile Ile Asp Ile Ala Pro Met Asp Ile
 145 150 155 160

Gly Gly Pro Glu Gln Glu Phe Gly Val Asp Ile Gly Pro Val Cys Phe
 165 170 175

Leu

<210> 106
 <211> 175
 <212> PRT
 <213> Homo sapien

<400> 106

Met Asn Ser Ile Ala Ser Val Arg Asp Thr His Phe Pro Gly Pro Asp
 1 5 10 15

Leu Ile Gly Ile Ser Val Ala Thr Asp Ser Ile Cys Glu Leu Ile Gln
 20 25 30

Tyr Ile Thr Arg Tyr Ile Ala Ser Leu Lys Gln Arg Tyr Thr Gln Ser
 35 40 45

Asn Gly Arg Arg Pro Phe Gly Ile Ser Ala Leu Ile Val Gly Phe Asp
 50 55 60

Phe Asp Gly Thr Pro Arg Leu Tyr Gln Thr Asp Pro Ser Gly Thr Tyr
 65 70 75 80

His Ala Trp Lys Ala Asn Ala Ile Gly Arg Gly Ala Lys Ser Val Arg
 85 90 95

Glu Phe Leu Glu Lys Asn Tyr Thr Asp Glu Ala Ile Glu Thr Asp Asp
 100 105 110

Leu Thr Ile Lys Leu Val Ile Lys Ala Leu Leu Glu Val Val Gln Ser
 115 120 125

93

Gly Gly Lys Asn Ile Glu Leu Ala Val Met Arg Arg Asp Gln Ser Leu
 130 135 140

Lys Ile Leu Asn Pro Glu Glu Ile Glu Lys Tyr Val Ala Glu Ile Glu
 145 150 155 160

Lys Glu Lys Glu Glu Asn Glu Lys Lys Lys Gln Lys Lys Ala Ser
 165 170 175

<210> 107
 <211> 501
 <212> PRT
 <213> Homo sapien
 <400> 107

Met Trp Pro Ser Glu Ser Thr Trp Gly Ser Lys Phe Gln Ile Leu Ala
 1 5 10 15

Ser Leu Val Pro Gly Arg Ala Tyr Lys Ser Arg Ala Ser Pro Phe Val
 20 25 30

Thr Cys Ile Phe Phe Leu Pro Leu Cys Thr Leu Cys Leu Ser Leu Pro
 35 40 45

Leu Ser Leu Phe Leu Cys Leu Leu Leu Trp Leu Ser Ser Pro Ser Ser
 50 55 60

Leu Arg Ser Gln Asp Arg His Asp Gly Val Pro Ser His Ser Ser Arg
 65 70 75 80

Leu Ser Gln Leu Gly Ser Val Ser Gln Gly Pro Tyr Ser Ser Ala Pro
 85 90 95

Pro Leu Ser His Thr Pro Ser Ser Asp Phe Gln Pro Pro Tyr Phe Pro
 100 105 110

Pro Pro Tyr Gln Pro Leu Pro Tyr His Gln Ser Gln Asp Pro Tyr Ser
 115 120 125

His Val Asn Asp Pro Tyr Ser Leu Asn Pro Leu His Gln Pro Gln Gln
 130 135 140

His Pro Trp Gly Gln Arg Gln Arg Gln Glu Val Gly Ser Glu Ala Gly
 145 150 155 160

Ser Leu Leu Pro Gln Pro Arg Ala Ala Leu Pro Gln Leu Ser Gly Leu
 165 170 175

Asp Pro Arg Arg Asp Tyr His Ser Val Arg Arg Pro Asp Val Leu Leu
 180 185 190

His Ser Ala His His Gly Leu Asp Ala Gly Met Gly Asp Ser Leu Ser
 195 200 205

Leu His Gly Leu Gly His Pro Gly Met Glu Asp Val Gln Ser Val Glu
 210 215 220

Asp Ala Asn Asn Ser Gly Met Asn Leu Leu Asp Gln Ser Val Ile Lys
 225 230 235 240

Lys Val Pro Val Pro Pro Lys Ser Val Thr Ser Leu Met Met Asn Lys
 245 250 255

Asp Gly Phe Leu Gly Gly Met Ser Val Asn Thr Gly Glu Val Phe Cys
 260 265 270

Ser Val Pro Gly Arg Leu Ser Leu Leu Ser Ser Thr Ser Lys Tyr Lys
 275 280 285

Val Thr Val Gly Glu Val Gln Arg Arg Leu Ser Pro Pro Glu Cys Leu
 290 295 300

Asn Ala Ser Leu Leu Gly Gly Val Leu Arg Arg Ala Lys Ser Lys Asn
 305 310 315 320

Gly Gly Arg Ser Leu Arg Glu Arg Leu Glu Lys Ile Gly Leu Asn Leu
 325 330 335

Pro Ala Gly Arg Arg Lys Ala Ala Asn Val Thr Leu Leu Thr Ser Leu
 340 345 350

Val Glu Gly Glu Ala Val His Leu Ala Arg Asp Phe Gly Tyr Ile Cys
 355 360 365

Glu Thr Glu Phe Pro Ala Lys Ala Val Ser Glu Tyr Leu Asn Arg Gln
 370 375 380

His Thr Asp Pro Ser Asp Leu His Ser Arg Lys Asn Met Leu Leu Ala
 385 390 395 400

Thr Lys Gln Leu Cys Lys Glu Phe Thr Asp Leu Leu Ala Gln Asp Arg
 405 410 415

95

Thr Pro Ile Gly Asn Ser Arg Pro Ser Pro Ile Leu Glu Pro Gly Ile
 420 425 430

Gln Ser Cys Leu Thr His Phe Ser Leu Ile Thr His Gly Phe Gly Ala
 435 440 445

Pro Ala Ile Cys Ala Ala Leu Thr Ala Leu Gln Asn Tyr Leu Thr Glu
 450 455 460

Ala Leu Lys Gly Met Asp Lys Met Phe Leu Asn Asn Thr Thr Thr Asn
 465 470 475 480

Arg His Thr Ser Gly Glu Gly Pro Gly Ser Lys Thr Gly Asp Lys Glu
 485 490 495

Glu Lys His Arg Lys
 500

<210> 108
 <211> 458
 <212> PRT
 <213> Homo sapien

<400> 108

Met Leu Trp Lys Leu Val Glu Asn Val Lys Tyr Glu Asp Ile Tyr Glu
 1 5 10 15

Met Leu Val His Thr Tyr Ser Ser Met Asp Arg His Asp Gly Val Pro
 20 25 30

Ser His Ser Ser Arg Leu Ser Gln Leu Gly Ser Val Ser Gln Gly Pro
 35 40 45

Tyr Ser Ser Ala Pro Pro Leu Ser His Thr Pro Ser Ser Asp Phe Gln
 50 55 60

Pro Pro Tyr Phe Pro Pro Pro Tyr Gln Pro Leu Pro Tyr His Gln Ser
 65 70 75 80

Gln Asp Pro Tyr Ser His Val Asn Asp Pro Tyr Ser Leu Asn Pro Leu
 85 90 95

His Gln Pro Gln Gln His Pro Trp Gly Gln Arg Gln Arg Gln Glu Val
 100 105 110

Gly Ser Glu Ala Gly Ser Leu Leu Pro Gln Pro Arg Ala Ala Leu Pro

96

115		120		125
Gln Leu Ser Gly Leu Asp Pro Arg Arg Asp Tyr His Ser Val Arg Arg				
130		135		140
Pro Asp Val Leu Leu His Ser Ala His His Gly Leu Asp Ala Gly Met				
145		150		155
				160
Gly Asp Ser Leu Ser Leu His Gly Leu Gly His Pro Gly Met Glu Asp				
		165		170
				175
Val Gln Ser Val Glu Asp Ala Asn Asn Ser Gly Met Asn Leu Leu Asp				
		180		185
				190
Gln Ser Val Ile Lys Lys Val Pro Val Pro Pro Lys Ser Val Thr Ser				
195		200		205
Leu Met Met Asn Lys Asp Gly Phe Leu Gly Gly Met Ser Val Asn Thr				
210		215		220
Gly Glu Val Phe Cys Ser Val Pro Gly Arg Leu Ser Leu Leu Ser Ser				
225		230		235
				240
Thr Ser Lys Tyr Lys Val Thr Val Gly Glu Val Gln Arg Arg Leu Ser				
		245		250
				255
Pro Pro Glu Cys Leu Asn Ala Ser Leu Leu Gly Gly Val Leu Arg Arg				
		260		265
				270
Ala Lys Ser Lys Asn Gly Gly Arg Ser Leu Arg Glu Arg Leu Glu Lys				
275		280		285
Ile Gly Leu Asn Leu Pro Ala Gly Arg Arg Lys Ala Ala Asn Val Thr				
290		295		300
Leu Leu Thr Ser Leu Val Glu Gly Glu Ala Val His Leu Ala Arg Asp				
305		310		315
				320
Phe Gly Tyr Ile Cys Glu Thr Glu Phe Pro Ala Lys Ala Val Ser Glu				
		325		330
				335
Tyr Leu Asn Arg Gln His Thr Asp Pro Ser Asp Leu His Ser Arg Lys				
		340		345
				350
Asn Met Leu Leu Ala Thr Lys Gln Leu Cys Lys Glu Phe Thr Asp Leu				
355		360		365

97

Leu Ala Gln Asp Arg Thr Pro Ile Gly Asn Ser Arg Pro Ser Pro Ile
 370 375 380

Leu Glu Pro Gly Ile Gln Ser Cys Leu Thr His Phe Ser Leu Ile Thr
 385 390 395 400

His Gly Phe Gly Ala Pro Ala Ile Cys Ala Ala Leu Thr Ala Leu Gln
 405 410 415

Asn Tyr Leu Thr Glu Ala Leu Lys Gly Met Asp Lys Met Phe Leu Asn
 420 425 430

Asn Thr Thr Thr Asn Arg His Thr Ser Gly Glu Gly Pro Gly Ser Lys
 435 440 445

Thr Gly Asp Lys Glu Glu Lys His Arg Lys
 450 455

<210> 109

<211> 469

<212> PRT

<213> Homo sapien

<400> 109

Met His Ser Pro Pro Arg Asp Gln Ala Ala Ile Met Leu Trp Lys Leu
 1 5 10 15

Val Glu Asn Val Lys Tyr Glu Asp Ile Tyr Glu Met Leu Val His Thr
 20 25 30

Tyr Ser Ser Met Asp Arg His Asp Gly Val Pro Ser His Ser Ser Arg
 35 40 45

Leu Ser Gln Leu Gly Ser Val Ser Gln Gly Pro Tyr Ser Ser Ala Pro
 50 55 60

Pro Leu Ser His Thr Pro Ser Ser Asp Phe Gln Pro Pro Tyr Phe Pro
 65 70 75 80

Pro Pro Tyr Gln Pro Leu Pro Tyr His Gln Ser Gln Asp Pro Tyr Ser
 85 90 95

His Val Asn Asp Pro Tyr Ser Leu Asn Pro Leu His Gln Pro Gln Gln
 100 105 110

98

His Pro Trp Gly Gln Arg Gln Arg Gln Glu Val Gly Ser Glu Ala Gly
 115 120 125

Ser Leu Leu Pro Gln Pro Arg Ala Ala Leu Pro Gln Leu Ser Gly Leu
 130 135 140

Asp Pro Arg Arg Asp Tyr His Ser Val Arg Arg Pro Asp Val Leu Leu
 145 150 155 160

His Ser Ala His His Gly Leu Asp Ala Gly Met Gly Asp Ser Leu Ser
 165 170 175

Leu His Gly Leu Gly His Pro Gly Met Glu Asp Val Gln Ser Val Glu
 180 185 190

Asp Ala Asn Asn Ser Gly Met Asn Leu Leu Asp Gln Ser Val Ile Lys
 195 200 205

Lys Val Pro Val Pro Pro Lys Ser Val Thr Ser Leu Met Met Asn Lys
 210 215 220

Asp Gly Phe Leu Gly Gly Met Ser Val Asn Thr Gly Glu Val Phe Cys
 225 230 235 240

Ser Val Pro Gly Arg Leu Ser Leu Leu Ser Ser Thr Ser Lys Tyr Lys
 245 250 255

Val Thr Val Gly Glu Val Gln Arg Arg Leu Ser Pro Pro Glu Cys Leu
 260 265 270

Asn Ala Ser Leu Leu Gly Gly Val Leu Arg Arg Ala Lys Ser Lys Asn
 275 280 285

Gly Gly Arg Ser Leu Arg Glu Arg Leu Glu Lys Ile Gly Leu Asn Leu
 290 295 300

Pro Ala Gly Arg Arg Lys Ala Ala Asn Val Thr Leu Leu Thr Ser Leu
 305 310 315 320

Val Glu Gly Glu Ala Val His Leu Ala Arg Asp Phe Gly Tyr Ile Cys
 325 330 335

Glu Thr Glu Phe Pro Ala Lys Ala Val Ser Glu Tyr Leu Asn Arg Gln
 340 345 350

His Thr Asp Pro Ser Asp Leu His Ser Arg Lys Asn Met Leu Leu Ala

99

355

360

365

Thr Lys Gln Leu Cys Lys Glu Phe Thr Asp Leu Leu Ala Gln Asp Arg
 370 375 380

Thr Pro Ile Gly Asn Ser Arg Pro Ser Pro Ile Leu Glu Pro Gly Ile
 385 390 395 400

Gln Ser Cys Leu Thr His Phe Ser Leu Ile Thr His Gly Phe Gly Ala
 405 410 415

Pro Ala Ile Cys Ala Ala Leu Thr Ala Leu Gln Asn Tyr Leu Thr Glu
 420 425 430

Ala Leu Lys Gly Met Asp Lys Met Phe Leu Asn Asn Thr Thr Thr Asn
 435 440 445

Arg His Thr Ser Gly Glu Gly Pro Gly Ser Lys Thr Gly Asp Lys Glu
 450 455 460

Glu Lys His Arg Lys
 465

<210> 110
 <211> 201
 <212> PRT
 <213> Homo sapien

<400> 110

Met Ala His Ala Met Glu Asn Ser Trp Thr Ile Ser Lys Glu Tyr His
 1 5 10 15

Ile Asp Glu Glu Val Gly Phe Ala Leu Pro Asn Pro Gln Glu Asn Leu
 20 25 30

Pro Asp Phe Tyr Asn Asp Trp Met Phe Ile Ala Lys His Leu Pro Asp
 35 40 45

Leu Ile Glu Ser Gly Gln Leu Arg Glu Arg Val Glu Lys Leu Asn Met
 50 55 60

Leu Ser Ile Asp His Leu Thr Asp His Lys Ser Gln Arg Leu Ala Arg
 65 70 75 80

Leu Val Leu Gly Cys Ile Thr Met Ala Tyr Val Trp Gly Lys Gly His
 85 90 95

100

Gly Asp Val Arg Lys Val Leu Pro Arg Asn Ile Ala Val Pro Tyr Cys
 100 105 110

Gln Leu Ser Lys Lys Leu Glu Leu Pro Pro Ile Leu Val Tyr Ala Asp
 115 120 125

Cys Val Leu Ala Asn Trp Lys Lys Lys Asp Pro Asn Lys Pro Leu Thr
 130 135 140

Tyr Glu Asn Met Asp Val Leu Phe Ser Phe Arg Asp Gly Asp Cys Ser
 145 150 155 160

Lys Gly Phe Phe Leu Val Ser Leu Leu Val Glu Ile Ala Ala Ala Ser
 165 170 175

Ala Ile Lys Val Arg Leu Ser Ser Leu Gln Asn Leu Tyr Val Asn Leu
 180 185 190

Arg Lys Gln Ser Asn His Phe Gly Ala
 195 200

<210> 111

<211> 133

<212> PRT

<213> Homo sapien

<400> 111

Met Asp Arg His Ser Ser Tyr Ile Phe Ile Trp Leu Gln Leu Glu Leu
 1 5 10 15

Cys Ala Met Ala Val Leu Leu Thr Lys Gly Glu Ile Arg Cys Tyr Cys
 20 25 30

Asp Ala Ala His Cys Val Ala Thr Gly Tyr Met Cys Lys Ser Glu Leu
 35 40 45

Ser Ala Cys Phe Ser Arg Leu Leu Asp Pro Gln Asn Ser Asn Ser Pro
 50 55 60

Leu Thr His Gly Cys Leu Asp Ser Leu Ala Ser Thr Thr Asp Ile Cys
 65 70 75 80

Gln Ala Lys Gln Ala Arg Asn His Ser Gly Thr Thr Ile Pro Thr Leu
 85 90 95

Glu Cys Cys His Glu Asp Met Cys Asn Tyr Arg Gly Leu His Asp Val

100 101 110
 Leu Ser Pro Pro Arg Gly Glu Ala Ser Gly Arg Trp Lys Pro Phe Leu
 115 120 125
 Thr Arg Met Pro Ala
 130
 <210> 112
 <211> 157
 <212> PRT
 <213> Homo sapien
 <400> 112
 Ile Ser Leu Gly Gly Val Ser Met Glu Phe Asp His Phe Leu Cys Thr
 1 5 10 15
 Pro Leu Gly Gln Gly Asn Arg Tyr Gln His Asp Gly Ser Arg Asn Leu
 20 25 30
 Ile Thr Lys Val Gln Glu Leu Thr Ser Ser Lys Glu Leu Trp Phe Arg
 35 40 45
 Ala Ala Val Ile Ala Val Pro Ile Ala Gly Gly Leu Ile Leu Val Leu
 50 55 60
 Leu Ile Met Leu Ala Leu Arg Met Leu Arg Ser Glu Asn Lys Arg Leu
 65 70 75 80
 Gln Asp Gln Arg Gln Gln Met Leu Ser Arg Leu His Tyr Ser Phe His
 85 90 95
 Gly His His Ser Lys Lys Gly Gln Val Ala Lys Leu Asp Leu Glu Cys
 100 105 110
 Met Val Pro Val Ser Gly His Glu Asn Cys Cys Leu Thr Cys Asp Lys
 115 120 125
 Met Arg Gln Ala Asp Leu Ser Asn Asp Lys Ile Leu Ser Leu Val His
 130 135 140
 Trp Gly Met Tyr Ser Gly His Gly Lys Leu Glu Phe Val
 145 150 155
 <210> 113
 <211> 121
 <212> PRT

102

<213> Homo sapien

<400> 113

Met Asp Arg His Ser Ser Tyr Ile Phe Ile Trp Leu Gln Leu Glu Leu
 1 5 10 15

Cys Ala Met Ala Val Leu Leu Thr Lys Gly Glu Ile Arg Cys Tyr Cys
 20 25 30

Asp Ala Ala His Cys Val Ala Thr Gly Tyr Met Cys Lys Ser Glu Leu
 35 40 45

Ser Ala Cys Phe Ser Arg Leu Leu Asp Pro Gln Asn Ser Asn Ser Pro
 50 55 60

Leu Thr His Gly Cys Leu Asp Ser Leu Ala Ser Thr Thr Asp Ile Cys
 65 70 75 80

Gln Ala Lys Gln Ala Arg Asn His Ser Gly Thr Thr Ile Pro Thr Leu
 85 90 95

Glu Cys Cys His Glu Asp Lys Glu Thr Gly Ile Ser Met Met Val Ala
 100 105 110

Glu Thr Leu Ser Pro Arg Cys Arg Ser
 115 120

<210> 114

<211> 149

<212> PRT

<213> Homo sapien

<400> 114

Met Arg Leu Met Glu Gly Asp Val Asn Ser Thr Glu Val Leu Ile Ser
 1 5 10 15

Ala Arg Ser Tyr Leu Cys Thr Leu Pro Pro Ala Leu Leu Ser Arg Glu
 20 25 30

Ile Leu Met Ala Asp Ser Glu Ala Leu Pro Ser Leu Ala Gly Asp Pro
 35 40 45

Val Ala Val Glu Ala Leu Leu Arg Ala Val Phe Gly Val Val Val Asp
 50 55 60

Glu Ala Ile Gln Lys Gly Thr Ser Val Ser Gln Lys Val Cys Glu Trp
 65 70 75 80

103

Lys Glu Pro Glu Glu Leu Lys Gln Leu Leu Asp Leu Glu Leu Arg Ser
 85 90 95

Gln Gly Glu Ser Gln Lys Gln Ile Leu Glu Arg Cys Arg Ala Val Ile
 100 105 110

Arg Tyr Ser Val Lys Thr Gly His Pro Arg Phe Phe Asn Gln Leu Phe
 115 120 125

Ser Gly Leu Asp Pro His Ala Leu Ala Gly Arg Ile Ile Thr Glu Ser
 130 135 140

Leu Asn Thr Ser Gln
 145

<210> 115
 <211> 204
 <212> PRT
 <213> Homo sapien

<400> 115

Gly Pro Val Trp Ala Val Pro Pro His Leu Ser Phe Leu Val Val Leu
 1 5 10 15

Ser Pro Gly Arg Tyr Thr Tyr Glu Ile Ala Pro Val Phe Val Leu Met
 20 25 30

Glu Glu Glu Val Leu Arg Lys Leu Arg Ala Leu Val Gly Trp Ser Ser
 35 40 45

Gly Asp Gly Ile Phe Cys Pro Gly Gly Ser Ile Ser Asn Met Tyr Ala
 50 55 60

Val Asn Leu Ala Arg Tyr Gln Arg Tyr Pro Asp Cys Lys Gln Arg Gly
 65 70 75 80

Leu Arg Thr Leu Pro Pro Leu Ala Leu Phe Thr Ser Lys Glu Val Gly
 85 90 95

Lys Arg His Arg Pro Asn Pro Gly Leu Leu Ile Leu Ile Ser Ser Gln
 100 105 110

Leu Ser Arg Asp Leu Pro Gly Leu Leu Pro Ala Leu Pro Thr Ser Ser
 115 120 125

104

Lys Ala Ser Leu Pro Pro Gly Gly Cys Ala Ser Phe Gln Ser Arg Arg
 130 135 140

Ser Ser Asn Cys Ser Cys Ser His Cys Leu Leu Phe Gly Gly Arg Gly
 145 150 155 160

Gly Ala Val Ser Ala Val Asp Thr Val His Thr Leu Pro Thr Gln Glu
 165 170 175

Cys Gly Leu Trp Thr Ser Ser Ile Gly Met Thr Trp Gly Leu Leu Glu
 180 185 190

Met Gln Asn Leu Ala Gly His Gly Asp Ser Arg Leu
 195 200

<210> 116

<211> 194

<212> PRT

<213> Homo sapien

<400> 116

Met Gln Arg Pro Gly Trp Trp Lys Gly Glu Glu Asn Trp Ala Gly Gln
 1 5 10 15

Ile Ser Gly Trp Gly Leu Trp Arg Trp Arg Gly Gln Gly Trp Ser Pro
 20 25 30

Gly Thr Lys Lys Gly Arg Gly Ser Ala Arg Pro Glu Glu Trp Glu Glu
 35 40 45

Met Gly Pro Gly Cys Arg Val Pro Arg Gly Leu Gly Gln Gly Pro Arg
 50 55 60

Cys Arg Arg Lys Met Arg Glu Phe Gly Phe Gly Asp Leu Val His Pro
 65 70 75 80

Gly Pro Val Leu Pro Pro Leu Pro Pro Gln Arg Arg Ala Ser Cys Ile
 85 90 95

Pro Phe Leu Trp Pro Glu Gly Ser Ser Val His Pro Ser Gln Ala Leu
 100 105 110

Ala Ser Ser His Ser Pro Ala Leu Gly Pro Ile Arg Leu Gly Arg Met
 115 120 125

Gly Glu Pro Val Val Ala Pro Gly Arg Gly Lys Gly Gly Arg Leu Gly
 130 135 140

105

Lys Pro Leu Leu Gly Arg Thr Gln Tyr Ser Gly Ser Ser Leu Ser Gly
 145 150 155 160

Lys Glu Arg Ile Cys Val Thr Arg Ser Tyr Arg Gly Thr Leu Arg Gly
 165 170 175

Leu Arg Gly Arg Ala Trp Ser Pro Pro Arg Gly Lys Glu Lys Phe Phe
 180 185 190

Glu Ser

<210> 117
 <211> 472
 <212> PRT
 <213> Homo sapien

<400> 117

Met Ser Asp Thr Ser Glu Ser Gly Ala Gly Leu Thr Arg Phe Gln Ala
 1 5 10 15

Glu Ala Ser Glu Lys Asp Ser Ser Ser Met Met Gln Thr Leu Leu Thr
 20 25 30

Val Thr Gln Asn Val Glu Val Pro Glu Thr Pro Lys Ala Ser Lys Ala
 35 40 45

Leu Glu Val Ser Glu Asp Val Lys Val Ser Lys Ala Ser Gly Val Ser
 50 55 60

Lys Ala Thr Glu Val Ser Lys Thr Pro Glu Ala Arg Glu Ala Pro Ala
 65 70 75 80

Thr Gln Ala Ser Ser Thr Thr Gln Leu Thr Asp Thr Gln Val Leu Ala
 85 90 95

Ala Glu Asn Lys Ser Leu Ala Ala Asp Thr Lys Lys Gln Asn Ala Asp
 100 105 110

Pro Gln Ala Val Thr Met Pro Ala Thr Glu Thr Lys Lys Val Ser His
 115 120 125

Val Ala Asp Thr Lys Val Asn Thr Lys Ala Gln Glu Thr Glu Ala Ala
 130 135 140

106

Pro Ser Gln Ala Pro Ala Asp Glu Pro Glu Pro Glu Ser Ala Ala Ala
 145 150 155 160

Gln Ser Gln Glu Asn Gln Asp Thr Arg Pro Lys Val Lys Ala Lys Lys
 165 170 175

Ala Arg Lys Val Lys His Leu Asp Gly Glu Glu Asp Gly Ser Ser Asp
 180 185 190

Gln Ser Gln Ala Ser Gly Thr Thr Gly Gly Arg Arg Val Ser Lys Ala
 195 200 205

Leu Met Ala Ser Met Ala Arg Arg Ala Ser Arg Gly Pro Ile Ala Phe
 210 215 220

Trp Ala Arg Arg Ala Ser Arg Thr Arg Leu Ala Ala Trp Ala Arg Arg
 225 230 235 240

Ala Leu Leu Ser Leu Arg Ser Pro Lys Ala Arg Arg Gly Lys Ala Arg
 245 250 255

Arg Arg Ala Ala Lys Leu Gln Ser Ser Gln Glu Pro Glu Ala Pro Pro
 260 265 270

Pro Arg Asp Val Ala Leu Leu Gln Gly Arg Ala Asn Asp Leu Val Lys
 275 280 285

Tyr Leu Leu Ala Lys Asp Gln Thr Lys Ile Pro Ile Lys Arg Ser Asp
 290 295 300

Met Leu Lys Asp Ile Ile Lys Glu Tyr Thr Asp Val Tyr Pro Glu Ile
 305 310 315 320

Ile Glu Arg Ala Gly Tyr Ser Leu Glu Lys Val Phe Gly Ile Gln Leu
 325 330 335

Lys Glu Ile Asp Lys Asn Asp His Leu Tyr Ile Leu Leu Ser Thr Leu
 340 345 350

Glu Pro Thr Asp Ala Gly Ile Leu Gly Thr Thr Lys Asp Ser Pro Lys
 355 360 365

Leu Gly Leu Leu Met Val Leu Leu Ser Ile Ile Phe Met Asn Gly Asn
 370 375 380

Arg Ser Ser Glu Gly Glu Trp Leu Gly Leu Gln Leu Asn Gly Trp Leu

385 390 395 400

Pro	Gln	Ala	Val	Thr	Met	Pro	Ala	Thr	Glu	Thr	Lys	Lys	Val	Ser	His
		115					120					125			

108

Val	Ala	Asp	Thr	Lys	Val	Asn	Thr	Lys	Ala	Gln	Glu	Thr	Glu	Ala	Ala	
130						135					140					
Pro	Ser	Gln	Ala	Pro	Ala	Asp	Glu	Pro	Glu	Pro	Glu	Ser	Ala	Ala	Ala	
145					150					155					160	
Gln	Ser	Gln	Glu	Asn	Gln	Asp	Thr	Arg	Pro	Lys	Val	Lys	Ala	Lys	Lys	
				165					170					175		
Ala	Arg	Lys	Val	Lys	His	Leu	Asp	Gly	Glu	Glu	Asp	Gly	Ser	Ser	Asp	
			180					185					190			
Gln	Ser	Gln	Ala	Ser	Gly	Thr	Thr	Gly	Gly	Arg	Arg	Val	Ser	Lys	Ala	
		195					200					205				
Leu	Met	Ala	Ser	Met	Ala	Arg	Arg	Ala	Ser	Arg	Gly	Pro	Ile	Ala	Phe	
	210					215					220					
Trp	Ala	Arg	Arg	Ala	Ser	Arg	Thr	Arg	Leu	Ala	Ala	Trp	Ala	Arg	Arg	
225					230					235					240	
Ala	Leu	Leu	Ser	Leu	Arg	Ser	Pro	Lys	Ala	Arg	Arg	Gly	Lys	Ala	Arg	
				245					250					255		
Arg	Arg	Ala	Ala	Lys	Leu	Gln	Ser	Ser	Gln	Glu	Pro	Glu	Ala	Pro	Pro	
			260					265					270			
Pro	Arg	Asp	Val	Ala	Leu	Leu	Gln	Gly	Arg	Ala	Asn	Asp	Leu	Val	Lys	
		275					280					285				
Tyr	Leu	Leu	Ala	Lys	Asp	Gln	Thr	Lys	Ile	Pro	Ile	Lys	Arg	Ser	Gly	
	290					295					300					
Lys	Val	Leu	Thr	Asn	Pro	Pro	Ser	Ala	Leu	Ser	Ser	Ala	Leu	His	Cys	
305					310					315				320		
Pro	Tyr	Thr	Ile	Val	Leu	Gly	Ile	Ser	Pro	Ala	Leu	Met	Leu	Met	Ser	
				325					330					335		
Leu	Ser	Ser	Gln	Ser	Ser	Asp	Leu	Ala	Val	Leu	Ala	Ser	Leu	Leu	Ile	
			340					345					350			
Ser	Thr	Glu	Pro	Gly	Tyr	Ala	Thr	Leu	Gly	Val	Val	Gly	Lys	Glu	Ser	
		355					360					365				

109

Ile Ala Trp Ala Ser Gly Pro Pro Gly Ile Ser Ser Val Arg Cys Ser
 370 375 380

Gln His Ser Pro Leu Ala Asp Met Leu Lys Asp Ile Ile Lys Glu Tyr
 385 390 395 400

Thr Asp Val Tyr Pro Glu Ile Ile Glu Arg Ala Gly Tyr Ser Leu Glu
 405 410 415

Lys Val Phe Gly Ile Gln Leu Lys Glu Ile Asp Lys Asn Asp His Leu
 420 425 430

Tyr Ile Leu Leu Ser Thr Leu Glu Pro Thr Asp Ala Gly Ile Leu Gly
 435 440 445

Thr Thr Lys Asp Ser Pro Lys Leu Gly Leu Leu Met Val Leu Leu Ser
 450 455 460

Ile Ile Phe Met Asn Gly Asn Arg Ser Ser Glu Ala Val Ile Trp Glu
 465 470 475 480

Val Leu Arg Lys Leu Gly Leu Arg Pro Gly Tyr Asp Trp Ala Leu Ser
 485 490 495

Ala Leu Ala Val Arg Val Val Leu Trp Gln Glu Arg Thr Val Leu Gly
 500 505 510

Leu His Gln Ser Gly Gly Leu Val Glu Arg Val Gly Cys Trp Thr Gly
 515 520 525

<210> 119

<211> 314

<212> PRT

<213> Homo sapien

<400> 119

Asp Met Ser Asp Thr Ser Glu Ser Gly Ala Gly Leu Thr Arg Phe Gln
 1 5 10 15

Ala Glu Ala Ser Glu Lys Asp Ser Ser Ser Met Met Gln Thr Leu Leu
 20 25 30

Thr Val Thr Gln Asn Val Glu Val Pro Glu Thr Pro Lys Ala Ser Lys
 35 40 45

Ala Leu Glu Val Ser Glu Asp Val Lys Val Ser Lys Ala Ser Gly Val
 50 55 60

110

Ser Lys Ala Thr Glu Val Ser Lys Thr Pro Glu Ala Arg Glu Ala Pro
 65 70 75 80

Ala Thr Gln Ala Ser Ser Thr Thr Gln Leu Thr Asp Thr Gln Val Leu
 85 90 95

Ala Ala Glu Asn Lys Ser Leu Ala Ala Asp Thr Lys Lys Gln Asn Ala
 100 105 110

Asp Pro Gln Ala Val Thr Met Pro Ala Thr Glu Thr Lys Lys Val Ser
 115 120 125

His Val Ala Asp Thr Lys Val Asn Thr Lys Ala Gln Glu Thr Glu Ala
 130 135 140

Ala Pro Ser Gln Ala Pro Ala Asp Glu Pro Glu Pro Glu Ser Ala Ala
 145 150 155 160

Ala Gln Ser Gln Glu Asn Gln Asp Thr Arg Pro Lys Val Lys Ala Lys
 165 170 175

Lys Ala Arg Lys Val Lys His Leu Asp Gly Glu Glu Asp Gly Ser Ser
 180 185 190

Asp Gln Ser Gln Ala Ser Gly Thr Thr Gly Gly Arg Arg Val Ser Lys
 195 200 205

Ala Leu Met Ala Ser Met Ala Arg Arg Ala Ser Arg Gly Pro Ile Ala
 210 215 220

Phe Trp Ala Arg Arg Ala Ser Arg Thr Arg Leu Ala Ala Trp Ala Arg
 225 230 235 240

Arg Ala Leu Leu Ser Leu Arg Ser Pro Lys Ala Arg Arg Gly Lys Ala
 245 250 255

Arg Arg Arg Ala Ala Lys Leu Gln Ser Ser Gln Glu Pro Glu Ala Pro
 260 265 270

Pro Pro Arg Asp Val Ala Leu Leu Gln Gly Arg Ala Asn Asp Leu Val
 275 280 285

Lys Tyr Leu Leu Ala Lys Asp Gln Thr Lys Ile Pro Ile Lys Arg Ser
 290 295 300

111

Gly Lys Val Leu Pro Ile Leu Pro Leu Pro
 305 310

<210> 120
 <211> 35
 <212> PRT
 <213> Homo sapien

<400> 120

Ala Leu Thr Ala Leu Pro Gly Ala Ala Gly Ala Arg Arg Arg His Asp
 1 5 10 15

Pro Leu Arg Leu Arg Gly Arg Arg Ala His Arg Glu Lys Ala Arg Gln
 20 25 30

Gly Ser Ala
 35

<210> 121
 <211> 80
 <212> PRT
 <213> Homo sapien

<400> 121

Gly Arg Arg Ile Phe Glu Arg Thr Leu Gln Ile Leu Arg Thr Ser Val
 1 5 10 15

Ala Leu Glu Thr Val Ser Trp Ile Ser Ile Phe Leu Cys Glu Gly Leu
 20 25 30

Leu Leu Met Ser Pro Arg Ile Gln Thr Gln Thr Tyr Phe Ser Lys Lys
 35 40 45

Val Gln Leu Gly Cys Tyr Ile Val Ala Arg Val Tyr Leu His Ala His
 50 55 60

Leu Ala Phe Gln Ala Pro Ile Thr Ser Lys Val Ser Leu Lys Leu Phe
 65 70 75 80

<210> 122
 <211> 33
 <212> PRT
 <213> Homo sapien

<400> 122

Ala Leu Thr Ala Leu Pro Gly Ala Ala Gly Ala Arg Arg Arg His Asp
 1 5 10 15

112

Pro Leu Arg Leu Arg Gly Arg Arg Ala His Arg Glu Lys Lys Pro Thr
 20 25 30

Gly

<210> 123
 <211> 80
 <212> PRT
 <213> Homo sapien

<400> 123

Gly Arg Arg Ile Phe Glu Arg Thr Leu Gln Ile Leu Arg Thr Ser Val
 1 5 10 15

Ala Leu Glu Thr Val Ser Trp Ile Ser Ile Phe Leu Cys Glu Gly Leu
 20 25 30

Leu Leu Met Ser Pro Arg Ile Gln Thr Gln Thr Tyr Phe Ser Lys Lys
 35 40 45

Val Gln Leu Gly Cys Tyr Ile Val Ala Arg Val Tyr Leu His Ala His
 50 55 60

Leu Ala Phe Gln Ala Pro Ile Thr Ser Lys Val Ser Leu Lys Leu Phe
 65 70 75 80

<210> 124
 <211> 73
 <212> PRT
 <213> Homo sapien

<400> 124

Met Ala Ile Arg Glu Leu Lys Val Cys Leu Leu Gly Asp Thr Gly Val
 1 5 10 15

Gly Lys Ser Ser Ile Val Cys Arg Phe Val Gln Asp His Phe Asp His
 20 25 30

Asn Ile Ser Pro Thr Ile Gly Ala Ser Phe Met Thr Lys Thr Val Pro
 35 40 45

Cys Gly Asn Glu Leu His Lys Phe Leu Ile Trp Asp Thr Ala Gly Gln
 50 55 60

Glu Arg Gly Gly Ser Pro Glu Gly Cys
 65 70

113

<210> 125
 <211> 94
 <212> PRT
 <213> Homo sapien

<400> 125

Thr Val Phe Arg Pro Thr Gly Tyr Leu Ala Tyr Cys Phe Asn Ile Ile
 1 5 10 15

Val Glu Thr Arg Pro Cys Ser Pro Val Val Leu Pro Cys Cys Ala Asn
 20 25 30

Cys Ser Phe Phe Ser Cys Phe Cys Lys Glu Leu Pro Ser Gly Leu Asp
 35 40 45

Pro Val Leu Ala His Thr Arg His Arg Cys Ser Gln Leu Gly Pro Phe
 50 55 60

Arg His Val Phe Tyr Ser Val Val Lys His Phe His Gln Gln Cys Leu
 65 70 75 80

Ile Val Ser Val Ile Phe Gly Leu Thr His Thr Asp Ser Tyr
 85 90

<210> 126
 <211> 54
 <212> PRT
 <213> Homo sapien

<400> 126

Val Asp Asp Arg Cys Leu Val Thr Leu Gly Asn Arg Cys Cys Ala Ala
 1 5 10 15

Lys Glu Trp Thr Val Arg Gly Arg Gln Ile Pro Pro Leu Asp Pro His
 20 25 30

Glu Asn Gly Asn Asn Gly Thr Ile Lys Val Glu Lys Pro Thr Met Gln
 35 40 45

Ala Ser Arg Arg Cys Cys
 50

<210> 127
 <211> 94
 <212> PRT
 <213> Homo sapien

114

<400> 127

Thr Val Phe Arg Pro Thr Gly Tyr Leu Ala Tyr Cys Phe Asn Ile Ile
 1 5 10 15

Val Glu Thr Arg Pro Cys Ser Pro Val Val Leu Pro Cys Cys Ala Asn
 20 25 30

Cys Ser Phe Phe Ser Cys Phe Cys Lys Glu Leu Pro Ser Gly Leu Asp
 35 40 45

Pro Val Leu Ala His Thr Arg His Arg Cys Ser Gln Leu Gly Pro Phe
 50 55 60

Arg His Val Phe Tyr Ser Val Val Lys His Phe His Gln Gln Cys Leu
 65 70 75 80

Ile Val Ser Val Ile Phe Gly Leu Thr His Thr Asp Ser Tyr
 85 90

<210> 128

<211> 284

<212> PRT

<213> Homo sapien

<400> 128

Met Gly Trp Ser Gly Arg Ser Gly Lys Gly Lys Leu Arg Arg Arg Ser
 1 5 10 15

Val Ser Gly Asn Met Ala Ser Arg Ser Lys Arg Arg Ala Val Glu Ser
 20 25 30

Gly Val Pro Gln Pro Pro Asp Pro Pro Val Gln Arg Asp Glu Glu Glu
 35 40 45

Glu Lys Glu Val Glu Asn Glu Asp Glu Asp Asp Asp Ser Asp Lys
 50 55 60

Glu Lys Asp Glu Glu Asp Glu Val Ile Asp Glu Glu Val Asn Ile Glu
 65 70 75 80

Phe Glu Ala Tyr Ser Leu Ser Asp Asn Asp Tyr Asp Gly Ile Lys Lys
 85 90 95

Leu Leu Gln Gln Leu Phe Leu Lys Ala Pro Val Asn Thr Ala Glu Leu
 100 105 110

115

Thr Asp Leu Leu Ile Gln Gln Asn His Ile Gly Ser Val Ile Lys Gln
 115 120 125

Thr Asp Val Ser Glu Asp Ser Asn Asp Asp Met Asp Glu Asp Glu Val
 130 135 140

Phe Gly Phe Ile Ser Leu Leu Asn Leu Thr Glu Arg Lys Gly Thr Gln
 145 150 155 160

Cys Val Glu Gln Ile Gln Glu Leu Val Leu Arg Phe Cys Glu Lys Asn
 165 170 175

Cys Glu Lys Ser Met Val Glu Gln Leu Asp Lys Phe Leu Asn Asp Thr
 180 185 190

Thr Lys Pro Val Gly Leu Leu Leu Ser Glu Arg Phe Ile Asn Val Pro
 195 200 205

Pro Gln Ile Ala Leu Pro Met Tyr Gln Gln Leu Gln Lys Glu Leu Ala
 210 215 220

Gly Ala His Arg Thr Asn Lys Pro Cys Gly Lys Cys Tyr Phe Tyr Leu
 225 230 235 240

Leu Ile Ser Lys Thr Phe Val Glu Ala Gly Lys Asn Asn Ser Lys Lys
 245 250 255

Lys Pro Ser Asn Lys Lys Lys Ala Ala Leu Met Phe Ala Asn Ala Glu
 260 265 270

Glu Glu Phe Phe Tyr Glu Val Val His Gly Gly Lys
 275 280

<210> 129

<211> 220

<212> PRT

<213> Homo sapien

<400> 129

Met Gly Trp Ser Gly Arg Ser Gly Lys Gly Lys Leu Arg Arg Arg Ser
 1 5 10 15

Val Ser Gly Asn Met Ala Ser Arg Ser Lys Arg Arg Ala Val Glu Ser
 20 25 30

Gly Val Pro Gln Pro Pro Asp Pro Pro Val Gln Arg Asp Glu Glu Glu
 35 40 45

116

Glu Lys Glu Val Glu Asn Glu Asp Glu Asp Asp Asp Asp Ser Asp Lys
 50 55 60

Glu Lys Asp Glu Glu Asp Glu Val Ile Asp Glu Glu Val Asn Ile Glu
 65 70 75 80

Phe Glu Ala Tyr Ser Leu Ser Asp Asn Asp Tyr Asp Gly Ile Lys Lys
 85 90 95

Leu Leu Gln Gln Leu Phe Leu Lys Ala Pro Val Asn Thr Ala Glu Leu
 100 105 110

Thr Asp Leu Leu Ile Gln Gln Asn His Ile Gly Ser Val Ile Lys Gln
 115 120 125

Thr Asp Val Ser Glu Asp Ser Asn Asp Asp Met Asp Glu Asp Glu Val
 130 135 140

Phe Gly Phe Ile Ser Leu Leu Asn Leu Thr Glu Arg Lys Gly Thr Gln
 145 150 155 160

Cys Val Glu Gln Ile Gln Glu Leu Val Leu Arg Phe Cys Glu Lys Asn
 165 170 175

Cys Glu Lys Ser Met Val Glu Gln Leu Asp Lys Phe Leu Asn Asp Thr
 180 185 190

Thr Lys Pro Val Gly Leu Leu Leu Ser Glu Arg Phe Ile Asn Val Pro
 195 200 205

Pro Gln Ile Ala Leu Pro Met Tyr Gln Gln Leu Gln
 210 215 220

<210> 130
 <211> 190
 <212> PRT
 <213> Homo sapien

<400> 130

Met Gly Trp Ser Gly Arg Ser Gly Lys Gly Lys Leu Arg Arg Arg Ser
 1 5 10 15

Val Ser Gly Asn Met Ala Ser Arg Ser Lys Arg Arg Ala Val Glu Ser
 20 25 30

Gly Val Pro Gln Pro Pro Asp Pro Pro Val Gln Arg Asp Glu Glu Glu
35 40 45

Glu Lys Glu Val Glu Asn Glu Asp Glu Asp Asp Asp Asp Ser Asp Lys
50 55 60

Glu Lys Asp Glu Glu Asp Glu Val Ile Asp Glu Glu Val Asn Ile Glu
65 70 75 80

Phe Glu Ala Tyr Ser Leu Ser Asp Asn Asp Tyr Asp Gly Ile Lys Lys
85 90 95

Leu Leu Gln Gln Leu Phe Leu Lys Ala Pro Val Asn Thr Ala Glu Leu
100 105 110

Thr Asp Leu Leu Ile Gln Gln Asn His Ile Gly Ser Val Ile Lys Gly
115 120 125

Thr Gln Cys Val Glu Gln Ile Gln Glu Leu Val Leu Arg Phe Cys Glu
130 135 140

Lys Asn Cys Glu Lys Ser Met Val Glu Gln Leu Asp Lys Phe Leu Asn
145 150 155 160

Asp Thr Thr Lys Pro Val Gly Leu Leu Leu Ser Glu Arg Phe Ile Asn
165 170 175

Val Pro Pro Gln Ile Ala Leu Pro Met Tyr Gln Gln Leu Gln
180 185 190

<210>	131
<211>	305
<212>	PRT
<213>	Homo sapien

<400> 131

Met Ala Ser Arg Lys Glu Asn Ala Lys Ser Ala Asn Arg Val Leu Arg
1 5 10 15

Ile Ser Gln Leu Asp Ala Leu Glu Leu Asn Lys Ala Leu Glu Gln Leu
20 25 30

Val Trp Ser Gln Phe Thr Gln Cys Phe His Gly Phe Lys Pro Gly Leu
35 40 45

Leu Ala Arg Phe Glu Pro Glu Val Lys Ala Cys Leu Trp Val Phe Leu
50 55 60

118

Trp Arg Phe Thr Ile Tyr Ser Lys Asn Ala Thr Val Gly Gln Ser Val
 65 70 75 80

Leu Asn Ile Lys Tyr Lys Asn Asp Phe Ser Pro Asn Leu Arg Tyr Gln
 85 90 95

Pro Pro Ser Lys Asn Gln Lys Ile Trp Tyr Ala Val Cys Thr Ile Gly
 100 105 110

Gly Arg Trp Leu Glu Glu Arg Cys Tyr Asp Leu Phe Arg Asn His His
 115 120 125

Leu Ala Ser Phe Gly Lys Val Lys Gln Cys Val Asn Phe Val Ile Gly
 130 135 140

Leu Leu Lys Leu Gly Gly Leu Ile Asn Phe Leu Ile Phe Leu Gln Arg
 145 150 155 160

Gly Lys Phe Ala Thr Leu Thr Glu Arg Leu Leu Gly Ile His Ser Val
 165 170 175

Phe Cys Lys Pro Gln Asn Ile Arg Glu Val Gly Phe Glu Tyr Met Asn
 180 185 190

Arg Glu Leu Leu Trp His Gly Phe Ala Glu Phe Leu Ile Phe Leu Leu
 195 200 205

Pro Leu Ile Asn Val Gln Lys Leu Lys Ala Lys Leu Ser Ser Trp Cys
 210 215 220

Ile Pro Leu Thr Gly Ala Pro Asn Ser Asp Asn Thr Leu Ala Thr Ser
 225 230 235 240

Gly Lys Glu Cys Ala Leu Cys Gly Glu Trp Pro Thr Met Pro His Thr
 245 250 255

Ile Gly Cys Glu His Ile Phe Cys Tyr Phe Cys Ala Lys Ser Ser Phe
 260 265 270

Leu Phe Asp Val Tyr Phe Thr Cys Pro Lys Cys Gly Thr Glu Val His
 275 280 285

Ser Leu Gln Pro Leu Lys Ser Gly Ile Glu Met Ser Glu Val Asn Ala
 290 295 300

119

Leu
305

<210> 132
<211> 582
<212> PRT
<213> Homo sapien

<400> 132

Met Ala Ala Arg Ser Trp Gln Asp Glu Leu Ala Gln Gln Ala Glu Glu
1 5 10 15

Gly Ser Ala Arg Leu Arg Glu Met Leu Ser Val Gly Leu Gly Phe Leu
20 25 30

Arg Thr Glu Leu Gly Leu Asp Leu Gly Leu Glu Pro Lys Arg Tyr Pro
35 40 45

Gly Trp Val Ile Leu Val Gly Thr Gly Ala Leu Gly Leu Leu Leu Leu
50 55 60

Phe Leu Leu Gly Tyr Gly Trp Ala Ala Ala Cys Ala Gly Ala Arg Lys
65 70 75 80

Lys Arg Arg Ser Pro Pro Arg Lys Arg Glu Glu Ala Ala Ala Val Pro
85 90 95

Ala Ala Ala Pro Asp Asp Leu Ala Leu Leu Lys Asn Leu Arg Ser Glu
100 105 110

Glu Gln Lys Lys Lys Asn Arg Lys Lys Leu Ser Glu Lys Pro Lys Pro
115 120 125

Asn Gly Arg Thr Val Glu Val Ala Glu Gly Glu Ala Val Arg Thr Pro
130 135 140

Gln Ser Val Thr Ala Lys Gln Pro Pro Glu Ile Asp Lys Lys Asn Glu
145 150 155 160

Lys Ser Lys Lys Asn Lys Lys Lys Ser Lys Ser Asp Ala Lys Ala Val
165 170 175

Gln Asn Ser Ser Arg His Asp Gly Lys Glu Val Asp Glu Gly Ala Trp
180 185 190

Glu Thr Lys Ile Ser His Arg Glu Lys Arg Gln Gln Arg Lys Arg Asp

120

195

200

205

Lys Val Leu Thr Asp Ser Gly Ser Leu Asp Ser Thr Ile Pro Gly Ile
 210 215 220

Glu Asn Thr Ile Thr Val Thr Thr Glu Gln Leu Thr Thr Ala Ser Phe
 225 230 235 240

Pro Val Gly Ser Lys Lys Asn Lys Gly Asp Ser His Leu Asn Val Gln
 245 250 255

Val Ser Asn Phe Lys Ser Gly Lys Gly Asp Ser Thr Leu Gln Val Ser
 260 265 270

Ser Gly Leu Asn Glu Asn Leu Thr Val Asn Gly Gly Gly Trp Asn Glu
 275 280 285

Lys Ser Val Lys Leu Ser Ser Gln Ile Ser Ala Gly Glu Glu Lys Trp
 290 295 300

Asn Ser Val Ser Pro Ala Ser Ala Gly Lys Arg Lys Thr Glu Pro Ser
 305 310 315 320

Ala Trp Ser Gln Asp Thr Gly Asp Ala Asn Thr Asn Gly Lys Asp Trp
 325 330 335

Gly Arg Ser Trp Ser Asp Arg Ser Ile Phe Ser Gly Ile Gly Ser Thr
 340 345 350

Ala Glu Pro Val Ser Gln Ser Thr Thr Ser Asp Tyr Gln Trp Asp Val
 355 360 365

Ser Arg Asn Gln Pro Tyr Ile Asp Asp Glu Trp Ser Gly Leu Asn Gly
 370 375 380

Leu Ser Ser Ala Asp Pro Asn Ser Asp Trp Asn Ala Pro Ala Glu Glu
 385 390 395 400

Trp Gly Asn Trp Val Asp Glu Glu Arg Ala Ser Leu Leu Lys Ser Gln
 405 410 415

Glu Pro Ile Pro Asp Asp Gln Lys Val Ser Asp Asp Asp Lys Glu Lys
 420 425 430

Gly Glu Gly Ala Leu Pro Thr Gly Lys Ser Lys Lys Lys Lys Lys
 435 440 445

121

Lys Lys Lys Gln Gly Glu Asp Asn Ser Thr Ala Gln Asp Thr Glu Glu
 450 455 460

Leu Glu Lys Glu Ile Arg Glu Asp Leu Pro Val Asn Thr Ser Lys Thr
 465 470 475 480

Arg Pro Lys Gln Glu Lys Ala Phe Ser Leu Lys Thr Ile Ser Thr Ser
 485 490 495

Asp Pro Ala Glu Val Leu Val Lys Asn Ser Gln Pro Ile Lys Thr Leu
 500 505 510

Pro Pro Ala Thr Ser Thr Glu Pro Ser Val Ile Leu Ser Lys Ser Asp
 515 520 525

Ser Asp Lys Ser Ser Ser Gln Val Pro Pro Ile Leu Gln Glu Thr Asp
 530 535 540

Lys Ser Lys Ser Asn Thr Lys Gln Asn Ser Val Pro Pro Ser Gln Thr
 545 550 555 560

Lys Ser Glu Thr Ser Trp Glu Ser Pro Lys Gln Ile Lys Lys Lys Lys
 565 570 575

Lys Ala Arg Arg Glu Thr
 580

<210> 133
 <211> 389
 <212> PRT
 <213> Homo sapien

<400> 133

Met Asp Ala Trp Ser Arg Pro Arg Tyr Ser Leu Glu Pro Val Ala Val
 1 5 10 15

Glu Leu Lys Ser Leu Leu Gly Lys Ser Lys Cys Gln Ala Leu Val Leu
 20 25 30

Val Asp Leu Trp Arg Gly Lys Leu Ser Ser Thr Leu Leu Leu Val Phe
 35 40 45

Asn Phe His Thr Ala Gln Val Ser Ser Ser Leu Pro Leu Leu Arg Asp
 50 55 60

122

Val Leu Phe Leu Lys Asp Cys Val Gly Pro Glu Val Glu Lys Ala Cys
 65 70 75 80

Ala Asn Pro Ala Ala Gly Ser Val Ile Leu Leu Glu Asn Leu Arg Phe
 85 90 95

His Val Glu Glu Glu Gly Lys Gly Lys Asp Ala Ser Gly Asn Lys Val
 100 105 110

Lys Ala Glu Pro Ala Lys Ile Glu Ala Phe Arg Ala Ser Leu Ser Lys
 115 120 125

Leu Gly Asp Val Tyr Val Asn Asp Ala Phe Gly Thr Ala His Arg Ala
 130 135 140

His Ser Ser Met Val Gly Val Asn Leu Pro Gln Lys Ala Gly Gly Phe
 145 150 155 160

Leu Met Lys Lys Glu Leu Asn Tyr Phe Ala Lys Ala Leu Glu Ser Pro
 165 170 175

Glu Arg Pro Phe Leu Ala Ile Leu Gly Gly Ala Lys Val Ala Asp Lys
 180 185 190

Ile Gln Leu Ile Asn Asn Met Leu Asp Lys Val Asn Glu Met Ile Ile
 195 200 205

Gly Gly Gly Met Ala Phe Thr Phe Leu Lys Val Leu Asn Asn Met Glu
 210 215 220

Ile Gly Thr Ser Leu Phe Asp Glu Glu Gly Ala Lys Ile Val Lys Asp
 225 230 235 240

Leu Met Ser Lys Ala Glu Lys Asn Gly Val Lys Ile Thr Leu Pro Val
 245 250 255

Asp Phe Val Thr Ala Asp Lys Phe Asp Glu Asn Ala Lys Thr Gly Gln
 260 265 270

Ala Thr Val Ala Ser Gly Ile Pro Ala Gly Trp Met Gly Leu Asp Cys
 275 280 285

Gly Pro Glu Ser Ser Lys Lys Tyr Ala Glu Ala Val Thr Arg Ala Lys
 290 295 300

Gln Ile Val Trp Asn Gly Pro Val Gly Val Phe Glu Trp Glu Ala Phe

Phe Ser Lys Val Leu Val Phe Leu Met
115 120

124

<210> 135
 <211> 121
 <212> PRT
 <213> Homo sapien

<400> 135

Met Val Ala Ser Ala Glu Met Phe Leu Gly Cys Glu Glu Leu Gly Val
 1 5 10 15

Ser Leu Glu Gly Pro Gln Asp Gln Met Thr Cys Glu Glu Tyr Val Ala
 20 25 30

Phe Ile Leu Ala Ala Gly Glu Ala Gly Arg Gly Val Arg Glu Ala Asn
 35 40 45

Gly Cys Phe Ala Glu Cys Phe Trp Gly Thr Asn Thr Ser Ser His Arg
 50 55 60

Gly Cys Ser Leu Lys Lys Gly Gly Asp Arg Trp Gly Ala Phe Leu Thr
 65 70 75 80

Tyr Ser Arg Asn Thr Cys Leu Phe Leu Lys Cys Phe His Leu Leu Lys
 85 90 95

Lys Lys Lys Met Pro Pro Lys His Tyr Ala Gly His Glu Leu Leu Gln
 100 105 110

Asn Val Glu Val Ile Lys Cys Asn Cys
 115 120

<210> 136
 <211> 232
 <212> PRT
 <213> Homo sapien

<400> 136

Met Ala Tyr His Ser Phe Leu Val Glu Pro Ile Ser Cys His Ala Trp
 1 5 10 15

Asn Lys Asp Arg Thr Gln Ile Ala Ile Cys Pro Asn Asn His Glu Val
 20 25 30

His Ile Tyr Glu Lys Ser Gly Ala Lys Trp Thr Lys Val His Glu Leu
 35 40 45

Lys Glu His Asn Gly Gln Val Thr Gly Ile Asp Trp Ala Pro Glu Ser
 50 55 60

125

Asn Arg Ile Val Thr Cys Gly Thr Asp Arg Asn Ala Tyr Val Trp Thr
 65 70 75 80

Leu Lys Gly Arg Thr Trp Lys Pro Thr Leu Val Ile Leu Arg Ile Asn
 85 90 95

Arg Ala Ala Arg Cys Val Arg Trp Ala Pro Asn Glu Asn Lys Phe Ala
 100 105 110

Val Gly Ser Gly Ser Arg Val Ile Ser Ile Cys Tyr Phe Glu Gln Glu
 115 120 125

Asn Asp Trp Trp Val Cys Lys His Ile Lys Lys Pro Ile Arg Ser Thr
 130 135 140

Val Leu Ser Leu Asp Trp His Pro Asn Asn Val Leu Leu Ala Ala Gly
 145 150 155 160

Ser Cys Asp Phe Lys Cys Arg Ile Phe Ser Ala Tyr Ile Lys Glu Val
 165 170 175

Glu Glu Arg Pro Ala Pro Thr Pro Trp Gly Ser Lys Met Pro Phe Gly
 180 185 190

Glu Leu Met Phe Glu Ser Ser Ser Ser Cys Gly Trp Val His Gly Val
 195 200 205

Cys Phe Ser Ala Ser Gly Ser Arg Val Ala Ser Ser Arg Leu Trp Pro
 210 215 220

Leu Lys His Tyr His Cys Trp Arg
 225 230

<210> 137

<211> 582

<212> PRT

<213> Homo sapien

<400> 137

Met Phe Tyr Tyr Pro Asn Val Leu Gln Arg His Thr Gly Cys Phe Ala
 1 5 10 15

Thr Ile Trp Leu Ala Ala Thr Arg Gly Ser Arg Leu Val Lys Arg Glu
 20 25 30

126

Tyr Leu Arg Val Asn Val Val Lys Thr Cys Glu Glu Ile Leu Asn Tyr
 35 40 45

Val Leu Val Arg Val Gln Pro Pro Gln Pro Gly Leu Pro Arg Pro Arg
 50 55 60

Phe Ser Leu Tyr Leu Ser Ala Gln Leu Gln Ile Gly Val Ile Arg Val
 65 70 75 80

Tyr Ser Gln Gln Cys Gln Tyr Leu Val Glu Asp Ile Gln His Ile Leu
 85 90 95

Glu Arg Leu His Arg Ala Gln Leu Gln Ile Arg Ile Asp Met Glu Thr
 100 105 110

Glu Leu Pro Ser Leu Leu Leu Pro Asn His Leu Ala Met Met Glu Thr
 115 120 125

Leu Glu Asp Ala Pro Asp Pro Phe Phe Gly Met Met Ser Val Asp Pro
 130 135 140

Arg Leu Pro Ser Pro Phe Asp Ile Pro Gln Ile Arg His Leu Leu Glu
 145 150 155 160

Ala Ala Ile Pro Glu Arg Val Glu Glu Ile Pro Pro Glu Val Pro Thr
 165 170 175

Glu Pro Arg Glu Pro Glu Arg Ile Pro Val Thr Val Leu Pro Pro Glu
 180 185 190

Ala Ile Thr Ile Leu Glu Ala Glu Pro Ile Arg Met Leu Glu Ile Glu
 195 200 205

Gly Glu Arg Glu Leu Pro Glu Val Ser Arg Arg Glu Leu Asp Leu Leu
 210 215 220

Ile Ala Glu Glu Glu Glu Ala Ile Leu Leu Glu Ile Pro Arg Leu Pro
 225 230 235 240

Pro Pro Ala Pro Ala Glu Val Glu Gly Ile Gly Glu Ala Leu Gly Pro
 245 250 255

Glu Glu Leu Arg Leu Thr Gly Trp Glu Pro Gly Ala Leu Leu Met Glu
 260 265 270

Val Thr Pro Pro Glu Glu Leu Arg Leu Pro Ala Pro Pro Ser Pro Glu

127

275

280

285

Arg Arg Pro Pro Val Pro Pro Pro Pro Arg Arg Arg Arg Arg Arg Arg
 290 295 300

Leu Leu Phe Trp Asp Lys Glu Thr Gln Ile Ser Pro Glu Lys Phe Gln
 305 310 315 320

Glu Gln Leu Gln Thr Arg Ala His Cys Trp Glu Cys Pro Met Val Gln
 325 330 335

Pro Pro Glu Arg Thr Ile Arg Gly Pro Ala Glu Leu Phe Arg Thr Pro
 340 345 350

Thr Leu Cys Lys Asn Gly Gly Gly Trp Ala Arg Ser Ile Leu Lys Thr
 355 360 365

Asn Ser Ser Phe Leu Val Leu Leu Thr Pro Gln Thr Leu Cys Leu Leu
 370 375 380

Pro Ser Val Ser Thr Ala Gly Trp Leu Pro Pro Glu Leu Leu Gly Leu
 385 390 395 400

Trp Thr His Cys Ala Gln Pro Pro Pro Lys Ala Leu Arg Arg Glu Leu
 405 410 415

Pro Glu Glu Ala Ala Ala Glu Glu Glu Arg Arg Lys Ile Glu Val Pro
 420 425 430

Ser Glu Ile Glu Val Pro Arg Glu Ala Leu Glu Pro Ser Val Pro Leu
 435 440 445

Met Val Ser Leu Glu Ile Ser Leu Glu Ala Ala Glu Glu Glu Lys Ser
 450 455 460

Arg Ile Ser Leu Ile Pro Pro Glu Glu Arg Trp Ala Trp Pro Glu Val
 465 470 475 480

Glu Ala Pro Glu Ala Pro Ala Leu Pro Val Val Pro Glu Leu Pro Glu
 485 490 495

Val Pro Met Glu Met Pro Leu Val Leu Pro Pro Glu Leu Glu Leu Leu
 500 505 510

Ser Leu Glu Ala Val His Arg Ala Val Ala Leu Glu Leu Gln Ala Asn
 515 520 525

128

Arg Glu Pro Asp Phe Ser Ser Leu Val Ser Pro Leu Ser Pro Arg Arg
 530 535 540

Met Ala Ala Arg Val Phe Tyr Leu Leu Leu Val Leu Ser Ala Gln Gln
 545 550 555 560

Ile Leu His Val Lys Gln Glu Lys Pro Tyr Gly Arg Leu Leu Ile Gln
 565 570 575

Pro Gly Pro Arg Phe His
 580

<210> 138
 <211> 456
 <212> PRT
 <213> Homo sapien

<400> 138

Lys Thr Arg Gly Thr Met Phe Tyr Tyr Pro Asn Val Leu Gln Arg His
 1 5 10 15

Thr Gly Cys Phe Ala Thr Ile Trp Leu Ala Ala Thr Arg Gly Ser Arg
 20 25 30

Leu Val Lys Arg Glu Tyr Leu Arg Val Asn Val Val Lys Thr Cys Glu
 35 40 45

Glu Ile Leu Asn Tyr Val Leu Val Arg Val Gln Pro Pro Gln Pro Gly
 50 55 60

Leu Pro Arg Pro Arg Phe Ser Leu Tyr Leu Ser Ala Gln Leu Gln Ile
 65 70 75 80

Gly Val Ile Arg Val Tyr Ser Gln Gln Cys Gln Tyr Leu Val Glu Asp
 85 90 95

Ile Gln His Ile Leu Glu Arg Leu His Arg Ala Gln Leu Gln Ile Arg
 100 105 110

Ile Asp Met Glu Thr Glu Leu Pro Ser Leu Leu Leu Pro Asn His Leu
 115 120 125

Ala Met Met Glu Thr Leu Glu Asp Ala Pro Asp Pro Phe Phe Gly Met
 130 135 140

129

Met Ser Val Asp Pro Arg Leu Pro Ser Pro Phe Asp Ile Pro Gln Ile
 145 150 155 160

Arg His Leu Leu Glu Ala Ala Ile Pro Glu Arg Val Glu Glu Ile Pro
 165 170 175

Pro Glu Val Pro Thr Glu Pro Arg Glu Pro Glu Arg Ile Pro Val Thr
 180 185 190

Val Leu Pro Pro Glu Ala Ile Thr Ile Leu Glu Ala Glu Pro Ile Arg
 195 200 205

Met Leu Glu Ile Glu Gly Glu Arg Glu Leu Pro Glu Val Ser Arg Arg
 210 215 220

Glu Leu Asp Leu Leu Ile Ala Glu Glu Glu Glu Ala Ile Leu Leu Glu
 225 230 235 240

Ile Pro Arg Leu Pro Pro Pro Ala Pro Ala Glu Val Glu Gly Ile Gly
 245 250 255

Glu Ala Leu Gly Pro Glu Glu Leu Arg Leu Thr Gly Trp Glu Pro Gly
 260 265 270

Ala Leu Leu Met Glu Val Thr Pro Pro Glu Glu Leu Arg Leu Pro Ala
 275 280 285

Pro Pro Ser Pro Glu Arg Arg Pro Pro Val Pro Pro Pro Pro Arg Arg
 290 295 300

Arg Arg Arg Arg Arg Leu Leu Phe Trp Asp Lys Glu Thr Gln Ile Ser
 305 310 315 320

Pro Glu Lys Phe Gln Glu Gln Leu Gln Thr Arg Ala His Cys Trp Glu
 325 330 335

Cys Pro Met Val Gln Pro Pro Glu Arg Thr Ile Arg Gly Pro Ala Glu
 340 345 350

Leu Phe Arg Thr Pro Thr Leu Cys Lys Asn Gly Gly Gly Trp Ala Arg
 355 360 365

Ser Ile Leu Lys Thr Asn Ser Ser Phe Leu Val Leu Leu Thr Pro Gln
 370 375 380

Thr Leu Cys Leu Leu Pro Ser Cys Pro Gln Leu Ala Gly Tyr Pro Leu

Gln Gly Glu Leu Ile Pro Pro Val Leu Arg Phe Thr Val Thr Tyr Leu
130 135 140

131

Arg Glu Lys Gly Leu Arg Thr Glu Gly Leu Phe Arg Arg Ser Ala Ser
 145 150 155 160

Val Gln Thr Val Arg Glu Ile Gln Arg Leu Tyr Asn Gln Gly Lys Pro
 165 170 175

Val Asn Phe Asp Asp Tyr Gly Asp Ile His Ile Pro Ala Val Ile Leu
 180 185 190

Lys Thr Phe Leu Arg Glu Leu Pro Gln Pro Leu Leu Thr Phe Gln Ala
 195 200 205

Tyr Glu Gln Ile Leu Gly Ile Thr Cys Val Glu Ser Ser Leu Arg Val
 210 215 220

Thr Gly Cys Arg Gln Ile Leu Arg Ser Leu Pro Glu His Asn Tyr Val
 225 230 235 240

Val Leu Arg Tyr Leu Met Gly Phe Leu His Ala Val Ser Arg Glu Ser
 245 250 255

Ile Phe Asn Lys Met Asn Ser Ser Asn Leu Ala Cys Val Phe Gly Leu
 260 265 270

Asn Leu Ile Trp Pro Ser Gln Gly Val Ser Ser Leu Ser Ala Leu Val
 275 280 285

Pro Leu Asn Met Phe Thr Glu Leu Leu Ile Glu Tyr Tyr Glu Lys Ile
 290 295 300

Phe Ser Thr Pro Glu Ala Pro Gly Glu His Gly Leu Ala Pro Trp Glu
 305 310 315 320

Gln Gly Ser Arg Ala Ala Pro Leu Gln Glu Ala Val Pro Arg Thr Gln
 325 330 335

Ala Thr Gly Leu Thr Lys Pro Thr Leu Pro Pro Ser Pro Leu Met Ala
 340 345 350

Ala Arg Arg Arg Leu
 355

<210> 140
 <211> 337
 <212> PRT
 <213> Homo sapien

132

<400> 140

Gln Ser Gln Arg Tyr Lys Lys Asn Leu Lys Ala Leu Tyr Val Val His
 1 5 10 15

Pro Thr Ser Phe Ile Lys Val Leu Trp Asn Ile Leu Lys Pro Leu Ile
 20 25 30

Ser His Lys Phe Gly Lys Lys Val Ile Tyr Phe Asn Tyr Leu Ser Glu
 35 40 45

Leu His Glu His Leu Lys Tyr Asp Gln Leu Val Ile Pro Pro Glu Val
 50 55 60

Leu Arg Tyr Asp Glu Lys Leu Gln Ser Leu His Glu Gly Arg Thr Pro
 65 70 75 80

Pro Pro Thr Lys Thr Pro Pro Pro Arg Pro Pro Leu Pro Thr Gln Gln
 85 90 95

Phe Gly Val Ser Leu Gln Tyr Leu Lys Asp Lys Asn Gln Gly Glu Leu
 100 105 110

Ile Pro Pro Val Leu Arg Phe Thr Val Thr Tyr Leu Arg Glu Lys Gly
 115 120 125

Leu Arg Thr Glu Gly Leu Phe Arg Arg Ser Ala Ser Val Gln Thr Val
 130 135 140

Arg Glu Ile Gln Arg Leu Tyr Asn Gln Gly Lys Pro Val Asn Phe Asp
 145 150 155 160

Asp Tyr Gly Asp Ile His Ile Pro Ala Val Ile Leu Lys Thr Phe Leu
 165 170 175

Arg Glu Leu Pro Gln Pro Leu Leu Thr Phe Gln Ala Tyr Glu Gln Ile
 180 185 190

Leu Gly Ile Thr Cys Val Glu Ser Ser Leu Arg Val Thr Gly Cys Arg
 195 200 205

Gln Ile Leu Arg Ser Leu Pro Glu His Asn Tyr Val Val Leu Arg Tyr
 210 215 220

Leu Met Gly Phe Leu His Ala Val Ser Arg Glu Ser Ile Phe Asn Lys
 225 230 235 240

133

Met Asn Ser Ser Asn Leu Ala Cys Val Phe Gly Leu Asn Leu Ile Trp
 245 250 255

Pro Ser Gln Gly Val Ser Ser Leu Ser Ala Leu Val Pro Leu Asn Met
 260 265 270

Phe Thr Glu Leu Leu Ile Glu Tyr Tyr Glu Lys Ile Phe Ser Thr Pro
 275 280 285

Glu Ala Pro Gly Glu His Gly Leu Ala Pro Trp Glu Gln Gly Ser Arg
 290 295 300

Ala Ala Pro Leu Gln Glu Ala Val Pro Arg Thr Gln Ala Thr Gly Leu
 305 310 315 320

Thr Lys Pro Thr Leu Pro Pro Ser Pro Leu Met Ala Ala Arg Arg Arg
 325 330 335

Leu

<210> 141
 <211> 237
 <212> PRT
 <213> Homo sapien

<400> 141

Met Gly Arg Gly Val Ser Tyr Asn Val Leu Glu Ala Leu Trp Ala Gly
 1 5 10 15

Thr Cys Glu Met Pro Gly Ser Ser Ser Pro Ala Gly Leu Arg Thr Glu
 20 25 30

Gly Leu Phe Arg Arg Ser Ala Ser Val Gln Thr Val Arg Glu Ile Gln
 35 40 45

Arg Leu Tyr Asn Gln Gly Lys Pro Val Asn Phe Asp Asp Tyr Gly Asp
 50 55 60

Ile His Ile Pro Ala Val Ile Leu Lys Thr Phe Leu Arg Glu Leu Pro
 65 70 75 80

Gln Pro Leu Leu Thr Phe Gln Ala Tyr Glu Gln Ile Leu Gly Ile Thr
 85 90 95

134

Cys Val Glu Ser Ser Leu Arg Val Thr Gly Cys Arg Gln Ile Leu Arg
 100 105 110

Ser Leu Pro Glu His Asn Tyr Val Val Leu Arg Tyr Leu Met Gly Phe
 115 120 125

Leu His Ala Val Ser Arg Glu Ser Ile Phe Asn Lys Met Asn Ser Ser
 130 135 140

Asn Leu Ala Cys Val Phe Gly Leu Asn Leu Ile Trp Pro Ser Gln Gly
 145 150 155 160

Val Ser Ser Leu Ser Ala Leu Val Pro Leu Asn Met Phe Thr Glu Leu
 165 170 175

Leu Ile Glu Tyr Tyr Glu Lys Ile Phe Ser Thr Pro Glu Ala Pro Gly
 180 185 190

Glu His Gly Leu Ala Pro Trp Glu Gln Gly Ser Arg Ala Ala Pro Leu
 195 200 205

Gln Glu Ala Val Pro Arg Thr Gln Ala Thr Gly Leu Thr Lys Pro Thr
 210 215 220

Leu Pro Pro Ser Pro Leu Met Ala Ala Arg Arg Arg Leu
 225 230 235

<210> 142
 <211> 248
 <212> PRT
 <213> Homo sapien

<400> 142

Met Cys Gly Gly Gln Pro Gln Val Gly Asp Ala Met Gly Arg Gly Val
 1 5 10 15

Ser Tyr Asn Val Leu Glu Ala Leu Trp Ala Gly Thr Cys Glu Met Pro
 20 25 30

Gly Ser Ser Ser Pro Ala Gly Leu Arg Thr Glu Gly Leu Phe Arg Arg
 35 40 45

Ser Ala Ser Val Gln Thr Val Arg Glu Ile Gln Arg Leu Tyr Asn Gln
 50 55 60

Gly Lys Pro Val Asn Phe Asp Asp Tyr Gly Asp Ile His Ile Pro Ala
 65 70 75 80

135

Val Ile Leu Lys Thr Phe Leu Arg Glu Leu Pro Gln Pro Leu Leu Thr
 85 90 95

Phe Gln Ala Tyr Glu Gln Ile Leu Gly Ile Thr Cys Val Glu Ser Ser
 100 105 110

Leu Arg Val Thr Gly Cys Arg Gln Ile Leu Arg Ser Leu Pro Glu His
 115 120 125

Asn Tyr Val Val Leu Arg Tyr Leu Met Gly Phe Leu His Ala Val Ser
 130 135 140

Arg Glu Ser Ile Phe Asn Lys Met Asn Ser Ser Asn Leu Ala Cys Val
 145 150 155 160

Phe Gly Leu Asn Leu Ile Trp Pro Ser Gln Gly Val Ser Ser Leu Ser
 165 170 175

Ala Leu Val Pro Leu Asn Met Phe Thr Glu Leu Leu Ile Glu Tyr Tyr
 180 185 190

Glu Lys Ile Phe Ser Thr Pro Glu Ala Pro Gly Glu His Gly Leu Ala
 195 200 205

Pro Trp Glu Gln Gly Ser Arg Ala Ala Pro Leu Gln Glu Ala Val Pro
 210 215 220

Arg Thr Gln Ala Thr Gly Leu Thr Lys Pro Thr Leu Pro Pro Ser Pro
 225 230 235 240

Leu Met Ala Ala Arg Arg Arg Leu
 245

<210> 143
 <211> 113
 <212> PRT
 <213> Homo sapien

<400> 143

Met Gly Phe Phe Ser Arg Arg Thr Phe Cys Gly Arg Ser Gly Arg Ser
 1 5 10 15

Cys Arg Gly Gln Leu Val Gln Val Ser Arg Pro Glu Val Ser Ala Gly
 20 25 30

136

Ser Leu Leu Leu Pro Ala Pro Gln Ala Glu Asp His Ser Ser Arg Ile
 35 40 45

Leu Tyr Pro Arg Pro Lys Ser Leu Leu Pro Lys Met Met Asn Ala Asp
 50 55 60

Met Asp Asp Leu Ser Ala Arg Val Asp Ala Val Lys Glu Glu Asn Leu
 65 70 75 80

Lys Leu Lys Ser Glu Asn Gln Val Leu Gly Gln Tyr Ile Glu Asn Leu
 85 90 95

Met Ser Ala Ser Ser Val Phe Gln Thr Thr Asp Thr Lys Ser Lys Arg
 100 105 110

Lys

<210> 144
 <211> 81
 <212> PRT
 <213> Homo sapien

<400> 144

Met Ala Pro Trp Ser Gly Lys Ala Arg Pro Thr Leu Phe Ser Pro Arg
 1 5 10 15

Ala Leu Cys Thr Arg Val Cys Cys Arg Cys Val Arg Gln Gly Gly Glu
 20 25 30

Asn Pro Gly Ala Arg Ala Ala Ser His Leu Leu Leu Gln Gly Leu Cys
 35 40 45

Gly Cys Val Ile Ser Trp Val Lys Ile Met Val Pro Gly Arg Glu Leu
 50 55 60

Asp Pro Ala Phe Pro Glu Asn Phe Trp Lys Asn Leu Lys Lys Glu Asn
 65 70 75 80

Ile

<210> 145
 <211> 126
 <212> PRT
 <213> Homo sapien

<400> 145

137

Phe Gly Thr Arg Gly Arg Arg Gly Ser Ser Phe Thr Ser Ala Gly Arg
 1 5 10 15

Leu Glu Lys Pro Arg Asn Ser Ser Phe Phe Leu Pro Pro Pro Ser Leu
 20 25 30

Arg Val Ser Val Leu Arg Arg Ala Leu Gly Ala Asn Arg Gly Ala Arg
 35 40 45

Arg Gly Asp Arg Pro Pro Ser Leu Gly Gly Ala Arg Gly Leu Ala Ala
 50 55 60

Thr Ala Gly Ala Ser Ala Pro Ala Arg Trp Val Ile Phe Ser Arg Val
 65 70 75 80

Ala Arg Ala Gly Leu Arg Val Ser Leu Arg Arg Tyr Thr Arg Ala Glu
 85 90 95

Tyr Glu Ser Glu Ala Glu Gly Val Met Gly Glu Ser Arg Val Ala Pro
 100 105 110

Arg Pro Ala Gly Pro Gly Leu Ser Glu Ala Tyr Gly Asp Pro
 115 120 125

<210> 146
 <211> 126
 <212> PRT
 <213> Homo sapien

<400> 146

Met Tyr Ser Thr Val Ala Leu Pro Val Asp Asn Val Ile Thr Phe Ser
 1 5 10 15

Phe Cys Phe Lys Thr Phe Leu Phe Leu Gln Ala Gly Gln Ala Phe Arg
 20 25 30

Lys Phe Leu Pro Leu Phe Asp Arg Val Leu Val Glu Arg Ser Ala Ala
 35 40 45

Glu Thr Val Thr Lys Gly Gly Ile Met Leu Pro Glu Lys Ser Gln Gly
 50 55 60

Lys Val Leu Gln Ala Thr Val Val Ala Val Gly Ser Gly Ser Lys Gly
 65 70 75 80

Lys Gly Gly Glu Ile Gln Pro Val Ser Val Lys Val Gly Asp Lys Val

139

<210> 148
 <211> 201
 <212> PRT
 <213> Homo sapien

<400> 148

Arg Asp Pro Leu Arg Leu His Pro Leu Asp Ser Gln Ala Ser Asn Asn
 1 5 10 15

Ala His Asp Gly Asp Gly Gly Leu Gly Arg Trp Leu Pro Ser Gln Gly
 20 25 30

Glu Gly Leu Arg Gln Pro Leu Met Leu Tyr Met Ala Cys Val Ser Leu
 35 40 45

Leu Phe Ser Arg Arg His His His Ser Cys Pro Leu Leu Glu Gly Ser
 50 55 60

Ile Ser Cys Trp Ser Gly Leu His Lys Leu Ser Val Leu Ser Leu Val
 65 70 75 80

Leu Ala Ile Pro Leu Pro Gly Gln Cys Asp Leu Arg Arg Val Glu Ala
 85 90 95

Gln Gly Pro Ala Pro Gln Gly Gly Leu Met Val Arg Asp Gly Val Val
 100 105 110

Gly His Val Cys Leu Trp Gly Val Arg Ala Leu Gln Arg Leu Leu Pro
 115 120 125

Val Leu Gln Val Ser Ala Glu Pro Leu His Ala Arg Ala Leu Gln Val
 130 135 140

Gly Ser His Leu Leu Arg His Thr Gly Arg Leu Pro Leu Ala Leu Gly
 145 150 155 160

Asp Leu Ser Arg Gly Val Arg Arg Gly Pro Gly Ala Gln Val Leu Val
 165 170 175

Gln Gly Asp Val Ile Leu Ala Val Val Gly Val Leu Val Met Pro Ala
 180 185 190

Glu Glu Ala Pro Val Arg Pro His Val
 195 200

<210> 149

140

<211> 168
 <212> PRT
 <213> Homo sapien

<400> 149

Met Arg Ser Gln Tyr Glu Val Met Ala Glu Gln Asn Arg Lys Asp Ala
 1 5 10 15

Glu Ala Trp Phe Thr Ser Arg Thr Glu Glu Leu Asn Arg Glu Val Ala
 20 25 30

Gly His Thr Glu Gln Leu Gln Met Ser Arg Ser Glu Val Thr Asp Leu
 35 40 45

Arg Arg Thr Leu Gln Gly Leu Glu Ile Glu Leu Gln Ser Gln Leu Ser
 50 55 60

Met Lys Ala Ala Leu Glu Asp Thr Leu Ala Glu Thr Glu Ala Arg Phe
 65 70 75 80

Gly Ala Gln Leu Ala His Ile Gln Ala Leu Ile Ser Gly Ile Glu Ala
 85 90 95

Gln Leu Gly Asp Val Arg Ala Asp Ser Glu Arg Gln Asn Gln Glu Tyr
 100 105 110

His Thr Ser Gly Ser Trp Thr Ser Ser Arg Gly Trp Ser Arg Arg Leu
 115 120 125

Pro Pro Thr Ala Ala Cys Ser Arg Asp Arg Lys Ile Thr Thr Thr Ile
 130 135 140

Cys Leu Pro Pro Arg Ser Ser Glu Ala Ala Gly Ser Gly Ala Ser Ala
 145 150 155 160

Val Leu Trp Arg Val Ser Ser Gly
 165

<210> 150
 <211> 194
 <212> PRT
 <213> Homo sapien

<400> 150

His Ala Arg Ala Ala Leu Cys Asp Gly Cys Val Val Ala Ala Glu Ile
 1 5 10 15

141

Ser Thr Leu Arg Gly Gln Val Gly Gly Gln Val Ser Val Glu Val Asp
 20 25 30

Ser Ala Pro Gly Thr Asp Leu Ala Lys Ile Leu Ser Asp Met Arg Ser
 35 40 45

Gln Tyr Glu Val Met Ala Glu Gln Asn Arg Lys Asp Ala Glu Ala Trp
 50 55 60

Phe Thr Ser Arg Thr Glu Glu Leu Asn Arg Glu Val Ala Gly His Thr
 65 70 75 80

Glu Gln Leu Gln Met Ser Arg Ser Glu Val Thr Asp Leu Arg Arg Thr
 85 90 95

Leu Gln Gly Leu Glu Ile Glu Leu Gln Ser Gln Leu Ser Met Lys Ala
 100 105 110

Ala Leu Glu Asp Thr Leu Ala Glu Thr Glu Ala Arg Phe Gly Ala Gln
 115 120 125

Leu Ala His Ile Gln Ala Leu Ile Ser Gly Ile Glu Ala Gln Leu Gly
 130 135 140

Asp Val Arg Ala Asp Ser Glu Arg Gln Asn Gln Glu Tyr Gln Arg Leu
 145 150 155 160

Met Asp Ile Lys Ser Arg Leu Glu Gln Glu Ile Ala Thr Tyr Arg Ser
 165 170 175

Leu Leu Glu Gly Gln Glu Asp His Tyr Asn Asn Leu Ser Ala Ser Lys
 180 185 190

Val Leu

<210> 151

<211> 265

<212> PRT

<213> Homo sapien

<400> 151

Met Thr Ser Tyr Ser Tyr Arg Gln Ser Ser Ala Thr Ser Ser Phe Gly
 1 5 10 15

Gly Leu Gly Gly Gly Ser Val Arg Phe Gly Pro Gly Val Ala Phe Arg
 20 25 30

142

Ala Pro Ser Ile His Gly Gly Ser Gly Gly Arg Gly Val Ser Val Ser
35 40 45

Ser Ala Arg Phe Val Ser Ser Ser Ser Ser Gly Gly Tyr Gly Gly Gly
50 55 60

Tyr Gly Gly Val Leu Thr Ala Ser Asp Gly Leu Leu Ala Gly Asn Glu
65 70 75 80

Lys Leu Thr Met Gln Asn Leu Asn Asp Arg Leu Ala Ser Tyr Leu Asp
85 90 95

Lys Val Arg Ala Leu Glu Ala Ala Asn Gly Glu Leu Glu Val Lys Ile
100 105 110

Arg Asp Trp Tyr Gln Lys Gln Gly Pro Gly Pro Ser Arg Asp Tyr Ser
115 120 125

His Tyr Tyr Thr Thr Ile Gln Asp Leu Arg Asp Lys Ile Leu Gly Ala
130 135 140

Thr Ile Glu Asn Ser Arg Ile Val Leu Gln Ile Asp Asn Ala Arg Leu
145 150 155 160

Ala Ala Asp Asp Phe Arg Thr Lys Phe Glu Thr Glu Gln Ala Leu Arg
165 170 175

Met Ser Val Glu Ala Asp Ile Asn Gly Leu Arg Arg Val Leu Asp Glu
180 185 190

Leu Thr Leu Ala Arg Thr Asp Leu Glu Met Gln Ile Glu Gly Leu Lys
195 200 205

Glu Glu Leu Ala Tyr Leu Lys Lys Asn His Glu Glu Glu Ile Ser Thr
210 215 220

Leu Arg Trp Gly Pro Gln Arg Val Gly Gly Asn Gly Gly Pro Arg Val
225 230 235 240

Pro Arg Cys Trp Thr Val Asp Pro Leu Gly His Asp Leu Ala Asp Leu
245 250 255

Ser Asp Met Arg Ala Tyr Glu Ser Cys
260 265

143

<210> 152
 <211> 69
 <212> PRT
 <213> Homo sapien

<400> 152

Cys Arg Ala Ala Gln Cys Asp Gly Ser Ala Ala Arg Ala Gly Thr Ser
 1 5 10 15

Gly Ser Trp Thr Ser Ser Arg Gly Trp Ser Arg Arg Leu Pro Pro Thr
 20 25 30

Ala Ala Cys Ser Arg Asp Arg Lys Ile Thr Thr Thr Ile Cys Leu Pro
 35 40 45

Pro Arg Ser Ser Glu Ala Ala Gly Ser Gly Ala Ser Ala Val Leu Trp
 50 55 60

Arg Val Ser Ser Gly
 65

<210> 153
 <211> 79
 <212> PRT
 <213> Homo sapien

<400> 153

Trp Ile Gly Arg Pro Gly Arg Ala Ala His Gly His Gln Val Ala Ala
 1 5 10 15

Gly Ala Gly Asp Cys His Leu Pro Gln Pro Ala Arg Gly Thr Gly Arg
 20 25 30

Ser Leu Gln Gln Phe Val Cys Leu Gln Gly Pro Leu Arg Gln Gln Ala
 35 40 45

Leu Gly Leu Leu Leu Ser Phe Gly Gly Cys Leu Leu Gly Arg Gly Met
 50 55 60

Gly Arg Lys Gly Pro Leu Pro Pro Ala Leu Leu Leu Thr Cys Gln
 65 70 75

<210> 154
 <211> 56
 <212> PRT
 <213> Homo sapien

<400> 154

144

Arg Pro Pro Thr Thr Thr Thr Ala Arg Ile Gln Ala Ser Asn Asp Val
1 5 10 15

Arg Gly Tyr Gln Arg Leu Met Asp Ile Lys Ser Arg Leu Glu Gln Glu
20 25 30

Ile Ala Thr Tyr Arg Ser Leu Leu Glu Gly Gln Glu Asp His Tyr Asn
35 40 45

Asn Leu Ser Ala Ser Lys Val Leu
50 55

<210> 155
<211> 90
<212> PRT
<213> Homo sapien

<400> 155

Arg Pro Pro Thr Thr Thr Thr Ala Arg Ile Gln Ala Ser Asn Asp Val
1 5 10 15

Arg Gly Ala Ala His Gly His Gln Val Ala Ala Gly Ala Gly Asp Cys
20 25 30

His Leu Pro Gln Pro Ala Arg Gly Thr Gly Arg Ser Leu Gln Gln Phe
35 40 45

Val Cys Leu Gln Gly Pro Leu Arg Gln Gln Ala Leu Gly Leu Leu Leu
50 55 60

Ser Phe Gly Gly Cys Leu Leu Gly Arg Gly Met Gly Arg Lys Gly Pro
65 70 75 80

Leu Pro Pro Ala Leu Leu Leu Thr Cys Gln
85 90

<210> 156
<211> 315
<212> PRT
<213> Homo sapien

<400> 156

Met Thr Ser Tyr Ser Tyr Arg Gln Ser Ser Ala Thr Ser Ser Phe Gly
1 5 10 15

Gly Leu Gly Gly Gly Ser Val Arg Phe Gly Pro Gly Val Ala Phe Arg
20 25 30

145

Ala Pro Ser Ile His Gly Gly Ser Gly Gly Arg Gly Val Ser Val Ser
 35 40 45

Ser Ala Arg Phe Val Ser Ser Ser Ser Ser Gly Gly Tyr Gly Gly Gly
 50 55 60

Tyr Gly Gly Val Leu Thr Ala Ser Asp Gly Leu Leu Ala Gly Asn Glu
 65 70 75 80

Lys Leu Thr Met Gln Asn Leu Asn Asp Arg Leu Ala Ser Tyr Leu Asp
 85 90 95

Lys Val Arg Ala Leu Glu Ala Ala Asn Gly Glu Leu Glu Val Lys Ile
 100 105 110

Arg Asp Trp Tyr Gln Lys Gln Gly Pro Gly Pro Ser Arg Asp Tyr Ser
 115 120 125

His Tyr Tyr Thr Thr Ile Gln Asp Leu Arg Asp Lys Ile Leu Gly Ala
 130 135 140

Thr Ile Glu Asn Ser Arg Ile Val Leu Gln Ile Asp Asn Ala Arg Leu
 145 150 155 160

Ala Ala Asp Asp Phe Arg Thr Lys Phe Glu Thr Glu Gln Ala Leu Arg
 165 170 175

Met Ser Val Glu Ala Asp Ile Asn Gly Leu Arg Arg Val Leu Asp Glu
 180 185 190

Leu Thr Leu Ala Arg Thr Asp Leu Glu Met Gln Ile Glu Gly Leu Lys
 195 200 205

Glu Glu Leu Ala Tyr Leu Lys Lys Asn His Glu Glu Glu Ile Ser Thr
 210 215 220

Leu Arg Gly Gln Val Gly Gly Gln Val Ser Val Glu Val Asp Ser Ala
 225 230 235 240

Pro Gly Thr Asp Leu Ala Lys Ile Leu Ser Asp Met Arg Ser Gln Tyr
 245 250 255

Glu Val Met Ala Glu Gln Asn Arg Lys Asp Ala Glu Ala Trp Phe Thr
 260 265 270

146

Ser Arg Leu Lys Ile Val Pro Gly Ala Leu Ala His Glu Glu Pro Lys
 275 280 285

Asn Gly Arg Tyr Ala Gln Gly Pro Gln Val Lys Arg Gly Thr Glu Ser
 290 295 300

Cys Asn Thr Lys Gly Gly Cys Gln His Thr Pro
 305 310 315

<210> 157

<211> 338

<212> PRT

<213> Homo sapien

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> X=any amino acid

<220>

<221> MISC_FEATURE

<222> (304)..(305)

<223> X=any amino acid

<220>

<221> MISC_FEATURE

<222> (308)..(309)

<223> X=any amino acid

<220>

<221> MISC_FEATURE

<222> (312)..(313)

<223> X=any amino acid

<220>

<221> MISC_FEATURE

<222> (315)..(317)

<223> X=any amino acid

<400> 157

Val Glu Ala Gly Val Asn Arg Xaa Arg Ala Ala Ser Glu Thr Arg Val
 1 5 10 15

Ala Pro Ser Val Leu Arg Leu Ala Met Thr Ser Tyr Ser Tyr Arg Gln
 20 25 30

Ser Ser Ala Thr Ser Ser Phe Gly Gly Leu Gly Gly Gly Ser Val Arg
 35 40 45

147

Phe Gly Pro Gly Val Ala Phe Arg Ala Pro Ser Ile His Gly Gly Ser
 50 55 60

Gly Gly Arg Gly Val Ser Val Ser Ser Ala Arg Phe Val Ser Ser Ser
 65 70 75 80

Ser Ser Gly Gly Tyr Gly Gly Gly Tyr Gly Gly Val Leu Thr Ala Ser
 85 90 95

Asp Gly Leu Leu Ala Gly Asn Glu Lys Leu Thr Met Gln Asn Leu Asn
 100 105 110

Asp Arg Leu Ala Ser Tyr Leu Asp Lys Val Arg Ala Leu Glu Ala Ala
 115 120 125

Asn Gly Glu Leu Glu Val Lys Ile Arg Asp Trp Tyr Gln Lys Gln Gly
 130 135 140

Pro Gly Pro Ser Arg Asp Tyr Ser His Tyr Tyr Thr Thr Ile Gln Asp
 145 150 155 160

Leu Arg Asp Lys Ile Leu Gly Ala Thr Ile Glu Asn Ser Arg Ile Val
 165 170 175

Leu Gln Ile Asp Asn Ala Arg Leu Ala Ala Asp Asp Phe Arg Thr Lys
 180 185 190

Phe Glu Thr Glu Gln Ala Leu Arg Met Ser Val Glu Ala Asp Ile Asn
 195 200 205

Gly Leu Arg Arg Val Leu Asp Glu Leu Thr Leu Ala Arg Thr Asp Leu
 210 215 220

Glu Met Gln Ile Glu Gly Leu Lys Glu Glu Leu Ala Tyr Leu Lys Lys
 225 230 235 240

Asn His Glu Glu Glu Ile Ser Thr Leu Arg Gly Gln Val Gly Gly Gln
 245 250 255

Val Ser Val Glu Val Asp Ser Ala Pro Gly Thr Asp Leu Ala Lys Ile
 260 265 270

Leu Ser Asp Met Arg Ser Gln Tyr Glu Val Met Ala Glu Gln Asn Arg
 275 280 285

148

Lys Asp Ala Glu Ala Trp Phe Thr Ser Arg Leu Lys Ile Asp Gly Xaa
 290 295 300

Xaa Ala His Xaa Xaa Pro Lys Xaa Xaa Arg Xaa Xaa Xaa Ala Pro Arg
 305 310 315 320

Leu Arg Gly Ala His Arg Ala Val Thr Pro Lys Gly Val Ala Ser Ile
 325 330 335

Arg Arg

<210> 158

<211> 266

<212> PRT

<213> Homo sapien

<400> 158

Met Leu Arg Lys Leu Cys Leu Ala Ala Thr Ile Ser Phe Glu Arg Phe
 1 5 10 15

Glu Thr Glu Gln Ala Leu Arg Met Ser Val Glu Ala Asp Ile Asn Gly
 20 25 30

Leu Arg Arg Val Leu Asp Glu Leu Thr Leu Ala Arg Thr Asp Leu Glu
 35 40 45

Met Gln Ile Glu Gly Leu Lys Glu Glu Leu Ala Tyr Leu Lys Lys Asn
 50 55 60

His Glu Glu Glu Ile Ser Thr Leu Arg Gly Gln Val Gly Gly Gln Val
 65 70 75 80

Ser Val Glu Val Asp Ser Ala Pro Gly Thr Asp Leu Ala Lys Ile Leu
 85 90 95

Ser Asp Met Arg Ser Gln Tyr Glu Val Met Ala Glu Gln Asn Arg Lys
 100 105 110

Asp Ala Glu Ala Trp Phe Thr Ser Arg Thr Glu Glu Leu Asn Arg Glu
 115 120 125

Val Ala Gly His Thr Glu Gln Leu Gln Met Ser Arg Ser Glu Val Thr
 130 135 140

Asp Leu Arg Arg Thr Leu Gln Gly Leu Glu Ile Glu Leu Gln Ser Gln
 145 150 155 160

149

Leu Ser Met Lys Ala Ala Leu Glu Asp Thr Leu Ala Glu Thr Glu Ala
 165 170 175

Arg Phe Gly Ala Gln Leu Ala His Ile Gln Ala Leu Ile Ser Gly Ile
 180 185 190

Glu Ala Gln Leu Gly Asp Val Arg Ala Asp Ser Glu Arg Gln Asn Gln
 195 200 205

Glu Tyr His Thr Ser Gly Ser Trp Thr Ser Ser Arg Gly Trp Ser Arg
 210 215 220

Arg Leu Pro Pro Thr Ala Ala Cys Ser Arg Asp Arg Lys Ile Thr Thr
 225 230 235 240

Thr Ile Cys Leu Pro Pro Arg Ser Ser Glu Ala Ala Gly Ser Gly Ala
 245 250 255

Ser Ala Val Leu Trp Arg Val Ser Ser Gly
 260 265

<210> 159
 <211> 263
 <212> PRT
 <213> Homo sapien

<400> 159

Pro Pro Tyr Gly Leu Leu Asn Ser Gly Glu Val Gly Lys Ser Ser Glu
 1 5 10 15

Met Leu Arg Lys Leu Cys Leu Ala Ala Thr Ile Ser Phe Glu Arg Phe
 20 25 30

Glu Thr Glu Gln Ala Leu Arg Met Ser Val Glu Ala Asp Ile Asn Gly
 35 40 45

Leu Arg Arg Val Leu Asp Glu Leu Thr Leu Ala Arg Thr Asp Leu Glu
 50 55 60

Met Gln Ile Glu Gly Leu Lys Glu Glu Leu Ala Tyr Leu Lys Lys Asn
 65 70 75 80

His Glu Glu Glu Ile Ser Thr Leu Arg Gly Gln Val Gly Gly Gln Val
 85 90 95

150

Ser Val Glu Val Asp Ser Ala Pro Gly Thr Asp Leu Ala Lys Ile Leu
 100 105 110

Ser Asp Met Arg Ser Gln Tyr Glu Val Met Ala Glu Gln Asn Arg Lys
 115 120 125

Asp Ala Glu Ala Trp Phe Thr Ser Arg Thr Glu Glu Leu Asn Arg Glu
 130 135 140

Val Ala Gly His Thr Glu Gln Leu Gln Met Ser Arg Ser Glu Val Thr
 145 150 155 160

Asp Leu Arg Arg Thr Leu Gln Gly Leu Glu Ile Glu Leu Gln Ser Gln
 165 170 175

Leu Ser Met Lys Ala Ala Leu Glu Asp Thr Leu Ala Glu Thr Glu Ala
 180 185 190

Arg Phe Gly Ala Gln Leu Ala His Ile Gln Ala Leu Ile Ser Gly Ile
 195 200 205

Glu Ala Gln Leu Gly Asp Val Arg Ala Asp Ser Glu Arg Gln Asn Gln
 210 215 220

Glu Tyr Gln Arg Leu Met Asp Ile Lys Ser Arg Leu Glu Gln Glu Ile
 225 230 235 240

Ala Thr Tyr Arg Ser Leu Leu Glu Gly Gln Glu Asp His Tyr Asn Asn
 245 250 255

Leu Ser Ala Ser Lys Val Leu
 260

<210> 160
 <211> 107
 <212> PRT
 <213> Homo sapien

<400> 160

Met Ser Arg Ser Val Ala Leu Ala Val Leu Ala Leu Leu Ser Leu Ser
 1 5 10 15

Gly Leu Glu Ala Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg
 20 25 30

His Pro Ala Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser
 35 40 45

151

Gly Phe His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu
 50 55 60

Arg Ile Glu Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp
 65 70 75 80

Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp
 85 90 95

Glu Ser Arg His Val Ser Ser Ile Met Glu Val
 100 105

<210> 161
 <211> 41
 <212> PRT
 <213> Homo sapien

<400> 161

Met Asp Gly Arg Pro Gly Arg Tyr Tyr Thr Glu Phe Thr Pro Thr Glu
 1 5 10 15

Lys Asp Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro
 20 25 30

Lys Ile Val Lys Trp Asp Arg Asp Met
 35 40

<210> 162
 <211> 47
 <212> PRT
 <213> Homo sapien

<400> 162

Ala Ala Ser Trp Arg Phe Glu Asp Ala Ala Phe Gly Leu Asp Glu Phe
 1 5 10 15

Gln Ile Leu Leu Ala Cys Phe Leu Ile Leu Ile Cys Leu Tyr Thr Tyr
 20 25 30

Thr Leu Cys Thr Lys Cys Arg Val Ile Ile Met Leu Thr Trp Thr
 35 40 45

<210> 163
 <211> 257
 <212> PRT
 <213> Homo sapien

152

<400> 163

Met Ser Gly Glu Glu Asn Pro Ala Ser Lys Pro Thr Pro Val Gln Asp
 1 5 10 15

Val Gln Gly Asp Gly Arg Trp Met Ser Leu His His Arg Phe Val Ala
 20 25 30

Asp Ser Lys Asp Lys Glu Pro Glu Val Val Phe Ile Gly Asp Ser Leu
 35 40 45

Val Gln Leu Met His Gln Cys Glu Ile Trp Arg Glu Leu Phe Ser Pro
 50 55 60

Leu His Ala Leu Asn Phe Gly Ile Gly Gly Asp Gly Thr Gln His Val
 65 70 75 80

Leu Trp Arg Leu Glu Asn Gly Glu Leu Glu His Ile Arg Pro Lys Val
 85 90 95

Ser Gly Ala Trp Val Gly Leu Tyr Asn Ile Phe Trp Leu Pro Pro His
 100 105 110

Arg Cys Phe Met Ser Leu Phe Pro Gln Ile Val Val Val Trp Val Gly
 115 120 125

Thr Asn Asn His Gly His Thr Ala Glu Gln Val Thr Gly Gly Ile Lys
 130 135 140

Ala Ile Val Gln Leu Val Asn Glu Arg Gln Pro Gln Ala Arg Val Val
 145 150 155 160

Val Leu Gly Leu Leu Pro Arg Gly Gln His Pro Asn Pro Leu Arg Glu
 165 170 175

Lys Asn Arg Gln Val Asn Glu Leu Val Arg Ala Ala Leu Ala Gly His
 180 185 190

Pro Arg Ala His Phe Leu Asp Ala Asp Pro Gly Phe Val His Ser Asp
 195 200 205

Gly Thr Ile Ser His His Asp Met Tyr Asp Tyr Leu His Leu Ser Arg
 210 215 220

Leu Gly Tyr Thr Pro Val Cys Arg Ala Leu His Ser Leu Leu Leu Arg
 225 230 235 240

Ala Ser Gly Asn Lys Arg Pro His Leu Ser Val Ile Leu Val Gly Glu
85 90 95

155

Asn Pro Ala Ser His Ser Tyr Val Leu Asn Lys Thr Arg Ala Ala Ala
 100 105 110

Val Val Gly Ile Asn Ser Glu Thr Ile Met Lys Pro Ala Ser Ile Ser
 115 120 125

Glu Glu Glu Leu Leu Asn Leu Ile Asn Lys Leu Asn Asn Asp Asp Asn
 130 135 140

Val Asp Gly Leu Leu Val Gln Leu Pro Leu Pro Glu His Ile Asp Glu
 145 150 155 160

Arg Arg Ile Cys Asn Ala Val Ser Pro Asp Lys Asp Val Asp Gly Phe
 165 170 175

His Val Ile Asn Val Gly Arg Met Cys Leu Asp Gln Tyr Ser Met Leu
 180 185 190

Pro Ala Thr Pro Trp Gly Val Trp Glu Ile Ile Lys Arg Thr Gly Ile
 195 200 205

Pro Thr Leu Gly Lys Asn Val Val Val Ala Gly Arg Ser Lys Asn Val
 210 215 220

Gly Met Pro Ile Ala Met Leu Leu His Thr Asp Gly Ala His Glu Arg
 225 230 235 240

Pro Gly Gly Asp Ala Thr Val Thr Ile Ser His Arg Tyr Thr Pro Lys
 245 250 255

Glu Gln Leu Lys Lys His Thr Ile Leu Ala Asp Ile Val Ile Ser Ala
 260 265 270

Ala Gly Met Ser Leu Gln Leu Leu Phe Gln Ser Ile Leu Met Arg Glu
 275 280 285

Gly Ser Ala Met Leu Phe Leu Gln Thr Arg Met Leu Met Ala Phe Met
 290 295 300

Leu Leu Leu
 305

<210> 166
 <211> 207
 <212> PRT
 <213> Homo sapien

156

<400> 166

Met Asp Arg Gly Glu Gln Gly Leu Leu Arg Thr Asp Pro Val Pro Glu
 1 5 10 15

Glu Gly Glu Asp Val Ala Ala Thr Ile Ser Ala Thr Glu Thr Leu Ser
 20 25 30

Glu Glu Glu Gln Glu Glu Leu Arg Arg Glu Leu Ala Lys Val Glu Glu
 35 40 45

Glu Ile Gln Thr Leu Ser Gln Val Leu Ala Ala Lys Glu Lys His Leu
 50 55 60

Ala Glu Ile Lys Arg Lys Leu Gly Ile Asn Ser Leu Gln Glu Leu Lys
 65 70 75 80

Gln Asn Ile Ala Lys Gly Trp Gln Asp Val Thr Ala Thr Ser Ala Tyr
 85 90 95

Lys Lys Thr Ser Glu Thr Leu Ser Gln Ala Gly Gln Lys Ala Ser Ala
 100 105 110

Ala Phe Ser Ser Val Gly Ser Val Ile Thr Lys Lys Leu Glu Asp Val
 115 120 125

Lys Leu Gln Ala Phe Ser His Ser Phe Ser Ile Arg Ser Ile Gln His
 130 135 140

Ser Ile Ser Met Pro Ala Met Arg Asn Ser Pro Thr Phe Lys Ser Phe
 145 150 155 160

Glu Glu Lys Val Glu Asn Leu Lys Ser Lys Val Gly Gly Thr Lys Pro
 165 170 175

Ala Gly Gly Asp Phe Gly Glu Val Leu Asn Ser Ala Ala Asn Ala Ser
 180 185 190

Ala Thr Thr Thr Glu Pro Leu Pro Glu Lys Thr Gln Glu Ser Leu
 195 200 205

<210> 167

<211> 81

<212> PRT

<213> Homo sapien

<400> 167

157

Ser Leu Leu Gly Arg Arg Arg Lys Leu His Leu Pro Asp Pro Asp Leu
1 5 10 15

Ala Ser Trp Gly Pro Gly Arg Ser Gly Ser Gly Gly Gly Arg Trp Asp
20 25 30

Cys Met Cys Glu Cys Glu Cys Ala Cys Val Gly Glu Arg Glu Arg Arg
35 40 45

Phe Trp Glu Val Ala Lys Gly Leu Ala Ser Gly Ala Gly Gly Arg Asp
50 55 60

Ala Leu Trp Val Glu Ser Arg Val Lys Gly Ala Arg Arg Ser Gln Leu
65 70 75 80

Leu

<210> 168
<211> 154
<212> PRT
<213> Homo sapien

<400> 168

Val Ala Leu Val Pro Pro Gly Leu Leu Arg Thr Asp Pro Val Pro Glu
1 5 10 15

Glu Gly Glu Asp Val Ala Ala Thr Ile Ser Ala Thr Glu Thr Leu Ser
20 25 30

Glu Glu Glu Gln Glu Glu Leu Arg Arg Glu Leu Ala Lys Val Glu Glu
35 40 45

Glu Ile Gln Thr Leu Ser Gln Val Leu Ala Ala Lys Glu Lys His Leu
50 55 60

Ala Glu Ile Lys Arg Lys Leu Gly Ile Asn Ser Leu Gln Glu Leu Lys
65 70 75 80

Gln Asn Ile Ala Lys Gly Trp Gln Asp Val Thr Ala Thr Ser Ala Tyr
85 90 95

Lys Lys Thr Ser Glu Thr Leu Ser Gln Ala Gly Gln Lys Ala Ser Ala
100 105 110

Ala Phe Ser Ser Val Gly Ser Val Ile Thr Lys Lys Leu Glu Asp Val

158

115

120

125

Lys Asn Ser Pro Thr Phe Lys Ser Phe Glu Glu Lys Val Glu Asn Leu
 130 135 140

Lys Ala Ser Arg Glu Met Asn Arg Val Phe
 145 150

<210> 169
 <211> 178
 <212> PRT
 <213> Homo sapien

<400> 169

Gly Gly Trp Val Thr Pro Gln Glu Ser Ala Pro Gly Arg Gly Arg Ala
 1 5 10 15

Ala Pro Pro Arg Pro Thr Pro Leu Gly Val Gly Thr Ser Arg Glu Ser
 20 25 30

Pro Ala Glu Ala Arg Arg Ser Ser Ala Arg Arg Gly Gly Arg Ser Glu
 35 40 45

Pro Gly Arg Ala Ala Gly Gly Gly Ala Ala Glu Asp Thr Arg Arg Arg
 50 55 60

Ala Gly Asp Met Asp Arg Gly Glu Gln Gly Leu Leu Arg Thr Asp Pro
 65 70 75 80

Val Pro Glu Glu Gly Glu Asp Val Ala Ala Thr Ile Ser Ala Thr Glu
 85 90 95

Thr Leu Ser Glu Glu Glu Gln Glu Glu Leu Arg Arg Glu Leu Ala Lys
 100 105 110

Val Glu Glu Glu Ile Gln Thr Leu Ser Gln Val Leu Ala Ala Lys Glu
 115 120 125

Lys His Leu Ala Glu Ile Lys Arg Lys Leu Gly Ile Asn Ser Leu Gln
 130 135 140

Glu Leu Lys Gln Asn Ile Ala Lys Gly Trp Gln Asp Val Thr Ala Thr
 145 150 155 160

Ser Ala Arg Ser Lys Leu Leu Ala Ala Glu Thr Glu Leu Leu Cys Leu
 165 170 175

159

Leu Tyr

<210> 170
 <211> 138
 <212> PRT
 <213> Homo sapien

<400> 170

Met Glu Lys Leu Ala Ala Ser Thr Glu Pro Gln Gly Pro Arg Pro Val
 1 5 10 15

Leu Gly Arg Glu Ser Val Gln Val Pro Asp Asp Gln Asp Phe Arg Ser
 20 25 30

Phe Arg Ser Glu Cys Glu Ala Glu Val Gly Trp Asn Leu Thr Tyr Ser
 35 40 45

Arg Ala Gly Val Ser Val Trp Val Gln Ala Val Glu Met Asp Arg Thr
 50 55 60

Leu His Lys Ile Lys Cys Arg Met Glu Cys Cys Asp Val Pro Ala Glu
 65 70 75 80

Thr Leu Tyr Asp Val Leu His Asp Ile Glu Tyr Arg Lys Lys Trp Asp
 85 90 95

Ser Asn Val Ile Glu Thr Phe Asp Ile Ala Arg Leu Thr Val Asn Ala
 100 105 110

Asp Val Gly Tyr Tyr Ser Trp Arg Cys Pro Lys Pro Leu Arg Thr Tyr
 115 120 125

Glu Val Pro Ser Ser Ile Arg Ser Cys Gln
 130 135

<210> 171
 <211> 187
 <212> PRT
 <213> Homo sapien

<220>
 <221> MISC_FEATURE
 <222> (13)..(13)
 <223> X=any amino acid

<220>
 <221> MISC_FEATURE

160

<222> (174)..(174)

<223> X=any amino acid

<400> 171

Tyr Ile Gln Ser Cys Ser Val Pro His Arg Phe Ala Xaa Pro Arg Lys
 1 5 10 15

Val Ala Ser Ala Ser Ala Ala Ala Ser Thr Leu Ser Glu Pro Pro Arg
 20 25 30

Arg Thr Gln Glu Ser Arg Thr Arg Thr Arg Ala Leu Gly Leu Pro Thr
 35 40 45

Leu Pro Met Glu Lys Leu Ala Ala Ser Thr Glu Pro Gln Gly Pro Arg
 50 55 60

Pro Val Leu Gly Arg Glu Ser Val Gln Val Pro Asp Asp Gln Asp Phe
 65 70 75 80

Arg Ser Phe Arg Ser Glu Cys Glu Ala Glu Val Gly Trp Asn Leu Thr
 85 90 95

Tyr Ser Arg Ala Gly Val Ser Val Trp Val Gln Ala Val Glu Met Asp
 100 105 110

Arg Thr Leu His Lys Ile Lys Cys Arg Met Glu Cys Cys Asp Val Pro
 115 120 125

Ala Glu Thr Leu Tyr Asp Val Leu His Asp Ile Glu Tyr Arg Lys Lys
 130 135 140

Trp Asp Ser Asn Val Ile Glu Thr Phe Asp Ile Ala Arg Leu Thr Val
 145 150 155 160

Asn Ala Asp Val Gly Tyr Tyr Ser Trp Ser Val Pro Ser Xaa Cys Glu
 165 170 175

Pro Met Arg Tyr Arg Ala Arg Phe Asp His Val
 180 185

<210> 172

<211> 201

<212> PRT

<213> Homo sapien

<400> 172

161

Met Glu Lys Leu Ala Ala Ser Thr Glu Pro Gln Gly Pro Arg Pro Val
 1 5 10 15

Leu Gly Arg Glu Ser Val Gln Val Pro Asp Asp Gln Asp Phe Arg Ser
 20 25 30

Phe Arg Ser Glu Cys Glu Ala Glu Val Gly Trp Asn Leu Thr Tyr Ser
 35 40 45

Arg Ala Gly Val Ser Val Trp Val Gln Ala Val Glu Met Asp Arg Thr
 50 55 60

Leu His Lys Ile Lys Cys Arg Met Glu Cys Cys Asp Val Pro Ala Glu
 65 70 75 80

Thr Leu Tyr Asp Val Leu His Asp Ile Glu Tyr Arg Lys Lys Trp Asp
 85 90 95

Ser Asn Val Ile Glu Thr Phe Asp Ile Ala Arg Leu Thr Val Asn Ala
 100 105 110

Asp Val Gly Tyr Tyr Ser Trp Arg Cys Pro Lys Pro Leu Lys Asn Arg
 115 120 125

Asp Val Ile Thr Leu Arg Ser Trp Leu Pro Met Gly Ala Asp Tyr Ile
 130 135 140

Ile Met Asn Tyr Ser Val Lys His Pro Lys Tyr Pro Pro Arg Lys Asp
 145 150 155 160

Leu Val Arg Ala Val Ser Ile Gln Thr Gly Tyr Leu Ile Gln Ser Thr
 165 170 175

Gly Pro Lys Ser Cys Val Ile Thr Tyr Leu Gly Pro Gly Gly Pro Gln
 180 185 190

Arg Leu Leu Thr Gln Val Gly Gly Glu
 195 200

<210> 173

<211> 387

<212> PRT

<213> Homo sapien

<400> 173

Gln Pro Gly Lys Ser Arg Ala Ala Ala Ala Glu Pro Pro Ser Pro Arg
 1 5 10 15

162

Ala Pro Ser Leu Ala Gly Arg Gly Ala Arg Gly Trp Gly Pro Gly Arg
 20 25 30

Gly Arg Ala Ala Gly Pro Thr Ala Pro Pro Thr Arg Ala Pro Ala Arg
 35 40 45

Pro Arg Val Ser Arg Ala Ala Ala Ala Ala Ala Leu Ala Pro Arg Pro
 50 55 60

Arg Arg Ala Pro Ala Glu Arg Arg Ala Lys Val Pro Gly Arg Trp Arg
 65 70 75 80

Gln His Leu Gln Pro Arg Arg Arg Cys Arg Ser Leu Pro Thr Leu Pro
 85 90 95

Met Glu Lys Leu Ala Ala Ser Thr Glu Pro Gln Gly Pro Arg Pro Val
 100 105 110

Leu Gly Arg Glu Ser Val Gln Val Pro Asp Asp Gln Asp Phe Arg Ser
 115 120 125

Phe Arg Ser Glu Cys Glu Ala Glu Val Gly Trp Asn Leu Thr Tyr Ser
 130 135 140

Arg Ala Gly Val Ser Val Trp Val Gln Ala Val Glu Met Asp Arg Thr
 145 150 155 160

Leu His Lys Ile Lys Cys Arg Met Glu Cys Cys Asp Val Pro Ala Glu
 165 170 175

Thr Leu Tyr Asp Val Leu His Asp Ile Glu Tyr Arg Lys Lys Trp Asp
 180 185 190

Ser Asn Val Ile Glu Thr Phe Asp Ile Ala Arg Leu Thr Val Asn Ala
 195 200 205

Asp Val Gly Tyr Tyr Ser Trp Arg Cys Pro Lys Pro Leu Lys Asn Arg
 210 215 220

Asp Val Ile Thr Leu Arg Ser Trp Leu Pro Met Gly Ala Asp Tyr Ile
 225 230 235 240

Ile Met Asn Tyr Ser Val Lys His Pro Lys Tyr Pro Pro Arg Lys Asp
 245 250 255

163

Leu Val Arg Ala Val Ser Ile Gln Thr Gly Tyr Leu Ile Gln Ser Thr
 260 265 270

Gly Pro Lys Ser Cys Val Ile Thr Tyr Leu Ala Gln Val Asp Pro Lys
 275 280 285

Gly Ser Leu Pro Lys Trp Val Val Asn Lys Ser Ser Gln Phe Leu Ala
 290 295 300

Pro Lys Ala Met Lys Lys Met Tyr Lys Ala Cys Leu Lys Tyr Pro Glu
 305 310 315 320

Trp Lys Gln Lys His Leu Pro His Phe Lys Pro Trp Leu His Pro Glu
 325 330 335

Gln Ser Pro Leu Pro Ser Leu Ala Leu Ser Glu Leu Ser Val Gln His
 340 345 350

Ala Asp Ser Leu Glu Asn Ile Asp Glu Ser Ala Val Ala Glu Ser Arg
 355 360 365

Glu Glu Arg Met Gly Gly Ala Gly Gly Glu Gly Ser Asp Asp Asp Thr
 370 375 380

Ser Leu Thr
 385

<210> 174
 <211> 224
 <212> PRT
 <213> Homo sapien

<400> 174

Met Val Pro Gly Arg Trp Arg Gln His Leu Gln Pro Arg Arg Arg Cys
 1 5 10 15

Arg Ser Leu Pro Thr Leu Pro Met Glu Lys Leu Ala Ala Ser Thr Glu
 20 25 30

Pro Gln Gly Pro Arg Pro Val Leu Gly Arg Glu Ser Val Gln Val Pro
 35 40 45

Asp Asp Gln Asp Phe Arg Ser Phe Arg Ser Glu Cys Glu Ala Glu Val
 50 55 60

Gly Trp Asn Leu Thr Tyr Ser Arg Ala Gly Val Ser Val Trp Val Gln

164

65	70	75	80
Ala Val Glu Met Asp Arg Thr Leu His Lys Ile Lys Cys Arg Met Glu	85	90	95
Cys Cys Asp Val Pro Ala Glu Thr Leu Tyr Asp Val Leu His Asp Ile	100	105	110
Glu Tyr Arg Lys Lys Trp Asp Ser Asn Val Ile Glu Thr Phe Asp Ile	115	120	125
Ala Arg Leu Thr Val Asn Ala Asp Val Gly Tyr Tyr Ser Trp Arg Cys	130	135	140
Pro Lys Pro Leu Lys Asn Arg Asp Val Ile Thr Leu Arg Ser Trp Leu	145	150	155
Pro Met Gly Ala Asp Tyr Ile Ile Met Asn Tyr Ser Val Lys His Pro	165	170	175
Lys Tyr Pro Pro Arg Lys Asp Leu Val Arg Ala Val Ser Ile Gln Thr	180	185	190
Gly Tyr Leu Ile Gln Ser Thr Gly Pro Lys Ser Cys Val Ile Thr Tyr	195	200	205
Leu Gly Pro Gly Gly Pro Gln Arg Leu Leu Thr Gln Val Gly Gly Glu	210	215	220

<210> 175
 <211> 314
 <212> PRT
 <213> Homo sapien

<400> 175

Met Val Pro Gly Arg Trp Arg Gln His Leu Gln Pro Arg Arg Arg Cys	5	10	15
Arg Ser Leu Pro Thr Leu Pro Met Glu Lys Leu Ala Ala Ser Thr Glu	20	25	30
Pro Gln Gly Pro Arg Pro Val Leu Gly Arg Glu Ser Val Gln Val Pro	35	40	45
Asp Asp Gln Asp Phe Arg Ser Phe Arg Ser Glu Cys Glu Ala Glu Val	50	55	60

165

Gly Trp Asn Leu Thr Tyr Ser Arg Ala Gly Val Ser Val Trp Val Gln
 65 70 75 80

Ala Val Glu Met Asp Arg Thr Leu His Lys Ile Lys Cys Arg Met Glu
 85 90 95

Cys Cys Asp Val Pro Ala Glu Thr Leu Tyr Asp Val Leu His Asp Ile
 100 105 110

Glu Tyr Arg Lys Lys Trp Asp Ser Asn Val Ile Glu Thr Phe Asp Ile
 115 120 125

Ala Arg Leu Thr Val Asn Ala Asp Val Gly Tyr Tyr Ser Trp Arg Cys
 130 135 140

Pro Lys Pro Leu Lys Asn Arg Asp Val Ile Thr Leu Arg Ser Trp Leu
 145 150 155 160

Pro Met Gly Ala Asp Tyr Ile Ile Met Asn Tyr Ser Val Lys His Pro
 165 170 175

Lys Tyr Pro Pro Arg Lys Asp Leu Val Arg Ala Val Ser Ile Gln Thr
 180 185 190

Gly Tyr Leu Ile Gln Ser Thr Gly Pro Lys Ser Cys Val Ile Thr Tyr
 195 200 205

Leu Ala Gln Val Asp Pro Lys Gly Ser Leu Pro Lys Trp Val Val Asn
 210 215 220

Lys Ser Ser Gln Phe Leu Ala Pro Lys Ala Met Lys Lys Met Tyr Lys
 225 230 235 240

Ala Cys Leu Lys Tyr Pro Glu Trp Lys Gln Lys His Leu Pro His Phe
 245 250 255

Lys Pro Trp Leu His Pro Glu Gln Ser Pro Leu Pro Ser Leu Ala Leu
 260 265 270

Ser Glu Leu Ser Val Gln His Ala Asp Ser Leu Glu Asn Ile Asp Glu
 275 280 285

Ser Ala Val Ala Glu Ser Arg Glu Glu Arg Met Gly Gly Ala Gly Gly
 290 295 300

166

Glu Gly Ser Asp Asp Asp Thr Ser Leu Thr
305 310

<210> 176
<211> 341
<212> PRT
<213> Homo sapien

<400> 176

Met Glu Lys Leu Ala Ala Ser Thr Glu Pro Gln Gly Pro Arg Pro Val
1 5 10 15

Leu Gly Arg Glu Ser Val Gln Val Pro Asp Asp Gln Asp Phe Arg Ser
20 25 30

Phe Arg Ser Glu Cys Glu Ala Glu Val Gly Trp Asn Leu Thr Tyr Ser
35 40 45

Arg Ala Gly Val Ser Val Trp Val Gln Ala Val Glu Met Asp Arg Thr
50 55 60

Leu His Lys Ile Lys Cys Arg Met Glu Cys Cys Asp Val Pro Ala Glu
65 70 75 80

Thr Leu Tyr Asp Val Leu His Asp Ile Glu Tyr Arg Lys Lys Trp Asp
85 90 95

Ser Asn Val Ile Glu Thr Phe Asp Ile Ala Arg Leu Thr Val Asn Ala
100 105 110

Asp Val Gly Tyr Tyr Ser Trp Arg Cys Pro Lys Pro Leu Lys Asn Arg
115 120 125

Asp Val Ile Thr Leu Arg Ser Trp Leu Pro Met Gly Ala Asp Tyr Ile
130 135 140

Ile Met Asn Tyr Ser Val Lys His Pro Lys Tyr Pro Pro Arg Lys Asp
145 150 155 160

Leu Val Arg Ala Val Ser Ile Gln Thr Gly Tyr Leu Ile Gln Ser Thr
165 170 175

Gly Pro Lys Ser Cys Val Ile Thr Tyr Leu Gly Pro Gly Gly Pro Gln
180 185 190

Ser Ser Leu Pro Lys Trp Val Val Arg Leu Leu Pro Arg Cys Pro Ala
195 200 205

167

Pro Arg Met Arg Leu Leu Val Leu Leu Trp Gly Cys Leu Leu Leu Pro
 210 215 220

Gly Tyr Glu Ala Leu Glu Gly Pro Glu Glu Ile Ser Gly Phe Glu Gly
 225 230 235 240

Asp Thr Val Ser Leu Gln Cys Thr Tyr Arg Glu Glu Leu Arg Asp His
 245 250 255

Arg Lys Tyr Trp Cys Arg Lys Gly Gly Ile Leu Phe Ser Arg Cys Ser
 260 265 270

Gly Thr Ile Tyr Ala Glu Glu Glu Gly Gln Glu Thr Met Lys Gly Arg
 275 280 285

Val Ser Ile Arg Asp Ser Arg Gln Glu Leu Ser Leu Ile Val Thr Leu
 290 295 300

Trp Asn Leu Thr Leu Gln Asp Ala Gly Glu Tyr Trp Cys Gly Val Glu
 305 310 315 320

Lys Arg Gly Pro Asp Glu Ser Leu Leu Ile Ser Leu Leu Val Ser Pro
 325 330 335

Pro Ser Pro Gly Leu
 340

<210> 177
 <211> 312
 <212> PRT
 <213> Homo sapien

<400> 177

Gly Gly Ser Gly Glu Phe Trp Arg Lys Arg Arg Val Leu Leu Glu Leu
 1 5 10 15

Tyr Arg Pro Cys Phe Ser Gly Pro Arg Lys Val Ala Ser Ala Ser Ala
 20 25 30

Ala Ala Ser Thr Leu Ser Glu Pro Pro Arg Arg Thr Gln Glu Ser Arg
 35 40 45

Thr Arg Thr Arg Ala Leu Gly Leu Pro Thr Leu Pro Met Glu Lys Leu
 50 55 60

168

Ala Ala Ser Thr Glu Pro Gln Gly Pro Arg Pro Val Leu Gly Arg Glu
65 70 75 80

Ser Val Gln Val Pro Asp Asp Gln Asp Phe Arg Ser Phe Arg Ser Glu
85 90 95

Cys Glu Ala Glu Val Gly Trp Asn Leu Thr Tyr Ser Arg Ala Gly Val
100 105 110

Ser Val Trp Val Gln Ala Val Glu Met Asp Arg Thr Leu His Lys Ile
115 120 125

Lys Cys Arg Met Glu Cys Cys Asp Val Pro Ala Glu Thr Leu Tyr Asp
130 135 140

Val Leu His Asp Ile Glu Tyr Arg Lys Lys Trp Asp Ser Asn Val Ile
145 150 155 160

Glu Thr Phe Asp Ile Ala Arg Leu Thr Val Asn Ala Asp Val Gly Tyr
165 170 175

Tyr Ser Trp Arg Cys Pro Lys Pro Leu Lys Asn Arg Asp Val Ile Thr
180 185 190

Leu Arg Ser Trp Leu Pro Met Gly Ala Asp Tyr Ile Ile Met Asn Tyr
195 200 205

Ser Val Lys His Pro Lys Tyr Pro Pro Arg Lys Asp Leu Val Arg Ala
210 215 220

Val Ser Ile Gln Thr Gly Tyr Leu Ile Gln Ser Thr Gly Pro Lys Ser
225 230 235 240

Cys Val Ile Thr Tyr Leu Ala Gln Val Asp Pro Lys Ala Pro Tyr Pro
245 250 255

Ser Gly Trp Cys Val Cys Ser His Gly Val Gln Arg Pro Glu Cys Gly
260 265 270

Phe Trp Ser Cys Tyr Gly Val Ala Cys Cys Ser Gln Val Met Lys Pro
275 280 285

Trp Arg Ala Gln Arg Lys Ser Ala Gly Ser Lys Gly Thr Leu Cys Pro
290 295 300

Cys Ser Ala Pro Thr Gly Lys Ser

169

305

310

<210> 178
 <211> 165
 <212> PRT
 <213> Homo sapien

<400> 178

Met Ser Tyr Tyr Gln Leu Trp Ala Asp Lys Ser Tyr Ser Tyr Leu Gly
 1 5 10 15

Asn Lys Ser Tyr Ser Ser Leu Gly Asn Lys Ser Tyr Ser Ser Leu Gly
 20 25 30

Asn Lys Ser Tyr Ser Ser Leu Gly Asn Lys Ser Tyr Ser Ser Leu Gly
 35 40 45

Asn Glu Gly Pro Arg Ala Ala Ser Ser Pro Thr Trp Ala Gln Val Asp
 50 55 60

Pro Lys Gly Ser Leu Pro Lys Trp Val Val Asn Lys Ser Ser Gln Phe
 65 70 75 80

Leu Ala Pro Lys Ala Met Lys Lys Met Tyr Lys Ala Cys Leu Lys Tyr
 85 90 95

Pro Glu Trp Lys Gln Lys His Leu Pro His Phe Lys Pro Trp Leu His
 100 105 110

Pro Glu Gln Ser Pro Leu Pro Ser Leu Ala Leu Ser Glu Leu Ser Val
 115 120 125

Gln His Ala Asp Ser Leu Glu Asn Ile Asp Glu Ser Ala Val Ala Glu
 130 135 140

Ser Arg Glu Glu Arg Met Gly Gly Ala Gly Gly Glu Gly Ser Asp Asp
 145 150 155 160

Asp Thr Ser Leu Thr
 165

<210> 179
 <211> 155
 <212> PRT
 <213> Homo sapien

<400> 179

170

Glu Leu Leu Leu Ala Trp Ala Ile Arg Ala Thr Pro Ala Trp Ala Ile
 1 5 10 15

Arg Ala Thr Pro Ala Trp Ala Ile Arg Ala Thr Pro Ala Trp Ala Ile
 20 25 30

Arg Ala Thr Pro Ala Trp Ala Ile Arg Pro Lys Ser Cys Val Ile Thr
 35 40 45

Tyr Leu Ala Gln Val Asp Pro Lys Gly Ser Leu Pro Lys Trp Val Val
 50 55 60

Asn Lys Ser Ser Gln Phe Leu Ala Pro Lys Ala Met Lys Lys Met Tyr
 65 70 75 80

Lys Ala Cys Leu Lys Tyr Pro Glu Trp Lys Gln Lys His Leu Pro His
 85 90 95

Phe Lys Pro Trp Leu His Pro Glu Gln Ser Pro Leu Pro Ser Leu Ala
 100 105 110

Leu Ser Glu Leu Ser Val Gln His Ala Asp Ser Leu Glu Asn Ile Asp
 115 120 125

Glu Ser Ala Val Ala Glu Ser Arg Glu Glu Arg Met Gly Gly Ala Gly
 130 135 140

Gly Glu Gly Ser Asp Asp Asp Thr Ser Leu Thr
 145 150 155

<210> 180
 <211> 21
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic

<400> 180
 cttgtgacag ccacgacttt g

21

<210> 181
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic

<400> 181

171

gcattccagcc aggtttctc

19

<210> 182

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic

<400> 182

tttggttgta atgtaattag agacaccag

29

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/053075 A3

(51) International Patent Classification⁷: C12Q 1/68, C12P
21/02, C12N 15/00, 15/12, 15/11, A61K 31/7088, 31/711

(21) International Application Number:
PCT/US2003/038739

(22) International Filing Date: 5 December 2003 (05.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/431,097 5 December 2002 (05.12.2002) US
60/431,122 5 December 2002 (05.12.2002) US

(71) Applicant (*for all designated States except US*): DI-
ADEXUS, INC. [US/US]; 343 Oyster Point Boulevard,
South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MACINA, Roberto,
A. [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136
(US). TURNER, Leah, R. [US/US]; 939 Rosette Court,
Sunnyvale, CA 94086 (US). SUN, Yongming [CN/US];
551 Shoal Circle, Redwood City, CA 94065 (US).

(74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrrel
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
4 November 2004

*For two-letter codes and other abbreviations, refer to the "Guide-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PRO-
TEINS

(57) Abstract: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast, identifying breast tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered breast tissue for treatment and research.



WO 2004/053075 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/38739

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68; C12P 21/02; C12N 15/00, 15/12, 15/11; A61K 31/7088, 31/711

US CL : 536/23.1, 23.5; 435/6, 320.1, 325, 252.3, 69.1; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5; 435/6, 320.1, 325, 252.3, 69.1; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Compugen, SEQ ID NO: 73

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GU, J.Z. et al, The human B22 subunit of the NADH-ubiquinone oxidoreductase maps to the region of chromosome 8 involved in branchio-oto-renal syndrome, Genomics, 1996, Vol. 36, No. 1, pages 6-10, see especially page 8, Figure 1.	1-3, 5, 6, 8, and 9
---		-----
Y		4 and 10

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

18 August 2004 (18.08.2004)

Date of mailing of the international search report

14 SEP 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

James Martineau

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/38739

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-10 and 15-17.

Remark on Protest

☐
☐

- The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-10 and 15-17, drawn to nucleic acids, nucleic acid molecular hybridization assays, vectors, host cells, methods for producing polypeptides, kits, vaccines, and methods of treatment using nucleic acids.

Group II, claim(s) 1, 12, and 16-18, drawn to polypeptides, kits, vaccines, and methods of treatment using polypeptides.

Group III, claim(s) 13-15, drawn to antibodies and protein binding assays.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The nucleic acids, vectors, host cells, nucleic acid containing kits, and nucleic acid vaccines of Group I are materially different from the polypeptides, kits containing polypeptide, and polypeptide vaccines of Group II, and the antibodies of Group III. The methods of Group I may be practiced without the products or compositions of Group II or the antibodies of Group III. The methods of Groups I-III may be practiced independently of one another. The polypeptides and vaccines of Group II are materially different from the antibodies of Group III and are not needed to practice the methods of Group III.

Each of the Groups mentions a matter which additional Group for search. Any additional SE of payment of additional search additional Groups to be search otherwise.

rate and unrelated nucleic acids and/or polypeptides. No ired to select for search one SEQ ID NO within the Group(s) ires one additional search fee per SEQ ID NO. In the absence Group I will be searched. Should applicant pay fee(s) for he selected Group will be searched unless applicant directs